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ABSTRACT
Dysarthria in early Parkinson’s disease
The aim of the present study was threefold. First, to examine the 
incidence of dysarthria in patients in the beginning of Parkinson’s disease by 
using a standardised test (Frenchay Dysarthria Assessment/FDA) and an 
intelligibility assessment tool. Second, to identify differences in speech and in 
measures of phonation between the Parkinsonian group and a matched control 
geriatric group using the FDA and electrolaryngography. Finally, to identify the 
effect of medication on speech and phonation in the dysarthric Parkinsonian 
group.
The results showed that 8 out of 12 (66%) Parkinsonian subjects 
exhibited lower scores in the FDA compared to controls. Qualitative differences 
between the two groups were found in the isolated movements of the articulators 
but not in running speech and speech intelligibility. An improvement in the FDA 
scoring was found 3-3.5 months after medication. This improvement focused on 
the areas of tongue and lips and was accompanied with significant increases in 
intelligibility. No differences in measures of phonation were found either between 
the two groups or in the same group after medication.
The above results suggest that in the beginning of Parkinson's disease,
I
dysarthria is expressed as slowness and may be related to the primary 
diagnostic symptom of bradykinesia. Due to the small sample and the lack of 
dosage control, the significance of these findings appears to be inconclusive and 
warrants further investigation. Future research should employ instrumental 
quantitative measures on isolated movements of the articulators that may 
correlate with running speech and will aim to find clinical markers of speech in 
the diagnosis of Parkinson’s disease.
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CHAPTER 1. BACKGROUND TO THE RESEARCH QUESTION
Speech symptomatology in Parkinson’s disease has been examined by 
numerous studies. The incidence of dysarthria has been reported to be variable, 
ranging from 3-89%. No study at the moment has examined the incidence of 
dysarthria immediately after the neurological diagnosis. The early inclusion of 
levodopa medication after the neurological diagnosis complicates the speech 
symptomatology in the disease. It is still unclear if dysarthric symptoms are 
improved, stay the same, or are worsened after the inclusion of medication.
This thesis examines the question of whether dysarthria exists in early- 
diagnosed Parkinson’s disease and what its features are. The role of medication 
on speech and on selected voice characteristics is also examined. This chapter 
reviews the published literature on dysarthria in Parkinson’s disease and frames 
the research questions.
1.1 Definitions and classification of Parkinsonism: Parkinson’s disease
Parkinsonism is a group of neurological disorders marked by tremor at 
rest (present in the extremities and sometimes in the lips, chin, or tongue), 
rigidity, flexed posture in the entire body, bradykinesia-hypokinesia, loss of 
postural reflexes, and the freezing phenomenon. The diagnosis of definite 
Parkinsonism involves at least two of the above features with at least one being 
tremor at rest or bradykinesia (Fahn, 1995; Marjama-Lyons & Koller, 2001). It is 
generally accepted that decreased dopaminergic neurotransmission in the basal 
ganglia reflects the biochemical pathologies in Parkinsonism.
The classification of Parkinsonism is based on aetiology and includes four 
categories (Stacy & Jankovic, 1992):
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• Primary or idiopathic Parkinsonism (Parkinson’s disease, juvenile 
Parkinsonism)
• Secondary acquired or symptomatic Parkinsonism (due to infections, 
drugs, toxins, multi-infarcts, traumas, and others)
• Heredodegenerative Parkinsonism (Huntington’s, Wilson’s, and other 
diseases)
• Parkinsonism plus or multiple system degenerations (including 
diseases such as progressive supranuclear palsy, Shy-Drager 
syndrome, Alzheimer’s disease, and others).
In the current study, emphasis will be given to idiopathic Parkinson’s disease 
which involves more than ‘70%-76% of new cases of Parkinsonism (Hughes, 
Daniel, Kilford, & Lees, 1992; Roche, 1970; Stacy & Jankovic, 1992; Stern & 
Koller, 1993).
Parkinson’s disease or idiopathic Parkinson’s disease is a progressive 
neurological disease of unknown origin which is characterised by eosinophillic 
cytoplasmic inclusions (Lewy bodies) in the neurons and a degeneration of the 
pigmented neurons in the brain stem, substantia nigra (pars compacta), and 
locus coeruleus. At the onset of symptomatology, there is a loss of 60% of 
dopaminergic neurons and an 80% decrease of the dopamine content 
in the striatum (Fahn, 1995).
Clinically, Parkinson’s disease is different to any other type of 
Parkinsonism (although this is a controversial issue among researchers). Its 
symptoms appear on only one side of the body, accompanied by an almost 
frequent rest tremor and it has a good response to levodopa treatment. If the 
patient does not respond well to levodopa, it is assumed that some other form of
13
Parkinsonism exists. So, levodopa treatment is not only a crucial factor in the 
alleviation of neurological symptomatology but also in the diagnosis of idiopathic 
Parkinson's disease.
1.1.1 Historical accounts of Parkinsonism and Parkinson’s disease
James Parkinson (1817) made the first clear clinical description of 
Parkinsonism. At that time, Parkinson relied only on inspection and observation 
to describe the disease that was named “shaking palsy” or “paralysis agitans". 
His contribution to the recognition of the disease was remarkable. He was the 
first to describe the disease as an entire entity, to distinguish its tremor from 
other tremors that were caused by alcoholism, senility, or caffeinism and his 
work led to further anatomical examination of Parkinsonism.
Before Parkinson many medical writers focused on the varieties of tremor 
(resting vs. action tremor) including Galen (200 AD) who however attributed the 
tremor to chronic alcoholism (Roche, 1970). Caine, Dubini, and Stern (1989) 
included Leonardo Da Vinci among the early contributors to the identification of 
the disease by his observations and associations of the problems of voluntary 
movement with the tremor. Parkinson (1817) stated that Hippocrates, Franciscus 
(Sylvious) de la Boe (1617-1672), and Boissier de Sauvages (1768) were early 
contributors in the identification of the disease signs. The first seemed to 
mention tremor in his scripts, the second separated clearly the resting tremor 
from tremor during a voluntary act and the latter described the characteristic gait 
of Parkinsonism.
In the early 19th century Charcot and Vulpian (1861-1862) proposed the 
name “Parkinson's disease" and noted tremor as the distinguishing symptom
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(together with memory and intellectual problems) during the late stages of the 
disease. After Charcot and his colleagues had placed a special emphasis on 
Parkinson’s disease, many authors devoted themselves to the description of the 
disease. Among them was Gowers (1893), who summarised and expanded the 
symptomatology of the disease in his personal notes of 80 cases. Tyler (1992) 
reports that the author who crystallised the modern conception of paralysis 
agitans was Gowers. It seems that Gowers was also the first who referred to the 
monotony of speech in Parkinson’s disease commenting on the delay in the 
beginning of the sentence and on the rapidity of the following uttered words.
1.1.2 Epidemiological factors of idiopathic Parkinson’s disease
Epidemiological studies suggest a worldwide appearance of the disease 
with a variable range of about 100-200 cases per 100,000 people (Marttila, 1992; 
Tanner & Ben-Shlomo, 1999). A concomitant variation of Parkinson’s disease is 
found in the incidence rates with a range from 5-24/100,000. In the UK and US 
the incidence rises about 1-2% in people after the age of 50 (Marjama-Lyons & 
Koller, 2001; Mutch, Strudwick, Roy, & Downie, 1986). No difference between 
the sexes or a slight male preponderance has been found (Marttila & Rinne 
1976; Rajput, Offord, Beard, & Kurland, 1984; Tanner & Ben-Shlomo, 1999). The 
epidemiology of Parkinson’s disease reflects a variability in the prevalence and 
incidence rates because of diagnostic difficulties in early recognition, a 
differential diagnosis of other tremors and extrapyramidal syndromes (Marttila, 
1992) and/or differences in study design (Tanner & Ben-Shlomo, 1999).
Aetiologically, many risk factors for developing Parkinson’s disease have 
been discussed. Tanner (1992) summarised eight risk factors that include: age.
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gender, race, genetic predisposition, toxicant exposure, trauma, and emotional 
stress. Age is an important risk factor of the disease. The current picture shows 
scarcity of the disease before the age of 30, a low incidence between 30 and 40 
years, a sharp increase in incidence thereafter with a peak between 70 to 79 
years and a declination of incidence for higher ages (Baldereschi et al., 2000; 
Marttila, 1992; Tanner, 1992; Tanner & Ben-Shlomo, 1999). Other authors report 
the peak of incidence in the ages between 75-84 years (Rajput et al., 1984).
As already noted, some reports show no gender differences in prevalence 
rates (Shastry, 2001; Tanner, 1992) or slight male preponderance (Tanner & 
Ben-Shlomo, 1999). Exceptions to these findings were two studies, one study in 
China (Li et al., 1985) which found that men were 3.7 times more likely to 
develop Parkinson’s disease than women, and, another study in Italy 
(Baldereschi et al., 2000) which found that men were twice as likely to develop 
Parkinson’s disease than women.
The Caucasian population has been reported to be at a greater risk 
compared to the other races, even though no conclusions have been extracted 
about the geographical pattern of the disease from this evidence (Marttila, 1983; 
Tanner, 1992). A lower occurrence of the disease is found in the African and 
Asian races compared to Caucasians who seem to have the highest prevalence 
rate of Parkinson’s disease. Exceptions to the above reports are the results from 
the studies of the Parsi colony in Bombay (India) and Copiah county in 
Mississippi (U.S). The first showed similar prevalence to that found in Europe 
and North America, while the second showed a similar prevalence rate between 
whites and blacks (Bharucha, Bharucha, Bharucha, Bhise, & Schoenberg, 1988; 
Schoenberg, Anderson, & Haerer, 1985).
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While studies in the earlier decades focused on the influence of 
environment, after 1990 there has been a focus on genetics to explain idiopathic 
Parkinson’s disease. The evidence shows that genetic factors are involved in 
early and late-onset Parkinson’s disease. Early-onset Parkinson’s disease refers 
to autosomal recessive forms of Parkinson’s disease while late onset 
Parkinson’s disease refers to the idiopathic form of Parkinson’s disease. The 
Parkin gene was found to contribute to the development of early-onset 
Parkinson’s disease while several genes were found to contribute to the 
development of late-onset Parkinson’s disease (Scott et al., 2001).
Other studies associate different types of exposures such as rural 
residence, farming, well-water drinking, smoking, or herbicide/pesticide with 
Parkinson’s disease (Koller et al., 1990; Tanner et al., 1989; Wong, Gray, 
Hassanein, & Koller, 1991). Recent evidence suggests that among other factors 
there is an association of the existence of domestic animals at home and 
Parkinson’s disease, with the Parkinsonian subjects (especially before the age of 
20) reported as having fewer domestic animals and lower duration of animal 
contacts. The appearance of domestic animals was suggested to have a 
protecting effect in the development of Parkinson’s disease (Kuopio, Marttila, 
Helenius, & Rinne, 1999). In this study, even though no negative association 
between smoking and Parkinson’s disease was found, the increased mean age 
of onset for Parkinson’s disease in ever-smoking subjects as compared to the 
never-smoking subjects possibly suggest that smoking delays the onset of 
Parkinson’s disease. In general, the picture of an infectious environmental agent 
and Parkinson’s disease is still not clear and further investigation is needed. It is 
unlikely that a sole etiologic environmental agent exists especially when it should
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be present for almost a century from the time that James Parkinson discovered 
this disease (Duvoisin, 1999).
Head injury also appears in the literature to be associated with 
Parkinson's disease (Bharucha et al., 1986; Tanner et al., 1987). However, 
recent evidence does not support this association (Kuopio et al., 1999). Other 
studies support the notion that the association of head trauma and Parkinson’s 
disease may be caused by a biased recall on the part of the patients (Tanner, 
1992; Tanner & Ben-Shlomo, 1999). Some authors include the effects of boxing 
on brain damage as a result of a syndrome called “punch drunk" that mimics 
some of the Parkinsonian features such as the shuffling gait and the dysarthria 
(Corsellis, Bruton, & Freeman-Browne, 1973; Corsellis, 1989). Although it is not 
recognised officially that boxing results in this syndrome, damage to the motor 
pathways in the cerebellum and the substantia nigra is reported. The clinical 
features of this pathological state include dysarthria with and without equilibrium 
and spasticity, or, rigidity and striatal tremor associated with dementia. As in 
Parkinson’s disease, the lack of large pigmented neurons -among other features­
in the substantia nigra is considered a histological finding of this syndrome.
Emotional stress has also been associated with the development of 
Parkinson’s disease, but more research is needed to give a clear picture of this 
risk factor. Duvoisin (1999) reports that age, gender, and stress may influence 
the exact moment of appearance of the disease and its clinical symptomatology.
Additional risk factors have been discussed by Marttila and Rinne (1986) 
including other diseases (cancer, occurrence of stroke, coronary heart disease, 
and common viral infections), essential tremor and specific diet, but rio 
associations have been found with Parkinson’s disease. In contrast to the above
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findings, Tannerand Ben-Shlomo (1999) report that there is an increased 
possibility of diet as a possible exposure factor. Evidence from a cohort study of 
Far East prisoners of war who experienced dietary insufficiency between 1942- 
1945 showed an increased prevalence rate of 512 cases / 100,000 persons (24 
people out of 4,684 subjects) far beyond the usual prevalence rate of 100-200 
cases / 100,000 people. Finally, other studies have found associations of 
Parkinson’s disease and increased exposure to mercury (Ngim & Devathasan,
1989) or increased exposure to manganese, iron, and aluminium (Zayed et al.,
1990).
The time of exposure to an environmental factor in relation to the cause of 
Parkinson’s disease has aflso been discussed (Marttila & Rinne, 1986). It has 
been suggested that there might be an exposure throughout the life of persons 
who develop Parkinson’s disease that has a low frequency during childhood and 
after 60 years of age and a maximum occurrence between 30 to 40 years. 
Tanner and Ben-Shlomo (1999) state that a long latency period of around 20-30 
years should exist as a time of exposure. This period is probably followed by a 
period in which there is a reduction of the number of substantia nigra neurons by 
70-80% and the reduction of striatal dopamine. Both of them were found long 
before the appearance of the clinical motor symptoms (Marsden, 1982; Tanner & 
Ben-Shlomo, 1999).
Marttila and Rinne (1986) support the notion that the incidence and 
prevalence rates of Parkinson’s disease have been stable many decades and so 
modern technology might not be the cause of the disease. Also, the specific 
environment (town, village) of the person prone to the disease, might be 
responsible for the disease but not the environment at the family level. Finally,
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the appearance of infections and toxins especially in postencephalitic 
Parkinsonism and MPTP-induced Parkinsonism that mimic the symptoms of 
Parkinson’s disease might be serious candidates among others for the 
development of the disease. What is uncertain at the moment is “the exact timing 
of the process leading to Parkinson’s disease...and the nature of the cause of 
this disease” (Marttila, 1992, p. 50). In contrast, other researchers argue that the 
existence of syndromes similar to Parkinson’s disease due to the effect of 
environmental agents does not necessarily prove their direct association to 
Parkinson’s disease. Furthermore, no agent seems to reproduce the same 
neuropathology of Parkinson’s disease (Duvoisin, 1999).
1.1.3 Neuropathology and aetiology in idiopathic Parkinson’s disease
It is well known and has been well established by researchers in the 20th 
century that Parkinson’s disease arises as a result of basal ganglia and more 
specifically substantia nigra pathology (Hornykiewisz, 1966; Wilson, 1912). Gibb 
(1992) summarised the neuropathology of Parkinson’s disease. According to 
him, there is a moderate to severe loss of cells in the zona compacta of the 
substantia nigra. At the same time the remaining cells include eosinophillic Lewy 
bodies in great quantity especially in the neurons with long axons. If there is no 
existence of Lewy bodies, the disease is excluded from the neurological 
diagnosis. Another type of cell inclusions that is found in Parkinson’s disease 
(substantia nigra and locus coeruleus) is the pale body. As the name suggests 
the loss of melanin pigment in the substantia nigra results in the characteristic 
pale colour.
The existence of Lewy bodies at an early stage is associated with the
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degeneration of nerve cells. Often Lewy bodies are found before any significant 
cell loss. Their distribution shows the sites of degeneration, namely, the 
substantia nigra, locus coeruleus, ventral tegmental area, nucleus basalis of 
Meynert, thalamus, the entire autonomic nervous system, raphe nuclei, and 
cerebral cortex. The cause of the degeneration of dopamine-containing cells and 
the existence of Lewy bodies in the zona compacta of the substantia nigra is still 
unknown (Jenner, 1992).
Even though in the past, the majority of studies that searched for 
aetiologic factors of Parkinson’s disease focused on possible environmental risk 
factors, recently this view has changed. The current view is that there might be 
"an interaction of genetic and environmental risk factors, in which specific 
genetic templates are more susceptible to the influences of environmental 
exposures" (Scott et al., 2001, p. 2243). More specifically, a deficiency of a gene 
product might be the trigger for the toxic action of an environmental factor to 
produce Parkinson’s disease (Duvoisin, 1999). Despite this interplay between 
genetics and environment, gene therapy in the future might be able to treat 
Parkinson’s disease (Shastry, 2001).
In summary, the neuropathological process of Parkinson’s disease is the 
result of the selective degeneration of the dopaminergic nigrostriatal pathway, 
which results in reduced striatal dopamine concentrations. The signs and 
symptoms of the disease (tremor, rigidity, and bradykinesia) emerge as a 
consequence of the above process. Further explanatory mechanisms of the lack 
of dopamine will be discussed in section 1.9.2. The current aetiological view is 
that Parkinson’s disease is the product of the interplay between genetic 
susceptibility and the toxic action of one or more environmental factors.
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1.2 Incidence of dysarthria in Parkinson’s disease
Dysarthria is defined as “...a collective name for a group of speech 
disorders resulting from disturbances in muscular control over the speech 
mechanism due to damage of the central or peripheral nervous system. It 
designates problems in oral communication due to paralysis, weakness, or 
incoordination of the speech musculature” (Darley, Aronson, & Brown, 1969a, p. 
246). Hypokinetic dysarthria is a motor speech disorder associated with lesions 
in the basal ganglia control circuit. It is primarily the result of Parkinson’s 
disease.
According to Darley et al. (1969a), the speech characteristics of 
hypokinetic dysarthria a re'(from most severe to least severe): monopitch, 
reduced stress, monoloudness, imprecise consonants, inappropriate silences, 
short rushes of speech, harsh voice quality, breathy voice (continuous), low 
pitch, and variable rate. Prosodic insufficiency is considered a cluster of 
abnormal speech characteristics in hypokinetic dysarthria as compared to other 
dysarthria types (Darley, Aronson, & Brown, 1969b). It includes monopitch, 
monoloudness, reduced stress, short phrases, variable rate, short rushes of 
speech, and imprecise consonants. Darley, Aronson, and Brown (1975) state 
that “the association of perceived acoustic characteristics most distinctive of 
hypokinetic dysarthria comprises significantly reduced variability in pitch and 
loudness, reduced loudness level overall, and decreased use of all vocal 
parameters for achieving stress and emphasis” (p. 195). All the other speech 
characteristics such as imprecise consonants, harsh and breathy voice quality 
occur at variable rates. More details about these studies will be given in section 
1.5.1.
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The speech characteristics of hypokinetic dysarthria are thought to be due 
to the reduced range of movement that is caused by the rigidity of muscles. This 
rigidity involves the laryngeal and the vocal tract musculature (Kent, 1990) as 
well as the respiratory musculature (Critchley, 1981). The consequences of 
rigidity might involve bowing of the vocal folds, fast rate, reduced movements, 
and inadequate oral closures.
The incidence of hypokinetic dysarthria in Parkinson’s disease has been 
found to be variable in different studies. A detailed overview of these studies will 
follow. A high incidence was found by Logemann, Fisher, Boshes, and Blonsky 
(1978). The authors examined 200 patients with Parkinson’s disease and found 
that 89% of them exhibited phonatory problems (breathiness, roughness, 
hoarseness, tremulousness), 45% exhibited articulatory problems, 20% exhibited 
rate abnormalities (short or long pauses, syllable repetition, and abnormally long 
syllables) and 10% of them exhibited hypernasality.
In a follow-up study, 227 subjects with Parkinsonism (183 subjects with 
idiopathic Parkinson’s disease and 44 subjects with postencephalitic 
Parkinsonism) exhibited variable incidence rates (Hoehn & Yahr, 1967). Seven 
subjects with idiopathic Parkinson’s disease (3%) and 12 subjects with 
postencephalitic Parkinsonism (27%) reported speech disturbances. However, 
no information was given in this study for medication status (this study coincided 
with the advent of levodopa, so probably no medication was given to patients) 
and speech was recorded as one of many other symptoms of the disease.
Scott, Caird, and Williams (1985) reported that, in general, speech 
disorders in Parkinson’s disease occur in half of all cases. Mutch et al. (1986) 
assessed 265 patients with idiopathic Parkinson’s disease (median duration of
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the disease 7.2 years) using two rating systems: the Webster scale and the 
Hoehn and Yahr rating system. The results, among others, showed that 64.9% 
of patients who were assessed with the Hoehn and Yahr rating system exhibited 
some speech difficulty and 71.5% of patients who were assessed with the 
Webster rating exhibited speech problems of varying severity: mild (37.4%), 
moderate (25.7%), and severe (8.4%).
Hartelius and Svensson (1994) found that 70% of Parkinsonian patients 
perceived that their speech and voice were impaired (duration of the disease 
from 3-10 years). More specifically, sixty one percent (61%) of the total number 
of the Parkinsonian patients (N = 195) reported weak voice, 36% reported 
imprecise articulation, 32% reported hoarseness, 27% reported difficulties 
getting started, and 17% reported monotonous voice. A strong positive 
correlation was found between the duration of the disease and the severity of 
speech symptomatology.
More recently, Coates and Bakheit (1997) found that 64.6% of 48 
Parkinsonian patients (mean duration of disease 6.7 years) exhibited speech 
problems (reduced intelligibility of speech). Fifty percent (50%) of them displayed 
mild speech disturbances and the remaining 14.6%, exhibited moderately severe 
or severe dysarthria. One third of the subjects were found to be unaware of their 
speech problems. Contrary to the study by Hartelius and Svensson (1994), this 
study found a poor correlation between the severity of Parkinson’s disease and 
reduced intelligibility of speech and a weak negative correlation between 
intelligibility of speech and duration of disease.
From the above findings, it seems that the sampling of the population of 
Parkinsonian patients occurred at different times during the course of the
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disease. In addition, the incidence rates of some studies were based on history 
forms (Hoehn & Yahr, 1967), questionnaires (Hartelius & Svensson, 1994) or 
speech assessment based on neurological scales alone or with intelligibility 
assessment (Coates & Bakheit, 1997; Mutch et al., 1986). The variable findings 
of these incidence rates may also be related “to the progressive nature of the 
disease and/or to the individual responses to anti-Parkinsonian medication” 
(Theodoros & Murdoch, 1998, p. 271). In order to exclude factors such as 
duration of disease and medication, it is suggested that new research may need 
to examine the dysarthria of patients with Parkinson's disease immediately after 
the neurological evaluation and diagnosis. In this way, medication will not have 
had chance to affect speech and a clearer picture of dysarthria as a primary 
symptom of idiopathic Parkinson’s disease will arise.
1.3 Cognitive impairment in Parkinson’s disease
This section aims to summarise how cognitive ability is affected by 
Parkinson’s disease. It is imperative in the present study that the examination of 
dysarthria will exclude factors such as cognitive impairment. The reported 
cognitive problems in Parkinson’s disease involve the appearance of dementia. 
Dementia is defined as a disorder that exhibits impairment in short term and long 
term memory and abnormalities in at least one of the areas of mental function: 
abstract thinking, judgement, language, praxis, visual recognition, constructional 
ability, or personality (American Psychiatric Association, 1987). Even though this 
definition is applied basically to the dementia of Alzheimer’s disease, it is not 
clear if the same criteria could be used in idiopathic Parkinson’s disease (Sagar, 
1992) due to probable behavioural differences between the two diseases. In
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general terms, dementia is defined with the appearance of two out of four 
cognitive domains (language, memory, executive function, and visuospatial 
function) (Piatt, Fields, Paolo, Koller, & Troster, 1999).
The prevalence of dementia in Parkinson’s disease is approximately 20- 
43% increasing with the duration of the disease (Aarsland et al., 2001; 
Cummings, 1988; Levy et al., 2002; Sagar, 1992). The risk of developing 
dementia has been investigated in cohort studies (Aarsland et al., 2001; Levy et 
al., 2002). Patients with Parkinson’s disease had a 6 times higher risk of 
dementia than general elderly people (Aarsland et al., 2001). Age, duration of 
disease. Mini Mental State Examination score, Hoehn and Yahr stage (>2), and 
levodopa dose were found to be predictors of dementia in the Parkinsonian 
group when the Parkinsonian patients were re-evaluated after 4 years (Aarsland 
et al., 2001). Levy et al. (2002) found that the combined effect of age and 
severity of extrapyramidal signs was a risk factor of developing dementia. 
Another study found that speech and bradykinesia were associated with incident 
dementia (Levy et al., 2000). No information about duration of the disease was 
given in this study. Also, dysphagia and Parkinson’s disease (with and without 
dementia) co-occur. In fact, one quarter of Parkinsonian subjects with dementia 
and one-half of the Parkinsonian subjects without dementia are documented to 
also have dysphagia (Bine, Frank, & McDale, 1995).
The dementia of Parkinson’s disease is often called subcortical dementia. 
Subcortical dementia is a syndrome that is characterised by dysarthria, memory 
impairments, executive deficits, depression, and prominent motor disability 
compared to dementia of Alzheimer’s disease. In contrast, dementia of 
Alzheimer’s disease is characterised by aphasia, long-term memory deficits.
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agnosia, normal mood, and minor motor disability (Sagar, 1992). However, there 
are researchers who oppose the distinction between cortical and subcortical 
dementia (Mayeux, Stern, Rosen, & Benson, 1983). The concept of subcortical 
dementia has been attributed to the effect of dopamine deficiency on intellectual 
function because:
• Dementia improves for the first 1-2 years of therapy with levodopa.
• Its severity has been correlated with dopamine loss and akinesia.
• It has been associated with other hypodopaminergic states such as 
supranuclear palsy and MPTP-induced Parkinsonism (Cummings, 1988).
More specifically, Cummings and Benson (1984) described and 
distinguished subcortical dementia compared to cortical dementia in different 
levels (severity, personality, motor system involvement, anatomy, and 
neurotransmitter involvement). In severity, memory and cognition are more 
impaired in cortical dementia rather than in subcortical dementia. In personality, 
cortical dementia is euphoric as compared to the subcortical dementia that is 
apathetic. In motor system involvement, the subcortical dementia presents with 
abnormalities in posture, gait, motor speed, movement, and speech (dysarthria). 
In anatomy, subcortical dementia involves the basal ganglia, the thalamus, and 
the mesenchephalon. Finally, in neurotransmitter involvement, subcortical 
dementia presents with a lack of dopamine in contrast to the cortical dementia of 
Alzheimer’s disease, which presents with a lack of acetylcholine.
Some studies aimed to prove differences between cortical vs. subcortical 
dementia by measuring capacities such as memory, visuospatial function, 
mental function, and language (Cummings, Darkins, Mendez, Hill, & Benson, 
1988; Goldman, Baty, Buckles, Sahrmann, & Morris, 1998; Huber, Shuttleworth,
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& Paulson, 1986). All studies assessed dementia using neuropsychological test 
batteries. Huber et al. (1986) found that dementia in Parkinson’s disease was 
characterised by mild impairment of memory and visuospatial function but not 
impairment of language or evidence of apraxia. Cummings et al. (1988) found 
that the Parkinsonian patients exhibited motor speech, writing, and language 
abnormalities (phrase length and grammatical complexity) compared to patients 
with Alzheimer’s disease. Parkinsonian patients with and without dementia 
showed more speech and writing abnormalities than the patients with 
Alzheimer’s disease and dementia. Murray (2000) examined differences in 
language between two groups, one with Huntington’s disease and one with 
Parkinson’s disease. The results showed that the subjects with Huntington’s 
disease exhibited shorter and less syntactically complex utterances (subject- 
verb-object utterances) when describing the Cookie-Theft picture. The author 
concluded that the neural structures that affected by Huntington’s disease (e.g., 
caudate nucleus, putamen) contribute more to syntax production than these of 
Parkinson’s disease (e.g., substantia nigra).
The manifestations of subcortical dementia compared to non dementia 
and healthy elderly people were also examined. Goldman et al. (1998) found a 
lower performance of Parkinsonian subjects with dementia compared to non 
demented Parkinsonian subjects and controls in logical memory (recalling of 
stories) block design (arrangement of blocks to match designs), digit symbol 
(transcription of numbers and symbols), and trailmaking (connection of numbers 
with lines). Piatt et al. (1999) found that demented Parkinsonian subjects scored 
more poorly in semantic, phonemic, and action fluency tasks compared to 
controls and Parkinsonian non demented subjects. According to the authors, the
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action fluency task is probably an early indicator of the conversion from 
Parkinson’s disease without dementia to Parkinson’s disease with associated 
dementia. This lateral finding agrees with other reports that action fluency was a 
more efficient task in the identification of Parkinson’s disease without dementia 
and Parkinson’s disease with dementia (Woods, Troster, & Fields, 2001).
Other studies examined grammar and syntax in Parkinsonian demented 
patients (Lieberman et al., 1992; Small, Lyons, & Kemper, 1997). The results of 
these studies show that grammatical ability is associated with the severity of 
dementia in Parkinson’s disease whereas syntactic comprehension is associated 
with the neurological stage of Parkinson’s disease and the complexity of the 
sentence.
Small et al. (1997) investigated the grammatical abilities of patients with 
mild and moderate dementia and Parkinson’s disease, patients with Parkinson’s 
disease and no dementia, and controls, by comparing written language samples 
of single sentences. The results showed that impairments in grammatical ability 
vary with severity of dementia. Thus, the Parkinsonian patients with mild 
dementia and no dementia exhibited normal grammatical production as 
compared to patients with moderate dementia who wrote shorter sentences with 
a reduced prepositional density. These findings when compared to the findings 
by Cummings et al. (1988) and Hies (1989) suggest that the dementia of 
Parkinson’s disease affects the lexical-semantic content more than the syntactic 
content of grammatical production (Small et al., 1997).
1.3.1 Cognitive impairment in early Parkinson's disease
Although studies of cognitive impairments in Parkinson’s disease have
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given variable results due to a possible mixture of subjects with variable duration 
of disease, less research has taken place with patients with early Parkinson’s 
disease. Levin and Katzen (1995) define early Parkinson’s disease to occur in 
less than five years duration, or for the severity of symptoms to be at stages I 
and II in the Hoehn and Yahr scale. Even though there is an apparent effort to 
exclude factors such as medication and duration of disease in order to study 
early Parkinson’s disease, there are still differences between studies. Duration of 
disease is the most apparent one. Even though the mean duration of disease 
does not seem to change across studies (21-28 months), the range of this 
duration is different. Other studies exhibit a range of 3-96 months (Farina et al.,
2000), other 6-36 months (Levin, Llabre, & Weiner, 1989), and others to 3-48 
months (Cooper, Sagar, Jordan, Harvey, & Sullivan, 1991; Lees & Smith, 1983).
In summary, a number of studies report the general preservation of 
naming and fluency (phonemic and semantic) as manifestations of language in 
early Parkinson’s disease (Farina et al., 2000; Lees & Smith, 1983; Levin et al., 
1989; Levin & Katzen, 1995). Two studies found some differences in phonemic 
fluency (Lees & Smith, 1983) and semantic fluency (Cooper et al., 1991) but 
these were not generalised (only one out of three letters in words that produced 
in one minute and only the semantic category of objects showed a significant 
difference).
Set-shifting (shift between different mental sets) has been reported to be 
consistently impaired in subjects with early Parkinson’s disease (Cooper et al., 
1991; Farina et al., 2000; Lees & Smith, 1983; Levin et al., 1989; Levin &
Katzen, 1995). The Parkinsonian subjects tended to make more errors when 
they were required to shift from one mental category to another. Farina et al.
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conclude that set shifting and maintaining is the first executive ability to be lost in 
the early stages of Parkinson’s disease. Kanazawa, Hirotaro, and Yoshikuni 
(2001) reported that executive function impairments coincide with the stage of 
Parkinson’s disease (Hoehn and Yahr ll-lll neurological stages) in which the 
bilateral symptoms start to show.
Immediate and delayed memory has been reported to be impaired in 
different studies (Cooper et al., 1991; Farina et al., 2000; Levin et al., 1989). The 
role of impairment of memory in early Parkinson’s disease is not so clear due to 
the effect of medication that may disrupt memory skills (Levin & Katzen, 1995). 
The authors support the notion that further research is needed to investigate if 
memory impairment is a marker of Parkinson’s disease or a precursor of 
dementia in Parkinson’s disease. Along the same lines. Cooper, Sagar, and 
Sullivan (1993) attributed the impairment of memory in the early Parkinsonian 
subjects to their deficits in attention and not to a generalized impairment of 
cognition.
1.4. Diagnostic criteria for Parkinson’s disease and the use of medication
The neurological diagnosis of Parkinson’s disease is based on the clinical 
examination. At the moment there is no physiological test to diagnose this 
disease. It is well known that the clinical diagnostic criteria for Parkinson’s 
disease do not exclude the possibility of a misdiagnosis. The clinical 
heterogeneity that is manifested in the Parkinsonian population further 
complicates the diagnosis (Koller, 1992). A broad approach involving not only 
inclusion but also exclusion criteria was suggested as a solution to the problem of 
accurate diagnosis of Parkinson’s disease (Koller & Montgomery, 1997).
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Most of the researchers agree that the inclusion criteria should involve the 
presence of two of the three cardinal features of Parkinsonism;
• Bradykinesia
• Tremor
• Rigidity
Some researchers include postural instability in the aforementioned criteria 
(Caine, Snow, & Lee, 1992; Gibb & Lees, 1989; Hermanowicz, 2001; Quinn,
1997). Specific diagnostic criteria have been established based on the results of 
the Parkinson’s Disease Society Brain Bank (PDSBB) which receives brain tissue 
from all over UK and examines it histologically. These criteria increased the 
accurate diagnosis of Parkinson’s disease to 82% (Hughes et al., 1992). Hughes 
et al. lists all the PDSBB clinical diagnostic criteria (inclusion and exclusion) for 
Parkinson’s disease (Figure 1).
1) Bradykinesia plus one of; rigidity, tremor, and postural instability.
2) Exclusion criteria: history of repeated strokes, history of repeated head injury, history of 
encephalitis, oculogyric crises, neuroleptic drugs at onset of symptoms, more than one 
Affected relative, sustained remission, strictly unilateral features after 3 years, supranuclear 
Gaze palsy, cerebellar signs, early severe autonomic involvement, early severe dementia 
With disturbances of memory, language and praxis, Babinski sign, presence of cerebral 
Tumour, negative response to large doses of levodopa, MPTP exposure.
3) Three or more of the following supportive positive criteria: unilateral onset, resting tremor 
present, progressive deterioration, persistent asymmetry affecting the side of onset. 
Excellent response to levodopa (70-100% ) initially, severe levodopa-induced chorea, 
Response to levodopa for 5 or more years, duration of disease of 10 years or more.
Figure 1. UK Parkinson's Disease Society Brain Bank clinical diagnostic criteria.
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Bradykinesia (slowness of movement) and tremor followed by rigidity are 
the most frequent features of Parkinson’s disease. Terms such as akinesia 
(paucity of movement), hypokinesia (reduced range of movement), and 
bradykinesia have been used interchangeably to describe the loss of the ability to 
move (Marsden, 1989). The absence of facial expression in Parkinsonian 
patients is an expression of akinesia while limb slowness during movement is an 
expression of bradykinesia. Finger tapping is a task that is used by neurologists 
to observe the existence of bradykinesia. Tremor is usually presented as a 
unilateral hand tremor, more noticeable at rest and decreased when the affected 
hand is used. Finally, rigidity (stiffness of movement) is manifested as an 
increased tone throughout the range of limb movement. While bradykinesia and 
tremor are usually reported by patients, rigidity is not (Hermanowicz, 2001).
The development and use of levodopa (L-DOPA) almost 25 years ago 
revolutionised the treatment approach for Parkinson’s disease. Levodopa 
restores the low cerebral dopamine levels in Parkinson’s disease. It is still the 
main medication for idiopathic Parkinson’s disease. However, as the disease 
progresses motor fluctuations and dyskinesias occur after 3-5 years of levodopa 
medication. For this reason, there are alternative treatment strategies that hope 
to slow or halt the progression of Parkinson’s disease. Some of them are 
proposed to be complementary to levodopa while others are used as early 
monotherapy. All the different medications for Parkinson’s disease tend to 
alleviate the mobility symptoms especially in large limb and body movements 
(Hermanowicz, 2001). Figure 2 lists all commonly described drugs for 
Parkinson’s disease in Europe and US.
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ACTION BRAND NAME GENERIC NAME
Anticholinergics Artane Trihexyphenidyl
• Tremen Trihexyphenidyl
Kemadrin Procyclidine
Akineton Biperiden
Cogentin Benztropine
Symmetrel Amantadine
Parsidoi Ethopropazine
Dopamine receptor agonists Parlodel Bromocriptine
Permax Pergollde
Dopergine Lisuride
Requip Topinirole hydrochloride
Mirapex Pramipexole
Levodopa-decarboxyiase Sinemet Carbldopa/levodopa
inhibitor combinations Sinemet CR Carbidopa/levodopa
Madopar Bensarizide/levodopa
Type B MAO inhibitors Deprenyi Selegiline
Eidepryi Selegiline
COM T inhibitors Comtan Entacapone
Tasmar Tolcapone
Figure 2. Commonly prescribed anti-Parkinsonian drugs 
(Hermanowicz, 2001; Yorkston, Miiier, & Strand 1995).
Each drug category has a differential role in the treatment of Parkinson’s 
disease. Figure 3 taken from Yorkston et al. (1995) explains the function of each 
drug category in order to balance the dopamine-acetylcholine relationship.
Anticholinergic Agents
MAO-a
Inhibitor
(Deprenyi)
Inhibits 
breakdown ai 
dopamine
(Ariane)
Replaces
Dopamine
Bloo<j-Brain Earner
Figure 3. Action of drugs to balance dopamine and acetylcholine systems.
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During the history of Parkinson’s disease three major categories of drugs 
were used; anticholinergics, dopamine agonists, and levodopa. The other drug 
categories (Type B MAO inhibitors and COMT inhibitors) are considered either 
neuroprotective or complementary to levodopa. The present discussion will give 
more emphasis on the three major categories of drug treatment while some 
comments will be spared for the other categories.
Selegiline as a type B MAO inhibitor was successfully used on animals to 
protect them from induced Parkinsonism (MPTP). The use of selegiline in 
humans after 1989 in the US aimed to decrease the dopamine breakdown in the 
brain and increase dopamine in the synapses (Hristova & Koller, 2000). As a 
result, the early use of selegiline might slow the progression of the disease and 
prevent nigral neuronal destruction. The results showed that the patients could 
benefit from selegiline during the first year of treatment (Parkinson Study Group, 
1989; Parkinson Study Group, 1993). There is, however, a controversy between 
researchers if selegiline is protective to the patients. Some researchers favour its 
use (Olanow, 1992) while others not (Wills, 1998). Recent evidence does not 
support these findings. Selegiline seems to have a little or no effect in the 
reduction of Parkinsonian symptomatology (Hermanowicz, 2001; Hristova & 
Koller, 2000; Oertel & Quinn, 1997). Furthermore, many neurologists in the U.K 
avoid its prescription because of increased mortality rates in patients who used it 
in combination with levodopa (Lees, 1995).
COMT inhibitors are used to delay the peripheral breakdown of levodopa 
by the enzyme COMT and so to increase the duration of levodopa in the brain 
(Hermanowicz, 2001). They are used as complementary drugs to levodopa to 
reduce motor complications and to increase the effectiveness of levodopa but
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they are not used as early monotherapy (Hristova & Koller, 2000).
Anticholinergic agents (the older symptomatic therapy for Parkinson’s 
disease) and amantadine are used to create a balance of dopamine and 
acetylcholine. Because of the lack of dopamine in Parkinson’s disease the 
balance of dopamine and acetylcholine is shifted towards acetylcholine. 
Suppression of the increased acetylcholine through the use of anticholinergics is 
thought to restore this balance. Nowadays, the use of anticholinergics is still 
frequent because of their low cost and because of their influence on resting 
tremor (Hermanowicz, 2001; Koller, 1992; Oertel & Quinn, 1997). However, they 
do not seem to be so effective for bradykinesia (Koller, 1992). Some authors 
state that the effectiveness of anticholinergics on tremor is not better than that of 
levodopa (Hermanowicz, 2001; Hristova & Koller, 2000). A disadvantage of 
anticholinergics is that they produce serious side effects such as memory 
problems, lack of concentration, confusion, and hallucinations (Ahlskog, 1996; 
Koller, 1992; Oertel & Quinn, 1997).
As with other anticholinergics, amantadine blocks the acetylcholine 
receptors. It is not considered to be the most beneficial drug for the maximum 
alleviation of Parkinsonian symptomatology (Hermanowicz, 2001). Nowadays, it 
is used to reduce motor fluctuations such as choreic movements that are 
produced as a side effect from the prolonged use of levodopa (Hermanowicz,
2001). Wills (1998) states that amantadine and anticholinergics as alternatives to 
dopamine agonists when used in combination with levodopa can either increase 
dopaminergic transmission (amantadine and levodopa) or relieve tremor and 
rigidity (anticholinergics and L-DOPA).
Dopamine agonists work as adjuncts to levodopa or as a synthetic
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levodopa. They act directly on post-synaptic dopamine receptors without 
requiring transformation or facilitation transport across the blood-brain barrier 
(Hermanowicz, 2001; Hristova & Koller, 2000; Koller, 1992; Koller & Rueda,
1998; Tolosa, Marti, Valldeoriola, & Molinuevo, 1998). Dopamine agonists are 
used both as monotherapy and as complementary therapy to levodopa-carbidopa 
to reduce motor fluctuations and dyskinesias (Hermanowicz, 2001; Oertel & 
Quinn, 1997). Fukuyama, Kawamura, Akigushi, Kimura, and Imai (1996) 
evaluated bromocriptine (the most extensively used dopamine agonist) 
monotherapy during the early stage of Parkinson’s disease (Hoehn and Yahr 
stage I or II) and found that 70% of patients benefited from this therapy. They 
concluded that the use of this therapy might be beneficial in an early stage of the 
disease. Olanow (1992) suggests the use of dopamine agonists to minimise the 
levodopa dosage. In contrast, Ahlskog (1996) supports the notion that the early 
use of dopamine agonists should not be recommended. Because of their high 
cost, dopamine agonists can be reserved for patients with more advanced 
disease and motor fluctuations. The disadvantages of their use involve side 
effects (visual hallucinations and orthostatic hypotension) in elderly patients 
(Hermanowicz, 2001) and a reduced effectiveness over time when compared to 
levodopa.
There is general agreement that the most used and most effective agent 
for the treatment of dopamine deficiency in Parkinson’s disease is levodopa. 
Levodopa is not only widely used, but also its responsiveness to the motor 
symptomatology is considered as a part of the diagnosis of Parkinson’s disease 
(Koller. 2000). Levodopa is well tolerated by most patients, and its use tends to 
alleviate symptoms such as bradykinesia and rigidity while it has a variable effect
37
on tremor (Koller, 1992). It is the hallmark of pharmacological treatment in 
idiopathic Parkinson’s disease and it is considered effective for both long and 
short-term duration. Its short duration effect is more prominent with chronic 
therapy but some patients who are starting the therapy show an immediate 
improvement. The mortality rate of Parkinsonian patients has been reduced due 
to levodopa medication (Agid et al., 1999).
The premature decarboxylation (breakdown) of levodopa to dopamine by 
gastric enzymes might create side effects. These involve primarily nausea and 
postural hypotension and after a prolonged use, motor fluctuations (“on-off’) and 
dyskinesias. The initiation of carbidopa in early Parkinson’s disease hoped to 
counter nausea, to potentiate the effect of levodopa and to decrease the 
percentage of levodopa that needs to be orally administered by 75% (Ahlskog, 
1996; Nutt, Hummerstad, & Gancher, 1992; Oertel & Quinn, 1997). A 
combination of levodopa-carbidopa (Sinemet) has been used in North America 
while a combination of levodopa-benserazide (Madopar) has been used outside 
North America. Carbidopa and benserazide inhibit the dopa decarboxylase 
enzyme and so increase the effectiveness of levodopa (Hristova & Koller, 2000). 
Adding sodium, controlled-released levodopa (CR), and dopamine agonists may 
also help to improve postural hypotension, motor fluctuations, and dyskinesias, 
respectively (Koller, 2000).
Controlled-released combinations of levodopa continuously stimulate 
dopamine receptors and so lessen motor complications (Hristova & Koller, 2000). 
The advantages of controlled-released levodopa-carbidopa depend on the 
circumstances in which the drug is taken, but include the better absorption by an 
empty stomach and the minimization of nausea if the drug is given with meals
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(Pahwa & Koller, 1996). The doses should not be more than 300-400 mg/day 
split in three equal doses in the early stages of the disease.
Problems arise when clinicians aim to find the best treatment approach for 
Parkinsonian patients. It is still controversial among researchers if levodopa 
should be started early or late during the course of the disease. Even though 
levodopa is characterised as the gold standard for the medication of Parkinson’s 
disease, side effects after some years of its use make researchers seek for 
alternative treatments in the early Parkinson’s disease. Olanow (1992) suggests 
that levodopa should be an adjunct to selegiline and dopamine agonists when the 
clinical response is no longer satisfactory in the early treatment for Parkinson’s 
disease. However, there is no evidence that the delay of levodopa will also delay 
its adverse effects, namely motor fluctuations and dyskinesias (Koller, 1992). The 
appearance of motor fluctuations is the result not only of the postsynaptic 
changes that are caused by the long-term intermittent administration of levodopa 
but also from the lack of dopaminergic neurons in the brain that is increased with 
time (Agid et al., 1999). Questions have arisen about long-term levodopa use, 
and whether or not it could cause or accelerate cell death. It is now assumed that 
levodopa does not create or promote cell death in healthy people or Parkinsonian 
patients (Agid et al., 1999; Koller, 2000). Because further research is needed to 
prove that levodopa is not toxic to dopamine neurons over time, it is advisable to 
be used only by older patients (> 70 years), or, by patients less than 70 years old 
when symptoms are not controlled by other agents (Agid et al., 1999).
In conclusion, it is at the discretion of the clinical neurologist to decide if 
levodopa should be started early in the course of the disease, by weighing 
factors such as the clinical symptoms of the patient, patient’s needs, and the
39
neurologist’s personal experience. Other opinions favour the combination of 
levodopa-carbidopa as the best choice for initial treatment based on patients 
needs (Ahlskog, 1996; Hristova & Koller, 2000; Scientific American Magazine, 
1997; Wills, 1998). The use of drugs other than levodopa in the early treatment of 
Parkinson’s disease, such as selegiline (to help patients to stabilize the condition 
of the disease) and dopamine agonists (to help patients control motor 
fluctuations), has a less clear role during the first year of the disease (Ahlskog, 
1996). The opposite opinions follow a more “conservative” way by using 
dopamine agonists in the beginning of therapy and reserving levodopa until the 
disease progresses (Agid et al., 1999; Oertel & Quinn, 1997).
1.4.1 The effect of medication on dysarthria of Parkinson’s disease
Few studies have investigated the effect of medication on hypokinetic 
dysarthria of Parkinson’s disease. They are characterised by heterogeneity in 
terms of both the neurological stages of Parkinson’s disease in their subjects 
and their instrumentation. It is probably this heterogeneity that has given rise to 
conflicting results in these studies. Among them, the older studies showed a 
tendency for improvement of speech after levodopa treatment while the newer 
studies did not confirm these findings (Schulz & Grant, 2000).
Historically, the advent of the levodopa era in the late sixties led to studies 
that searched the effect of this new medication on speech and voice 
(perceptually and instrumentally). In the nineties, most of the studies used 
kinematics and seemed to give more emphasis on the force of the articulators 
during speech and non speech tasks. In addition, speech and voice were 
investigated under new drug combinations. Because the number of all studies
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that examined speech and voice before and after medication is rather small and 
because these studies involve different instrumentation and different drugs, a 
detailed description of them will follow.
Two fairly recent studies were found to investigate the effect of type B- 
MAO inhibitors (selegiline) on speech and voice. One study measured 40 
variables in respiration, phonation, resonance, articulation, and prosody in 10 
patients with a moderate disease (expressed by the stage 3 in Hoehn and Yahr 
scale) and a duration of disease of 6-12 years (Shea, Drummond, Metzer, & 
Krueger, 1993). The tasks involved diadochokinesis, sustained phonation, and 
reading. The variables that showed significant improved differences before and 
after selegiline treatment involved respiration (vital capacity), rate, and 
diadochokinesis (labial pursing during 5 consecutive ‘oo-ee’, 5 lingual 
protrusions and retractions, 5 lingual elevations and depressions, and 5 
diadochokinetic productions of ‘ka-ta’). The other study perceptually examined 
the speech and voice abnormalities of 12 non depressed and non demented 
patients with early Parkinson’s disease (the duration of disease ranged from 18 
months to 5 years and 10 months) before medication and after medication with 
Deprenyi (Stewart, et al., 1995). No improvement was found after medication. 
The results showed that all subjects exhibited at least two perceptual 
characteristics of mild dysarthria before and after medication. The 
inconsistencies in the results of these studies are probably due to the 
heterogeneity (different neurological stage and duration of disease) between 
their samples.
There are no studies to date, which have investigated the effect of 
anticholinergics on speech and voice of Parkinson’s disease. One report in the
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early eighties referred that anticholinergics do not seem to improve speech 
(Critchley, 1981). This is probably logical because their use aims to relieve limb 
tremor (Hermanowicz, 2001; Koller, 1992; Oertel & Quinn, 1997). If there were to 
be any effect of anticholinergics this would probably be on voice tremor.
Most of the studies that investigated the effect of medication on 
hypokinetic dysarthria used levodopa as a primary treatment in their subjects. 
Some of them took place in the early seventies and focused on the effect of 
dopatherapy on labial musculature, articulation timing, intelligibility, rate, and 
voice quality. The results of these studies showed an improvement after 
levodopa medication on lips, clarity of speech, articulation timing, voice quality, 
and pitch (Leanderson, Meyerson, & Persson, 1971; Mawdsley & Gamsu, 1971; 
Nakano, Zubick, & Tyler, 1973; Wolfe, Garvin, Bacon, & Waldrop, 1975). With 
the exception of two studies (Cahill et al., 1998; Gallena, Smith, Zeffiro, &
Ludlow, 2001), newer studies do not support these results (Daniels, Oates, 
Phyland, Feiglin, & Hughes, 1996; Gentil, Tournier, Perrin, & Poliak, 1998;
Gentil, Tournier, Poliak, & Benabid, 1999; Poluha, Teulings, & Brookshire, 1998). 
Metter and Hanson (1986) suggest a variable effect of levodopa on speech in 
one patient with Parkinson’s disease. When “o ff levodopa the patient showed a 
decrease in articulatory precision (shown in a worse intelligibility score), prosody, 
relative intensity, and a slower rate. In contrast, mean fundamental frequency 
and dysphonia did not show changes.
The studies that employed levodopa on labial movement gave conflicting 
results. Two earlier, and one recent study showed an improvement in labial 
movement (Cahill et al., 1998; Leanderson et al., 1971; Nakano et al., 1973) 
while two recent studies showed no difference after levodopa medication (Gentil
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et al., 1998; Gentil et al., 1999).
Leanderson et al. (1971) examined the effect of levodopa on labial 
musculature before and after medication using electromyography (EMG). Seven 
Parkinsonian patients with dysarthria produced VCV utterances. The results 
showed an improvement of speech in six patients when their recorded speech 
samples were compared before and after medication. The after medication 
results were accompanied by live facial expression, smooth and fast lip 
movements, the re-establishment of reciprocal muscular activation, and a 
reduction in muscle background activity.
Nakano et al. (1973) examined speech intelligibility and labial movement 
in 18 patients and in four conditions: no treatment, placebo, procyclidine 
hydrochloride, and levodopa. An intelligibility subtest was given before and after 
treatment and speech samples were recorded. The results showed an 
improvement in intelligibility and labial movement (11 out of 18 subjects) after the 
administration of levodopa and no significant improvement after the 
administration of procyclidine hydrochloride compared to placebo. The 
improvement of labial movement was manifested as a decreased latency 
between the initiation of labial movement and speech, with increased speed and 
symmetry.
Cahill et al. (1998) examined the effect of levodopa therapy on lip strength 
and endurance in 16 subjects with variable duration of disease, neurological 
stage, and age across the levodopa cycle. Lip pressures in non speech tasks 
involved maximum pressure and maximum sustained lip pressure (squeezing 
the lips for 7 seconds), fine lip pressure (standard deviation of pressure changes 
when the subject compressed the lips for 5 seconds at 50% of maximum lip
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pressure), repetitions of maximum lip pressure with a rate of one per second 
(mean pressure over 10 repetitions), and maximum rate of repetitive lip pressure 
(number of repetitions in 10 seconds). Lip pressures in speech tasks (2 
sentences measuring pressures of [ p ]) were recorded. All pressures were 
measured with a use of a pressure transducer. The results showed an increased 
performance of lip measures (maximum and maximum sustained lip pressure 
and fine lip pressure at 50% of maximum pressure) in non speech and speech 
tasks after 1.5 hour of medication.
Two studies measured the effect of dopatherapy alone (Gentil et al.,
1998) and dopatherapy as compared to subthalamic nucleus stimulation (Gentil 
et al., 1999) on intelligibility (Unified Parkinson Disease Rating Scale - 
UPDRRS), force finger, and force movements of the articulators (upper and 
lower lips and tongue). These studies used a pressure transducer during non 
speech tasks to record changes. The results of both studies showed no effect of 
dopatherapy on force of the articulators, while a significant result was found on 
force finger. The authors emphasised that the differences of the effect of 
medication on forefinger force as compared to no differences in the force of 
articulatory organs, might reflect that the orofacial system involve other 
mechanisms resulting from non dopaminergic lesions. However, further research 
is needed to verify this hypothesis for many reasons. First, the above studies 
employed subjects with moderate disease involvement and motor fluctuations. It 
is possible that after many years of treatment the orofacial system does not 
respond well to levodopa (as occurs in all mobility symptoms of Parkinson’s 
disease). Second, the scoring scale of intelligibility was not so sensitive to 
extract accurate measurement. Third, it is unknown if lip and tongue pressures
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as measured by a pressure transducer correlate with dysarthria characteristics in 
running speech.
One study (Wolfe et al., 1975) perceptually evaluated the speech and 
voice of 17 patients with different forms of Parkinsonism (7 patients with 
idiopathic Parkinson’s disease, 7 patients with postencephalitic Parkinsonism, 
and 3 patients with arteriosclerotic Parkinsonism). Articulation, voice quality, 
pitch variation (inflectional changes), and rate before and after levodopa 
administration were measured. Significant improvements after medication were 
found in voice quality, pitch variation, and articulation while no significant 
differences were found in the rate of speech, even though there was a tendency 
for the patients to speak faster after treatment. Voice quality was the most 
affected factor of mild to moderate dysarthria pre and post treatment with 
levodopa. A significant positive correlation of improvement in speech was also 
found when compared to the amount of improvement in physical findings. In the 
same study, another parameter that influenced the response to levodopa was 
the duration of the disease. Two patients that exhibited the greatest amount of 
improvement of speech had the disease for only one year. Both short-term and 
long-term levodopa treatment had a positive influence on speech and voice even 
though the number of patients who were examined on a long-term basis was too 
small (only 4 subjects), to permit generalisations.
Two studies emphasised the duration of phonation and the vocal 
characteristics of Parkinsonian patients after the administration of levodopa 
(Daniels et al., 1996; Mawdsley & Gamsu, 1971). Mawdsley and Gamsu (1971) 
examined the duration of phonation and the duration of pauses in 20 
Parkinsonian patients (16 patients with Parkinson’s disease) while the patients
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were counting from 1-10 in two conditions: before medication and after 
medication. The results showed no improvement in the rate of speech, but the 
production of each digit during counting took a shorter time after medication, and 
it was separated from the previous and next productions by lengthened pauses. 
The authors emphasised that this improvement occurred only in the patients with 
idiopathic Parkinson’s disease and not in the other four postencephalitic 
Parkinsonian patients.
Daniels et al. (1996) did not find any perceptual or acoustic differences in 
intensity, variability of fundamental frequency and intensity, whisperiness and 
harshness in 30 subjects with idiopathic Parkinson’s disease while sustaining an 
[ a ] and while conversing for 30 seconds. All subjects exhibited dysphonia and 
motor fluctuations. Even though the authors conclude that vocal dysfunction is 
probably not related to nigrostriatal dopamine deficiency their results may be 
caused by the non response of dopatherapy to voice symptomatology due to 
advanced state of the disease (existence of motor fluctuations).
Finally, one study used electromyography (EMG) to examine voice onset 
and offset after levodopa therapy in Parkinsonian patients not previously 
medicated (Gallena et al., 2001). The results showed a beneficial effect of 
levodopa after therapy. Before medication, laryngeal bowing of the vocal folds 
was associated with increased activity of thyroarytenoid muscle (TA) and 
cricothyroid muscle (CT) to a lesser degree, but the reverse was found after 
levodopa treatment. The activity of thyroarytenoid decreased and breathiness 
and speech improved (measured perceptually). In normal voicing the combined 
contraction of TA and CT is to increase pitch while TA shortens vocal folds and 
closes the vestibule of larynx, and CT stretches vocal folds. The results of this
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study confirm that vocal fold bowing is a manifestation of rigidity. However, the 
amount of levodopa that was given to the untreated patients was too high (250- 
300 mg) for patients who were not previously treated with levodopa. It is possible 
that this higher amount of levodopa decreased the laryngeal muscles’ activity. In 
early Parkinson’s disease the insertion of levodopa follows a consistent way 
starting with smaller doses (100 mg). It is not known what the results on muscle 
activity would be if smaller doses would be given. However, this assumption 
does not preclude the fact that levodopa produced a beneficial effect on voicing 
in this study.
Problems in speech and voice after chronic use of levodopa have been 
reported. Marsden and Parkes (1976) reported “on-off effects in 15-40% of 
patients with Parkinson’s disease treated with levodopa medication for 2-3 years. 
These effects were defined as fluctuations of activity and they occurred 
sometimes more than 3 times per day. Clinical observations of “on-off effects 
showed early-morning akinesia, freezing episodes (i.e., a sudden immobility 
during a difficult task), end-of-dose deterioration, peak dose dyskinesia 
(hyperkinetic involuntary movement as in tic or spasm) which was accompanied 
by oromandibular dystonia (sustained muscle contractions causing twisting and 
repetitive movement or abnormal postures) often causing difficulties in speaking 
or swallowing and peak dose akinesia. In contrast, Critchley (1976) reports the 
appearance of dysphonias or aphonias with simultaneous peak-dose akinesia. 
The akinesia and dysphonia, although rare, were associated with the 
disappearance of rigidity and tremor at the peak of levodopa action. Duffy (1995) 
states that the side effects of anti-Parkinsonian medication involve dystonia, 
dyskinesias, confusion, and symptom fluctuations during a dosage cycle.
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According to him. the “on-off’ effects may determine the appearance of 
hyperkinetic dysarthria or the deterioration of hypokinetic dysarthria.
The so-called “Yo-Yo-ing” effect happens when the above effects occur 
many times during the day. During this state, the voice becomes soft, the speech 
becomes unintelligible, walking and standing become impossible. The symptoms 
may occur for a few seconds or minutes and thereafter disappear. “Yo-Yo-ing” is 
characterised by unpredictability, occurs after 1-3 years of levodopa treatment 
and seems unrelated to the time of dosage. Also, it occurs in patients who have 
achieved a good response to treatment and it is not treated successfully. “Yo-Yo­
ing” may be due to excessive levodopa dosage and/or progression of the 
disease (Marsden & Parkes, 1976). The influence of levodopa on speech and 
voice denotes the key role of neurotransmitter substances (it is already known 
that levodopa replaces the neurotransmitter dopamine) to speech and voice 
(Critchley, 1981).
Most of the studies examining the effects of levodopa treatment on 
dysarthria are characterised not only by different use of instrumentation but also 
by a variable duration of disease and neurological stage among their patients. 
This may be a confounding factor for the investigation of the effect of 
dopatherapy on speech and voice because the motor fluctuations may determine 
the effect to therapy. The existence of motor fluctuations is an unexplained 
phenomenon. They may be caused by both chronic levodopa use and 
dopaminergic cell loss due to the progression of the disease. In order to draw 
conclusions about the effect of medication on speech and voice, the existence of 
homogeneous populations in neurological stage and duration of disease is 
needed. The present study aims to accomplish this purpose by investigating
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dysarthria in subjects only recently diagnosed with idiopathic Parkinson’s 
disease (Hoehn and Yahr stage I).
1.5 Perceptual and acoustic studies of hypokinetic dysarthria
in the past, the identification of different types of dysarthria was based 
primarily on perception. Today, perceptual methods are still the primary 
tool in the assessment of motor speech disorders, but are followed by acoustic 
methods. However, inconsistencies have arisen after attempts to classify 
dysarthria using different methods (perceptual, neurological, or site of lesion). 
Netsell (1986) supports the notion that case studies with highly restricted, well- 
documented lesions to pathways or modules of the speech motor system may 
be more effective in connecting different types of dysarthria with an associated 
lesion. In the present study, a review of the literature in hypokinetic dysarthria 
that was diagnosed with either perceptual or acoustic methods, or both, will be 
given.
1.5.1 Prominent perceptual studies of hypokinetic dysarthria
Before a description of prominent perceptual studies in Parkinson’s 
disease will take place, it is noteworthy to mention the work by Laver (1980). He 
was the first to attempt to emphasise the importance of phonetic description of 
voice quality (Green & Mathieson, 1997; Wirz & Beck, 1995). For Laver (1980) 
the study of phonetic components of voice quality is related to the study of 
spoken language. In contrast to other researchers, he conceived voice quality in 
a broad sense to mean the characteristic auditory colouring of an individual 
speaker’s voice. He classified phonation types (harsh, whispery, breathy, creaky,
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falsetto and modal) and gave tension ratings in the positions of labial, 
mandibular, lingual, velopharyngeal and laryngeal structures. The so-called 
Vocal Profile Analysis (VPAS) (Laver, 1991) was important to show the variety of 
vocal qualities and phonetic gestures possible, and it is a useful indicator of 
vocal features of dysphonia (Greene & Mathieson, 1997).
Laver’s work is more holistic than other methods of perceptual 
assessment of voice (Buffalo Profile of Voice Disorder, Missouri Profile of Voice 
Disorder, and GRBAS). It includes factors such as replicability, interjudge 
reliability and unambiguous definitions of to what constitutes voice (Wirz & Beck, 
1995). The contribution of the whole vocal apparatus to voice quality, the 
comparison of all vocal features with a specified neutral baseline and the overall 
impression of voice quality as derived by various potentially independent 
components make his work different from other perceptual schemes of voice 
assessment (Wirz & Beck, 1995). According to Kent (1997), Laver’s approach 
may be suitable for the description of quality impairments in motor speech 
disorders.
In neurological disorders, perceptual studies were the first to describe 
dysarthria and voice symptomatology. The perceptual studies by Darley and his 
colleagues in the late sixties and seventies (Darley et al., 1969a, 1969b, 1975). 
The perceptual studies by Darley and his colleagues in the late sixties and 
seventies (Darley et al., 1969a, 1969b, 1975) are used as a reference in any 
current study of dysarthria. As a result of their work, distinctive patterns of 
dysarthria were established and associated with each neurological disorder. 
Darley et al. (1969a) perceptually rated patients (N = 212) on seven neurological 
disorders in a number of dimensions of speech and voice, using a 7 point scale
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of severity (from 1 = normal to 7 = very severe). Figure 4 below shows the 
speech characteristics and their dimensions on which patients were rated.
SPEECH CHARACTERISTICS DIMENSIONS
Pitch Pitch level, pitch breaks, monopitch, voice 
. tremor.
Loudness Monoloudness, excess loudness variation, 
loudness decay, alternating loudness, 
loudness level (overall).
Vocal quality Harsh voice, hoarse (wet) voice, breathy 
voice (continuous), breathy voice (transient), 
strained-strangled voice, voice stoppages, 
hypernasality, hyponasality, nasal emission.
Respiration Forced inspiration-expiration, audible 
inspiration, grunt at end of expiration.
Prosody Rate, phrases short, increase of rate in 
segments, increase of rate overall, reduced 
stress, variable rate, intervals prolonged, 
inappropriate silences, short rushes of 
speech, excess and equal stress.
Articulation Imprecise consonants, phonemes prolonged, 
phonemes repeated, irregular articulatory 
breakdown, vowels distorted
General Impressions Intelligibility, bizareness
Figure 4. Perceptual speech characteristics and speech dimensions 
(Darley et al., 1969a).
Detailed definitions of the most important dimensions are given in Appendix A. 
Appendix A also includes medical and other terms that were judged necessary to 
be defined. A review of prominent perceptual studies of hypokinetic dysarthria 
follows.
In Darley et al. (1969a), the speech characteristics that were found to be 
more deviant in Parkinsonism were, in order of severity (from most severe to
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least severe): monopitch, reduced stress, monoloudness, imprecise consonants, 
inappropriate silences, short rushes, harsh voice, breathy voice (continuous), low 
pitch, and variable rate. The combination of monopitch, reduced stress, and 
monoloudness according to the authors presented the most striking 
phenomenon in Parkinsonism. The researchers also reported that the alternating 
speech movements in the Parkinsonian group were reduced in range and tended 
to become progressively smaller even though at times they were perceived as 
slow. The imprecise consonants were considered to be the result of reduced 
excursion of the articulators, rather than the variability of the rate. Moreover, 
imprecise consonants showed the highest correlation with intelligibility (0.91) 
followed by short rushes cff speech (0.79) and reduced stress (0.78) while 
monoloudness showed an even lower correlation (0.60) with intelligibility.
Darley et al. (1969b) correlated the 10 prominent deviant dimensions of 
each neurological group in order to find possible “clusters". The results for 
Parkinsonism showed one distinctive cluster. The authors named this cluster 
“prosodic insufficiency” and they hypothesised that it was again due to the 
reduced range of movements, a characteristic of Parkinsonism. This cluster 
involved:
• Monopitch
• Monoloudness
• Reduced stress 
and extended to include
• Short rushes of speech
• Variable rate
• Imprecise consonants.
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The authors reported that the extent of this cluster was unique to Parkinsonism 
when compared to the other neurological groups and it reflected its 
neuromuscular quality (the fast repetitive movements of restricted range). In 
addition, while single movements as in a sustained [ a ] tend to be slow, the 
repetitive movements as in [ pa ] produced at a fast rate tend to be either slow or 
abnormally fast, with a very limited range. Decay of loudness or decreased 
loudness were dimensions that were found only in Parkinsonism compared to 
the other neurological disorders and were not correlated with the above- 
mentioned cluster. In general, Darley et al. (1975) emphasise that respiratory, 
phonatory, and articulatory muscles are limited in excursion and produce 
prosodic dysfunction, the Most prominent feature of hypokinetic dysarthria.
Recently, Duffy (1995) reviewed the perceptually distinguishing speech, 
speech-related findings, and oral-mechanism findings in hypokinetic dysarthria. 
Duffy added dimensions, such as physical characteristics and patients’ 
complaints to the overall description of hypokinetic dysarthria. Figure 5 below, 
shows his work.
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Phonatory-Respiratory Reduced loudness.
Articulatory Repeated phonemes, palilalia, rapid or “blurred" 
alternating motion rates (AMRs).
Prosodic Reduced stress, monopitch, monoloudness, 
inappropriate silences, short rushes of speech, 
variable rate, increased rate in segments, increased 
overall rate.
Physical Masked facial expression, tremulous jaw, lip, 
tongue, reduced rate of motion in AMR tasks, head 
tremor.
Patient complaints Reduced loudness, rapid rate, "mumbling", 
“stuttering", difficulty initiating speech, stiff lips.
Figure 5. Primary speech and speech-related findings in hypokinetic dysarthria
(Duffy, 1995).
Similar results to the results of the studies by Darley et al. (1969a, 1969b) 
have been reported (Chenery, Murdoch, & Ingram, 1988; Logemann et al.,
1978). Aronson (1990) reports that reduced loudness and breathy voice quality 
might be early signs of hypokinetic dysarthria. In contrast, Critchley (1981) 
supports the notion that the initial defect in the untreated Parkinsonian patient 
involves an inability to control respiration for speech that progresses to include 
phonation and articulation. Chenery et al. reported the prominence of 
abnormalities in phonation followed by respiration and articulation in the context 
of reading a passage. Imprecise articulation accounted for approximately 85% of 
the variance in overall intelligibility while loudness variation contributed 10%. The 
results of the Frenchay Dysarthria Assessment (FDA) in the study by Chenery et 
al. showed similar patterns. Larynx, tongue mobility, and mild disturbances in the 
movement of lips and jaw were found in a descending order of severity (most 
severe to less severe). However, no information about the duration of the
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disease was reported in this study.
Because of the size of its sample, the study by Logemann et ai. (1978) 
occupies a special position in the research of dysarthria in Parkinsonism. The 
authors examined the frequency and the patterns of vocal tract dysfunction in 
200 Parkinsonian patients (idiopathic or postencephalitic) in all five stages of the 
disease. All patients were withdrawn from medication for 2 weeks or they were 
newly diagnosed. The patients read the sentence version of the Fisher- 
Logemann test of articulation competence and conversed for 3-5 minutes. 
Speech samples were recorded and were listened to by 2 trained listeners for 
rate, voice, resonance, and articulation disorders. Laryngeal disorders 
(breathiness, roughness, hoarseness, and tremulousness) were found in 89% of 
the patients, followed by articulation disorders (lingual, labial, or both) that were 
found in 45% of the patients. Disturbed rate and disturbances of resonance 
(hypernasality) were found in 20% and 10% of the patients, respectively. 
According to the authors, the typical Parkinsonian patient is highly like to have 
impaired voice quality and an articulation disorder. Further analysis of the co­
occurrence of vocal tract dysfunction showed that 45% of the patients showed 
laryngeal dysfunction without articulatory errors while the remaining showed 
laryngeal dysfunction together with articulatory errors. In this study, no analysis 
took place of the speech/voice abnormalities and neurological stage of 
Parkinson’s disease.
1.5.2 Studies examining respiration
Physiological measurements of respiratory parameters that did not involve 
speech showed that the respiratory dysfunction in Parkinson's disease (PD)
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becomes evident after neurological stage 3 in Hoehn and Yahr scale (De Pandis 
et al., 2002; Hovestadt, Bogaard, Meerwaldt, Meché, & Stigt, 1989). In fact, the 
major inclusion criterion in these studies was the existence of at least stage 3 in 
Hoehn and Yahr scale. Respiratory dysfunction is considered asymptomatic or at 
least infrequent in early Parkinson's disease (Shill & Stacy, 1998).
Studies that measure respiration on speech tasks showed the same trend 
including Parkinsonian subjects with either a disease duration of more than 5 
years (Lethlean, Chenery, & Murdoch, 1990) or at least stage 3 in Hoehn and 
Yahr scale (Murdoch, Chenery, Bowler, & Ingram, 1989; Solomon & Hixon,
1993).
Murdoch et al. (1989) report task specific respiratory abnormalities. 
Irregularities that were found in chest wall movements during vowel prolongation 
and syllable repetition were not shown in reading and conversation. Also, a 
greater breathing rate and minute ventilation was found in Parkinsonian subjects 
as compared to the controls as well as small rib cage volumes and abnormally 
large abdominal volumes at the initiation of speech (Solomon & Hixon, 1993).
The rigidity of the respiratory muscles was suggested as the primary cause of 
respiratory abnormalities (Duffy, 1995; Murdoch et al., 1989) and was followed 
by hypokinesia and difficulty initiating speech movements (Duffy, 1995).
The findings of the above studies may be confounded by the involvement 
of subjects in advanced neurological stage of the disease and by the effect of 
motor complications that take place at this stage. Individual variation among 
subjects in respiratory features (Theodoros & Murdoch, 1998) may also be a 
confounding factor in the explanation of the results. Accordingly, Duffy (1995) 
reports that the contribution of certain breathing abnormalities (reduced vital
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capacity, reduced amplitude of chest wall movements, irregularities in breathing 
patterns and increased respiratory rates) to speech of Parkinson’s disease is not 
clear.
In conclusion, it appears that respiration for speech/voice is not affected 
at the beginning of Parkinson’s disease (PD). The existence of phonatory 
problems in early PD is probably not due to respiratory abnormalities. This is 
supported by findings where tracheal pressure was found normal between PD 
and control subjects while the oral pressure in the PD subjects was smaller 
(Solomon & Hixon, 1993). Also, this fact is supported by the absence of studies 
that measure the effect of respiration on speech in early PD and by the existence 
of studies that show respiratory problems in advanced neurological stages of the 
disease (De Pandis et al., 2002; Hovestadt et al., 1989).
1.5.3 Studies examining phonation
It is without doubt that the phonatory system in hypokinetic dysarthria is 
being affected by the process of the disease. Perceptual studies have 
investigated vocal quality, pitch, and loudness, while acoustic studies have 
investigated the correlates of maximum sustained phonation time, fundamental 
frequency and intensity. More specifically, in acoustic studies, average 
fundamental frequency, standard deviation of fundamental frequency, jitter and 
shimmer have been employed to correlate with vocal quality. Different aspects of 
fundamental frequency and intensity have also been used during reading and 
monologue/conversation. Because the present study uses a different type of 
instrumentation (electrolaryngography) and a limited number of 
electrolaryngographic studies in hypokinetic dysarthria exist, an overview of
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acoustic studies that focused on all of the above measures will be presented 
here. A review of electrolaryngographic studies on hypokinetic dysarthria will 
follow in the next section. Finally, other physiological studies on hypokinetic 
dysarthria will be used in the literature review but their reference in the current 
study will not be exhaustive.
Although Darley et al. (1975) did not report hoarseness to be a deviant 
speech dimension, other perceptual studies emphasise its existence in a range 
of 33-100% of their sample (Chenery et al., 1988; Logemann et al., 1978; Ludlow 
& Bassich, 1984). Harshness has been found in 77-84% of their sample 
(Chenery et al., 1988; Ludlow & Bassich, 1984; Zwirner & Barnes, 1992). Some 
studies have found breathiness to occur in 50-95% of hypokinetic dysarthric 
speakers (Chenery et al., 1988; Zwirner & Barnes, 1992) or being double 
compared to normal controls (Ludlow & Bassich, 1983), while others have found 
it to a lesser degree (Logemann et al., 1978; Ludlow & Bassich, 1984).
Levodopa medication may play a role in the variable incidence rates of 
breathiness among subjects (the subjects' voices are becoming closer to 
hyperkinetic) but this is a hypothesis that needs to be tested (Adams, 1997; 
Ludlow & Bassich, 1984). Glottal fry and vocal tremor (as a manifestation of 
deficits in pitch steadiness) have been perceived in 68% of cases (Chenery et 
al., 1988). However, Holmes, Oates, Phyland, and Hughes (2000) perceived 
tremor as a feature of late disease rather than early Parkinson’s disease.
Acoustic evidence seems to support the perception of impairment of vocal 
quality in hypokinetic dysarthria. Vocal quality has been investigated through 
sustained phonation that is frequently used in order to minimise the effects of 
articulatory adjustments and to isolate the phonatory system (Zwirner, IVIurry, &
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Woodson, 1991). Reduced duration in sustained phonation time has been found 
in Parkinsonian patients due to phonatory inefficiency and disturbed vocal quality 
(Canter, 1965a; Ludlow & Bassich, 1983). Increased average fundamental 
frequency has been found in some studies (Gamboa et al., 1997; Hertrich & 
Ackermann, 1995; Ludlow & Bassich, 1983; Ludlow, Coulter, & Gentges, 1983; 
Ramig, Scherer, Titze, & Ringel, 1988) while no significant differences were 
found in one study (Kent et al., 1994). Two of these studies (Hertrich & 
Ackermann, 1995; Gamboa et al., 1997) found the increased mean fundamental 
frequency only in the male subgroup of Parkinsonian patients compared to 
controls. The different findings in the study by Kent et al. may be due to the fact 
that no matching in age and duration of disease occurred in his Parkinsonian 
subjects compared to control subjects.
Standard deviation of fundamental frequency (SDFo) is used to evaluate 
phonatory stability in hypokinetic dysarthria (Zwirner & Barnes, 1992). SDFo has 
been proposed in studies that investigated normal voicing and ageing as a better 
predictor of vocal age (Linville, 2000). It has been used as a better approach to 
fundamental frequency range to measure the average distance of values from 
the mean as an index of variability (Baken, 1997). SDFo as a measure of a long 
term phonatory instability (differentiated from jitter and shimmer as measures of 
short term phonatory instability) has been found to increase (Zwirner & Barnes, 
1992; Zwirner et al., 1991). However, no statistical significance was found in 
these studies.
Perceptually, the pitch in hypokinetic dysarthria has been reported to be 
monotonous and the pitch range (variability) restricted with more limited pitch 
inflections (Darley et al., 1969a, 1969b, 1975; Gentil & Poliak, 1995). Acoustic
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evidence supports the perceptual impressions. In reading and monologue, 
increased mean fundamental frequency has been found in the Parkinsonian 
patients (Canter, 1963; Holmes et al., 2000; Ludlow & Bassich, 1983, 1984). 
Holmes et al. report that increased mean fundamental frequency is attributed to 
the late stage of the disease while no differences were found in patients with 
early Parkinson’s disease compared to controls.
Duffy (1995) discusses the discrepancy on pitch between perceptual and 
acoustic studies. The perceived pitch in the study by Darley et al. (1969a) was 
reported to be low while the aforementioned acoustic studies found a higher 
fundamental frequency. According to Duffy, this discrepancy may reflect 
intersubject variability among these studies or the insensitivity of mean 
fundamental frequency itself (not in combination with other measures) to 
distinguish features of hypokinetic dysarthria. Other factors may also contribute 
to these discrepancies.
One such factor is the issue of gender differences. Gender differences in 
relation to perceived pitch have also been reported to normal voice production 
(Baken, 1997; Beck, 1997; Green & Mathieson, 1997; Linville, 2000). In the ages 
60-69 (where between the mean age of appearance of Parkinson’s disease 
occur) the average speaking fundamental frequency in normal voice production 
during reading in males is 112 Hz (Baken, 1997; Greene & Mathieson, 1997) 
while in females is 199 Hz (see a summary of relevant studies in Baken, 1997).
Beck (1997) supports the notion that average fundamental frequency (Fo) 
lowers during the life span (from childhood to adulthood) but in a different way 
for the two sexes. Different patterns of physiological changes seem to be the 
cause of these sex differences. Furthermore, considerable individual variation
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exists.
In females, there is a slight drop in fundamental frequency in older people. 
A possible cause of this drop may be a generalised loss of muscle tone, 
ossification of laryngeal cartilages and hormonal changes. Hormonal changes 
are the possible reason that women may show a rise in fundamental frequency 
around the age of 50 years and a drop thereafter (Green & Mathieson, 1997; 
Linville, 2000).
In contrast, fundamental frequency and age in males do not have a 
straightforward relationship. A slight increase in fundamental frequency after the 
sixth decade of life has been reported, reaching the highest level by the age of 
85+ (Linville, 2000), and is due to possible stiffness of the vocal folds (Beck,
1997; Linville, 2000). Anatomical changes in an increased rate than in females 
occur in older males due to ossification and calcification of cartilages, erosion of 
joint surfaces and thinning of the lamina propria (Linville, 2000).
Three studies showed gender specific differences where the male 
Parkinsonian subjects exhibited increased mean fundamental frequency while 
the female subjects did not compared to controls (Gamboa et al., 1997; Hertrich 
& Ackermann, 1995; Kent et al., 1994). However, these results do not seem to 
be consistent (no statistical significance was reached in Kent et al. study). 
Hertrich and Ackermann (1995) discuss that the gender differences in their study 
may be the result of age in the male subjects (mean fundamental frequency was 
correlated with age). Along the same lines. Holmes et al. (2000) report that the 
mean speaking fundamental frequency was associated with advanced age in the 
male group of Parkinsonian subjects with early Parkinson's disease compared to 
controls.
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A restricted variability of fundamental frequency (Fo range) has also been 
found (Canter, 1963; Gamboa et al., 1997; Ludlow & Bassich, 1983, 1984). In 
range, Canter (1965a) reported the same results in Parkinsonian subjects 
compared to controls while they were singing the word [ no ] at lowest and 
highest pitches. Using the same technique as Canter, fundamental frequency 
range (Fo range) as difference in Hz, of an ascending [ a ] production (between 
low and high points divided by the mean fundamental frequency) was found to 
be restricted in the Parkinsonian patients (Ludlow & Bassich, 1983, 1984). The 
standard deviation of fundamental frequency (SDFo) has been found to 
decrease in a male Parkinsonian subgroup (Gamboa et al., 1997) and in a 
female subgroup with late'Parkinson’s disease (Holmes et al., 2000). Metter and 
Hanson (1986) found an inverse relation of fundamental frequency variability 
(expressed as a ratio of the mean standard deviation of fundamental frequency 
divided by the mean fundamental frequency) to dysarthria severity and clinical 
disability. In other words, as dysarthria severity increased the fundamental 
frequency variability decreased. Ludlow and Bassich (1984) found a relationship 
between monopitch (perceptual measure) and reduced Fo range as measured 
acoustically on the pitch glide task (low to high pitch glide on [ a ]). They 
suggested that the pitch glide task is a valid assessment for monopitch.
In the measurement of “pitch range” in a voice many factors need to be 
taken into consideration that may limit the application of the results in a study. 
These include age, gender, race, muscle misuse, personality differences and 
psychosocial or linguistic code of the person. Some or all of these factors may 
interact to confound the diagnosis of a voice disorder (Baken, 1997; Rammage, 
Morrison, & Nichol, 2001). Linville (2000) suggests that the restricted maximum
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phonational range in normal voice production is attributed in older women only 
while in men not. However, she admits that this is a contradictory issue among 
researchers. Factors such as personality differences and psychosocial 
differences among the Parkinsonian subjects and their pair matched controls 
may be limiting factors in the interpretation of the results. For example, 
psychosocial conflicts and not the neurological disorder itself (Parkinson’s 
disease) may determine a narrow pitch range. Finally, speaking fundamental 
frequency range is based statistically on extremes and a single instance of a 
high frequency can determine the upper limit of the range of observed 
fundamental frequencies even though this might be a momentary “slip of the 
larynx” (Baken, 1997). The non existence of norms in the Greek language in 
fundamental frequency range is a limiting factor to the interpretation of the 
results in the present study. More research is needed to clarify these limiting 
factors. However, the present study is a first attempt to describe dysarthria and 
more specifically phonation in a Greek sample at the beginning of Parkinson’s 
disease.
Paralinguistic, sociolinguistic, and extralinguistic factors may also play a 
role in the measurement of voice (Beck, 1997). Paralinguistic aspects of voice 
source variation signal a speaker’s mood, emotion and attitude to the listener. 
The sociolinguistic function of voice source variation differentiates voice quality 
among linguistic, regional and social groups. Finally, extralinguistic factors such 
as size and shape of the laryngeal structures and physical and mental health 
may show variation in the voice source that may be reflected in changes in 
fundamental frequency, intensity and quotients. Although some care was taken 
to control some of these factors (appearance of dementia and matching of
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groups in age, gender, and education), no systematic manipulation of the other 
factors has been taken.
Baken (1997) supports the use of jitter or frequency perturbation (a 
measure of variability of fundamental frequency or how a period differs from the 
period that immediately follows it) to show variability of the fundamental period in 
the evaluation of laryngeal and vocal pathologies. Although jitter cannot be used 
as a sole diagnostic criterion, it is a sensitive measure for pathological changes 
in the phonatory mechanism (Baken, 1997). Jitter was found to elevate 
(statistically and not statistically) in Parkinsonian subjects compared to controls 
in some studies (Gamboa et al., 1997; Hertrich & Ackermann, 1995; Holmes et 
al., 2000; Kent et al., 1994; Ramig et al., 1988; Zwirner et al., 1991). One study 
showed a decrease in jitter in the Parkinsonian patients but not statistical 
significance was reached (Ludlow et al., 1983). The statistically significant 
increased jitter measure was found in three studies (Gamboa et al., 1997; 
Hertrich & Ackermann, 1995; Zwirner et al., 1991). Holmes et al. report that 
increased jitter is attributed to the late stage of the disease while no differences 
were found in Parkinsonian subjects with early disease compared to controls. 
The latter conclusion seems logical in the light of studies that report an increased 
jitter and shimmer in aged voices (Linville, 2000) evôn though other factors such 
as the general state of health and fitness may also play a role (Colton & Casper, 
1996; Linville, 2000; Ramig & Ringel, 1983).
A number of numerical indices of jitter have been proposed (see a 
relevant discussion by Baken, 1997). Absolute measures (perturbation factor 
and directional perturbation factor) and frequency related measures (period 
variability index, relative average perturbation, and deviation from linear trend)
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have been used. Most of the studies that measure jitter in Parkinson’s disease 
use the relative average perturbation measurement (Koike’s algorithm) that is 
derived from the acoustic signal of the CSL speech software (Hertrich & 
Ackermann, 1995; Holmes et al., 2000; Gamboa et al., 1997). Differences in 
measurement of jitter in the present study compared to the aforementioned 
studies exist. In the present study a fundamental frequency cycle by cycle 
analysis is derived from the Lx waveform comparing directly the periodic 
structure of the wave (Howard, 1998) (see a relevant discussion of the rationale 
for the level of precision of this type of measurement in Titze, Horii, and Scherer, 
1987).
Shimmer or intensity perturbation (summation of absolute differences in 
consecutive period amplitudes divided by the number of periods minus one), was 
found to elevate (not statistical significance) in a group of Parkinsonian patients 
(Gamboa et al., 1997; Holmes et al., 2000; Ramig et al., 1988) or in a female 
subgroup of Parkinsonian patients (statistical significance) compared to controls 
(Kent et al., 1994). Finally, one study found that increased shimmer was 
correlated with breathiness (Ludlow & Bassich, 1984). This finding probably 
reflects the bowing of the vocal folds. In hypokinetic dysarthria, the bowing of the 
vocal folds may result in “greater airflow turbulence and, therefore, more 
variation in intensity between periods” (Ludlow & Bassich, 1984, p. 187). The 
relationship between breathiness (perceptual measure) and shimmer was a valid 
procedure for intensity variation for speech (Ludlow & Bassich, 1984).
The measurements of shimmer are done in the same way as the 
measurements of jitter. However, in contrast to jitter, its data are obtained from 
the maximal peak-to-trough amplitudes of the individual waves. Shimmer
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measurements include directional perturbation factor, amplitude variability index, 
shimmer in dB and amplitude perturbation quotient. Some of the studies in 
Parkinson’s disease use shimmer in dB (Horii’s algorithm) that is derived from 
the acoustic signal of the CSL speech software (Holmes et al., 2000; Gamboa et 
al., 1997). Alternatively, Ludlow and Bassich (1984) use the deviation from the 
linear trend in amplitude measurement which again is analogous to the same 
method from which jitter is derived. Shimmer in the present study was derived 
from the corresponding to the Lx signal speech signal using the Gold-Rabiner 
algorithm and the cepstrum analysis (Howard, 1998).
Perceptually determined, impairment of vocal loudness has been reported 
by Parkinsonian patients to be a frequent symptom of phonation (Duffy, 1995; 
Ludlow & Bassich, 1984; Schulz & Grant, 2000). Reduced loudness range 
(variability) is also a frequent perceptual feature (Gentil & Poliak, 1995). As a 
correlate to vocal loudness, average speech intensity was not found to be 
impaired in different studies (Canter, 1963; Ludlow & Bassich, 1984; Metter & 
Hanson, 1986). However, when Parkinsonian patients were asked to produce 
intensity in different levels (quiet, average, loud, and shout) during the production 
of the word [ no ], significant differences in mean intensity were found in the loud 
and shouted conditions (Canter, 1965a), and in the mean intensity that was 
driven from the final word of six sentences (Ludlow & Bassich, 1983). Finally, a 
reduced intensity range (difference between peak sound pressure level on shout 
production minus that on soft production in [a ]  and [ no ]) has been reported in 
patients with hypokinetic dysarthria (Ludlow & Bassich, 1983, 1984).
In reading and monologue, no differences were found in mean intensity 
(Canter, 1963; Holmes et al., 2000) and intensity range (Canter, 1963).
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However, the standard deviation of intensity has been found to increase in 
controls as compared to Parkinsonian subjects (Gamboa et a!., 1997) while no 
difference was found in early duration of disease Parkinsonian patients 
compared to late duration of disease patients (Holmes et al., 2000).
Special attention should be given to one fairly recent study that measured 
phonatory ability in Parkinsonian patients in early disease (mean duration 2.4 
years), late disease (mean duration 13.2 years), and controls (Holmes et al., 
2000). The authors reported that the progression of the disease is accompanied 
by the progression in severity of its phonatory features. No significant differences 
were found in the Parkinsonian group with early Parkinson's disease compared 
to controls. In contrast, spëaking fundamental frequency in monologue, standard 
deviation of fundamental frequency, jitter and shimmer in sustained phonation 
were found to be significant in patients with late Parkinson’s disease compared 
to controls. No information about matching in age between the groups is a major 
disadvantage of this study.
Fox and Ramig (1997) suggested that the sound pressure level (SPL) 
should be evaluated in a variety of tasks including maximum phonation time, 
reading, monologue, and picture description. Their results showed that SPL was 
significantly lower (2-4 dB SPL) in the Parkinsonian patients compared to 
controls in all tasks. Impaired laryngeal functioning of vocal fold adduction rather 
than of respiratory effort is probably the cause of the significant differences, 
which were found between the groups in SPL (Fox & Ramig, 1997). 
Electromyographic evidence supports the latter assumption. One study 
examined the activity of the thyroarytenoid muscle during sustained phonation, 
reading, and conversation (Baker, Ramig, Luschei, & Smith, 1998) in three
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groups of subjects (one Parkinsonian and two controls). Under 
laryngostroboscopic examination, the Parkinsonian group exhibited reduced 
loudness, breathiness, and vocal fold incompetence. The electromyographic 
results showed that the Parkinsonian group exhibited the lowest amplitude of 
thyroarytenoid activity compared to the other groups. Although an acoustic 
analysis also took place, no significant results among groups were found. The 
authors supported the notion that these findings are associated with the 
neurological symptom of bradykinesia and the voice symptom of hypophonia. 
However, no information was given about probable motor fluctuations in the 
Parkinsonian subjects since the duration of the disease post onset was 4-5 years 
and the neurological stagë in Hoehn and Yahr scale was 3-4.
Recently, other researchers examined the hypothesis that the reduced 
loudness of patients' speech and voice is attributed to a sensory processing 
deficit (Dromey & Adams, 2000; Ho, lansek, & Bradshaw, 1999). In other words, 
when patients speak with a soft voice or reduced loudness it is because they 
perceive their voice to be at a normal level. The results of both studies showed 
no deficit in perception (at least at a severe level). Dromey and Adams (2000) 
hypothesised that the existence of no differences in their study may be caused 
by the insensitivity of their task (sustained phonation). Ho et al. (1999) 
hypothesised that the speech amplitude of Parkinsonian patients is preset lower 
due to a reduction of set production in basal ganglia. So, although their patients 
could regulate volume during different distances as well as their matched 
controls, their volume in conversation was lower than the controls. According to 
the authors, these results in voice volume mimic the symptoms of limb 
movement in Parkinson's disease (the relation of stride length and stepping rate
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stays the same but the stride length is smaller).
The reported variability of speech and voice symptomatology in 
Parkinson’s disease is the result of different instrumentation and tasks among 
studies and a differential selection of subjects (Kent et al., 1994). Factors such 
as duration of disease and neurological stage were not consistent in most of the 
studies (an exception to this fact was the study by Holmes et al., 2000). Kent et 
al. suggest that a careful choice of matching variables such as age and gender 
(between Parkinsonian groups and controls) and a similar neurological stage (in 
Parkinsonian groups) must be taken into account. The present study aims to 
investigate speech and voice in a homogeneous group of patients with an early 
diagnosis of Parkinson’s disease (Hoehn and Yahr stage. I) matched in age, 
gender, and education with a normal control group of subjects. However, limiting 
factors such as differences between the Parkinsonian and the control groups in 
paralinguistic aspects (emotion), extralinguistic aspects (size and shape of 
laryngeal structures as well as physical health (Ramig & Ringel, 1983), and the 
lack of norms in the Greek population in fundamental frequency, fundamental 
frequency range, and intensity are limiting factors to the interpretation of the 
results of the present study.
1.5.4 Studies examining articulation
Even though laryngeal dysfunction in Parkinson’s disease has an 
increased incidence compared to articulation (imprecise consonants), the latter 
is useful to describe the intelligibility of speech and the subsystem involvement 
(Kent, Kent, Duffy, & Weismer, 1998b). Because almost all of the studies that 
investigated articulation in Parkinson’s disease included subjects with a
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moderate to severe dysarthria and no control on duration of disease and 
neurological stage (mostly advanced neurological stage), the discussion on 
articulation will be limited to the most prominent studies.
In articulation, consonant imprecision has been the perceptual deviation 
reported most commonly (Canter, 1965b; Chenery et al., 1988; Darley et al., 
1969a, 1969b, 1975; Logemann et al., 1978; Zwirner & Barnes, 1992). 
Logemann and Fisher (1981) studied 90 patients diagnosed with idiopathic and 
post encephalitic Parkinson’s disease (at all five stages of the disease). Speech 
samples of the sentence version of the Fisher-Logemann Test of Articulation 
competence were recorded and analyzed by two trained phoneticians. Table 1 
below shows the progression of misarticulations in each phoneme with the 
associated number of patients exhibiting them.
Table 1. Misarticulated phonemes in Parkinson's disease 
(taken from Logemann & Fisher, 1981).
Phonemes Misarticulated Number of Patients
/k. g/ 90
/k, g/ + /s,zJ 63
/k, g/ + Is, zJ + /j, 3 / 43
/k, g/ + Is, zJ + 11 3 / + /tj. d3/ 39
/k, g/ + Is, zJ + /j, 3 / +  /tj, d3/  + Ip, bl 29
/k, g/ + Is, z / + 11 3 / + /tL d3/ + Ip, bl + If, v/ 21
Ik, g/+ Is, zJ + /J, 3/ + /tj, d3/ + Ip, bl + It, 61 18
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The authors emphasised that all of the misarticulations had a consistent 
pattern, which was characterised by incomplete closures for stops ([ k ] -> [ x ]) 
and a partial but insufficient constriction of the vocal tract for fricatives 
([ s ] -> [ s"^  ]) when T denotes lowering position of the tongue. This pattern 
represents an inadequate narrowing of the vocal tract at the point of articulation 
and it might be explained by the accelerated rate or reduced range of movement 
due to the neurogenic weakness of Parkinsonian patients (Canter, 1965b; Duffy, 
1995; Logemann & Fisher, 1981). Gentil and Poliak (1995) explain the 
mechanism of the distortions in stop consonant production. While the normal 
production of a stop consonant involves a complete articulatory obstruction to 
the airstream, this is not the case in hypokinetic dysarthria. The complete 
obstruction is replaced by an incomplete obstruction resulting in the airflow to 
pass through a narrow constriction to generate a turbulent noise and a fricative­
like production (spirantization).
The acoustic analyses supported the above findings (Ackermann & 
Ziegler, 1991; Kent & Rosenbek, 1982; Weismer, 1984a). A reduction of acoustic 
contrast or detail, indistinct syllable boundaries and spirantization were found in 
which stop gaps are replaced by low-intensity frication (Kent & Rosenbek, 1982; 
Weismer, 1984a). In addition, Weismer (1984a) discussed that the most 
important articulatoty feature of hypokinetic dysarthria is the shortened duration 
of voiceless fricatives measured from the glottal pulse preceding aperiodic 
energy to the first glottal pulse following the aperiodic waveform. However, no 
control of stage and duration of the disease took place in this study.
Ackermann and Ziegler (1991) examined the speech of 12 patients 
diagnosed with idiopathic Parkinson's disease during sentence imitation. Their
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results were similar to the previous studies in stop consonant production. 
However, the phenomenon of spirantization was not uniform but was influenced 
by the specific linguistic demands (the intensity in the openings and closures that 
were associated with a stressed vowel and a post vowel consonant were 
performed at the expense of post vowel unstressed consonant). The rate 
between opening and closing movements of the articulators in sentence 
production seemed undisturbed.
Electromyographic studies (EMG) showed the same pattern of gradual 
decrease in velocity of lip displacement and a synchronous activation of agonist- 
antagonist muscles (anterior digastric and mentalis muscles for the production of 
[ pa ]) instead of a reciprocal action. This lack of reciprocity occurred only during 
the production of [pa]  in fast rates and not in regular performance. The 
reduction in the range of movements is probably the cause of such findings 
(Hirose, Kiritani, Ushijima, Yoshioka, & Sawashima, 1981).
Gentil and Poliak (1995) report that the perceptual impression of 
imprecise consonants is a complicated entity and it involves (among others) a 
number of possible manifestations such as incomplete closure of stop 
consonants, imprecision in articulatory location, reduction of acoustic contrast 
and voicing of voiceless stops due to the reduced range of movement and the 
rigidity of the articulators. However, it seems to be an agreement in the 
perceptual and acoustic findings of the studies on articulation. An excessive 
difference in intensity (between stressed vowel vs. the following unstressed stop) 
in one study (Ackerman & Ziegler, 1991), the reports of spirantization (Kent & 
Rosenbek, 1982; Weismer, 1984a) and the perceptual impressions of Logemann 
and Fisher (1981) on stop consonant production show the same tendencies
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(Kent et al., 1998b).
Logemann et al. (1978) hypothesised that the progression of voice and 
articulatory features in Parkinson’s disease follows a consistent pattern. Early 
Parkinson’s disease is accompanied by laryngeal abnormalities and followed by 
posterior tongue, anterior tongue, and labial abnormalities (severe Parkinson’s 
disease). Adams (1997) challenges this notion. Differential effects of production 
can happen when 2 vocal tract structures are equally affected. A 50% increase 
in lips and vocal fold rigidity will have an important effect on vocal fold vibration 
but not at the same level in lip movement.
Canter (1965b) states that the involvement of tongue in articulatory errors 
was higher than the lips. There were a limited number of reports during the 
nineties that investigated the relation of strength and endurance of the tongue 
with the speech of Parkinsonian subjects (Solomon, Lorell, Robin, Rodnitzky, & 
Luschei, 1995; Solomon, Robin, & Luschei, 2000). The results were conflicting. 
The first study that employed mild to moderate Parkinsonian subjects (I and II 
grades in Hohn & Yahr scale), found that tongue strength was correlated 
negatively to disease severity and overall speech defectiveness. This simply 
means that a greater number of articulatory errors (perceptually determined) 
were associated with a weaker tongue. However, when the data of this study 
were combined with another study that investigated the same variables in 
subjects with a variable disease severity, no correlations were found between 
speech and non speech measures (Solomon et al., 2000). Even though the 
effect of medication seems to be the same in both studies (both studies involved 
medicated subjects) differences in the study design of the second study may 
account for these discrepancies. No correlations occurred between speech and
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non speech measures according to neurological stage of the disease in the 
Parkinsonian subjects. A consistent manipulation of disease severity 
(neurological stage) and speech/non speech movements may result in different 
findings.
Connor and Abbs (1991) investigated task dependency in the duration 
and velocity of jaw movement (visually guided opening of the jaw, opening of the 
jaw in syllable and phrase production) in Parkinsonian and control subjects. 
Differential effects were found. Increased duration of jaw movement was found in 
the Parkinsonian subjects compared to controls in visually guided movements 
but the opposite occurred in the phrase length. Similarly, a decreased ratio of 
velocity to movement amplitude was found in the visually guided jaw movements 
while the opposite was found in the phrase production. Even though the subjects 
were under medication and the effect of medication is beneficial to jaw 
movement, these findings suggest differential impairments in putamen and 
globus pallidus of the basal ganglia where different anatomical regions (leg, arm 
and face) and different specialised subgroupings of cells evoke certain types of 
movement.
1.5.5 Studies examining rate
Even though perceptually determined speech rate abnormalities in 
Parkinson’s disease are frequent, there seem to be variable (slow or fast) in 
different studies (Chenery et al., 1988; Ludlow & Bassich, 1983; Netsell, 1986; 
Scott et al., 1985; Zwirner & Barnes, 1992). Adams (1997) reports that only 10% 
of Parkinsonian patients exhibit rapid speech rates. Metter and Hanson (1986) 
found the variability in rate (slow and fast) in Parkinsonian patients to increase
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with an increase in dysarthria severity. Ludlow and Bassich (1984) reported that 
83% of their Parkinsonian subjects were perceived as having variable rate. This 
tendency was reported as the most severe speech difficulty of their subjects. A 
mismatch between the perceptual impressions and the results of acoustic 
studies in speech rate exists. It is possible that the perceptual results in 
articulatory rate in Parkinson’s disease may overestimate the actual rate that is 
based on physical measures (Tjaden, 2000).
Weismer (1984a) suggested that the perception of fast rate might be due 
to the articulatory imprecision and continuous voicing that reduces acoustic 
contrasts and results in a “blurring” of speech. Other studies suggest that the 
perception of accelerated 'speech or fast rate might be the result not in increases 
of the rate of articulatory movements but in the reduced range of movements 
(Kent & Rosenbek, 1982; Tjaden, 2000).
Many studies have found the additional feature of “short rushes of 
speech” perceived as an “accelerated” speech pattern (Chenery et al., 1988; 
Darley et al., 1975; Scott et al., 1985; Zwirner & Barnes, 1992) and considered it 
as one of the most prominent features of hypokinetic dysarthria. Its 
manifestations are apparent in Alternating Motion Rates (AMRs) or 
diadochokinetic rates in syllable production ([ pa ] [ ta ] [ ka ]). AMRs have been 
used to evaluate the speed and regularity of jaw, lips, and tongue. Rapid or 
accelerated rate in AMRs shows the speech rate abnormalities. Canter (1965b) 
has found significant differences in the Parkinsonian subjects compared to 
controls in AMRs. Other studies found no rate differences in AMRs or syllable 
repetition tasks (Connor, Ludlow, & Schulz, 1989; Ludlow, Connor, & Bassich, 
1987). Hirose et al. (1981) using physiological methods, found a tendency for
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increased rate and reduced range of lower lip movement on syllable repetition 
tasks. However, their results were descriptive in nature since no group 
comparisons were attempted (only 2 Parkinsonian subjects were employed).
One study suggested that Alternating Motion Rates (AMRs) might be 
sensitive measures to identify speech problems in the preclinical period of 
Parkinson’s disease (Parnell & Amerman, 1996). AMRs were investigated 
longitudinally in normal elderly subjects in an 11 year follow-up. One subject who 
took part in the study was diagnosed with Parkinson's disease 5 years after the 
first speech assessment. His AMR scores were measured acoustically, and 
separately from the group of his peers in the first and second speech 
assessment (after 11 year's). The results showed that the rate of variability in 
AMRs (average period difference between 20 consecutive movement cycles in 
[ ta ] divided by the average vowel-to-vowel period and multiplied by 100) was 
higher in the Parkinsonian subject 5 years before the neurological diagnosis (first 
speech assessment). In the first speech assessment, the non speech volitional 
control of the Parkinsonian subject in most tongue movements was found to be 
slow. The authors suggest that AMRs may be sensitive indicators of changes in 
the central nervous system in tasks of maximum oral performance which are not 
however necessarily perceptible.
Acoustic analyses have shown an intersubject variability in speech rate 
(Canter, 1963; Hammen & Yorkston, 1996). No statistically significant 
differences were found. Canter (1963) reported differences in some of his 
subjects, with some subjects exhibiting slow rates, and other subjects exhibiting 
extremely fast rates. Hammen and Yorkston (1996) reported longer pauses in 
the habitual speech in their subjects, an increased percentage of pauses to
76
occur within clause/phrases (‘inappropriate pauses’), and shorter speech 
duration (excluding pause duration). Ludlow and Bassich (1983) found the 
Parkinsonian subjects to exhibit a slower rate in fast sentence production than 
the controls. Ludlow et al. (1987) did not find sentence production rates 
abnormally fast. In general, the Parkinsonian group did not differ from the control 
group in the speech rate but instead in the change of speech rate from regular to 
fast during sentences and phrases. So, the Parkinsonian subjects exhibited a 
reduced ability to alter speech rate. In particular, what distinguished the 
Parkinsonian group from the normal control group was a change in sentence 
duration (duration difference between a regular minus a fast rate in production of 
a sentence) (Ludlow & BaSsich, 1984; Ludlow et al., 1987). in addition, a percent 
reduction in phrase duration was found as a difference in milliseconds between 
regular minus fast time divided by the regular time and multiplied by 100 (Ludlow 
et al., 1987). During longer and more complex utterances (sentences and 
phrases) compared to syllables (no difference was found), a reduced percent 
duration change was manifested in the Parkinsonian group. The authors 
concluded that the basal ganglia disease seems to affect the rate of speech 
movements and their controlled alteration during speech execution but not 
during initiation or planning. However, Kent et al. (1998b) report that the above 
findings are not unique in hypokinetic dysarthria of Parkinson’s disease but occur 
in other dysarthrias.
1.5.6 Studies examining consistencies between perception and acoustics
The great variability of the results of perceptual research on the laryngeal 
system not only in Parkinsonism and idiopathic Parkinson’s disease but also in
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other neurological disorders have often been discussed (Leuschel & Docherty, 
2000). This is a problem of perceptual judgement and some authors have 
pointed it out. F ex (1992) considered whether the great variability of 
characteristics found on perceptual assessment may be due to the abstractness 
of definitions and to different opinions from listener to listener based on 
individuality of reference levels in voice quality. According to Baken (1997) 
perceptual judgements alone may mislead the clinician due to factors such as 
unreliability of listeners’ judgement of pitch and interaction in a complex way of 
frequency, intensity and spectral properties to determine pitch perception. For 
example, the perceived abnormality of pitch may reflect the speaker’s vocal 
intensity. In contrast, the instrumental methods of voice measurement enable the 
examiner to isolate specific parameters for measurement, but they still cannot 
replace the human ear (Baken, 1997). An ideal instrumental or acoustic analysis 
will be able to isolate parameters from the signal and relate them to physiological 
factors and perceived voice quality (Wirz & Beck, 1995). One solution to this 
problem could be if the clinicians/researchers were trained through acoustic 
recordings, and if high quality tape recordings could be used for assessment 
based on sustained phonation and running speech samples with well-defined 
noise components (Fex, 1992).
in dysarthria, a few studies have found consistencies between perception 
and acoustics. This may create a problem especially in the present study in 
which the subjects are at the beginning of Parkinson’s disease and, at least 
perceptually, are predicted to be close to normal. Baken (1997) concludes that 
“Comparison to a norm requires that both the norm and the behaviour in 
question be based on unbiased and objective scales...’’ (p. 125-126). The lack of
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norms in the speaking fundamental frequency in the Greek language further 
complicates the problem and limits the interpretation of the results in the present 
study.
The examination of perceptual ratings and acoustic measures of 
hypokinetic speech to find the most appropriate measures for assessment has 
been carried out by Ludlow and Bassich (1984) in 12 patients diagnosed with 
idiopathic Parkinson’s disease and the same number of controls matched by age 
and gender. The speech samples were perceptually and acoustically analysed 
(from spectrograms). The most important acoustic measures that were related to 
perceptual measures included factors that reflected laryngeal control (from most 
severe to less severe);
• The number of on-off phonations on vowel [ a ] repetition (the number of 
vowels produced in 5 seconds minus the number of gaps in phonation in 5 
seconds)
• The number of consonant voicing errors (the number of syllable repetitions 
produced in 5 seconds minus the number of gaps in phonation in 5 seconds)
• The total range in fundamental frequency on a pitch glide task (the difference 
in Hz, between low and high points of an ascending vowel production divided 
by mean fundamental frequency in sentences) and,
• The range in intensity between soft and shouting voice during the production 
of [ a ]  and the word [ no ] (difference between peak sound pressure level on 
shouting production and that on soft production).
In conclusion, acoustic measurements in this study indicate an inability of 
the Parkinsonian patients to manoeuvre speech range in fundamental frequency 
and intensity. Correlation coefficients between Fo range and monopitch on the
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one hand and intensity range and monoloudness on the other were high (.65 and 
.67 respectively). This fact, points to the possibility that patients with Parkinson’s 
disease are unable to use their larynges and articulators in order to provide the 
prosodic aspects of speech, and that this may be caused by rigidity. Zwirner et 
al. (1991) found a relation of the severity of dysphonia, and the acoustic 
measure of standard deviation of fundamental frequency (SDFo) during 
sustained phonation in patients with Parkinson’s disease.
One possible reason that not many studies have found consistencies 
between perceptual and acoustic findings is the use of tasks that require 
maximum performance. Many of the studies that measured phonation and 
speech rate in Parkinson’s disease have used maximum performance tests 
(maximum phonation duration, fundamental frequency range, maximum 
expiratory pressure, maximum sound pressure level, and maximum 
diadochokinetic rate) (Canter, 1963, 1965a, 1965b; Connor et al., 1989; Fox & 
Ramig, 1997; Hirose et al., 1981; Ludlow & Bassich, 1983, 1984; Ludlow et al., 
1987; Parnell & Amerman, 1996; Solomon et al., 1995, 2000). These tests 
examine the upper limits of performance for selected speech tasks (Kent, Kent, 
and Rosenbek, 1987). Although the application of such tests In motor speech 
disorders seems reasonable because of their similarity to tests that are used in 
clinical neurology and measure strength, range, or speed (Kent et al., 1987) they 
also have disadvantages which can confound the results. Kent et al. (1987) 
review the merits and drawbacks of maximum performance tests.
Their advantages involve their frequent use in screening and assessment 
of motor speech disorders, their potential for international use since they do no t . 
require a specific language, and their ability to fit to the demands of ordinary
80
speech production, which falls well within their limits (Kent et al., 1987; Kent & 
Kent, 2000). Non speech tasks of the oral mechanism may also provide 
information about the existence of motor speech disorders including 
Parkinsonism by assessing the interaction between the motor and linguistic 
contributions and by separating the motor processes and the linguistic levels of 
constraint (Robin, Solomon, Moon, & Folkins, 1997). Finally, they are helpful in 
assessing the relative contribution of a given speech production subsystem 
(respiratory, phonatory, velar, and articulatory) to the disorder (Robin et al.,
1997).
However, a number of disadvantages make them suitable for use only in 
conjunction with other tasks, e.g. reading and conversation. The major 
disadvantages of these tests involve (Kent et al., 1987):
• The lack of standardised procedures for their application
• The large intrajudge and interjudge variability in the performance of subjects 
due to the effect of practice, motivation, inappropriate instructions, 
differences in age and sex and other physical variables among subjects.
• The lack of normative data, especially in view of life-span considerations.
• The non established relationship to speech. Each of the maximum 
performance tests is a non speech behaviour that has a presumed 
relationship to speech or a stylised speech activity such as the prolongation 
of a vowel.
Kent et al. (1987) conclude that “properly used, the maximum performance 
measures may be useful and justifiable...but the problems outweigh the 
suggested solutions in some, and perhaps many, of the areas of concern.” (p. 
384). In contrast. Robin et al. (1997) support the notion that despite their
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weaknesses the combined u^e of speech and non speech tasks may be 
beneficial for the assessment of the speech motor mechanism.
In the present study these tasks were considered useful to show possible 
motor abnormalities since the Parkinsonian subjects were at the beginning of the 
disease and it was predicted to be close to normal. The use of maximum 
performance tasks in the present study took place through the Frenchay 
dysarthria assessment, the advantages and disadvantages of which will be 
discussed in section 2.5.
1.5.7 Other studies
The term prosody refers to linguistic and non linguistic information and 
involves intonation, sentence accent, word stress, and rhythm of speech. The 
perception of prosody relies, into a large extent, on fundamental frequency, 
intensity, and syllabic duration. All of these aspects have been discussed 
separately in the previous sections. This section will deal with studies on 
dysarthria that focus on stress and intonation and studies in the Greek language 
of normal speech production since there is a lack of Greek studies in dysarthric 
speech. Also, an additional study will be considered because it used different 
methodology from the aforementioned studies even though this study does not 
deal with stress and intonation.
Prosodic disturbances in the form of reduced stress exist in most of the 
perceptual studies (Chenery et al., 1988; Darley et al., 1969a, 1969b, 1975). 
Ludlow and Bassich (1984) found that reduced stress was correlated with the 
acoustic measure of interword interval length. This measure was defined as a 
difference in time between two words with equal stress (“blue bell) and one
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compound noun (“bluebell") when produced in same sentences. In this way, 
duration changes in time to mark word barriers were found. The Parkinsonian 
patients exhibited shorter intervals than normal controls.
Stress and intonation have been examined acoustically (Hertrich & 
Ackermann, 1993; Kent & Rosenbek, 1982; LeDorze, Ryalls, Brassard, 
Boulanger, & Ratté, 1998; Ludlow & Bassich, 1983; Murry, 1983; Renner, Miller, 
Hertrich, Ackermann, & Schumm, 2001). All studies are characterised by 
different ways to assess stress and intonation even though they used acoustics 
as a method of instrumentation. Kent and Rosenbek (1982) found an overall 
reduction in acoustic contrast or detail and “a flattening of the acoustic relief 
across the syllable chain” (p. 282). in sentences with linguistic meaning, Ludlow 
and Bassich (1983) found a severely restricted range of fundamental frequency 
during stress contrasts and during imitation of sentence fundamental frequency 
contours. Murry (1983) found increases in frequency and intensity during effort to 
stress a word in initial and final position. Hertrich and Ackermann (1993) found a 
slightly decreased duration of the stressed syllable in Parkinsonian subjects 
exhibiting dysarthria.
Intonation (difference in mean fundamental frequency on the last syllable 
of the same sentence produced as both question and as a statement) was found 
to be lower in the Parkinsonian group compared to controls (Le Dorze et al.,
1998). Another study investigated intonation by examining pitch accent patterns 
instead of variability in one sentence produced with three ways: descriptive, 
angry, and interrogative (Penneret al., 2001). The Parkinsonian subjects 
exhibited a tendency toward a lower rise in relative fundamental frequency than 
the controls. However, a high performance variability between the subjects, their
83
small number (N = 3), and the different duration of the disease (9-14 years) were 
major disadvantages in this study.
Variation in the voice source may be associated not only with segmental 
elements of a language (contrastive use of voice quality for vowels or 
consonants in some Asian, African and American languages) but also with 
suprasegmental elements of a language (relation of fundamental frequency to 
intonation, tone and stress). Individual differences in voice quality may be the 
result of a number of factors involving the physical properties of the vocal 
apparatus and linguistic, paralinguistic and sociolinguistic influences (Chasaide 
& Gobi, 1997). Any or all of these factors may signal variation in the voice source 
and show differences in numerical indexes such as fundamental frequency and 
intensity.
Although the present study aims to identify phonatory differences between 
Greek Parkinsonian subjects and controls, its assumptions were based on 
studies which focused on English speaking populations. Linguistic differences 
between Greek and English may be important factors in how pathological voice 
is used by the Parkinsonian subjects. A significant limitation in the interpretation 
of the results of the present study is the differences between stress and 
intonation in the Greek language and the English language. Stress is an 
important factor that differs among various languages. In normal speech 
production of the Greek language, research on these aspects starts to unveil its 
differences compared to other languages.
In normal speech production of English rhythm, there is an even 
alternating of stressed and unstressed syllables, while in Greek this is not the 
case. In the Greek language a requirement for alternation of strong and weak
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syllables does not exist since there is no elimination of stress lapses that is 
observed in English and other stress-timed languages (Arvaniti, 1994). 
Irregularity and sparsity of stresses and relatively stable duration of syllables 
(with the exception of syllables with primary stress) are characteristics of the 
Greek language similar to the Italian language (Arvaniti, 1994). The resolution of 
clashes is achieved by different ways in syllable-timed languages (such as the 
Greek language) compared to stress-timed languages (such as the English 
language). In the Greek language distressing or inserting extra duration between 
clashing syllables is the primary strategy while in English shifting stress results in 
more evenly alternating prominent syllables (Arvaniti, 1994).
Other characteristics of lexical stress in the Greek language involve the 
existence of Stress Well Formedness Condition (SWFC) which allows stress to 
occur on any of the last three syllables of a word and no further to the left. 
However, with the addition of an enclitic to a host stressed on the 
antepenultimate a stress is added two syllables to the right of the lexical stress 
(Arvaniti, 1992). The SWFC induced stress becomes the most prominent in the 
group and it is not perceptually different from the lexical stress. Arvaniti (1992) 
suggests that Greek may not have rhythmic stresses at all. Finally, an important 
characteristic of Greek stress is that the Fo high in the Fo contour is associated 
with the end of the stressed syllable and the beginning of the following and not 
with the beginning of the stressed syllable (Botinis, 1989; Arvaniti, 1992).
On the same lines, linguistic research in intonation in Greek shows that 
the H target (max turning point in an Fo contour) is very precisely aligned just 
after the beginning of the first post accentual vowel and it is very stable relative 
to the onset of the first post accentual vowel (independently of differences such
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as the combined duration of the accented syllable and the immediately following 
consonant) (Arvaniti, Ladd, & Mennen, 1998). So, the Greek prenuclear accents 
are represented as bitonal accents of the form L (min turning point in an fo 
contour) and H (max turning point in an fo contour). The authors conclude that 
the “L and the H of the accent are anchored to segmentally defined positions, 
and the duration and slope of the pitch movement are completely determined by 
the segmental composition of the accented word” (p. 24).
The description of the aforementioned features is beyond the scope of the 
present study but they have been mentioned in order to show that their existence 
limits the interpretation of the results of the present study and prohibits their 
generalisation. For example, due to differences in stress and intonation, 
dysarthria in Parkinson’s disease in the Greek language may show different 
compensations compared to the English language. Although, the present study 
focused on phonatory aspects only and stress and intonation were not 
measured, the complex relationship between fundamental frequency and 
intensity during reading and monologue may unveil the differences between 
languages and limit the interpretation of the results.
Finally, one study that used different methodology from the other studies 
will be described. This study used a different way to identify differences in 
Parkinsonian levodopa treated subjects. Metter and Hanson (1986) investigated 
brain anatomy and glucose metabolism with the speech characteristics in 
reading of 8 Parkinsonian patients and 2 patients diagnosed with supranuclear 
palsy and having variable degrees of hypokinetic dysarthria. Ten control subjects 
were matched to the experimental group by age. The acoustic measures of 
speaking rate, mean fundamental frequency, relative intensity, and vowel
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phonation time were taken from tape-recorded speech samples and were 
compared to age-matched samples of controls. The results showed that there 
was a trend of increase in Fo with increased clinical disability and with increased 
severity of dysarthria. However, the mean fundamental frequency (Fo) for each 
patient was within the normal range compared to controls.
1.6 Electrolaryngography as a technique of voice measurement
Electrolaryngography (ELG) or electroglottography^ (EGG) has been used 
in the last two decades as a clinical and assessment tool in the field of speech 
and voice pathology and therapy. Its basic aim is to monitor vocal fold closure 
and to record changes of vocal fold vibration during voiced sounds (Abberton, 
Howard, & Fourcin, 1989). Qualitatively, electrolaryngographic analysis can be 
used to complement auditory voice quality assessment including vocal registers 
and intonation analysis. On a quantitative basis, it can be used to measure 
physical and statistical characteristics of phonation and fundamental frequency.
In addition, by analysing the vocal fold vibration (mode and rate), 
electrolaryngography relates them to the perception of voice quality and 
intonation (Abberton et al., 1989). Knowledge of basic physical measurements of 
voice can be associated with different disorders that affect voice. The extensive 
use of other instrumental methods in speech pathology, such as acoustics, is 
based upon this logic. In the end, change in these physical measurements with 
speech therapy may improve voice. In a sense, quantification could provide the 
stable ground.for monitoring therapy.
 ^ Fourcin (1981) uses the name electrolaryngography while other reseachers prefer the name 
electroglottography (Baken,' 1992; TItze, 1990). Baken (1992) commented that the term 
electroglottography does not really represent Its actual use because the signal does not give 
Information about the glottis and Its size but Instead provides Information about the closed phase 
of the vocal fold vibratory cycle. To avoid confusion, both terms will be used In this study 
reflecting the Individual view of each researcher.
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The electrolaryngograph measures conductance by using 2 electrodes, 
one on each side of the larynx at the level of the thyroid alae, and by passing a 
current between them during the production of voiced sounds. Its underlying 
purpose is to measure the electrical impedance (or conductance) during the 
opening and closing phases of the vibrating vocal folds. Air is an extremely poor 
conductor while tissue is a moderately good conductor. During the glottal cycle 
the electrical impedance in the larynx is increased when the glottis is open (air is 
between the vocal folds) and decreased when the glottis gradually closes. Under 
normal conditions impedance will show the details of laryngeal function (Baken, 
1992, 1997; Colton & Conture, 1990; Kitzing, 1990).
Baken (1992) describes the function of a ‘generic’ electrolaryngograph. 
Figure 6 is taken from Baken and it has been modified for the purpose of this 
study. It shows a block diagram of a typical electrolaryngograph.
Electrodes attached in the .neck Y
Gx
ELECTRODE
CIRCUIT
AUTOMATIC
GAIN
CONTROL
A M
DETECTOR
HIGH -  PASS 
FILTER
HIGH
FREQUENCY
OSCILLATOR
Figure 6. Block diagram of a typical electrolaryngograph (taken from Baken, 1992).
The oscillator generates a high frequency current (300 kHz - few 
megahertz). This current is coupled to the neck through the use of the 
electrodes. In modern electrolaryngographs, a guard ring that is attached to the
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electrodes shields the electrodes from noise and restricts the spread of the 
electrical current in the neck. The voltage that is generated across the neck is 
0.5 V. The high frequency current varies with changing impedance due to vocal 
fold movement. This results in a voltage drop between the electrodes. The 
decoding of this signal with the elimination of the high frequency waves produces 
waves that involve only their amplitude. This amplitude signal represents trans­
neck impedance over time. The automatic gain control is used to change the 
amplitude of the carrier wave or the sensitivity of the detector system. In this 
way, a stable and large output will be obtained. The automatic gain control is 
also used to reduce a slow drift of the output baseline that is due to changes in 
the characteristics of the electrode-skin interface that occur over time. The high- 
pass filtering eliminates slow changes due to perilaryngeal activity and it passes 
rapid impedance variations for further amplification. As a result, a change in the 
amplitude of the carrier current occurs and an amplified clear signal appears 
(Lx). This signal shows only the glottal behaviour that is taking place during 
phonation, in contrast to another signal (Gx) that shows the large changes in 
impedance before and after the phonatory event (including the perilaryngeal 
activity).
The electrolaryngographic excitation output waveform (Lx) is the output 
waveform that has peaks when there is a contact of vocal folds (minimal 
impedance) and troughs when there is no contact (maximal impedance) and it 
gives the current flow as a function of time. The vibration of the vocal folds 
during voiced sounds results in a quasi-periodic Lx waveform with the 
continuous opening and closing of the vocal folds. More specifically, the start of 
each steep rise in the Lx output is associated with the onset of vocal fold closure,
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the peak of each cycle is associated with maximal closure (horizontal and 
vertical) and the trough is associated with vocal fold separation (Abberton et al., 
1989).
1.6.1 Relationship of electrolaryngography to vocal fold contact
Fourcin (1981) describes the details of the contact of the vocal folds on an 
Lx waveform. According to him, the first phase of the Lx signal involves the 
production of a mucus bridge between the approximating epithelial cover 
surfaces. This is the end of the open phase of vocal fold vibration and it is 
associated with contact between the covers at the lower edges of the glottis. The 
mucus bridge gives a very rapid jump up in electrical conductance across the 
neck. After this, the maximum electrical contact is associated with the snapping 
together of the covers of the two folds. An illustrated diagram (taken from Baken, 
1997) shows the above demarcations of the Lx signal (Figure 7).
Figure 7. Electrolaryngographic views and corresponding positions of the vocal folds 
(Baken, 1997 based on MacCurtain & Fourcin, 1982).
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Fourcin (1981) emphasises the importance of 5 points in the examination of Lx 
waveforms in normal voice:
• Uniform Lx peaks are associated with a uniform acoustic output.
• A sharp Lx contact is associated with a good acoustic excitation of the vocal 
tract.
• Long closure duration is associated with undamped formants.
• Regular sharply defined contact periodicity is associated with well defined 
pitch.
• A progressive change in sharply defined Lx period lengths is associated with 
a changing voice pitch.
Long samples (more than'l minute) of speech are necessary in the ELG 
analysis. The reason is that in speech samples of more than one minutes there 
is a possibility that production difficulties (pathological voice) will arise more 
clearly. Even though the nature of the sample may affect the analysis, it is clear 
that a close to monotone or a monotone voice (as in Parkinson’s disease) will 
probably give a narrower fundamental frequency distribution (Abberton & 
Fourcin, 1984).
Carlson (1995) states that Fourcin, compared to other researchers, 
modified the phase of the displayed output waveform in ELG. So, the Lx 
waveform is positive (upward) when there is an increase in vocal fold contact 
and negative (downward) when there is a decrease in vocal fold contact. A left 
tilt in the Lx waveform denotes the abruptness of closure compared to the 
gradual opening phase. As was stated above, the steepness of the slope of the 
Lx output waveform for the closing phase of the vocal folds also determines the 
acoustic excitation of the vocal tract. Finally, a simultaneously recorded acoustic
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speech pressure waveform (Sp) can also be displayed and this denotes the 
output waveform of the microphone.
1.6.2 Quantitative measures of electrolaryngography
The modern use of electrolaryngography can provide quantitative 
measures of voice. These measures have been discussed extensively in many 
articles (Abberton et al., 1989; Abberton & Fourcin, 1984, 1997; Fourcin, 
Abberton, Miller, & Howells, 1995; Fourcin, 2000). By measuring the time during 
vocal fold closures, the researcher is able to find the fundamental period of 
excitation (Tx) and to derive the fundamental frequency of excitation (Fx). Based 
on Lx, many other voice parameters can be measured. Fundamental frequency 
changes on a period-by-period basis (Fx) are correlated with the perception of 
intonation or pitch patterns.
In general, Dx (the distribution of excitation fundamental frequencies on a 
probability histogram) during voiced speech gives a measure of vocal fold 
closure regularity and, in particular, a measure of frequency regularity and range. 
Intensity regularity and intensity range can also be displayed. Dx is presented in 
2 orders (first order and second order). The first order gives the raw Tx data 
while the second order includes pairs of laryngeal periods that occurred twice in 
the same statistical ‘bin’. Dx is plotted on a logarithmic scale corresponding to 
perceived pitch. Its frequency axis is divided into 128 logarithmically equal 
spaced ‘bins’ having an overall range from 30.52-1000 Hz. Each bin is a few Hz, 
in width (Abberton et al., 1989). In addition to Dx, a scatterplot (Cx) of each Fx 
(every measured Fo value) against the one that follows can also be used. Cx plot 
is comparable to the first order Dx plot. In Speech Studio (the computer program
92
that is used for the quantification of Fx measurements) the Tx values in the 
second order distribution are admitted based on a cycie-to-cycle control of vocal 
fold vibration. In this way, a large number of samples are included.
Both Dx orders, but especially the second order, represent vocal fold 
regularity (Abberton et al., 1989; Fourcin, 1981, 2000). Theoretically, the second 
order distribution is preferable to the first order because it does not include data, 
irrelevant to voicing, that might affect the calculations of Fx parameters 
(swallowing or excessive gross laryngeal movement during recording). However, 
the irregularities that are discarded by the second order may be a part of the 
voice. Because the present study measures fundamental frequency in a sample 
of experimental subjects that are predicted to be close to normal (at least 
neurologically with no serious decline of performance due to early beginning of 
the disease), both orders are used to examine if differences in the results 
between them exist.
Qx is defined as the mean percentage of time the vocal folds are closed 
(measured 70% down from the waveform peak) to the total period and it is 
related to the quality of excitation of the vocal tract as the vocal folds vibrate 
(Abberton & Fourcin, 1997; Fourcin, 2000; Fourcin et al., 1995). It is derived from 
the Lx waveform by determining the period of time between closing and opening 
of the vocal folds.
In summary, most of the measures that can be derived from 
electrolaryngography include:
• Measures of central tendency of fundamental frequency
• Fundamental frequency range
• Probability density functions of the duration of laryngeal silence
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corresponding to voiceless portions and silence
• Durations of continuous larynx activity corresponding to voiced portions of 
speech
• Measures of vocal fold closed and open phases in each vibratory cycle and
• A phonetogram (range of intensities against their vocal fold frequencies).
1.6.3 Electrolaryngography in the analysis of voice in neurological 
disorders
In voice measurement of different disorders, many researchers have 
reported the use of electrolaryngography (ELG) alone or together with other 
techniques (Gerratt, Hansbn, & Berke, 1987, 1988; Hanson, Gerratt, & Ward, 
1983; Horiguchi, Tomoyuki, Baer, & Gould, 1987; Jiang, Lin, Wang, & Hanson,
1999). Fourcin (1981) states that Lx is important in voice assessment since 
events that occur when the vocal folds come into contact depend on the 
physiological condition of the vocal folds. So, different pathologies are 
associated with different contact phenomena. In a sense, quantitative measures 
of phonation depend on vocal fold contact. Because the studies that used ELG in 
neurological disorders are limited, an extensive description of them will follow.
In the eighties, Hanson, Gerratt, and his colleagues (Gerratt et al., 1987, 
1988; Hanson et al., 1983) emerged as advocates of measuring voice 
abnormalities in neuromuscular disorders. They suggested the use of a 
combined method of phottoglottography (PGG) and electroglottography (EGG) to 
measure laryngeal structure and function. PGG was suggested to provide 
information about the open glottis while EGG was suggested to describe glottal 
contact during the closing phase. The authors reported that the combination of
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both methods can give information about the opening and closing phases of 
vocal fold vibration and the use of measures such as speed quotient (SQ) and 
open quotient (OQ) could be beneficial to accomplish this task. Speed quotient 
was defined as the ratio of the duration of the lateral excursion of the vocal folds 
(in ms) divided by the duration of medial excursion of the vocal folds (in ms). The 
authors also suggested that the speed quotient measure might be related to 
myoelasticity. Open quotient was defined as the ratio of the duration when the 
glottis is open divided by the total duration of the glottal cycle. According to them, 
the visual aspect of the EGG signal makes it an attractive method of vocal 
assessment. In addition, EGG offers insights into the more subtle vibratory and 
tension abnormalities that'are associated with abnormal phonation. The authors 
stated that “information obtained from glottographic studies is often 
diagnostically helpful, particularly in patients with voice abnormalities associated 
with neuromuscular disorders" (Hanson et al., 1983, p. 418).
Hanson et al. (1983) compared sustaining [ i ] sound measurements of 
voice in 3 subjects with different voice pathology (one Parkinsonian subject, one 
subject diagnosed with spastic dysphonia and one subject poisoned by arsenic) 
to a control subject of the same sex. The Parkinsonian subject was found to 
have an increased fundamental frequency mean compared to the subject with 
the normal voice (PD Fo mean = 119 Hz, PD OQ = 0.84, Normal Fo mean = 106 
Hz, Normal 0 0  = 0.44). The EGG waveform of the Parkinsonian subject showed 
a remarkably longer time for the opening portion of the glottal cycle (71% of the 
entire cycle) and a significant reduced closing portion of the cycle (15% of the 
entire cycle was spent “in the most closed period"). The waveform shape also 
varied from cycle to cycle indicating a marked variability of vocal fold posture.
95
The physiological interpretation of the results was that the vocal folds of the 
Parkinsonian subject during phonation moved toward the midline but did not 
make complete contact at their medial edges. As a result, the rising and falling 
slopes lacked the continuities associated with the medial contact of the upper 
and lower vocal fold margins that should occur during normal phonation. So, the 
vocal folds of the Parkinsonian patient looked bowed during phonation. 
Furthermore, the glottic gap was visibly greater during phonation correlating with 
a breathy voice production, short phrasing of speech, and decreased ability to 
sustain phonation. All of these findings were associated with the laryngoscopic 
examination. The authors emphasised the importance of glottographic 
waveforms to provide diagnostic information such as abnormally increased vocal 
fold tension or cycle-to-cycle variability in vibration.
Using the same technique, the authors analyzed recordings of sustained 
[ i ] in subjects with reported damage to the nervous system that in turn affected 
their phonatory ability (Gerratt et al., 1987). Emphasis on these aspects could 
enhance the ability to understand the normal motor control of laryngeal function. 
Four subjects (one male with recurrent nerve paralysis, one male with superior 
laryngeal nerve paralysis, one male with Parkinson’s disease, and one normal 
control male) were examined. The Parkinsonian patient, as compared to the 
normal control subject, exhibited increased fundamental frequency, speed 
quotient, frequency perturbation ratio (jitter ratio), and amplitude fluctuation ratio 
(shimmer ratio). Table 2 is taken from Gerratt et al. and shows the 
measurements of all subjects in this study.
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Table 2. Voice measurements in a normal control subject, a Parkinsonian subject and 
two subjects with laryngeal nerve paralysis.
SUBJECTS Speed Quotient 
In ms
Fo 
in Hz
Frequency 
Perturbation 
Ratio 
(iitter ratio)
Amplitude 
Fluctuation Ratio 
(Shimmer ratio)
Normal Control Subject 0.98 110 8.64 29.80
Parkinsonian Subject 2.90 118 9.74 39.90
Subject with Superior 
Laryng. Nerve Paralysis
1.28 187 18.46 107.70
Subject with Recurrent 
Nerve Paralysis
0.35 154 8.15 33.40
Figure 8 shows illustratively the waveforms of the Parkinsonian subject 
vs. the normal control subject. For the sake of the current discussion the lower 
diagram was reversed to represent the electroglottographic signal with the 
closing phase represented at the top of the signal (upward). DPGG is the change 
of acceleration of the vocal folds from opening to closing.
m
Q.
Fo = 118 Hz 
SQ = 2.9 
00  =  1.0
Fo = 110 Hz 
SQ = 0.98  
OQ = 0.60
Figure 8. Photoglottographic and electroglottographic signals of a patient with Parkinson’s 
disease (left) and a person with normal phonation (right).
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Supported evidence came from other studies that used electromyography. 
Bizarre high frequency discharges and big potentials during phonation were 
found in two out of eight Parkinsonian patients in the region of posterior 
cricoarytenoid muscles and in the interarytenoid respectively (Guidi, Bannister, & 
Gibson, 1981) and in the region of the intrinsic laryngeal muscles (Hirose, 
Sawashima, & Niimi, 1988). Gerratt et al. (1987) explained that this activity could 
cause a greater than normal resistance to the opening of the vocal folds since 
subglottal pressure increase during phonation (slower opening of the vocal folds 
and a long open phase). When the vocal folds travel to the limits of the 
excursion, increased myoelasticity could cause the folds to move back to the 
midline quickly. In this study, an increased SQ and stiffness of the vocal folds in 
the Parkinsonian patient and a decreased SQ in the patient with unilateral lower 
motor neuron paralysis were found. Murdoch, Manning, Theodores, and 
Thompson (1995a) did not confirm the above results. The authors found no 
differences between control subjects and 20 Parkinsonian subjects in 
fundamental frequency and closing time even though the perceptual assessment 
revealed that 89.5% of the Parkinsonian subjects exhibited laryngeal features 
such as breathiness, glottal fry, hoarseness, and pitch unsteadiness.
Except from quantitative measures, electrolaryngography has also been 
used clinically to observe traces of dysphonias in 432 patients (Motta, Cesari, 
lengo, & Motta, 1990). Of the 432 patients, 50 were not affected by dysphonia,
66 presented hypokinetic dysphonia, 85 exhibited hyperkinetic dysphonia, 92 
had nodules in one or both vocal folds, 86 had polyps of vocal folds, and 53 
exhibited Reinke’s edema. The results showed the appearance of different 
traces characteristic of the disorder in the Lx record. The glottal wave from
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patients with hypokinetic dysphonia showed a sharp peak and reduced 
amplitude in almost all of the patients (93% of cases).
There is only one study that measured the effect of pharmacology on 
voice (Jiang et al., 1999). The authors found that acoustic and 
electroglottographic signals were useful in monitoring the pharmacological 
response of Parkinson’s disease on voice parameters. The speed quotient that 
was obtained from EGG signals was analysed to detect change in vocal fold 
rigidity while jitter and shimmer were obtained to detect change in phonatory 
instability. Ideally, in normal subjects speed quotient equals 1. The results of 
EGG vs. acoustic measures showed high correlation (r = 0.99, N = 30) in 
fundamental frequency. Although there was a great variability between subjects, 
and across speech performance, the findings of EGG supported the notion that 
in some subjects medicated with levodopa the speed quotient decreased. This 
finding may also suggest that the increased speed quotient measured from EGG 
signals in Parkinsonian patients before treatment may be related to muscle 
rigidity, thereby causing increased vocal fold stiffness. In the same study, other 
results showed that levodopa treatment increased acoustic SPL, a conclusion 
that suggests that levodopa may improve either vocal efficiency through 
increasing respiratory volume or amplitude of vocal fold vibration, or both.
1.6.4 Frequency perturbation and amplitude perturbation as measures of
voice quality in electrolaryngography
As it was indicated in previous sections, jitter and shimmer are measures 
that can be related to the perceptual evaluation of voice quality. Increases of 
jitter and shimmer have been connected to greater phonatory instability.
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Horiguchi et al. (1987) reported that the amplitude perturbation measure of the 
electroglottographic (EGG) signal (shimmer) reflects the irregularity of vocal fold 
contact during phonation and it could be used as a good parameter of laryngeal 
pathology. As indicated in Horiguchi et al., perturbations of EGG and acoustic 
signals in normal subjects and subjects with pathological larynges were 
measured. Frequency and amplitude perturbation measures (jitter and shimmer 
respectively) of the voice signal were compared with perceptual ratings and 
acoustic measures of the voice samples. Their results showed that the shimmer 
of the EGG signal was highly correlated with auditory-perceptual ratings of 
hoarseness (0.6968, p < 0.001). The amplitude perturbation of the EGG signal 
showed the highest percentage of correct detection of pathology. Jitter of the 
EGG signal was highly correlated with that of the acoustic signal in normal 
subjects but not with the same measure in the patients. Horiguchi et al. 
concluded that jitter and shimmer in EGG signal, especially shimmer, could be 
very useful adjuncts to the evaluation of irregularity of vocal fold vibratiori. 
According to them, EGG signals facilitate computer analysis because they seem 
to be simple and do not require pre-processing.
1.7 The motor circuit, the role of dopamine in the motor circuit, thoughts
on neural speech control and theories of speech production
It is well established now in neuroanatomy that different circuits or “loops” 
connect separate cortical regions to the basal ganglia and the thalamic nuclei 
with specific areas of the frontal lobe. Four such circuits have been identified: 
skeletomotor (motor), oculomotor, association, and limbic. Martin (1996) uses a 
practical example (the action of reaching a cup of coffee) to demonstrate the
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function of these four circuits of the basal ganglia. The limbic circuit might help in 
the initial decision to move, the association circuit might help in determining 
where to direct the grasp of the cup while the motor and oculomotor circuits 
might help in the planning and guidance of the movement. The origins in each of 
the circuits are multiple cortical regions with similar general functions. Each 
circuit projects to different parts of basal ganglia and thalamic nuclei or separate 
portions of the same nucleus and innervates in separate portions of the frontal 
lobe. The motor circuit is considered an important circuit for human movement 
and probably in the movement for speech production. A discussion on the 
specific neuronal architecture and function of the motor circuit will follow.
1.7.1 Structure and function of the motor circuit
The structure of the motor circuit involves different connections. These 
connections include structures such as the putamen, the globus pallidus, the 
substantia nigra, and the thalamus. The putamen have connections to globus 
pallidus and substantia nigra pars reticulata and from there to thalamus and 
cortex. The major connections within the motor circuit are:
• The putamen project to specific portions of Globus pallidus external 
(Gpe), Globus pallidus internal (Gpi), and substantia nigra pars 
reticulata (SNr).
• GPi and SNr project to specific thalamic nuclei (nucleus ventralis 
lateralis pars oralis (VLo), nucleus ventralis anterior pars 
parvocellularis (VApc), and centromedian nucleus (CM).
• VLo and lateral nucleus ventralis anterior pars magnocellularis (VAmc) 
project to 8MA.
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• Lateral VApc and VLo project to premotor cortex.
• VLo and CM project to motor cortex.
The major anatomical connections of the motor circuit are in Figure 9 (Duffy, 
1995).
Cortical 
motor 
areas /
Caudate, nucleus
Thalamus
Internal capsule
Subthalamic nucleus
Putamen
Globus pallidus
Midbrain
Substantia nigra
Reticular formation
Pons
Figure 9. Major anatomical connections of the motor circuit (Duffy, 1995).
Alexander and Crutcher (1990) suggest that there are topographic 
projections of neurons in the motor circuit. A discussion on their pilot work will 
follow. In primates, the putamen receive topographic projections from the 
primary motor cortex (PMC), the arcuate premotor area (APA), and the 
supplementary motor area (SMA). Other topographic projections to the putamen 
come from the somatosensory cortex. According to the authors, there is a 
somatotopic organisation of these projections that consists of a dorsolateral zone
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(representation of leg), ventromedial zone (representation of mouth and face) 
and an in-between them region (representation of the arm). Figure 10 is taken 
from Alexander and Crutcher and shows the zones and their topographic 
somatotopic projections to all areas.
PMC “ C
Put
S T N /% ;
taca arm teg
Figure 10. Zones and topographic somatotopic projections between the basal ganglia
and different cortical areas.
For example, the arm region of the putamen receives non overlapping 
projections from the respective arm representations of SMA, PMC, and APA. 
According to the authors, “there may be separate sub-channels (e.g.,
SMA- and motor cortex-specific) within each of the somatotopically defined 
channels (leg, arm, and orofacial) of the motor circuit" (Alexander & Crutcher. 
1990, p. 269).
At all stages of the circuit (cortical, striatal, and pallidal) there is a
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functional specificity of neurons. Experiments in monkeys showed motor 
performance of tasks involving a dissociation of the direction of limb movement 
from the pattern of muscle activity. So, large populations of movement-related 
neurons act irrespective of the associated pattern of muscle activity but in 
connection with the direction of limb movement.
The motor circuit may be also involved in the preparation of movement as 
has been shown in studies with primates in whom premotor cortex, SMA, and 
motor cortex contain neurons such that their discharge rates change with the 
presentation of an instructional stimulus. So, individual neurons exhibit 
movement-related responses or preparatory responses, but not both. During the 
preparation and execution'of limb movements, different aspects of motor 
processing take place in parallel (in different points within the motor circuit). A 
sequence of defined levels of motor processing translates the spatial 
characteristics of the target of movement into an appropriate pattern of muscle 
activations.
All regions of the circuit (SMA, putamen, and motor cortex) contain different 
groups of neurons that discharge selectively in relation to variables concerning; the 
location of the target in space, the direction of limb movement (independent of the 
muscle pattern), and the force of the movement and/or muscle pattern. The timing of 
neuronal activity that is related to the various processing levels was found to concur. 
All of the above suggest the existence of a deeper level of organization within each 
somatotopic channel of the circuit (leg, arm, orofacial). This organization involves 
specific sub-channels that encode in parallel but selectively, information about 
location of the target, limb kinematics and muscle pattern. It is assumed that within 
these basal ganglia-thalamocortical circuits a functional integration takes place
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based upon the temporal coincidence of processing within pathways whose 
functional segregation is rather strictly maintained. This can be better understood by 
the simultaneous processing of information relating to coordinated hand and eye 
movements within the domains of motor and oculomotor circuits.
Alexander and Crutcher (1990) conclude that the functional organization 
of basal ganglia circuitry reflects the parallel form of neural architecture. Their 
activity possibly has a unified role “in modulating the operations of the entire 
frontal lobe, influencing in parallel and by common mechanisms such diverse 
‘frontal lobe’ processes as the maintenance and switching of various behavioral 
sets (via the prefrontal and limbic circuits) and the planning and execution of limb 
and eye movements (via the motor and oculomotor circuits)" (p. 270).
1.7.2 The role of dopamine in the motor circuit
Wichmann and DeLong (1993) supported the hypothesis that the 
symptoms of Parkinson’s disease are developed due to abnormalities of the 
“motor" circuit of the basal ganglia. The loss of nigrostriatal dopamine is 
responsible for these abnormalities. The input to the motor circuit is parts of 
putamen while the output is the internal segment of the globus pallidus and the 
substantia nigra pars reticulata. Dopaminergic projections from the substantia 
nigra pars compacta modulate the activity in the circuit. Other dopaminergic 
neurons project to globus pallidus (in external segment mostly and in internal 
segment to a less degree) and a small number of them terminate in subthalamic 
nucleus.
Two pathways (direct and indirect) arise from the neurons in putamen and 
terminate to globus pallidus internal and the substantia nigra pars reticulata
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(output of the motor circuit). The direct pathway is considered inhibitory and it 
projects to the internal segment of the globus pallidus and the substantia nigra 
pars reticulata, while the indirect pathway is considered excitatory making 
connections to the external pallidal segment, then to subthalamic nucleus and 
finally to the internal segment of the globus pallidus and the substantia nigra 
pars reticulata. Portions of this pathway, primarily to the external pallidal 
segment and secondary to the subthalamic nucleus, are inhibitory while the 
portion of the subthalamic nucleus to the output of the circuit is excitatory.
Figure 11 is taken by Wichman and DeLong (1993) and shows the role of 
dopamine in normal human movement and in Parkinsonism. A detailed 
explanation follows.
A. Normal 6. Parkinsonism
Brain stem 
Spinal cord
Figure 11. The role of dopamine in the motor circuit and the development of Parkinsonism.
In normal conditions, the role of dopamine is to regulate the activity in the direct 
pathway and indirect pathway through facilitation of motion in the direct pathway.
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It has the opposing effect in the indirect pathway. In other words, dopamine 
excites the direct pathway and inhibits the indirect pathway. Because these 
pathways have opposing effects, dopamine tends to facilitate motion. In 
Parkinson’s disease, dopaminergic neurons that are located in the substantia 
nigra pars compacta and in the ventral tegmental area are destroyed. The lack of 
dopamine creates the opposite effect (slowness of movement) and it is ' 
responsible for the existence of clinical symptomatology.
A detailed explanation of the resulting clinical symptomatology in 
Parkinson’s disease will follow. The excessive output of the GPi is caused by the 
lack of dopamine. This excessive output results in an increased tonic inhibition of 
the thalamocortical neurons, which in turn reduce their responsiveness through a 
reduction of their activity. Finally, this will result in insufficient decline in the 
frequency of firing of the a-motoneurons during attempted movement (decreased 
phasic activation).
Lack Of Dopamine :
Excessive Output from G Pi 
Increased tonic inhibition of thalamocortical neurons 
Insufficient phasic activation of a -motoneurons during attempted movements
Marsden (1982, 1994) discusses the general role of the basal ganglia in 
the normal human movement and in Parkinson’s disease. He suggests that the 
basal ganglia allow the automatic (subconscious) execution (running of a 
sequence of motor programs to achieve a motor plan) of learned (laid bv 
practice) motor plans. According to him, a motor plan “is the concept of an
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action, whose execution requires the sequential operation of a number of simple 
motor programs" (Marsden, 1982, p. 535). Examples of motor plans according to 
him are the writing of a signature, the driving of a car, or the riding of a bicycle. 
The execution of a motor plan is irrespective of the muscles required and 
involves a series of stages from one point to another “whereas the signal of 
arrival at each point being the trigger to delivery of the motor program required to 
shift to the next point in the sequence” (p.535). Marsden states that the basal 
ganglia are involved in running the sequences of motor programs to complete a 
motor plan.
1.7.3 Possible relationstiips of neural architecture and dopamine function
to speech production and hypokinetic dysarthria
This section aims to relate the aforementioned reports on neural 
architecture (structure and function) and the consequences of dopamine 
dysfunction to speech/voice. Possible relationships about neural architecture, 
lack of dopamine and hypokinetic dysarthria will involve only assumptions since 
there is no experimental evidence to prove them.
It is well known that speech production involves a series of movements of 
the articulators. Speech is considered a complex “product” rather than a simple 
series of movements involving levels such as semantic, syntactic, morphological 
and phonological. For reasons of simplicity these levels are not covered in this 
discussion. Instead, they will be partially covered in the following section that 
deals with theories of speech production. It is assumed that in the beginning of 
Parkinson’s disease (at least in the sample of Parkinsonian patients that are 
employed in this study), there are no cognitive problems (Levin et al., 1989;
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Levin & Katzen, 1995) that are associated with speech production (Murray,
2000).
Functionally, movement in leg and arm, but more importantly in mouth 
and face, is regulated through neuronal firing activity in the basal ganglia 
(Alexander & Crutcher, 1990). The pattern of this activity takes place through a 
sequence of levels of motor processing that translate the spatial characteristics 
of the target movement into an appropriate pattern of muscle activation. As has 
been stated, there is a specificity of function in neuronal groups in the basal 
ganglia regarding the location of target, the direction of limb movement, and the 
force of movement and/or muscle pattern. Movement in the mouth and face (and 
probably the speech movement) should be regulated through the basal ganglia. 
In speech, this is proven by the existence of hypokinetic dysarthria itself, where 
there is a dysfunction of basal ganglia. However, the time of the appearance of 
hypokinetic dysarthria may determine if speech/voice dysfunction is attributed to 
basal ganglia dysfunction or to other structures involved. Because Parkinson’s 
disease is a progressive neurological disease, it could be possible that 
hypokinetic dysarthria would be the result of the destruction of other 
neuroanatomical sites rather than basal ganglia that occur during the disease 
process. The question to be answered is when dysarthria affects the speech 
system. If it is affected early in the course of the disease then it is possible that 
the lack of dopamine creates speech/voice symptomatology in Parkinson’s 
disease as it does in the limb movement.
As stated above, the role of dopamine in normal human movement is to 
regulate the activity of the basal ganglia pathways. The destruction of 
dopaminergic neurons creates the clinical symptomatology of idiopathic
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Parkinson’s disease through an insufficient decline in the frequency of firing of a- 
motoneurons. This result involves bradykinesia (slowness of movement), rigidity, 
and tremor. Functionally, the lack of dopamine creates an incoordination of the 
automatic motor programs to complete a learned motor plan (Marsden 1982, 
1989, 1994). Marsden (1982) uses the example of a person who walks through 
the lobby of a hotel to pay his bill. As he walks he puts his hand in his pocket to 
take his wallet. The incoordination of the simultaneous activity of the motor 
programs (walking and putting the hand in the pocket) results in only one of them 
in time and makes the person to freeze in his position (motor plan was the idea 
of paying the bill). This incoordination is manifested not only in the simultaneous 
activity of different motor programs but also in the repetition of the same motor 
program (Marsden, 1989). Degradation in the repetition of movement as in finger 
tapping, micrographia, and hypophonia imposes a difficulty in generating long 
sequences of movement and reveals how the loss of dopamine can influence 
movement (Marsden, 1989). Under this concept, it would be logical to 
hypothesize that repetition of volitional movement of the articulators might reveal 
dysarthric symptomatology in Parkinson’s disease.
Along the same lines, Tetrud (1991) assumes that if dopamine is the chief 
modulator of automatic motor programs then its deficiency might be apparent in 
complex motor programs such as speech production and handwriting. Anecdotal 
reports by patients prove this fact (Critchley, 1981; Tetrud, 1991). Also, the 
majority of studies show that ievodopa reverses speech/voice symptomatology 
(Cahill et al., 1998; Gallena et al., 2001; Leanderson et al., 1971; Mawdsley & 
Gamsu, 1971; Nakano et al., 1973; Wolfe et al., 1975). However, there are 
studies that oppose the favourable effect of Ievodopa (Daniels et al., 1996; Gentil
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et al., 1998; Gentil et al., 1999; Poluha et al., 1998). The employment of subjects 
with variable duration of disease, a moderate disease in neurological 
symptomatology and different methodological issues may be the cause of these 
discrepancies. Duration of disease and the existence of motor complications 
may be confounding factors to the effect of Ievodopa not only in speech/voice 
but also in limb movement.
The primary neurological symptom in early Parkinson’s disease has been 
reported to be bradykinesia (Marsden, 1994; Scharre & Mahler, 1994; Tetrud, 
1991). In fact, the diagnosis of idiopathic Parkinson’s disease involves 
bradykinesia plus one of tremor or rigidity. It is also clear that rigidity creates the 
speech and voice symptomatology in hypokinetic dysarthria (Darley et al.,
1969a, 1969b; Duffy, 1995; Gentil & Poliak, 1995; Jiang et al., 1999; Kent, 1990; 
Ludlow & Bassich, 1984). One report however, states that it is bradykinesia that 
is responsible for hypophonia in Parkinson’s disease (Quinn, 1997). It remains to 
be answered if there is dysarthria in a sample of Parkinsonian subjects in the 
beginning of the disease where bradykinesia and tremor are the chief 
neurological symptoms. Tetrud (1991) supports the notion that speech/voice are 
sensitive measures to detect changes of the disease during its preclinical period, 
even before the neurological diagnosis. Similar studies in limb movement have 
found that the time for the upper limb movement as a correlate of bradykinesia 
was a useful measure to detect motor disturbances in early Parkinson’s disease 
(Watts et al., 1991).
In contrast, Marsden (1994) mentions that speech symptomatology start 
later in the disease process. It is possible that the discrepancies among these 
reports lie in the definition of dysarthria. Tetrud (1991) involves voice in
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dysarthria while Marsden does not. Medical specialists tend to involve 
hypophonia (reduction of voice volume) as a distinct entity that does not relate to 
dysarthria. This is one of the reasons that numerous studies in hypokinetic 
dysarthria involve different incidence rates (Coates & Bakheit, 1997; Hartelius & 
Svensson, 1994; Hoehn & Yahr, 1967; Logemann et al., 1978; Mutch et al.,
1986; Scott et al., 1985). The primary purpose of this study is to shed a light to 
these discrepancies and to propose possible explanations. Attempts will be 
given to explain the findings of this study through a presumed relationship of 
human movement to speech movement. Under this logic, a detailed discussion 
of the findings and a proposed mechanism of the speech symptomatology will be 
further explained in chapter 6.
In conclusion, studies in neuroscience and in neurology probably give 
important clues to speech pathology because they emphasize the role of basal 
ganglia in movement. A proposed relation of limb movement to speech 
movement will be assumed since speech production involves a series of 
automatic learned motor programs to produce a motor plan (articulate an idea). 
Even though this presumed relationship has not been considered straightforward 
by some researchers (Kent, Duffy, Slama, Kent, & Clift, 2001; Murdoch, 2001) 
their notions are based on evidence of the speech in advanced Parkinson’s 
disease. In contrast, the hypophonia and micrographia that are considered early 
symptoms of the disease prove this relationship along with studies that found 
that the simultaneous activity of walking and reciting names was more difficult in 
Parkinsonian patients than controls in both time and number of steps (Camicioli, 
Oken, Sexton, Kaye, & Nutt, 1998). A proposed synthesis of the 
neurophysiological findings with the neurological and speech symptomatology
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during the progress of Parkinson’s disease is shown below in Figure 12.
NEUROPHYSIOL
FINDINGS
THALAMOCORTICAL
NEURONS
a - MOTONEURONS 
DURING ATTEMPTED 
MOVEMENTS
NEUROL
SYMPTOMS
NORMAL High firing rate 
of BG output
Normal output -> 
activity
Normal frequency -> 
of firing
Kinesis
(movement)
PD Excessive -> 
output from 
pallidum
Reduced -> 
activity
Reduced frequency -> 
of firing
Bradykinesia 
Hypokinesia 
and tremor
ASSOCIATION OF NEUROLOGICAL AND SPEECH SYMPTOMATOLOGY 
AS THE DISEASE PROGRESSES
Bradykinesia -> Increased muscle -> Increased resistance Rigidity -> 
Hypokinesia tone in passive movements (slow and stiff
movement)
Hypokinetic
dysarthria
Figure 12. A proposed relationship of neural findings to speech symptomatology in idiopathic
Parkinson’s disease.
The reduced range of movement can be the result of hypokinesia itself but this 
did not seem to occur so consistently as bradykinesia in the findings of the 
present study.
1.7.4 Thoughts on neural speech control
Before giving an introduction to the theories of speech production, it would 
be appropriate to mention recent thoughts on neural speech control that are 
based primarily on a review chapter by Kent and Tjaden (1997). An 
understanding of neural speech control will help to clear inconsistencies or 
confusion about the role of basal ganglia in the overall complex of speech 
production. A brief outlook of structures that seem to be considerably important 
in speech production will follow together with a proposed function between them.
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Supplementary motor area (SMA) seems to have a particular role in 
speech production. The internal generation of movement and the execution of 
complex sequential movements are listed in the literature, among others, as 
capabilities of the SMA (Jonas, 1981; Kent, Kent, & Weismer, 2000; Kent & 
Tjaden, 1997). Kent and Tjaden (1997) hypothesise that if speech could be 
considered to consist of internally generated movements then SMA would be an 
active participant in speech control. Jonas (1981) states that the SMA:
• Makes easier the initiation of transmission of ideas (prepositional speech)
• Helps in the suppression of non prepositional (automatic) speech
• Might be involved in pacing of prepositional and non prepositional speech
• Can slow speech and cause variability in rate of speech emission.
In general, the control of articulation, phonation and rhythm mechanisms that 
underlie audible speech involves an intact SMA. Lesions in SMA can cause a 
different range of speech problems characterised by paroxysmal involuntary 
phonation/aphonia and articulation.
The concept of neuronal networks that has been discussed in the role of 
basal ganglia from Wichman and DeLong (1993) seems to influence ideas on 
cognition, and speech organisation and production. The general logic of a 
network is the transmission and retransmission of converging outputs from 
multiple cortical areas to other cortical and subcortical areas through specific 
functional patterns. In cognition, it is hypothesised that discrete cortical regions 
might be important for localization in elementary functions while widespread 
cortical and subcortical networks can be parallel processed for information and 
complex functions (BressJer, 1995). Bressler (1995) states that “this process may 
underlie the coordinated transfer of multimodal cortical information which has
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been postulated to occur both to the hippocampal region and to the basal 
ganglia” (p. 299). The same concept is proposed to underlie speech production 
(Kent & Tjaden, 1997). Paulesu, Frith, and Frackowiak (1993) suggested that 
SMA, cerebellum, and possibly sensory-motor areas might be involved in a 
general neuronal network that may be responsible for language planning and 
execution. Figure 13 below is from Kent and Tjaden (1997) and it describes 
neural structures and associated neurogenic disorders of speech.
Function Primarv Neural Structures Disorder
- Intention Fronto-limbic formations of the forebrain Mutism
- Linguistic- Cortico-cortical connections Aphasia,
Symbolic apraxia of
Processing speech
- Motor speech Wernicke’s area, Broca’s area, premotor Apraxia
Programming cortex, supplementary motor area, inferior of speech
or planning parietal lobule, inferior dorsolateral cortex 
cerebellum, basal nuclei
- Coordination Basal nuclei, cerebellum, motor cortex Dysarthria
- Execution Pyramidal and extrapyramidal motor pathways Dysarthria
Figure 13. Function, neural structures and associated disorders of speech (Kent & Tjaden, 1997).
Kent and Tjaden (1997) suggest a general framework of cortical and 
subcortical areas that might be involved in speech production. The inputs of 
information or neural impulses are the areas motor cortex, SMA, premotor 
cortex, somatosensory cortex, and superior parietal lobule. After their processing 
through the basal ganglia these inputs retransmit to premotor fields (SMA, 
premotor cortex, Broadman’s area 44, and cingulate cortex). From premotor 
fields the inputs are funnelled to motor cortex together with somatosensory 
inputs from the areas 1, 2, 5. Finally, the output is projected to motoneurons,
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premotor cortex, thalamic nuclei, striatum, red nucleus, brain stem and spinal 
cord (durai and ventral horns). The following diagram that is taken form Kent and 
Tjaden shows the aforementioned connections.
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Figure 14. Connections of cortical and subcortical areas that may be involved in speech
production (Kent & Tjaden, 1997).
Neuroanatomically, in each structure, there are neural specializations that 
contribute to its function. Kent et al. (2000) propose that the motor regulation of 
speech is organised in subcomponents (modules), in which every 
neuroanatomical site has its own role to speech.
Physiologically, the motor cortex is regarded as the area in which there 
are representations of muscles. Efferent microzones with each microzone 
representing individual muscles or muscle synergies are suggested to exist in 
the motor cortex. Many non contiguous motor cortex areas can give stimuli to a
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microzone and so a response will be triggered (Wiesendanger, 1986). Motor 
cortex is a working funnel for movement information from cortical and subcortical 
areas and can be considered to work as a keyboard whose keys are specific 
muscles or muscle synergies. Each muscle or muscle synergy will be 
represented by more than one key and damage to the whole system (keyboard) 
will affect the muscle responses, although multiple representation can overcome 
this result by triggering responses in the context of other movements (Kent & 
Tjaden, 1997). The motor cortex selects the activation of individual muscles in 
order to accomplish a motor plan (Kent et al., 2000).
However, it is not clear how all the information that is organised and 
processed by the motor cdrtex is produced by the speech production 
mechanism. Numerous theories of speech production have been proposed to 
solve this problem. A brief review of some of them will follow.
1.7.5 Theories of speech production
Many theories are trying to answer the question of how speech is 
organised and produced. These theories struggle to address three major 
problems: the regulation of serial order of speech, the degrees of freedom, and 
the context-sensitivity problem (Kent, 1997; Lofqvist, 1997). The regulation of 
serial order of speech aims to answer what is the minimum unit of speech 
production and how it is ordered to produce speech. The degrees of freedom are 
the different movements or the muscle contraction alternatives. The degrees of 
freedom problem aims to discuss how a system can manage so many different 
movements (degrees of freedom) to produce a specific motor response. Finally, 
the context-sensitivity problem is concerned with the variation of sound
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production in relation to the context of production.
Stage theories (translation theories) support the notion that speech is 
produced in a series of stages starting with the translation of a mental 
representation and ending with an articulatory command (Kent, 1997; Lofqvist, 
1997). Information from one stage is passed to the next stage. Stages (from the 
highest to the lowest level) such as segment specification, feature composition 
and motor command generation, are involved in these theories. Segment 
specification is related to language formulation by defining the segments that 
construct the phonetic message. Feature composition involves the redefinition of 
the segments as phonetic features. Place and manner of articulation are such 
features. Finally, motor cohnmands are involved to make features into 
movements by giving instructions to individual muscles for the duration and 
length of their contractions.
, In stage theories the results of every stage are passed on to following 
stages in a ‘top-down’ fashion and this creates a challenging issue “to 
demonstrate the reality of any one stage in the sequence” (Kent, 1997, p. 408).
In other words, every muscle needs to take commands from stages above and 
this probably creates problems when a series of muscles are needed for an 
intended sentence to be produced. This phenomenon points to the concept of 
the degrees of freedom. The control of a motor system that is explained by the 
translation theories needs an enormous amount of information processing in its 
higher levels in order to give instructions to specific muscles to carry out the 
speech production. In contrast to translation theories, research on physiology 
showed that even complex motor actions are not controlled and coordinated in a 
purely ‘top-down’ fashion, but at the lower levels (Wilson & Morton, 1990).
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Because this study aims to explain physiological phenomena in speech 
production (lack of dopamine in the basal ganglia), the top-down fashion of the 
translation theories does not seem to suit to its purpose.
The action theory of speech production aims to solve the degrees of 
freedom problem. This theory was thoroughly discussed during the eighties 
(Fowler, Rubin, Remez, & Turvey, 1980; Kelso, Saltzman, & Tuller, 1986). It 
states that the vocal tract, including the mandible, the lips, and the larynx, works 
as a system that is connected by equations of constraints. The components of 
this system function under this principle. Coordinative structures “marshall the 
articulators temporarily and flexibly into functional groupings of joints and 
muscles that can accomplish particular goals in speech” (Kelso et al., 1986). 
Lofqvist (1997) adds that the coordinative structures are coherent patterns of 
muscle activity that are set spatially (same set of muscles could be activated), 
temporally (synchronous movement and stable order) and connected with scaled 
relationships.
The notion of coordinative structures resembles ideas from physiology 
that the brain is organised into efferent microzones innervating into muscle 
synergies (Wiesendanger, 1986). The muscle synergies or the idea of a motor 
area that works as a “keyboard” points to the concept of the coordination of 
muscles. A group of muscles or a group of muscle collectives functions as a 
coordinative structure (muscle synergy) in which “indices^ of the individual 
muscles or individual muscle collectives appear to covary in terms of a relatively 
fixed relationship that is indifferent to overall magnitude changes in the indices” 
(Kent, 1997, p. 394). Wilson and Morton (1990) state that “individual muscles or
 ^According to Kent (1997), the index of a muscle is defined as the level of innervation or the time 
relative to the group of muscles behaviour at which a nnuscle is innervated.
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muscle groups will be constrained to act in a coordinate fashion by the output of 
subcortical systems for pattern generation” (p. 346).
Figure 15 is taken from Wilson and Morton (1990) and shows the 
organization of coordinative structures. In this figure “m" represents a muscle 
and “CS” a coordinative structure. In this ‘nested’ organisation the coordinative 
structures at the lower level form elements at the higher level tied up with 
equations of constraint. In this organisation lies the basic difference between the 
action theory and the translation theories (Wilson & Morton, 1990).
CS
OSCS
CS C SCS
m1 m2 m3 m4 m5 m6 m7 m8 m9 m10 m11 m12
Figure 15. Nested coordinative structures (taken from Wilson & Morton, 1990).
Neurophysiologically, Grillner (1982) supports the notion that locomotion 
is attained by a system with a ‘nested’ structure as it is shown above. This 
structure is responsible for coordinating all necessary muscles and muscle 
groups to achieve a walking pattern. One nesting (the most basic) is called ‘unit 
central generator’ or ‘central pattern generator’ (CFG) and it is responsible for
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ccntrolling the-rhythmic activity among the members of its respective muscle 
gnups. CPGs provide the necessary rhythm for life functions such as 
respiration, locomotion, and mastication (Chandler & Goldberg, 1984).
Speech is viewed as a complex function that is based and developed on 
functions such as mastication. Gracco (1992) hypothesises that a central rhythm 
generator provides the framework on which the speech patterns (phonemes) 
sequence. It is generally hypothesised that CPGs are present in the brainstem 
and so, it is there that the centre for sequential speech production exists. The 
unt central generators do not have the need to be controlled every single time 
from a higher level. Instead, they have the neural mechanisms for independent 
bursting output and independent control of muscle phasing or coordination of 
muscle action. A central pattern generator network activates a number of unit 
generators that are responsible for the coordinated activity of muscle groups and 
joirts throughout the limb. The function of the motor-control network involves a 
scaling of constraint in which the number of specific elements in the system that 
must be controlled to achieve patterned motor action at output is reduced at the 
nested levels.
Equations of constraint govern the functioning of the coordinative 
structures. In particular, the coordination of muscles depends on the 
specification of the equations of constraints. An equation of constraint is the 
base at which individual muscles will work. Wilson and Morton (1990) provided 
an example of an equation of constraint.
GOAL <-(0.2 of muscle 1) x (0.7 of muscle 2) x ...(n of muscle j)
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In this example, the goal is a particular position of the tongue following the action 
of several extrinsic tongue muscles. A change in one parameter of the 
coordinative structure for the achievement of the goal will create reciprocal 
changes in the activity of the other elements of the system, and so, the goal will 
remain constant.
If one of the variables in the equation of constraint is fixed, the other 
variables will adjust to meet the fixed value of the equation. If for example a bite 
block is inserted in the mouth during the production of a vowel, the muscle 
synergy will be adjusted to take values that will attempt to preserve the vowel 
quality (if it is attainable). If this happens the effect of the bite block will be 
negligible. For example, the closure of the lips can be attained in different ways:
• The contraction of the muscles of the upper and lower lips if the jaw is 
immobile
• The cooperation of the jaw if it is free with the lip muscles or
• The movement of the jaw to hold the lips if the lip muscles are inactive 
(Kent, 1997).
Another theory that attracted much attention after the late eighties is the 
theory of spreading activation of retrieval in sentence production (Dell, 1986). 
This theory is a part of a general framework of theories, the so-called 
connectionist theories. An alternative name for these theories is neural networks 
because of their assumptions on the organisation of information to resemble 
neural circuits (Kent, 1997),
The spreading activation theory of retrieval in sentence production attracts 
more attention because of its modelling application of speech errors in some 
neurological disorders including the apraxia of speech (Kent, 1997). A
122
description of this theory will follow based primarily on the work by Dell (1986) 
together with possible inferences for speech errors in hypokinetic dysarthria.
The roots of this theory are in spreading activation models which 
hypothesise the existence of a network of linguistic units and rules. In Dell’s 
theory, this network contains nodes for linguistic units (concepts, words, 
morphemes, phonemes, and phonemic features) that are connected to each 
other without an order and together represent the lexicon. Dell’s theory is 
primarily based on three general assumptions about the information:
• It is stored in the lexicon
• it is represented as generative rules at different levels and
• There are additional rules that connect the lexicon and the different 
levels (insertion rules).
A principal assumption of this theory is the existence of different levels 
and the construction of each planned utterance at various times in each level. 
Dell (1986) describes five levels: semantic, syntactic, morphological, 
phonological, and motor. The ordering of the differential representation in 
different levels of this theory presents similarities to the translation theories. One 
of the basic differences between them seems to be the existence of nodes in 
each level of representation.
Each level is the final product of rules (generative rules) operating in it. 
These rules define or codify the language specific acceptable combinations of 
items at each level. The syntactic rules represent syntactic categories (noun, 
verb, etc.), the morphological rules represent morphological categories (stem, 
prefix, suffix, etc.), and the phonological rules represent phonological categories 
(initial stop, vowel, etc.). This codification is created by frames and categorised
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slots. Finally, the selection of words at the syntactic level, the selection of 
morphemes at the morphological level, and the selection of phonemes at the 
phonological level is attained by insertion rules that operate to connect the 
lexicon and the generative rules. A description of how each representation is 
built will follow. Figure 16 represents the frames and slots in each level using an 
example sentence by Dell (1986).
THIS CO W
i
EATS
1
GRASS
1
Syntactic frame Determiner Noun Present-tense verb Noun
M orphol. Frame Stem Stem Stem-Affix Stem
Phono!. Frame I C V F C I C V F C
1C = initial consonant 
V = vowel
FC = final consonant
Figure 16. Frames and slots at each rule system operating at each level
of representation.
Each representation at each level consists of an ordered set of items that 
exists in the lexicon. Dell (1986) describes it as “a collection of ordered tags that 
are attached to nodes in the lexical network, dictating the contents of the 
representation and their order” (p. 287). The construction of a higher 
representation precedes the construction of a lower representation. A spreading- 
activation mechanism helps in the processing, of activation of nodes that may be 
used for a lower representation while the higher representation already has its 
own tagged nodes. So, a frame for the lower representation is built by the 
generative rules and the insertion rules fill in its slots through spreading 
activation. Spreading activation is considered the major mechanism of prediction
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of speech errors in Dell’s theory. An item selection for a slot, results in the 
receipt of a tag. The rate of processing depends on the mechanism of the level 
and the level above it.
The mechanism of spreading activation is based on processes such as:
• Spreading (it is defined as the process by which a node with an 
activation level greater than zero sends a proportion of its activation 
level to all nodes)
• Summation (it is defined as the adding to the activation level of a node 
of the activation that this node receives from other nodes) and
• Decay (it is defined as the natural decay of activation and it is 
determined by tfie time of its activation).
According to Dell, spreading occurs when a node has an activation level above 
zero, and decay occurs when a node has an activation level toward zero. The 
theory speculates that the construction of the lower representation begins after 
the node of the higher representation is tagged. An important hypothesis of the 
theory is that the connections between the nodes are two sided (from node A to 
B and from node B to A) in order for the message to deliver positive feedback 
from the later stages to the earlier stages. Excitatory rather than inhibitory 
processes are involved in the theory.
According to Dell (1986), articulatory errors generally happen from the 
function of spreading activation and the construction of multiple representations. 
As it is logically expected the process of articulatory errors involves higher 
activation of incorrect items instead of correct items. Speech errors can be 
explained by this theory through factors such as output biases (tendency of 
speech errors to create meaningful combinations of units), similarity effects
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(when interacting items or words in an error tend to be similar), speech rate 
effects (when there is not enough time for the retrieval of the correct items), and 
distance effects (when misordered sounds tend to move to adjacent content 
words that are in the same phrase).
In general, none of the theories that mentioned in this section have a 
direct association with hypokinetic dysarthria. This is because the articulatory 
errors in hypokinetic dysarthria are predicted to be more as distortions of the 
phoneme target rather than substitutions or deletions. More specifically, the 
errors appear to reflect an inadequate tongue elevation to achieve complete 
closure on some phoneme categories (stops and affricates) and less constriction 
(open aperture) in fricatives (Logemann & Fisher, 1981). A general theory of 
speech motor control needs to include internal models of the articulators, 
rhythm-based sensory-motor integration and specification of articulatory 
dynamics within a motor program (Kent et al., 2000). Up to now, no such a 
theory has explained hypokinetic dysarthria of Parkinson’s disease.
Translation theories have the disadvantage of the degrees of freedom 
problem and serial ordering to explain physiological phenomena. The action 
theory addresses the degrees of freedom problem but still has not address yet 
problems in dysarthria. The spreading-activation of sentence retrieval theory has 
been applied to apraxia and conduction aphasia and its modelling performed 
fairly well for errors in normal speech (Kent, 1990). However, no apparent 
connection of this theory with dysarthric errors has been modelled.
However, Kent and his colleagues hypothesise the existence of sensory 
trajectories or templates that include patterns of auditory, proprioceptive and 
tactile information and precede the motor commands for speech production
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(Kent, 1990; Kent et al., 2000). These trajectories are assumed to be the next 
stage of the phonological level in Dell’s theory and help in the motor realisation 
for speech. Kent assigns a sensorimotor role to the basal ganglia and 
hypothesises that damage to the sensory trajectories due to impairments in 
afference, together with the motor role of the basal ganglia, are responsible for 
hypokinetic dysarthria. This hypothesis comes in contrast to the ideas by 
Marsden (1982, 1994) about the unitary motor function of the basal ganglia in 
human movement. In any case, it is doubtful (even though not improbable) that 
impaired sensory information occurs in the beginning of Parkinson’s disease (as 
the present study examines).
1.8 Conclusion and research questions
The present study aims to investigate the existence of hypokinetic 
dysarthria in the beginning of Parkinson’s disease. The perceptual features that 
were reported to be more prominent in hypokinetic dysarthria were monopitch 
and monoloudness (Darley et al., 1969a, 1975). The advent of new techniques 
(electrolaryngography), might be able to measure quantitatively aspects of voice 
such as fundamental frequency and intensity that correlate to the perceptual 
impressions (monopitch, monoloudness) in various tasks including sustained 
phonation, reading, and conversation. Dysarthria and intelligibility as parts of a 
motor speech examination are also addressed and possible inferences about 
movements (speech and non speech) of the articulators are emphasised.
More specifically, the experimental questions that are addressed here 
involve:
1 ) What is the incidence of hypokinetic dysarthria in patients recently diagnosed
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with idiopathic Parkinson’s disease as defined by the Frenchay Dysarthria 
assessment and intelligibility?
2) What is the effect of Parkinson’s disease on speech/voice parameters in 
patients early diagnosed with idiopathic Parkinson’s disease and compared to a 
control group matched by age and gender?
3) What is the effect of medication on speech/voice parameters of the dysarthric 
Parkinsonian group 3-3.5 months after the neurological and speech diagnosis?
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CHAPTER 2. BACKGROUND TO THE METHODOLOGY
The purpose of this chapter is to analyse and further justify the decisions that 
were taken during this study. This chapter aims to explain the choice of the 
research design, the use of the particular instruments, and the control of extraneous 
factors (vision, hearing, and posture). It was developed using the logic of a critical 
examination of the literature and the procedures of research study, which are 
outlined in chapter three. In order to facilitate its reading the sections in this chapter 
are organised in much the same way as the order of the motor speech assessment 
procedure.
In contrast to chapter 3, which describes the current study, this chapter 
analyses and discusses in detail the methodological advantages and 
disadvantages.
2.1 Matching criteria in the experimental/control group and the validity of
the research design in this study
This section aims to explain the reasons for the inclusion of a normal control 
group to the experimental group, the criteria of matching and other factors that may 
affect the internal and external validity of the study.
In general, Parkinson’s disease is considered a geriatric disease, in later 
developmental stages of life, general health problems (e.g., diabetes) and specific 
health problems (hearing, vision) may arise. Among the geriatric population, there is 
a greater variability in the appearance of these health problems and a reported 
variability in speech performance when older subjects were compared to young
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subjects (Liss, Weismer, & Rosenbek, 1990; Weismer, 1984a; Weismer & Martin, 
1992). The Inclusion of a normal geriatric group to be compared to the Parkinsonian 
group in speech/aspects of voice aims to counterbalance this variability.
Pair matching is a technique that is used to minimise the differences between 
populations. It generally provides more control than matching around the mean 
(Schiavetti & Metz, 1997). Pair matching is considered a method that increases the 
sensitivity of the study to small effects of the independent variable to dependent 
variable (Schiavetti & Metz, 1997). In the present study, pair matching was selected 
to decrease the variability that may contribute to the measurement of 
speech/aspects of voice between the two samples (Parkinsonian and control). 
Differences such as age, gender, and education were considered in the pair 
matching.
The criteria of matching were as follows:
• In age: a difference of less than 3 years between the pair members
• In gender: no sex differences between the pair members
• In education: fluent reading as defined by at least 4 years of education at 
elementary level. As such, emphasis was given to finding pairs with no 
difference between the pair members in terms of education: elementary 
education (4-6 years), high school (12 years), and university level (more 
than 12 years).
Age and gender matching criteria are used in most of the studies that compare an 
experimental and a control group. Education was added as a criterion in the present 
study because similar reading abilities between the subjects (Parkinsonians and
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controls) were considered essential to evaluate voice variables through a reading 
task.
In theory, mood disorders may also influence and be influenced by speech 
but more specifically voice (Aronson, 1990; Darby, Simmons, & Berger, 1984). The 
voice changes are prominent in affective disorders (psychiatric syndromes) 
exhibiting narrow pitch range, infrequent pitch changes, reduced stress or emphasis 
patterns and harsh voice quality (Aronson, 1990). Distinctive speech patterns that 
were improved after pharmacological treatment were found in bipolar and unipolar 
disorders (Darby et al., 1984). However, the association between speech 
disturbance and scores on the Hamilton depression scale was found to be non 
significant (Darby et al., 1984).
In Parkinson’s disease (PD) the prevalence of depression is about 40% as 
shown in review studies (Cummings, 1992; Poewe & Luginger, 1999). Depression 
has been found to be unrelated to the duration/response to levodopa therapy 
(Dooneief et al., 1992) and the disease duration (Cummings, 1992; Rojo et al., 
2003). Poewe and Luginger (1999) discuss if depression is an early or late feature 
of PD. They report that there are two peaks in its occurrence. The beginning of PD 
and its late advancement affect depressive episodes. Also, advanced Hoehn and 
Yahr staging was found to be associated with depression (Rojo et al., 2003) while 
the opposite was reported in another study (Cummings, 1992). Finally, depression 
has also been associated with low scoring in Mini Mental State Examination 
(MMSE) (Rojo et al., 2003).
Diagnostic difficulties may affect the results in the prevalence of depression
(McDonald, Richard, & belong, 2003). A deficit in facial expression of patients with
Parkinson's disease due to motor abnormalities (akinesia or bradykinesia) may be
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perceived as depression in the absence of actual depression (Poewe & Luginger, 
1999).
Although speech/voice have been associated with depression (Aronson, 
1990; Darby et a!., 1984), only one fairly recent study has been found to examine 
their association with the depression of Parkinson’s disease (Sapir et al., 2001).
This study aimed to associate perceptual ratings of speech/voice with other 
variables including depression in 42 Parkinsonian patients. Only 6 out of these 
patients had a disease duration of 1 year (average disease duration = 7.1 years) 
and only one was in stage 1 of the Hoehn and Yahr scale (average Hoehn and Yahr 
stage = 2.6). The results of this study showed that the prevalence and number of 
voice and speech abnormalities were unrelated to depression scores.
In summary, further research is needed to associate speech/voice 
abnormalities to depression in Parkinson’s disease. The results by Sapir et al.
(2001) show that depression in PD does not affect phonation in subjects with 
moderate stages of Hoehn and Yahr scale and a mean of 7 years of disease 
duration. However, it seems reasonable to hypothesise that in the absence of more 
studies to examine this area, the assessment of depression needs to be included in 
studies examining speech/voice in neurological diseases. It is a limitation of the 
present study that no assessment of depression took place, although the possibility 
of its occurrence seems to be low according to the aforementioned studies.
2.1.1 Internal and external validity between groups
The main purpose of the between subjects design is to eliminate influences
of extraneous variables that can threaten the internal and external validity of the
results. In every research study, the internal validity is dependent on the degree to
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which the between groups design has accomplished what it set out to accomplish. 
The external validity asks about the degree to which the results can be generalised.
In internal validity, test-practice effects, instrumentation, differential selection 
of subjects, and the Hawthorne effect may crucially affect the differences between 
the Parkinsonian and the control group. These factors will be explained in detail 
below.
In the current study, familiarity with the assessment items (test-practice 
effects) between the two groups was not considered a factor that could influence 
subjects' performance because each assessment session involved different 
assessment tools. The first session involved the completion of the history form and 
the administration of the Mini Mental State Examination (MMSE). The second 
session involved the administration of the Frenchay Dysarthria Assessment (FDA) 
and intelligibility testing, and the third session involved the recording using 
electrolaryngography (ELG).
The administration of the tests took place in the same order for each subject 
to avoid variability in measurement-(instrumentation). With regard to the testing, the 
Frenchay Dysarthria Assessment (Enderby, 1983) and the Mini Mental State 
Examination (Folstein, Folstein, & McHugh, 1975) are standardised tests. The 
intelligibility testing involved a list of words based on minimal pairs for both the 
experimental and the control groups. The subject's reliability in intelligibility 
estimation was not an issue in this study because all subjects scored above 90%. 
With regard to instrumentation, the electrolaryngograph was a calibrated machine 
newly purchased specifically for this study. With regard to the conditions of the 
electrolaryngographic recordings, the placement of the equipment and the location
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of the recordings were the same for all subjects. Efforts were made to ensure that 
the control and experimental subjects were recorded at the same time of the day.
As stated above, the experimental subjects were matched in pairs to the 
controls so no differential selection threatened the internal validity. Changes in 
behaviour because of knowledge of experimental participation might have been a 
threat to the present study (Hawthorne effect). These changes might have occurred 
because the psychological state of the experimental subjects was not appropriate in 
the first session for a person who has just been informed that he/she has 
Parkinson’s disease. For this reason, a general conversation was carried out 
between the subject and the experimenter before the assessment, especially during 
the first meeting, to acclimatise them to the research situation.
External validity is a problem for all comparative research, especially when 
human beings are measured in performance. Reactive arrangements are factors 
that can be a threat to external validity. Reactive arrangements on the part of the 
subjects involve the degree to which the setting of the research might react with the 
classification variable (Parkinson’s disease) in determining the subjects’ 
performance on the criterion variable (speech/aspects of voice). For example, 
reactive arrangements in the current study involved the use of a quiet place for the 
recordings. Careful consideration was taken to exclude other influences such as 
telephone ringing. The electrolaryngographic measurements were all taken in the 
same place (the examiner’s office), at a specific time and with each subject in the 
identical position. Even though no consideration was given to controlling the level of
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noise in the room (use of a sound level meter)^ the necessary precautions were 
taken (closed door and windows and the absence of third parties during the 
recording).
2.1.2 Internal validity within group (medication state)
After discussing the factors that could affect the internal and external validity 
in the between - groups design, attention must also be given to factors in the within 
-group design (the effect of medication). In general, the within subjects research 
design is considered a more powerful design than the between - groups design 
because the experimental subjects act as their own control group by participating 
before and after medication. However, sequencing effects (order effect and carry­
over effect) may affect the performance of subjects.
The order effect involves an improvement or a decrease in the performance 
of each subject either through learning the task by participating in it or because of 
fatigue. The fatigue in the present study was controlled by splitting the examination 
into 3 consecutive sessions of a short duration (one for every day). The provision of 
different tasks of short duration in every session controlled the learning effect. The 
carry-over effect Involves the influence of one task on subject's performance on the 
subsequent task. In this study, this involved the period of time that elapsed between 
sessions. In the pre-medication state, the first session that involved the completion 
of the history form took place in the hospital and did not last more than 40 minutes. 
The second session took place in the home of the subject and lasted no more than
 ^The sound level meter is calibrated in dBs with a reference level tc provide accurate measurements 
of intensity. In the absence of a sound level meter, relative intensity of the voice signal was 
measured. The electrolaryngographic fundamental frequency measures are not affected by extreme 
noise.
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an hour Finally, the third session took place in the researcher’s office and did not 
last more than 30 minutes. Each session involved different aspects of performance 
and so the subject’s interest was assured. Because this was the first time that such 
a study was being carried out in Greece, the subjects reacted positively. In the post­
medication state, the sessions took place after 3-3.5 months and the subjects could 
not remember the content of the previous test. In conclusion, fatigue, order and 
carry-over effects did not seem to affect the external validity of this study.
2.2 Hoehn and Yahr neurological scale
The Hoehn and Yahn Functional Rating Scale (Hoehn & Yahr, 1967) has 
been used in the majority of neurological studies to indicate level of severity in 
Parkinson’s disease. A short description of this scale will follow.
Hoehn and Yahr (1967) stated that their scale has two basic advantages: it is 
practical and it allows for reproducible assessments by independent examiners.
This scale ranges symptomatology from mild to severe disability. It is divided into 5 
stages (I - V). In each stage the symptomatology progressively worsens until the 
final stages. For example, stage IV involves the existence of rigidity, akinesis, poor 
standing balance, and poor fine motor coordination with severely disabling results 
for the patient (affecting ambulation at home and the need for assistance in self- 
care skills). In contrast, stage III involves a festinating gait but the attendant’s 
assistance is not as frequently required. In this stage the patient’s disability is 
manifested when he/she starts, turns, stops, and steps backward. According to the 
authors, a longer duration of the disease is associated with the later stages. A 
description of the scale cited by Yorkston et al. (1995) is given in Appendix B. In the
present study, all experimental subjects were in stage I of Hoehn and Yahr scale.
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According to Hoehn and Yahr, the symptoms of the disease in stage I involve mild 
resting tremor, rigidity, bradykinesia, dysarthria, trunk tilt, fine motor incoordination, 
and facial immobility. These symptoms are unilateral and just noticeable (not 
disabling).
2.3 Exclusion criteria in this study. Factors other than the experimental 
variables controlled for in the study
The exclusion criteria involved developmental problems of speech and 
language, visual problems, hearing problems, reading problems, and cognitive 
problems. The existence of each one of these extraneous factors could add doubtful 
matching between the subjects and could lead to arbitrary confounded results. A 
discussion for the control of these factors together with factors that could influence 
the quality of the recordings will follow.
2.3.1 History of speech and language problems, vision, hearing and reading 
skills
A previous history of speech and language problems, inadequate vision, 
impaired hearing, and inadequate reading skills were determined as factors that 
needed to be controlled in this study. Also, present history of laryngeal pathology 
and levodopa medication before the neurological diagnosis, were also taken into 
account. It is a common practice in almost all studies of dysarthria to control the 
aforementioned factors. All these factors were assessed informally through the 
administration of the history form and through a conversation with the subjects and 
relatives.
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Questions involved the existence of any speech and language problems 
during childhood and whether these problems still interfered with the subjects’ lives. 
Other questions explored the existence of present hearing and visual problems that 
could affect performance in the tasks of the study. Finally, the reading ability of the 
subjects was assessed through questions during the interview and the assessment 
of cognitive status. Illiterate subjects were excluded from the study. The task that 
was predicted to interfere most with all the aforementioned factors was the reading 
of a Greek passage. This passage is complex because it involves most of the 
consonants and consonant clusters in almost all positions in the Greek language. 
Two subjects were found to^exhibit a present history of laryngeal pathology (PX9) 
and a past history of levodopa medication (PM7). For this reason, PX9 was not 
compared with her matched pair control (in the between - groups design) but she 
was used in the effect of medication to see if levodopa medication had a differential 
effect on her speech/voice. PM7 stopped levodopa medication 6 months before the 
speech/voice assessment. Because this period of time is felt to be insufficient to 
interfere with his speech/voice, this subject was included in the sample.
2.3.2 Cognitive status-The Mini Mental State Examination (MMSE)
The Mini Mental State Examination (MMSE) is a quick test to assess
cognitive function and it is especially useful in the recognition of dementia in
patients (see Appendix C for the English and Greek copies of the test). In its original
form (Folstein et al., 1975), it was proposed as “a quantified assessment of
cognitive status of demonstrable reliability and validity” (p. 195). MMSE has been
used around the world and has been proved to be robust to assess cognitive ability.
Furthermore, it has been used as a core cognitive measure in a number of major
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epidemiological studies and instruments including the Medical Research Council 
Cognitive Function and Ageing Study in the United Kingdom (Shulman & Feinstein, 
2003). Its construct validity in longitudinal studies of dementia shows a decline of 
scores (2-5 points) per year in subjects.
In most of the studies, the MMSE cut-off value that indicates cognitive 
disturbance is 23 or 24 out of 30 (30 being the maximum score). Anthony,
LeResche, Niaz, Von Korff, and Folstein (1982) found that the sensitivity (probability 
of correctly identifying any case) and specificity (probability of correctly identifying 
any non case) percentages for the MMSE scores (from 0-23) were 87% and 82% 
respectively. According to them, the test was highly specific in detecting delirium 
and dementia in subjects less than 60 years old with more than eighth grade level of 
education. However, some limitations of the MMSE have been reported.
The MMSE's total score proved not to be a strong predictor of cognitive 
status in 251 Swedish adults over 75 years (Hill & Backman, 1995) and in subjects 
over 85 years, subjects from manual social class and subjects with some visual 
impairment in the United Kingdom (dagger, Clarke, Anderson, & Battcock, 1992). 
However, when taken separately, the questions that test memory, spatial skill, and 
the ability to follow commands proved to be good predictors of cognitive ability (Hill 
& Backman, 1995).
Grigoletto, Zappalà, Anderson, and Lebowitz (1999) aimed to find norms for 
the MMSE in 908 healthy adults aged 20-79 years. The authors found that the 
norms proved to be higher in the population with higher education. Elderly women 
with a low educational background exhibited difficulties during the administration of 
MMSE. Similar to the other studies, this study proved that low educational
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background, age, and gender were important factors for lower performance in the 
MMSE.
The current study used the Mini Mental State Examination (MMSE) to assess 
cognitive ability. However, the Parkinsonian subjects expected to be close to normal 
in MMSE scoring, being at the beginning of the disease. Impairments in executive 
function in Parkinson's disease coincide with stages 2 and 3 in Hoehn and Yahr 
scale and with the appearance of bilateral symptomatology (Kanazawa et al., 2001). 
So, the use of MMSE was a further factor of insurance of no cognitive impairment at 
the beginning of Parkinson’s disease, even though MMSE is not considered a 
detailed test for cognitive assessment (see a recent discussion by Shulman and 
Feinstein, 2003). The score below 24 was used as a cut-off score for cognitive 
status. Only one subject was excluded from the study (KM 12). This subject had a 
low educational background, and as expected she exhibited a lower performance. 
Moreover, the appearance of other factors in this subject (hearing problems) made 
any further testing unnecessary. One subject (SB5 ) was above 75 years of age but 
he was from an upper social class and with a higher education.
In conclusion, the existence of dementia/cognitive problems in the present 
study was examined in two ways. First, during the administration of the history form 
that took place by checking the accuracy of the demographic and other information 
provided by the subject together with a relative who accompanied the subject. 
Second, through the administration of the MMSE and its scoring. Therefore, none of 
the prohibiting factors of cognitive score that mentioned in the aforementioned 
studies, seemed to affect the present study.
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2.3.3 Posture, microphone, setting, and location during recording
During recording, extraneous variables such as posture, location, and 
microphone distance were stable. In this study, the control of these variables was 
similar to other studies, especially acoustic studies that used the same standard 
procedures. With regard to posture and setting, it was necessary for the subjects to 
sit on a chair either in their homes (second meeting) or in the office of the 
experimenter (third meeting). During the administration of the dysarthria 
assessment and the consequent intelligibility scoring, the recording took place at 
the subject’s house in a quiet room and it was attempted to ensure that noises such 
as the telephone would not disturb its quality. It was imperative to the current study 
that the electrolaryngographic recordings would be carried out in the same location 
(the office of the examiner) and that all subjects would be seated in the same 
position.
With regard to microphone distance, different procedures took place in the 
assessment of the intelligibility score and in the electrolaryngographic 
measurement. In the intelligibility assessment it was necessary for the subject to 
read one word on each card.that was presented by the examiner while his/her 
speech was tape-recorded through a stereo microphone located on a boom stand 
on the table. The experimenter asked the subjects to keep a constant distance from 
the microphone (about 15-20 cm). During the electrolaryngographic recordings, a 
standard distance from the microphone to the mouth of the subject was maintained 
at all times. The microphone was attached to velcro about 12 cm from the 
electrodes (on the neck of the subject). The subjects were asked to move their 
heads as little as possible during recording in order to keep the microphone
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distance stable and to ensure the best quality of electrolaryngographic 
measurement.
2.3.4 Time of assessment
In general, the time of the day in neurological studies is considered an 
essential factor for the success of the study, because of the influence of the disease 
on the physical state of the patient during the day. In many studies the subjects’ 
relatives have been reported to observe that “his/her speech worsens in the evening 
and at night”.
In the present study, 'the above observations were taken into consideration 
even though the experimental subjects were at the early beginning of the disease 
and it was predicted that they would not exhibit such fatigue problems. Most of the 
recordings took place in the morning (approximately 10:00-11:00 am). However, 
there were cases when the experimental subjects were unable to come to the 
examiner’s office due to work commitments. In such cases, the recordings took 
place in the early evening (6:00-7:00 p.m.). In order to control for such changes of 
time within the experimental and control groups, efforts were made to record control 
subjects’ speech/voice at almost the same time as their matched experimental 
subjects.
2.4 Motor speech examination and the development of the history form
An analytical motor speech examination should include the following:
• A completion of a history form (which the examiner will go through with 
the patient and/or relatives during the interview)
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• An examination of the speech mechanism during non speech activities
• An assessment of speech intelligibility
• An acoustic analysis including vowel prolongations, Alternating Motion 
Rates (AMRs), reading of a passage, and conversation.
The development of the history form will be discussed in this section while the 
examination of the speech mechanism during non speech activities, the 
assessment of speech intelligibility and the acoustic analysis of speech are 
explained in the subsequent sections.
The development of the history form requires detailed knowledge-of specific 
parameters that may have crucial importance to the motor speech examination. 
Such parameters involve detailed biographical data, facts about the onset and 
course of the speech symptomatology and other relevant data. The history form is 
based on the patient's and/or family’s perceptions of the speech problem.
Duffy (1995) suggested a list of factors that a history form should include. 
The current study used these suggestions in the development of the history form. 
These factors were organised in the form of groups of questions to the subjects. 
The first group included biographical information about age, education, occupation, 
marital and family status, developmental speech/language problems, and 
visual/hearing problems if they existed. The date of diagnosis as well as the 
duration for the completion of the history form was also included.
The second group of questions included information about the onset and 
course of the speech deficit and the patient’s perception of it. Questions that were 
considered useful included:
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“ Do you have any difficulty with your speech? If not, has someone else 
commented on a change or problem with your speech?” (Duffy, 1995,
p. 68).
“Has the speech problem changed over time? Is it better, worse, stable, 
better-then-stable, fluctuating?” (Duffy, 1995, p. 68).
This group of data also included questions about associated deficits such as 
problems in chewing, swallowing, emotional fluctuations, and medication that 
seemed to affect speech.
The third group included questions about the patients’ perception of deficit 
(i.e., how their speech sounded when the disease began), a description of the 
current speech difficulty and the consequences of the disorder on the 
disability/handicap of the patient (if any), in addition, questions about possible voice 
problems were also included. The final group of questions sought information about 
the management of the speech problems and the awareness of diagnosis and 
prognosis by the patient. Other questions that seemed to be relevant in this study 
were also included. These included information on smoking, drinking, and any 
medication that may have been taken by the patient before the motor speech 
examination. Appendix D involves copies of case history forms in the Greek and the 
English language.
Overall, the history form that was developed for the current study aimed to
gather a detailed description of all the information that may be beneficial to the
examiner. Apart from the history form, an examination of the speech mechanism, an
intelligibility assessment and an acoustic analysis of speech should normally be
included in the motor speech examination. In the present study, the examination of
the speech mechanism during non speech activities took place through the
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administration of the Frenchay Dysarthria Assessment (Enderby, 1983). The 
intelligibility assessment took the form of a score that reflected an overall judgement 
of speech ability. The acoustic analysis of speech was replaced by an 
electrolaryngographic analysis for reasons that will be explained later in this 
chapter. A description of all these procedures will follow in the next sections.
2.5 The Frenchay Dysarthria Assessment (FDA)
An easily administered dysarthria test in Greek was considered to be 
appropriate to examine the speech mechanism during some speech, non speech, 
and voicing activities. However, at present, such a test does not exist in the Greek 
literature, it was hypothesized that a test translated from the English language to 
the Greek language could be used. The Frenchay Dysarthria Assessment (FDA) 
test was constructed in 1980 to fit some presuppositions in the British population: 
easy application to therapy, easy use and short duration of administration, little 
requirement for training in its use, and easy communication to other professionals of 
its results (Enderby, 1980). Although the FDA as a maximum performance test is 
administered in the English language, its structure and form of administration could 
be considered “international” because it comprises some (but not all) subtests with 
non speech, speech, and voicing tasks that could be used in any language. Kent et 
al. (1987) support the international use of maximum performance tests.
The test is divided into the following sections: reflex, respiration, lips, jaw,
palate, laryngeal, tongue, intelligibility, rate, sensation, and associated factors. Each
section contains tasks measurable in seconds. In speech pathology, the non
speech tasks are considered a major form of discrimination between dysarthria and
apraxia of speech (Duffy, 1995). They are also useful to give information about the
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absence or presence of neurological diseases including Parkinsonism (Robin et al., 
1997) and to show changes before associated changes in perceptually adequate 
speech occur (see a relevant discussion about the merits and drawbacks of these 
tests in section 1.7.5). Examples of two non speech tasks, one speech task and one 
voicing task will follow.
Examples of non speech tasks involve the elevation and lateral movement of 
tongue that have the patient moving the tongue up and down (outside the mouth 
towards the nose and chin) or left and right (from side to side of the mouth) five 
times. The timing of each task determines the subject’s score. In the elevation of the 
tongue “a” is the score for the completion of the task in 6 seconds, “b” within 8 
seconds, "c” when tongue moves well but laboriously and incompletely, and so on.
A speech task involves the production of vowel combinations [ u i f  ten times to 
check the function and shape of the lips (“lips” section). Finally, a voicing task 
involves maximum sustained phonation (prolongation of [ a ] for a measurable 
period of 15 seconds® to check laryngeal stability (“laryngeal section”). Apart from 
phonation in the laryngeal area, the FDA also measures intonation (singing a scale) 
(Leuschel & Docherty, 2000). Considering the similarities of the Greek to English 
phonology it was hypothesised by the examiner that these tasks can be used in the 
Greek language. The scoring form of the Frenchay Dysarthria Assessment (FDA) 
was used and its guidelines were translated into Greek.
As stated above, the administration of the FDA to the Greek population is 
considered useful because of its easy application,, its ability to diagnose dysarthric
 ^“a ” score for 10 sec, “b” score for 15 sec, “c" score for latbored movement of the lips, “d” score for 
different shapes in the "oo ee" production and “e” score for an inability to produce any shape.
 ^“a" score for prolongation in 15 sec, “b" score for prolongattion in 10 sec, “c" score for prolongation 
in 5-10 sec, “d” score for prolongation in 3-5 sec and "e" score for prolongation in 0-3 sec.
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symptoms (timing of the articulators), its short duration and its ability to differentiate 
the dysarthria among an experimental group (Parkinsonian patients) and a control 
group (normal population). The FDA was intended to identify dysarthric 
symptomatology only in one population (idiopathic Parkinsonian patients) and to 
compare the results with another population (control group). So, it was 
hypothesised that the FDA could distinguish differences in conditions such as 
dysarthria compared to non dysarthria. So, it was used not as a differential 
diagnostic test of dysarthria, as Duffy (1995) commented, but as a diagnostic test 
per se. The examiner has been trained in the use of the FDA during his graduate 
studies in United States.
Compared to the other two well known dysarthria tests for the English 
speaking populations (Robertson Dysarthria Profile and Motor Speech Examination) 
the FDA includes phonation, loudness and Fo variation in connected speech in 
addition to maximum performance tasks (Leuschel & Docherty, 2000). Also, , 
although the Robertson Dysarthria Profile includes a more detailed investigation of 
connected speech and involves intonation and stress patterns in reading, 
conversation and stress drills, these hardly can be translated into another language 
(Greek) due to differences between the languages in intonation and stress patterns. 
The Motor Speech Examination does not contain maximum performance tasks that 
are considered essential in a study such as this to show changes at the beginning 
of Parkinson’s disease where the subjects expected to be close to normal.
In general, although the FDA has a high intrajudge, interjudge, and test retest
reliability in the British population, it is not clear if this stands for the Greek
population. A translated test from another language has its own limitations. Stages
such as translation and back translation and piloting are important for the
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application of tests that are used in another language. Any text has inherent 
limitations due to social, cultural, historical, racial and sexual factors. Since 
knowledge in the era of relativism is a human social product (Smith & Deemer, 
20,03), the importance of society as a factor in the development of new tools is 
paramount. So, the development of new tools or the translation of tools used in 
another culture needs to take into consideration these limitations. It is a limitation of 
the current study that these stages were omitted in the application of the FDA in the 
Greek language.
However, some precautions have been taken in the application of the 
translated FDA in Greek to counterbalance some of its limitations. The existence of 
the control group in this study aimed to counterbalance some of the reliability 
problems during the administration of a test that has not had yet high intrajudge and 
interjudge reliability in a language other than English.
The FDA has also received criticisms about its ability to distinguish between 
different types of dysarthria (Duffy, 1995) and about its ability to evaluate 
intelligibility (Duffy, 1995; Kent, Weismer, Kent, & Rosenbek, 1989). Duffy (1995) 
states that there is an overlap in the sections of FDA between different types of 
dysarthria and a lack of specified criteria to determine each dysarthria type. He 
concludes that FDA “may be viewed as a test that distinguishes among patients 
with different lesion loci on the basis of non verbal oral findings and certain speech 
characteristics, rather than a differential diagnostic test of dysarthria per se" (p. 88). 
As mentioned above in the present study, FDA was not used as a differential 
diagnostic test of dysarthria but as a diagnostic test per se, distinguishing between 
Parkinsonian subjects and control subjects.
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Kent et al. (1989) and Duffy criticise the FDA’s ability to measure intelligibility 
overall. They reported that FDA might be beneficial for measuring single word 
intelligibility but might not be useful for measuring intelligibility in sentences and in 
connected speech. With regard to the intelligibility estimation, the current study 
followed Kent’s et al. (1989) suggestions to construct an intelligibility test that could 
possibly be replicated (if standardised) for use in future studies in the Greek 
population. So, the section on intelligibility of the FDA (repetition, description, 
conversation) is omitted from the current research as not representative of 
intelligibility testing and is replaced by a different intelligibility test whose logic will be 
explained in a following section. Since the sensation and associated factors 
sections had already been extensively covered in the section on the history form no 
further coverage was needed.
2.6 The intelligibility testing
This section aims to discuss the concept of intelligibility from different 
perspectives. Intelligibility is defined and the most preferable method of its 
estimation in dysarthria is discussed. The following subsections discuss the 
relationship of intelligibility to phonation and articulation in motor speech disorders, 
the logic upon which a Greek list of words for intelligibility estimation was 
constructed for the present study and issues such as familiarisation and judgement 
that may affect the intelligibility scoring. .
According to Schiavetti (1992), intelligibility is defined as “the match between
the intention of the speaker and the response of the listener to the speech passed
through the transmissiori system" (p. 13). Intelligibility has been used for different
purposes in the literature. Some authors have used it as one criterion for the
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assessment of the severity of speech disorders in the hearing impaired population 
(Metz, Schiavetti, & Sitler, 1980) and others have used it as a useful tool in 
explaining the basis of a speech disorder regarding specific articulatory deficits 
(Weismer, Kent, Hodge, & Martin, 1988). In other studies, intelligibility has been 
used as an index of progress in speech therapy with deaf children (Monsen, 1981) 
and as a functional index of communicative performance (Beukelman & Yorkston, 
1979). Hustad, Beukelman and Yorkston (1998) include intelligibility in a broader 
model of chronic disability that involves assessment in pathophysiology, 
impairment, functional limitation, disability, and societal limitation. The assessment 
of functional limitation involves the issue of intelligibility.
Schiavetti (1992) reviewed the different intelligibility measurement methods
(scaling procedures vs. word identification tests). The pilot study by Darley et al.
(1969a) is an example of a scaling procedure method. In this method the examiner
assigns a number that reflects his/her impression of intelligibility severity. Word
identification tests involve the examiner to write down or match to similar words the
word that he/she listened from the patient. According to Schiavetti, the word
identification test is preferable compared to scaling procedures, for many reasons.
First, its score is calculated as a percentage of correctly heard words. Therefore, it
can be easily used by the speech pathologist and easily communicated to other
professionals. Second, it is well associated with the information transfer in
dysarthric speakers (Beukelman & Yorkston, 1979). Third, it is easier to administer
and score than scaling procedures (Schiavetti, Sitler, Metz, & Houde, 1984). Fourth,
there is a good relationship between word identification test and the acoustic
characteristics of speech (Kent et al., 1989; Weismer et al., 1988). Along the same
lines, Yorkston and Beukelman (1978) compared different techniques for measuring
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assessment of the severity of speech disorders in the hearing impaired population 
(Metz, Schiavetti, & Sitler, 1980) and others have used it as a useful tool in 
explaining the basis of a speech disorder regarding specific articulatory deficits 
(Weismer, Kent, Hodge, & Martin, 1988). In other studies, intelligibility has been 
used as an index of progress in speech therapy with deaf children (Monsen, 1981) 
and as a functional index of communicative performance (Beukelman & Yorkston, 
1979). Hustad, Beukelman and Yorkston (1998) include intelligibility in a broader 
model of chronic disability that involves assessment in pathophysiology, 
impairment, functional limitation, disability, and societal limitation. The assessment 
of functional limitation involves the issue of intelligibility.
Schiavetti (1992) reviewed the different intelligibility measurement methods
(scaling procedures vs. word identification tests). The pilot study by Darley et al.
(1969a) is an example of a scaling procedure method. In this method the examiner
assigns a number that reflects his/her impression of intelligibility severity. Word
identification tests involve the examiner to write down or match to similar words the
word that he/she listened from the patient. According to Schiavetti, the word
identification test is preferable compared to scaling procedures, for many reasons.
First, its score is calculated as a percentage of correctly heard words. Therefore, it
can be easily used by the speech pathologist and easily communicated to other
professionals. Second, it is well associated with the information transfer in
dysarthric speakers (Beukelman & Yorkston, 1979). Third, it is easier to administer
and score than scaling procedures (Schiavetti, Sitler, Metz, & Houde, 1984). Fourth,
there is a good relationship between word identification test and the acoustic
characteristics of speech (Kent et al., 1989; Weismer et al., 1988). Along the same
lines, Yorkston and Beukelman (1978) compared different techniques for measuring
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intelligibility of dysarthric speech. Among others, the multiple choice intelligibility 
scoring technique (as an example of a word identification test) produced the highest 
score.
Intelligibility is a problematic issue in respect to its definition and assessment 
method (Connolly, 1986; Kent, 1997). For this reason, a number of different tasks 
have been used to assess it. Different scores in each task have been found 
(spontaneous speech, repetition, reading, repeated singing, and spontaneous 
singing). Kempler and Lancker (2002) report an increased score in reading and a 
decreased score in spontaneous speaking in a Parkinsonian patient. Also, large 
differences were found among these tasks ranging from 29% in spontaneous 
utterances to 88% in spontaneous singing utterances.
The complexity of the issue of intelligibility is due to many factors (Connolly, 
1986; Hustad et al., 1998). These include;
• It is a not an all-or-nothing phenomenon but it is a matter of degree that a 
message can be understood.
• It is inherently context-dependent and varies with the awareness of the 
listener in the topic of conversation, familiarity with the speaker’s voice, 
and/or accent/dialect.
• It is involved in the broader concept of indeterminability (the condition in 
which the listener is not able to recover correctly the intended cognitive 
meaning of an utterance that may be unintelligible, ambiguous, or illusive. 
Supervenient indeterminability is a special case of indeterminability that is 
related to the presence of a disorder (Parkinson’s disease.in the present 
study).
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• Finally, communicative effectiveness (success of the speaker in a social 
role in specific social situations) is the product of interaction of a number 
of variables including the intelligibility of speech, the comprehensibility of 
speech when the context is provided and the complexity and adversity of 
communication situations.
Other authors include intelligibility to the concept of comprehensibility in which 
factors pertaining to the speaker and the listener may change the listener’s ability to 
understand the message (Hustad et al., 1998).
In general, intelligibility in the present study functioned as an index of 
communicative performance in both groups (experimental group before/after 
medication and control group). More specifically, intelligibility assessment intended 
to address how well each subject of the Parkinsonian group is understood when 
talking, compared to a matched control subject and compared to himself/herself 
after 3-3.5 months of medication. More comments on this will follow in section 2.6.2.
2.6.1 The relationship of intelligibility to phonation and articulation
An intelligibility assessment in every motor speech examination can give an 
estimation of communicative performance of the subjects. Kent (1988) underlined 
the importance of intelligibility as an essential feature of speech communication and 
the assessment of intelligibility as an issue of fundamental clinical importance in 
dysarthria.
Ramig (1992) reviewed the role of phonation in speech intelligibility. 
According to her, phonatory disruptions due to neuromuscular malfunctions can 
reduce speech intelligibility. Her results showed high correlations of monotone and
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developed an intelligibility test that aimed to address the above conditions. This test 
was the framework for the construction of the Greek list for intelligibility and for this 
reason it will be described in detail.
Kent’s test is considered systematic in a sense that it aims to evaluate the 
“phonetic underpinning of intelligibility deficits” (Weismer & Martin, 1992, p. 69). 
Kent et al. (1989) grouped words that had a minimal-pair or a near minimal-pair 
relationship to the target word. The development of their test was based on 
nineteen acoustic-phonetic contrasts characterised by minimal pairs that are 
sensitive to dysarthria and could contribute to speech intelligibility. The pairs 
differed in phonetic dimensions such as voicing, front vs. back vowels, and so forth. 
According to the authors, this testing could reflect the errors that have been found in 
different studies in dysarthria. These errors, especially the variables that are 
focused on imprecise articulation, can possibly have a major impact on speech 
intelligibility. Kent’s test also provides a quantifiable score of intelligibility together 
with interpretations in terms of the phonetic and acoustic bases of an intelligibility 
deficit (Weismer & Martin, 1992). Obviously, these interpretations could guide the 
therapy process if they are well described and defined.
More specifically, Kent’s et al. (1989) work is a multiple choice test with a
target word and three other words similar to the target word (total number of words
was 280). The experimenter records the target words on tape as the patient reads
them. The person who is responsible for estimating intelligibility (listener) chooses
the word that he/she listened to out of 4 words (that have a minimal-pair relationship
to the target word) by listening to the tape. The percentage of correctly heard words
is the overall intelligibility score. The selection of the words in this test meets three
criteria. First, it allows the examination of several phonetic contrasts as important
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dimensions of intelligibility. Second, it represents through the words, as was stated 
above, phonetic features or contrasts that are vulnerable in the dysarthrias. Third, 
these phonetic contrasts can be analysed with one or more measures (e.g., 
acoustics). The concept of random selection of the target words in each tetrad is 
one of the benefits of the test.
Similar procedures to the work by Kent et al. (1989) were employed in the 
construction of the intelligibility list of Greek words. This list of words contained the 
same number of words (280) as in Kent’s. Appendices E and F give a description 
of the Greek word list, the different phonetic contrasts it employed and the 
similarities/differences between the two tools. The number of parameters for the 
Greek list of words was found to be double (39) that of Kent’s list (19). Differences 
between the two languages contribute to this difference. Also, three categories in 
Kent’s list with a frequency of occurrence of 8-11 times (alveolar-palatal place 
contrast, vowel duration contrast, and initial glottal-null contrast) were found not to 
exist in the Greek language.
The use of a multiple choice intelligibility testing (Kent’s list and the Greek 
list) presents some advantages:
• It is easier to administer. It may take no more than 5 minutes to 
administer and so, it eliminates/minimises the risk of tiredness in the 
subject’s performance.
• It permits quantification of correct intelligibility percentage.
• It can be used as both a research and a descriptive tool. Although in the 
present study it may not be relied upon as a descriptive tool, the Greek 
test could be used in the future in Greece to describe the phonetic
155
features of dysarthric speech. At the moment, however, where no 
standardisation process has taken place, the quantification intelligibility 
estimate is its only purpose.
• As an intelligibility test it is more elaborate and detailed than the
intelligibility section of the Frenchay Dysarthria Assessment, which gives 
intelligibility estimation from only 12 words and 12 sentences.
Compared to the Assessment of Intelligibility in Dysarthric Speakers (AIDS) 
(Yorkston & Beukelman, 1981a) the Greek word list presents one advantage and 
one disadvantage. Its advantage is that it does not require construction at the 
sentence level. Construction at such a level calls for knowledge of other variables 
(Greek syntax, Greek language complexity) that are difficult to control and match 
with AIDS. Its disadvantage is that a Greek test similar to AIDS could better 
estimate the speech rate of dysarthric subjects in addition to the quantification of 
intelligibility. Again, the existence of no research in Greek language and no reported 
average rates of speech in the healthy Greek population prohibited the use of AIDS.
An inherent limitation to this method of assessment of intelligibility (word 
identification testing) is that it involves only information on the adequacy of the 
speech signal in isolation, ignoring the context, the event, or the purpose of 
communication. The consequences of this approach may be the underestimation of 
the functional communication abilities in some dysarthric speakers. Intelligibility 
measures such as the word lists may not be predictive of real-world communication 
situations where listeners take into consideration factors such as situation and 
contextual information in addition to the speech signal (Hustad et al., 1998).
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other factors in intelligibility list of words inherent not to the speech signal but 
to variables pertaining to the dysarthric speaker (speech supplementation 
strategies, signalling semantic cues such as topics on a communication board to set 
the context, and paralinguistic variables such as gestures and facial expressions) or 
listener (familiarity with the speaker or knowledge of importance to the speaker) 
may also apply. One study (Crow & Enderby, 1989) that examined some of the 
aforementioned factors in intelligibility assessment reported an increase to 
intelligibility of 11% at a word level in Parkinsonian subjects. Also, the issue of 
having the subject to read test materials (a list of words, sentences, a passage of 
continuous text, or spontaneous conversation) has its own limitations (Connolly, 
1986). This is due to factors such as the change of the speaking style when reading 
compared to spontaneous speech.
Weaknesses, inherent to its development, prohibit the use of the Greek list to 
describe articulatory errors. Differences between the Greek language and the 
English language, no piloting of the Greek list, differences in the frequency of 
contrasts between sets of words, and differences in the overall number of each 
phonetic contrast category in each set are enough to distort the results of the test 
and mislead the examiner if this test would be used for descriptive purposes. Also, 
no justifiable inferences could be made on the nature of errors that the subjects 
made, simply because the list does not guarantee that each experimental subject 
was exposed to the same contrasts in the words provided for reading. In other 
words, each experimental subject read a different set of words even though this list 
had a minimal pair relationship to the 3 other sets of words.
However, the Greek list is an early attempt to measure intelligibility in the
dysarthric speech and for this reason is used in the present study. Since an
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intelligibility test does not exist in the Greek language further refinement of the 
present list can lead to a more complete intelligibility assessment list. Furthermore, 
it is based on factors that contribute to dysarthria even though in a different 
language than the Greek language (Beukelman & Yorkston, 1979; Kent et al., 1989; 
Weismer et al., 1988; Weismer & Martin, 1992). The selection of 70 words that was 
administered to each experimental subject was randomly selected as in Kent’s list 
(out of 4 sets of similar sounding words). The number of words of the list and the 
time that elapsed between the first assessment (before medication) and the second 
assessment (3-3.5 months after medication) inhibits familiarisation of the 
experimental subject with the words.
2.6.3 Familiarisation of intelligibility testing and judgement of intelligibility
score
This section will discuss issues such as the selection of the listeners for 
intelligibility estimation and the familiarisation with the intelligibility list. Beukelman 
and Yorkston (1980) studied the influence of passage familiarity on intelligibility 
estimates of dysarthric speech among different listeners. Judges included speech 
pathologists and lay people, all unfamiliar with the specific task for intelligibility.
Their results showed that unfamiliar listeners gave lower intelligibility scores 
compared to speech pathologists. Furthermore, for mild and severely dysarthric 
speakers, passage familiarity did not influence judges’ scores. On the other hand, 
for the moderately dysarthric speaker, the scores increased markedly with 
increasing passage familiarity.
In the present study, the intelligibility serves as an index of communicative
performance. Two listeners unfamiliar with the intelligibility task were selected for
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intelligibility estimation. Both listeners had a university level education in different 
areas and they were at the same age level (31 years). The judges listened each 
audiotape and selected 1 word out of 4 that they thought the subject had said (total 
number of words = 280). Appendix G shows the list of words that was given to the 
listeners for intelligibility estimation. The listeners were not familiar with the speaker 
and no contextual cues were given to them. Judge familiarity in the current study 
seemed not to be an issue of concern because of the nature of the speech sample 
that gives a random selection of words and because of the fairly big number of 
words given (70 words).
From the spontaneous conversation between the experimenter and the 
experimental subjects during the administration of the history form, it was perceived 
that intelligibility would not be a problem for the particular experimental group. All 
patients were at the beginning of the disease and the experimenter did not need to 
ask them to repeat what they said because of possible problems in understanding. 
The intelligibility scores proved the above hypothesis. Both groups (experimental 
and control) were judged by the listeners to have intelligibility scores above 90% 
and no differences in each intelligibility estimation were found between the scores of 
the judges.
2.7 Passage development
Currently there is no available Greek non standardised or standardised
reading passage to provide the “stable” ground for quantitative analyses in motor
speech disorders. The need for such a passage, led to a first attempt at its
development during this study. The Greek passage is given in Appendix H. A
number of parameters were set for the development of this passage:
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The first parameter was that the position (initial, medial, and final) of all 
vowels of the Greek language need to occur in as many as possible different words 
in the passage. Appendices I and J show the vowels of the Greek language and the 
combinations of vowels in the words in the reading passage, respectively. The 
description of the Greek vowels in a triangle in Appendix I was taken from the 
Aristotle University of Thessalonika, Greece (Institute Neoellinikon Spoudon, 1996).
Appendix K includes the Greek vowels and consonants in initial, medial, and 
final position of words included in the reading passage. A short explanation will 
follow. In the passage, there are 44 words with a vowel in initial position and 12 with 
the vowel after a consonants the initial syllable (total number was 56). Out of the 
44 words that start with a vowel, in 10 words the vowel stands alone (as a word), in 
19 words the vowel is in a VCV combination, in 8 words is in a VCVC combination, 
and in the remaining 7 words is in other combinations (VC, VOW, VCWC, VCVCV, 
VCCV, and VCCVC). Out of the 12 words that the vowel follows a consonant in the 
initial syllable of a word, in 8 words the vowel is in a CVCV combination and in the 
remaining 4 words it is in different combinations (CVCVC and CVCVGV). The 
frequency of occurrence of particular vowels was also taken into account but not in 
a systematic way. For example, the vowel [ i ] stands alone as an article throughout 
the text 7 times and the vowel [ o ] 3 times.
In medial position, there are 17 words where the vowels follow a consonant. 
The vowel [ i ] occurs 6 times (4 times in a CVC combination), the vowels [ u ], [ o ] 
and [ a ] occur 3 times each, and the vowel [ e ] 2 times, all in different combinations
(cyc, ccyc, ccycv, cvcycv, cvcyv, cvcccycw, vcyc, vcycycvc, and
VCyCVCCVC). In the final position, there are 26 words where the vowels occur in
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different combinations ending with CV. Out of them, 11 words stand in a CV 
combination and the remaining 15 words in other combinations (CCV, CVCV,
CVC VCV, V C ^  and VCCV). Finally, there are 5 words in which the final vowels are 
not in CV combinations (CVCVC, VCCVC, VCVC, VCVV, and VCVCV).
The second parameter was that the position (initial, intervocalic, and final) of 
all consonants and consonant clusters of the Greek language need to occur in as 
many as possible different words in the passage (see Appendix L for a list of Greek 
and English phonemes in the International Phonetic Alphabet).
The third parameter was that the presence of as many as possible 
diphthongs of the Greek language needs to occur in the passage.
Moreover, attention was given so that the duration of the passage and the 
total number of its words was as short as possible compared to other passages 
(Rainbow passage, Arthur the Rat passage). The overall length of the “Greek 
Islands Passage” consists of 397 words Including the headings. In the present study 
the last paragraph of the passage was omitted to avoid tiredness of the patients.
So, the experimental and control group read a total of 316 words. Considering the 
complexity of the Greek language, the Greek islands passage has a reasonable 
length. An alternative to the construction of this passage would be the translation of 
the Arthur the Rat passage from the English to Greek. This undertaking was 
attempted and the translated passage consisted of 335 words. However, because in 
the translated Arthur the Rat passage no controlled parameters existed as in the 
Greek Islands passage, the latter was preferred for this study.
Finally, the topic of the passage was well known to Greeks and therefore,
more easily readable (at least at a semantic level). It involved general geographical
and cultural information about the Greek islands, a familiar topic. A small dialogue
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was inserted in the passage to reflect different speaking conditions (narrative and 
dialogue) and inflections of stress. Similar conditions are appeared in other 
passages (“Arthur the Rat”, “Rainbow Passage”).
However, the development of a reading passage should satisfy a number of 
additional criteria, such as:
• Equal representation of the length of words used in the passage
• Involvement of phonotactic patterning (sequencing of sounds)
• Similar frequencies of words in the passage with words in the Greek language.
• A standardisation process.
To compensate for the absence of the above criteria, this passage was 
administered to both the experimental and the control group. Moreover, its use was 
limited to the analysis of phonation.
2.8 Usefulness of eiectroiaryngographic measurement
This section is divided in 3 other subsections and it aims to address concerns 
during eiectroiaryngographic measurements, the reliability of the 
electrolaryngography and the establishment of eiectroiaryngographic measures in 
the present study.
Many authors discuss the usefulness of electrolaryngography as well as 
some of the problems encountered in it (Abberton et al,, 1989; Baken, 1992, 1997; 
Colton & Conture, 1990; Fourcin, 2000; Kitzing, 1990; Titze, 1990). In the eighties, 
electrolaryngography (ELG) was used more for qualitative purposes (descriptions of 
laryngeal action) to give a better picture of the performance of the vocal folds 
especially during the closed phase of vibration.
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In the nineties. Baken (1992) discusses that the microphonie effect of the 
acoustic signal does not influence a significant portion of the electrolaryngogram, 
that the Lx signal actually represents the surface area of contact of the vocal folds, 
and that Lx wave can discriminate the three major modes of laryngeal function 
(normal, breathy, and falsetto). In addition, ELG is reported to be effective as a 
biofeedback tool in the management of dysphonias together with a display on a 
oscilloscope screen (Baken, 1997). Furthermore, the Lx signal can be used 
confidently for the extraction of fundamental frequency (Fo) and jitter measures, 
less commonly for amplitude-perturbation measurement, but not with amplitude 
measures and numerical measures (e.g., open quotient) because of ambiguities 
about the exact instant of glottal opening or closure (Baken, 1992; Colton &
Conture, 1990).
2.8.1 Concerns during eiectroiaryngographic measurement
A number of studies give a comprehensive analysis of electrolaryngography 
(ELG) characteristics (Baken, 1992; Colton & Conture, 1990; Kitzing, 1990). In this 
section, some concerns during the ELG measurement will be discussed in the form 
of instrumental, procedural, and subject/speaking characteristics. Its solutions will be 
also reviewed.
Instrumentally, the use of automatic gain control and the high-pass frequency
characteristics of the ELG may create problems in the interpretation of the output
signal. The automatic gain control is used for compensation of variations of the
signal level due to varying neck resistance. It has its own time constant to respond
rapidly to the changes of the signal level. An increase of its time constant might
produce a distortion in the open phase of the signal (Colton & Conture, 1990). This
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is an additional reason why many authors support the notion that ELG gives more 
information on the closed phase of the vocal folds (Abberton & Fourcin, 1984; 
Baken, 1997). If high pass filtering is not specified in order to interpret the details of 
the waveform, erroneous conclusions could be reached.
Procedurally, electrode placement, degree of electrode-to-skin contact, and 
electrode movement during recording might create problems in the output signal.
The incorrect placement of the electrodes might give a low signal amplitude. Trial 
movement of the electrodes up and down along the neck while the subject sustains 
a vowel will help to overcome this difficulty and to determine the highest possible 
signal level (Abberton et al., 1989; Colton & Conture, 1990; Kitzing, 1990). 
Resistance of the skin to the current might also be created because of the properties 
of human skin. Cleaning the skin with alcohol before the placement of the electrodes 
will eliminate this resistance. Finally, the movement of the electrodes during the 
production of running speech can also create problems for the signal even if a 
flexible neckband is used to keep the electrodes in a stable position on the neck. If 
the subject holds the electrodes with his/her hands during phonation, this movement 
might be avoided and a clearer signal will appear.
Subject and speaking task concerns are also reported to create problems in
the final output signal. In female voices, less current fluctuation in the signal will take
place due to the small size of female vocal folds and due to the large angle of the
thyroid cartilages. However, these observations cannot be generalised because
there are cases of women where a perfect signal was created and cases of men
where the opposite occurred. Colton and Conture (1990) report least usefulness of
the eiectroiaryngographic (ELG) signal in unilateral vocal fold adductor paralysis and
in large mass lesions. Unilateral vocal fold adductor paralysis creates an interfold
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gap with little or no vocal fold contact and large mass lesions create no complete 
vocal fold closure. In speaking conditions especially during running speech, low 
frequency variations might take place due to vertical laryngeal movement. The use 
of high pass filtering might help to accommodate this problem.
In general, problems in ELG waveform interpretation may also arise due to:
• Vocal fold contact vs. glottal area (not exact points and exact time that 
vocal fold contact occur)
• The existence of mucus strands (especially during the open phase when 
mucus might create a path for the current even though the vocal folds are 
open)
• The relation of the ELG signal to the aspects of vocal fold vibration (the 
precision in exact time of the opening of the vocal folds). In contrast, 
vocal fold closure especially in subjects with no obvious voice problem 
can be determined (Baken, 1992, 1997; Colton & Conture, 1990; Kitzing, 
1990).
2.8.2 Reliability of eiectroiaryngographic measures compared to other 
techniques
As stated above, one of the criticisms on electrolaryngography (ELG) is its 
apparent instrumental difficulty to define the precise and appropriate points for 
measurement especially from the closed phase of the vocal folds to the open phase. 
However, there are measurements that were proposed to be reliable and useful in a 
study that aims to investigate patterns of vocal fold vibration. For example, 
fundamental frequency and its distributions can differentiate normal compared to
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abnormal voice characteristics and the simplicity of the eiectroiaryngographic signal 
in comparison to the acoustic signal helps to extract the fundamental frequency. The 
closing time (Qx) as the mean percentage of time that the vocal folds are closed to 
the total period (measured 70% down from waveform peak) can also be used to give 
reliable measurements especially in patients with voice problems (see a recent 
discussion in Fourcin, 2000). In general, the advantages of ELG include accurate 
measurement of the glottal vibratory period resulting in its use for measurement of 
intonation contours, the calculation of mean and range of voice fundamental 
frequency, and the registration/recording of aperiodicities.
More specifically, period measurements, pitch range, fundamental frequency, 
and the relation of ELG measures to acoustic measures have been discussed. 
According to Kitzing (1990), electrolaryngography is dependable for the 
measurement of glottal vibratory period. Periodicity analysis can be used to 
establish the characteristics of the fundamental frequency of the voice. One recent 
report emphasises that the fundamental frequency of electrolaryngography is highly 
correlated to the fundamental frequency of the acoustic signal, r = 0.99 (Jiang et al.,
1999).
Fourcin (1981, 2000) suggests the use of computerised statistics of period 
measurements. Numerical data can be extracted and measures of central tendency 
(mean, median, mode) and range can be shown as a distribution of frequencies 
(DFx) derived from a period by period basis. The statistics of Fx histograms (mean, 
median, mode, and range) are correlated with the mean pitch and range of the 
voice (Kitzing, 1990).
Other reports emphasise the advantages of electrolaryngography (ELG) as
compared to acoustic methods. For example, intonation curves based on ELG are
166
being presented as a string of instantaneous discrete values in contrast to an 
average estimate as in acoustic fundamental frequency (Abberton & Fourcin, 1997; 
Fourcin, 1981, 2000; Kitzing, 1990). ELG can also be a very dependable method to 
show a correlate of perceived harshness or hoarseness through scatterplots (CFx) 
that show successive periods against each other.
In general, the advantages of electrolaryngography when compared to other 
techniques are (Baken, 1992; Fourcin, 2000; Kent 1997):
• It generates signals that are not affected by supraglottal influences.
• It is non invasive, innocuous and inexpensive.
• It does not interfere with other variables for example, airflow or glottal 
area.
• It gives details of aspects of vocal fold function that other techniques are 
not able to do.
• It is immune to acoustic noise and it can be used in many work 
environments.
In conclusion, ELG may give us important information about impaired voice quality 
and possibly about monotonous voice by monitoring the smoothness of 
fundamental frequency of excitation contour, slope and range, and the distribution 
of frequencies in the overall fundamental frequency excitation range (Abberton & 
Fourcin, 1984; Fourcin, 2000).
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2.8.3. Establishment of eiectroiaryngographic measures in the present study
The purpose of this section is to state the factors that are important in voice 
measurement in neurological disorders and to describe the measures that have 
been used in other studies together with specific tasks. Finally, based on this 
discussion the eiectroiaryngographic measures that have been selected in the 
present study are outlined.
A number of factors needs to be addressed in a study that aims to 
investigate voice in populations with a neurological disease. These factors should 
involve:
• Precise definition'of neuropathology.
• Adequate medical and pharmacological information.
• Categorisation of subject groups by stage of disease to reduce 
heterogeneity.
• Categorisation of subject groups by chronological age.
• Categorisation of subject groups by vocal use.
These factors are considered important for accurate voice measurement and 
subsequently for the validity of the results (Ramig et al., 1988). The present study 
took into consideration the aforerhentioned factors in the selection of the sample.
The majority of studies that used quantitative measures of phonatory function 
in motor speech disorders employed acoustic methods that involve:
• Measures of central tendency of fundamental frequency (mean, median, 
or less frequently mode).
• Measures of intensity (less frequently because of difficulties in amplitude 
control where a sound level meter is required).
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• other measures of voice to examine the open and closed phases of the 
vocal folds (speed quotient, open quotient, etc.).
These measures are used mostly in sustained phonation. However, there are 
authors who state that long-term measures of phonatory instability such as the 
standard deviation of fundamental frequency in sustained phonation (square root of 
the variance around the mean fundamental frequency) and phonatory measures in 
connected speech could prove more useful in the extraction of laryngeal dysfuctions 
in neurological disorders (Kent et al., 1994; Zwirner et al., 1991). Some authors 
reject specific measures because they found such measures to contribute little to 
the extraction of laryngeal dysfuctions in neurological disorders. Kent et al. (1994) 
for example, concluded that there is little evidence that fundamental frequency, jitter 
and shimmer in sustained phonation have the power to identify speakers with 
specific neurological disorders. In contrast, other authors state that jitter and 
shimmer may be useful in clinical diagnosis of laryngeal pathology (Heiberger & 
Horii, 1982; Horiguchi et al., 1987).
Other researchers favour the assessment of phonetic or voice variation in a 
combination of tasks such as sustained phonation, reading a passage, and a 
natural conversation (Brown & Docherty, 1995; Fox & Ramig, 1997; Kent & Kent,
2000). Kent and Kent (2000) add diadochokinesis in the assessment of motor 
speech disorders. The use of all of the above tasks helps in the classification of 
different types of dysarthria, in the description of subgroups and individual variations 
within a dysarthria type, and in the manifestation of pathophysiology in the 
subsystems of speech production (Kent & Kent, 2000). The employment of all tasks 
is preferred as a more suitable method because there are indications that
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differences in speech behaviour in structured (read material) compared to 
unstructured tasks (naturalistic conversation) exist. So, the results from structured 
tasks may be unrepresentative of natural speech behaviour and they cannot be 
generalised without caution (Brown & Docherty, 1995; Leuschel & Docherty, 2001). 
Finally, it is during the reading of a passage and during conversation that various 
prosodic disturbances become evident (Brown & Docherty, 1995; Leuschel & 
Docherty, 2001). In hypokinetic dysarthria, these disturbances include 
monoloudness, monopitch, reduced stress, and variable rate with short rushes or 
accelerated speech.
The present study took into consideration the above findings. Monopitch, 
primarily, and monoloudness secondarily were chosen to be measured as the most 
prominent voice features in hypokinetic dysarthria. A detailed quantitative 
measurement of fundamental frequency, relative intensity, and voice quality in a 
number of tasks (sustained phonation, reading a passage, and a natural 
conversation of 3 minutes) took place.
Electrolaryngography (ELG) instead of acoustic methods was used to 
quantify these aspects of voice. Its advantages and disadvantages were discussed 
in previous sections. The characteristics of ELG to collect data from the summation 
of sampling from a connected speech sample and its ability to analyse both tasks 
(sustained phonation, and reading/conversation) without supraglottal interference 
(Baken, 1997; Fourcin, 2000) makes it a more favourable instrument in the present 
study. So, the eiectroiaryngographic measures that have been used in the present 
study involve the following:
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• Mean Fx (fundamental frequency of excitation derived from the 
measurement of the time distance, Tx, between successive epochs of 
excitation), and standard deviation Fx.
• 90% Fx range as the frequency values above and below the average 
between which 90% of the observed frequencies fall. .
• Mean Ax (as mean relative intensities measured from the correspondent 
to Lx acoustic peak in each acoustic period), standard deviation Ax, and 
90% Ax range.
• Jitter and shimmer.
• Average Qx, standard deviation Qx, and Qx range (maximal Qx-minimal 
Qx).
In the current study, possible correlates of monopitch and monoloudness as 
the primary features of hypokinetic dysarthria were proposed. Table 3 at the end of 
this section, explains the proposed interrelationships of the laryngeal 
pathophysiology in idiopathic Parkinson’s disease (PD), the perceptual 
characteristics of speech and the eiectroiaryngographic variables for measurement 
in this study. In reading and conversation both first and second order distributions 
were measured (DFx1, DFx2, DAx1, DAx2) but for reasons of clarity they are 
excluded from table 3. However, Fx denotes both DFx1 and DFx2 (first and second 
order of fundamental frequency) and the same occurs for relative intensity (for a 
description of these measures, see the relevant section in literature review). The 
mean and the standard deviation (SD) of the above proposed measures were 
calculated. Also the ranges of fundamental frequency, relative intensity, and the 
ratio of time during the closed phase divided by the total period (measured 70%
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down of the waveform peak) were measured. In Figure 17, a list of all tasks and the 
corresponding fundamental frequency variables are shown.
Sustained Phonation R eadino Conversation
- Average Fx - Mean DFx1 - Mean DFx1
- SDFx - SD D Fxl - SDDFxl
- Jitter - 90% Range DFxl - 90% Range DFx1
- Mean DFx2 - Mean DFx2
- SDDFx2 - SDDFx2
- 90% Range DFx2 - 90% Range DFx2
Figure 17. Fundamental frequency variables used in the study in all tasks.
Figure 18 shows a list of all tasks and the corresponding relative intensity variables. 
Relative intensity is derived from the corresponding to Lx period acoustic peak in 
each acoustic signal period (Fourcin, 2000). Caution, however, should be taken in 
the interpretation of the results in relative intensity because of a lack of a sound 
level meter. However, all the necessary precautions were taken to insure the better 
collection of intensity measurements.
Sustained Phonation Readino Conversation
- Shimmer - Mean DAxI - Mean DAxI
- SDDAxI - SDDAxI
- 90% Range DAxI - 90%  Range DAx1
- Mean DAx2 - Mean DAx2
-SD D A x2 - SDDAx2
- 90% Range DAx2 - 90%  Range DAx2
Figure 18. Relative intensity variables used in the study in all tasks.
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Figure 19 below shows the closed period of excitation variables/contact phase 
ratios (DQx) that have been used in the current study in the different tasks.
Sustained Phonation Readino C onversation
- Average Qx - Mean DQxl - Mean DQx1
-S D Q x - SDDQxl - SDDQ xl
- Qx Range - 90% Range DQxl - 90% Range DQx1
Figure 19. Closed periods of excitation variables used in the study in all tasks.
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Table 3. Hypothesised interaction of pathophysiology, perceptual speech characteristics and 
eiectroiaryngographic measures in Parkinson's disease
Laryngeal Pathophysiology Perceptual Characteristics ELG Variables Measured
1. Bowed vocal folds, rigidity, 
hypokinesia in the laryngeal 
muscles (Critchley, 1981; 
Hanson et al., 1983)
2. Rigidity of the cricothyroid 
muscle and thyroarytenoid 
muscle (Aronson, 1990; 
Gallena et al., 2001)
Sustained Phonation Reading
Reduced loudness, weak voice 
(Baker et al., 1998;
Fox & Ramig, 1997;
Logemann et al., 1978)
Reduced pitch variability, 
monopitch (Darley et al.,
1969a, 1969b, 1975;
Gentil & Poliak, 1995)
Breathy voice quality 
(Chenery et al., 1988;
Ludlow & Bassich, 1983; 
Zwirner & Barnes. 1992; 
Gallena et al., 2001)
Shimmer
Jitter
Mean Ax 
St. Deviation Ax 
Ax Range
Mean Fx 
St. Deviation Fx 
Fx Range
Qx
St. Deviation Qx 
Qx Range
Conversation
• Mean Ax
• St. Deviation Ax
• Ax Range
Mean Fx 
St. Deviation Fx 
Fx Range
Qx
St. Deviation Qx 
Qx Range
CHAPTER 3. METHODOLOGY
This study examines the following questions:
• Do patients who have been diagnosed with early idiopathic 
Parkinson’s disease (PD) exhibit dysarthria?
• Are their speech and aspects of voice different from the speech of 
people without a neurological disease?
• Does medication affect their speech and aspects of voice?
This chapter describes the research design, the subjects and the procedure of 
the current study.
3.1 The research design
Descriptive research is used in behavioural sciences to examine group 
differences and/or group relationships. By definition, descriptive research does 
not make cause-effect inferences because other factors inherent to human 
nature (e.g., psychological factors, family environment), may be responsible for 
the results rather than the independent variable (classification variable). 
Comparative research is also used very often in the field of Speech and 
Language Pathology to observe speech differences, whereby two or more types 
of groups are compared to make conclusions about their differences or 
similarities. Ideally, a large number of subjects in descriptive comparative studies 
help the experimenter to make more valid conclusions in contrast to a study that 
employs a smaller number of subjects. However, there are some studies where 
this is not possible. Studies that aim to investigate in depth the differences 
between medicated/unmedicated persons with neuromuscular disorders usually 
employ a small number of subjects because other factors (e.g., type and time of 
medication, variability in the effects of the disease) prohibit adequate matching
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between groups. Also, the organisation of the health system itself may raise 
difficulties in finding subjects that have not been treated before. For example, in 
the present study a decision had to be made, due to specificities of the Greek 
health system (similar to the English health system), either to employ a large 
number of unmedicated subjects with a high degree of misdiagnosis (see a 
relevant discussion by Hughes et al., 1992), or a smaller sample size with a 
more definite neurological diagnosis.
The current study is a descriptive comparative study. A Parkinsonian 
group (before medication and 3-3.5 months after medication) and a matched (in 
age, sex and education) control group were compared in terms of their speech 
and phonatory ability (criterion or dependent variable). This study examined the 
speech symptomatology of subjects in the beginning of Parkinson’s disease in 
an outpatient university clinic over an eighteen-month period.
The planned research design of this study was a pretest-posttest matched 
descriptive design in which the two groups would be measured at two specific 
times. Because of the mortality effects that took place after the pre-test, 
especially in the control group (almost half of the subjects either left the study or 
was not possible to locate them), this design could not be used. Instead, a 
different research design was chosen for each experimental question. 
Experimental Questions 1 and 2: This is a between group research design in 
which the two groups (one Parkinsonian and one control group) were measured 
once. The classification variable (independent variable) that was manipulated in 
these experimental questions was Parkinson’s disease and the criterion 
variables (dependent variables) were aspects of voice (fundamental frequency, 
relative intensity, voice quality) and speech (Frenchay dysarthria assessment 
scoring and intelligibility scoring). However, due to the small size of the
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experimental group it was decided to employ a methodology, which looks at both 
individual and group analyses. With the group analysis statistical comparisons of 
the averages in different groups form the basis for conclusions. However, the 
size of the sample makes these comparisons vulnerable to individual extreme 
scores and limits their generalizability. Therefore, observation of the individual 
data was judged as necessary in order to identify possible tendencies or 
generate hypotheses that need to be tested in future research. Question 1 was 
used as a general question that involved the inferences of the findings in 
question 2 (speech and intelligibility).
Experimental Question 3: This is a within - group research design In which one 
group (mildly dysarthric Parkinsonian group) was measured at a specific time 
and it was re-measured after 3-3.5 months of medication. The classification 
variable in this experimental question was medication and the criterion variable 
was speech and a number of aspects of voice (as for experimental question 2). 
Inferences about differences in the criterion variable were made. As in 
experimental question 2 due to the small size of the sample, a methodology that 
looked at both individual and group analyses took place.
3.2 Subjects
3.2.1 Subjects-Experimental group
The exclusion criteria that were employed in this study have been 
analysed in detail in chapter 2. Briefly, these involved:
• The appearance of speech and language problems during childhood
• The existence of laryngeal pathology at the time of speech 
assessment
• The levodopa medication at the time of diagnosis
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• Visual and hearing problems severe enough to interfere with reading 
and listening
• Illiteracy
• Other neurological problems and cognitive problems as measured by 
the Mini Mental State Examination (MMSE) (Folstein et al., 1975).
The experimental subjects in this study were diagnosed with Parkinson’s 
disease a few hours before the speech assessment and exhibited bradykinesia 
and tremor as neurological signs. All subjects were found to be at stage 1 on the 
Hoehn and Yahr scale. Two neurologists specialising in Parkinson’s disease in 
the outpatient university neurological clinic of the “Aiginitio Hospital” of Athens 
and in the neurological clinic of the General Peripheral Hospital of Athens 
“Georgies Gennimatas” made the diagnosis. Two of the experimental subjects 
(KP6, GE113) were diagnosed with Parkinson’s disease in the General 
Peripheral Hospital of Athens “Georgies Gennimatas”. The remaining 
experimental subjects were diagnosed with Parkinson’s disease in the outpatient 
university clinic in "Aiginitio Hospital” of Athens.
Sixteen subjects (10 males and 6 females) were found in a period of 18 
months. From this initial group, 13 subjects (8 males and 5 females) took part in 
the study. The subjects ranged in age from 43-80 years (mean age 63 years). 
Their education ranged from 4-24 years (mean education time 11.8 years). The 
different medication (no levodopa) of 2 subjects (KP6, GEI13) compared to the 
other 11 subjects reflects the different clinical approach of the consultant 
neurologists. The general profile of the 13 experimental subjects is listed in 
Table 4.
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Table 4. Experimental subjects’ biographical information.
SUBJECTS SEX D O B -A G E SMOKING
PER
DAY
L-DOPA
MEDICATION
BEFORE
DIAGNOSIS
L-DOPA
MEDICATION
AFTER
DIAGNOSIS
EDUCATION
TZS2 F 6/2/1935
64,8
No No -Akineton 1*3  
-M adopar1x3 
-Symmetrel 1x3
5 years
KD4 M 30/10/1933
66,1
No No -M adopar1x3  
-Akineton 14x2 
-Symmetrel 1 x2
18 years 
(Univ. level)
SB5 M 2/1/1921
79,9
No No -M adopar1x3 
Stopped after 
2 months of 
medication
16 years 
(Univ. level)
KP6 M 7/1/1937
62,10
No No -Requip 2x3 24 years 
(Univ. level)
PM7 M 17/12/1934
65,1
No Akineton
Sinemet
Symmetrel®
-Madopar 1.5x3 
-Akineton 1x3
6  years
BIS M 7/2/1926
74,2
4 Akineton 1 %2 -Madopar %x3  
-Akineton 1x i
12 years
PX9 F 18/9/1936
63,8
No No -M adopar1x3 
-Akineton 14x3
9 years
SI10 M 6/2/1946
54,4
30 No -M adopar1x3 
-Akineton 1x3
6  years
GN11 M 23/3/1936
64,3
No No -M adopar1 x3  
-Akineton 14x3
12 years
GEI13 F 28/3/1956
44,4
No No -Mirapex 1x3 14 years
LI14 M 27/8/1957
42,10
No No -Madopar 14x3 
-Mirapex 14x3
16 years 
(Univ. level)
KA15 F 15/1/1935
65,9
No No -M adopar1x3 
-Akineton 1x3
4 years
MD16 F 15/12/1927
72,11
No No -M adopar1x3 
-Akineton 1x3
12 years
So, the final number of subjects enrolled in the present study was thirteen. 
One subject (PX9) reported laryngeal pathology due to surgery and it was 
decided to exclude her from the between group results. A group of 8 
Parkinsonian subjects scored lower in the Frenchay Dysarthria Assessment 
(FDA) and were characterised as mildly dysarthrics. The intelligibility 
assessment did not further differentiate between the two groups. This group of 
eight mildly dysarthric subjects was used for the electrolaryngographic (ELG) 
analysis. However, in one subject (KA15) it was not possible to establish ELG
Stopped six months ago
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signal due to fatty neck tissue. Then this subject left the study. Finally, another 
subject (SB5) in the group of mildly dysarthrics, stopped taking medication and 
for this reason it was decided to treat his ELG results separately.
The mildly dysarthric subjects were used to examine the effect of 
medication. As mentioned before, one subject (KA15) left the study and another 
subject (SB5) was treated as a separate case. Finally, the subject with the 
laryngeal pathology (PX9) was included in the within group results, to observe 
the effect of medication especially on the FDA, and then on the intelligibility 
assessment and ELG measurement. In the beginning of chapter 4 and 5, more 
details are given regarding the numbers of subjects and the rationale for their 
inclusion or exclusion. Table 5 below explains who left the study, who remained 
and who had medication.
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Table 5. Subject participation in the present study
Subjects KD4
Male
SB5
Male
KP6
Male
PM7
Male
BI8
Male
SI10
Male
GN11
Male
LI14
Male
TZS2
Female
GEI13
Female
KA15
Female
MD16
Female
PX9
Female
BETW EEN
GROUPS
FDA
scoring
MD MD Normal MD MD MD Normal Normal MD MD MD Normal MD
not included due 
to laryngeal 
pathology
Intelligibility NORMAL ABOVE 95% IN INTELLIGIBILITY
ELG + Separate
Case
(stopped
medication)
+ + + + + No ELG 
Signal
W ITHIN
GROUP
FDA
scoring
+ + + + + + Left
Study
+
Intelligibility + + + + +, + +
ELG + + + + + + +
MD = Mildly Dysarthric, Participation = symbol (+)
3.2.2 Subjects-Control group
Thirteen control subjects were matched to the experimental subjects in 
age, gender and education. The control subjects ranged in age from 44-78.5 
years (mean age 63.6 years). Their education ranged from 4-24 years (mean 
education time 13 years). The general profile of the control subjects is listed in 
Table 6 (in order of pair matching with the experimental subjects). The same 
exclusion criteria as for the experimental group were used in the control group.
Table 6. Control subjects' biographical information
SUBJECTS SEX D O B -A G E SMOKING
PER
DAY
EDUCATION
BA3 F 11/1936
63,6
No 4 years
BE1 M 14/3/1932
67,10
No 24 years 
(univ. level)
BI6 M 13/1/1922
78,5
No 12  years
NP13 M 22/11/1935
65
5 24 years 
(univ. level)
KP10 M 2/4/1933
67,10
No 4 years
AN2 M 20/8/1925
74,9
No 12  years
AA9 F 23/6/1937
63
No 13 years
SB7 M 18/6/1945
55
No 12  years
PK4 M 26/1/1936
64,4
30 13 years
THM5 F 31/10/1956
44,4
No 19 years 
(Univ. level)
PN12 M 9/12/1954
45,11
No 15 years 
(univ. level)
PE11 F 16/2/1933
67,9
No 6  years
GD14 F 22/7/1929
71,4
No 14 years 
(univ. level)
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3.3 Research procedure
As soon as the neurological diagnosis had taken place, the patients were 
informed about the scope of the study and they agreed to take part. Following 
this, they signed a consent form and agreed to delay their medication for 48 
hours in order to participate in the study. Then a motor speech examination took 
place involving;
• A history form for speech and voice and the administration of the Mini 
Mental State Examination (MMSE) in the first meeting,
• The Frenchay Dysarthria Assessment (FDA) and an intelligibility 
assessment in the second meeting, and
• Electrolaryngographic measurement in sustained phonation, reading 
of a passage and a conversation in the third meeting.
The intelligibility assessment and the whole of the third meeting were tape- 
recorded.
The first meeting took place in the hospital immediately after the 
neurological diagnosis. A history form was administered to the patients and/or 
relatives (when the patients were accompanied by relatives). As stated in 
chapter 2, in the history form critical information involved:
Developmental speech and language problems 
Speech problems 
Voice problems 
Dysphagia problems 
Smoking and drinking information.
The Mini Mental State Examination (MMSE) was then administered and the 
subjects with a score of 24 and above were judged to have normal cognitive 
functions.
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At the second meeting that took place in the patient’s home, the Frenchay 
Dysarthria Assessment (FDA) was administered. The sections of Reflex, 
Respiration, Lips, Jaw, Palate, Laryngeal and Tongue were administered 
according to the instructions included in the assessment (Enderby, 1983). As 
mentioned in chapter 2, the intelligibility section of the FDA was omitted. 
Similarly, the “Influencing Factors" section was omitted from the assessment 
because this information had been collected through the history form.
After the administration of the FDA, the intelligibility assessment took 
place and was tape-recorded. A list of 4 sets of words (70 Greek words in each 
set), a total of 280 words, was constructed based on the work by Kent et al. 
(1989). Each word was typed on a flash card with big letters (0.5 cm tall) to 
facilitate reading. The subject randomly picked one out of the 4 sets of cards (A, 
B, C, D). The examiner presented a card to the subject at a rate of one per two 
seconds, and the subject read each of the 70 cards aloud.
The subject sat on a chair in front of a table and the examiner sat on the 
right side of the subject to control the volume of the recording. A CP 430 
Marrantz Model tape recorder was used, connected to mains power. A Marrantz 
EM-8 stereo microphone was placed about 15-20 cm from the mouth of the 
subject on a boom stand on a table. All the recordings took place using TDK SA 
60 or 90 chromium dioxide tapes to ensure as far as possible a high quality tape 
recording. The subject was asked to count twice from 1-10 in order for the 
examiner to adjust the volume of the recording (the needle on the VU meter was 
positioned in the midrange of the dial). The following instructions were given 
before each recording:
“ I want you to read some words from the cards. Each card has one word. 
Some of the words that you will read have no meaning but try to read
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whatever you see. Please, read as we speak together naturally, not loudly 
and not whispery”.
During the recording, verbal reinforcement was given (eg. “you are doing 
well”). All the recordings were made in the morning or early afternoon to ensure 
that the subjects were given a rest. After the recording the examiner thanked the 
subject for his/her help and arranged an appointment for the third meeting on the 
following day. At the end of the meeting the tape was marked with the initials of 
the subject, the number of the subject and the date. During the second and third 
meetings, recording protocols were filled out (Appendix M).
Two independent listeners listened to the tapes using the same tape 
recorder (Marrantz CP 430) and a set of stereo dynamic AIWA HP-X705 
headphones. Each listener received a list of the 280 words (all sets). They 
selected the word they believed to have been spoken in the recording from a 
choice of four words (the target word and three similar words). The listeners 
could choose to repeat the recorded words as many times as they wanted.
After this, the examiner scored each list from each listener using the 
following procedure. The number of correct words divided by 70 (the total 
number of words) and multiplied by 100 represented the subject’s percentage 
intelligibility for that listener. The average of the two listeners was the final 
intelligibility score of the subject. The research practice showed that the listeners’ 
intelligibility scores did not differ by more than 2-3%. The criterion level of the 
intelligibility score was established at 90%^. No subject with an intelligibility score 
below 90% was found, possibly because the subjects were at the very beginning
 ^This study did not aim to measure articulation. Some of the tasks in the motor speech 
examination will be used in another study to measure articulation with acoustic measures. The 
criterion of 90% intelligibility serves this logic. The criterion of 80% intelligibility has been used in 
some studies to ensure that intelligibility was not a major factor in the acoustical measures 
(Caruso & Burton, 1987; Seikel, Wilcox, & Davis, 1991).
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of the disease and no worsening of their physical abilities was evident except 
from their clinical symptoms during the neurological examination. There was no 
clear information about how long each subject had had the symptoms that sent 
them to the neurologist. Only two subjects reported that “they did not feel their 
hand" for almost a year prior to going to the neurologist. This is a common 
problem in Parkinson’s disease in which it is likely that the preclinical phase can 
extend years before the patients go for their first neurological examination.
The third meeting took place in the office of the examiner one day after 
the second meeting. All recordings took place in the morning except where this 
was impossible because the subject was working in the morning. In this case, 
the meeting took place in the afternoon and the same time was used for the 
meeting with the pair-matched control subject. The subject was seated on a 
chair in front of a table and the examiner sat to their left to control the level of the 
recordings. Before the recordings, the examiner explained to each subject the 
use of electrolaryngography. The examiner made a trial recording of himself in 
order to make the subject feel more comfortable with the instrument.
The recordings were made using a portable TCD-D8 SONY DAT tape 
recorder that was connected to a electrolaryngograph processor (PCLX) and a 
Thandar SC110 portable oscilloscope. The oscilloscope was used to offer visual 
representation of the glottal signal. One set of electrodes connected to the 
electrolaryngographic processor was used to trace the glottal signal. All three 
instruments were connected to each other and to mains power. A set of 
headphones was connected to the DAT tape recorder and used by the examiner 
to control the quality of the recordings. A blank digital audio tape SONY 60 or 90 
was used for each recording. Figure 20, taken from Carlson (1995), shows the 
recording and processing system that was used.
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Figure 20. The PCLX system used in the present study.
The examiner pushed the recording and pause button. Then he put the 
electrodes on the thyroid alae of his neck while phonating [ a ] showing the 
signal that appeared in the oscilloscope screen. In this way, the subjects were 
visually familiarised with the signal and the instrument. The proper position of the 
electrodes was also explained to each subject. It was also emphasised that it 
might be difficult to place them exactly on their thyroid wings to ensure that the 
subjects would be patient during the procedure. Following this, the electrodes 
were set and held with an elastic band on the thyroid wings of the larynx of the 
subject while he/she sustained the vowel [a ]  to ensure that the oscilloscopic 
signal was strong and to ensure that the processor was receiving the voice 
signal. Then, the examiner controlled the recording level by asking the subject to 
count from 1-10 twice. Finally, the experimenter released the pause button to 
record Alternating Motion Rates (AMRs), sustained phonation of each Greek 
vowel, reading of the Greek passage and conversation with the subject on a 
topic (the effect of earthquakes on the subject’s life) for 3 minutes. A detailed 
description of the recording procedure follows.
First, the subject was asked to produce AMRs. The examiner gave the 
following instructions:
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“The first thing I’ll ask you to do is to repeat as fast as you can /papapa/ 
until I'll tell you to stop”.
The same instructions were given for /tatata/, /kakaka/ and /pataka/.
Following this, the subjects were asked to sustain each vowel of the 
Greek language twice for approximately 3-4 seconds at a comfortable pitch as 
steadily as possible. The examiner gave specific instructions;
“Now, I am going to ask you to do sustained phonation. In other words, to 
hold an [a ]  without a change of pitch”.
The examiner demonstrated to each subject how to sustain a vowel. When the 
subject finished this task, the examiner asked him/her to read the Greek 
passage.
“Now, we are going to read a passage. It is a story that has most of the 
sounds of the Greek language”.
At the end of the reading of the passage the examiner asked each subject to 
converse about a common topic:
“Now, we are going to talk a little bit about the earthquake that happened 
a year ago. What was your experience of it?”
Because an earthquake occurred in Athens a year ago, it was judged that all 
subjects would be interested to express their ideas of where they were when the 
earthquake struck, what they did at that time and how they reacted to it. The 
majority of the subjects were eager to talk about this topic and most of them 
extended the recording time to 5-10 minutes.
No subject seemed to exhibit discomfort or tiredness during the session. 
At the end of the session the examiner marked the tape with the subject’s initials, 
number and date, and thanked them for their patience. All subjects were 
reminded that the experimenter would carry out the same procedures after 3-3.5
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months in order to see any changes in their speech and voice after taking 
medication. The same procedures were followed for the control subjects.
After 3-3.5 months the examiner called the experimental subjects to set 
up a meeting for a new recording. At the beginning of the first meeting the 
examiner talked with the subjects about their general condition and if they felt 
there had been any change in their speech and voice because of the medication. 
They were also asked what their current medication state (type and dosage) 
was. Subjects reported no other medical problems. The same standard research 
procedure that was followed before medication, was followed after medication 
(including the MMSE, the Frenchay Dysarthria Assessment and the recordings).
The DAT tapes wefe analysed with a computer program (Speech Studio) 
that digitised the recorded electrolaryngographic signals at a sampling rate of 20 
KHz and saved the data as a computer file.
The electrolaryngographic signals were low pass filtered as indicated by 
the instrument’s specifications and displayed on the computer monitor. The 
experimenter located the points for the demarcation measures for sustained 
phonation. A one second segment in the middle of the signal (steadiest airflow) 
was selected for analysis. The electrolaryngographic analysis of the one second 
segment was derived from the second trial. A similar analysis was made for the 
reading of the Greek passage (demarcation points in the beginning of the 
passage and the end of the passage) and conversation (demarcation points from 
the beginning of the patient’s monologue to the end of the third minute).
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CHAPTER 4. RESULTS BETWEEN THE PARKINSONIAN AND 
THE CONTROL GROUP
For reasons of simplicity, the results of the present study are divided in two 
chapters. Chapter 4 compares the results between the experimental group 
(Parkinsonian group before medication) and the control group while chapter 5 
compares thé results between the experimental group before and after medication. 
The structure of the results in both chapters follows the order of the speech 
assessment:
• The results of the Frenchay Dysarthria Assessment (FDA)
• The results of the intelligibility testing
• The electrolaryngographic (ELG) results
As mentioned in the methodology chapter (see table 5) the final number of 
subjects enrolled in the present study was thirteen. One subject (PX9) reported 
laryngeal pathology because of surgery of the parathyroid glands and one thyroid 
gland in 1990. In the present study the voice of this subject was perceived as harsh 
and for this reason it was decided to exclude her from the between group analysis 
in order not to confound the between group results. Since harshness in this 
subject’s voice may be due to either Parkinson’s disease or surgery, the 
comparison of this subject with her matched pair control would have given 
questionable results. So, in this chapter the results of the twelve remaining subjects 
are presented and analysed. The Frenchay dysarthria assessment gave a group of 
8 mildly dysarthric Parkinsonian subjects when compared with their matched pair 
controls. The intelligibility assessment did not further differentiate between the 
groups. All Parkinsonian subjects scored 95% and above. This group of 8 mildly
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dysarthric subjects was used for the electrolaryngographic (ELG) analysis. 
However, in one subject (KA15) it was not possible to establish ELG signal due to 
fatty neck tissue. This subject then left the study. Finally, another subject (SB5) 
stopped taking medication two months after its initiation and for this reason he was 
treated as a separate case and his results are presented in chapter five. So, the 
number of subjects whose ELG results are analysed in this chapter is six.
4.1 Results of the Frenchay Dysarthria Assessment
The Frenchay Dysarthria Assessment (FDA) showed the areas where the 
experimental group scored lower than the control group. The sections of the FDA 
where differences were found of at least a scale (i.e., a to b) are shown below in 
table 7. Reflex and palate were omitted from the table because of their scarcity of 
appearance in the results. However, their results were presented in the individual 
figures of the matched pairs of subjects, where necessary. No differences in all 
subjects were found in the areas of respiration and jaw.
In table 7, the following symbols were used:
• A positive sign (+) when the experimental subjects scored lower than the 
controls
• A negative sign (-) when the experimental subjects scored higher than the 
controls
• An equal sign (=) when no difference was found between the experimental 
subjects and the controls.
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Only one control subject (GD13) scored lower than its corresponding experimental 
subject (MD16) did. Probably this occurred because the control subject reported 
spastic bronchitis at the time that the dysarthria testing took place.
Overall, eight of the twelve experimental subjects (KD4, SB5, PM7, BI8,
SI10, TZS2, GEM 3, KA15) were found to have lower scores than their matched 
controls. The areas that were mostly affected in the dysarthria assessment were the 
tongue area (6 positive signs) followed by the laryngeal area (5 positive signs) and 
the lips area (4 positive signs). Copies of the completed Frenchay Dysarthria 
Assessment forms of all subjects are shown in Appendix N.
Table 7. Differences between the Parkinsonian group and the matched 
pair control group in the Frenchay Dysarthria Assessment.
Subjects Lips Laryngeal Tongue
Males
KD4 vs. BE1 + + +
SB5 vs. BI6 = = +
KP6  vs. NP12 No difference
PM7 vs. KP9 + = =
BI8 vs. AN2 + + +
8110 vs. SB7 = +•
GN11 vs. PK4 No difference
L114 vs. PN11 No difference
Females
TZS2 vs. BA3 + + +
GEI13VS. THM5 + =
KA15 vs. PE10 = + +
MD16 vs. GD13 - =
The results of the subjects in the Frenchay Dysarthria Assessment (FDA) are 
presented in an order of involvement (the subjects that showed involvement in more
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areas of the FDA are presented first). Figures 21-25 show the results of the FDA for 
the subjects who revealed differences compared to their controls in more than one 
area of the FDA. One experimental subject (TZS2) exhibited lower scores than its 
matched pair in 4 areas of the FDA (lips, palate, laryngeal and tongue). Figure 21 
below shows the areas that TZS2 differed from its matched pair control subject 
BA3.
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Figure 21. Results of the Frenchay Dysarthria Assessment 
in the matched pair of subjects TZS2 and BA3.
Three experimental subjects (BIB, KD4, KA15) exhibited lower scores than 
their matched pairs in 3 areas of the FDA. BIB and KD4 scored lower in lips, 
laryngeal and tongue while KA15 scored lower in reflex, laryngeal and tongue. 
Figures 22, 23 and 24 below show the areas that BIB, KD4 and KA15 differed from 
their corresponding matched pair controls.
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Figure 22. Results of the Frenchay Dysarthria Assessment 
in the matched pair of subjects BI8 and AN2.
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Figure 23. Results of the Frenchay Dysarthria Assessment 
in the matched pair of subjects KD4 and BE1.
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Figure 24. Results of the Frenchay Dysarthria Assessment 
in the matched pair of subjects KA15 and PE10.
One experimental subject (PM7) exhibited lower scores than its matched pair in two 
areas of the FDA (reflex and lips). Figure 25 below, shows the areas that PM7 
differed from its matched pair control subject (KP9).
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Figure 25. Results of the Frenchay Dysarthria Assessment 
in the matched pair of subjects PM7 and KP9.
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Finally, three experimental subjects (SB5, SI10, GEI13) exhibited lower scores in 
one area of the Frenchay Dysarthria Assessment. SB5 and S110 scored lower in the 
area of tongue (elevation and protrusion) while GEM 3 scored lower in the area of 
laryngeal (laryngeal time).
4.2 Intelligibility results
The intelligibility scores of the Parkinsonian and the control groups are 
shown below in table 8. All intelligibility scores are in the form of a percentage. The 
total number of correctly heard words that were identified by the two listeners was 
divided by 140 (70 words imeach listener, total words = 140) to give a proportion of 
correct words for each subject. This proportion was multiplied by 100 to give the 
average percentage of correct words pronounced by the subjects in the intelligibility 
testing. The parentheses below the intelligibility percentage show the average 
number of words pronounced correctly by each subject.
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Table 8. Intelligibility scores between the Parkinsonian group and 
the matched pair controi group.
Experimental
Subjects
Inteliigibiiity
Scoring
Controi Subjects Inteliigibiiity
Scoring
TZS2 96.42%
(67.5/70)
BA3 94.28%
(66/70)
KD4 98.57%
(69/70)
- BEI 1 0 0 .0 0 %
(70/70)
SB5 98.57%
(69/70)
BI6 99.28%
(69.5/70)
KP6 99.28%
(69.5/70)
NP12 97.14%
(68/70)
PM7 95.00
(66.5/70)
KP9 98.57%
(69/70)
BI8 98.57%
(69/70)
AN2 97.85%
(68.5/70)
8110 96.42%
(67.5/70)
SB7 98.57%
(69/70)
GN11 1 0 0 .0 0 %
(70/70)
PK4 1 0 0 .0 0 %
(70/70)
GEI13 97.14%
(68/70)
THM5 98.57%
(69/70)
LI14 98.57%
(69/70)
PN11 99.28%
(69.5/70)
KA15 95.71
(68/70)
PE10 91.42%
(64/70)
MD16 98.57%
(69/70)
GD13 97.14%
(68/70)
Group Mean 97.68% Group Mean 97.67%
Standard Deviation 1.62 Standard Deviation 2.52
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The Mann-Whitney test was used to identify differences in intelligibility 
between the group of the 12 Parkinsonian subjects and the group of their matched 
pair controls. The results of Mann Whitney U analysis indicated no significant 
between group differences in intelligibility (Mann Whitney U = 63.5, Z = -0.501, 
p > 0.05). Both groups had the same average percentage of correctly pronounced 
words (97.68% and 97.67% respectively) that accounted for an average of 68/70 
words (2 errors).
The Mann-Whitney test was used to identify differences in the intelligibility 
between the group of 8 Parkinsonian subjects that scored lower in the FDA (TZS2, 
KD4, SB5, PM7, BI8, SI10, OEMS, KA15) and the group of their matched pair 
controls (BA3, BEI, BI6, KP9, AN2, SB7, THM5, PE10). The results of Mann 
Whitney U analysis indicated no significant between group differences in 
intelligibility (Mann Whitney U = 23.5, Z = -0.917, p > 0.05). Descriptively, the 
Parkinsonian group had a slightly lower mean percentage of intelligibility (96.96%) 
than the control group (97.32%) that accounted for 2 errors for both groups.
4.3 Results in electrolaryngographic measures
The eight experimental subjects who scored lower than their controls in the 
FDA indicated a group of Parkinsonian subjects that may be considered as mildly 
dysarthric. Out of these eight subjects, as mentioned in the beginning of this 
chapter, six were used in the analysis of aspects of voice (BI8, GEM 3, KD4, PM7, 
S110 and TZS2).
The Parkinsonian mildly dysarthric and the control groups were compared in
three speaking tasks: sustained phonation, reading, and conversation. The results
of electrolaryngographic measures in sustained phonation are presented first and
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are followed by the results of the main effect of Parkinson’s disease and speaking 
task (reading and conversation) on voice.
Due to the small size of the sample, both descriptive analysis and statistical 
significance testing were employed. The descriptive analysis was used to show 
possible tendencies in the individual scores of the subjects, while the statistical 
analysis was used to examine if there are differences between the means of the 
groups. Statistical significance was set at 0.05 level with no Bonferroni corrections 
because each T-test or analysis of variance (ANOVA) was completed separately.
Logarithmically transformed data were used to ensure normality of the 
distributions of the groups. The use of data transformations in the analysis of the 
results presents some advantages. These involve the remedy of outliers and the 
remedy of failures of normality. Tabachnick and Fidell (2001) discuss the major 
advantages and disadvantages of data transformations by emphasising that an 
improvement in the results of the analysis occurs after transformations of almost 
every data set.
4.3.1 Results in sustained phonation
In review, the following variables were used in the current study in sustained 
phonation:
• Average fundamental frequency and standard deviation
• Average closed vocal fold contact, standard deviation and range (Qx)
• Jitter and shimmer (‘short-term’ cycle to cycle variations in frequency and 
amplitude).
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Table 9 presents a summary of the eiectroiaryngographic results in sustained 
phonation including variables, descriptive data, and T-tests. Independent samples 
T-tests were used to identify possible differences in sustained phonation, T-tests did 
not find any statistically significant differences between the Parkinsonian mildly 
dysarthric group and its matched pair control group in any logarithmically 
transformed variable.
Table 9. Summary results including variables, descriptive data, and t-tests (N = 6).
VARIABLE
DESCRIPTIVE DATA 
Comparison of the scores between the two groups T -  tests
Average Fx (Hz)
- Decreased scores in 4 of 6  PD subjects
- Increased scores in PD and controls females 
compared to males
p > 0.05
Standard deviation Fx (Hz) - Increased scores in 4 of 6  PD subiects p > 0.05
Average Qx (%) - Decreased scores in 5 of 6  PD subiects p > 0.05
Qx standard deviation (%)
- Equal distribution of increased and decreased 
scores p > 0.05
Qx Range (%)
- Equal distribution of increased and decreased 
scores p > 0.05
Jitter First (%)
- Equal distribution of increased and decreased 
scores p > 0.05
Shimmer First (%) - Decreased scores in 4 of 6  PD subjects p > 0.05
Table 10 shows a summary of the statistics (means and standard deviations) 
of all variables measured during sustained phonation between the Parkinsonian 
mildly dysarthric group and its matched pair control group.
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Table 10. Summary statistics of the variables measured during sustained phonation
between Parkinsonian mildly dysarthric and control groups (N = 6).
VARIABLE
GROUP
Parkinson Control
Mean SD Mean SD
Average Fx (Hz) 170.68 66.89 153.52 29.06
Standard deviation Fx (Hz) 1.94 1.03 1.52 0.34
Average Qx (%) 40.37 3.67 46.09 6.39
Qx standard deviation (%) 0.04 0.06 0.01 0 .0 2
Qx Range (%) 4.32 2.34 4.75 1.82
Jitter First (%) 0.99 1.25 0.48 0.24
Shimmer First (%) 4.05 1.86 4.64 2.46
An examination of the individual scores of the two groups showed no specific 
patterns according to age and gender. Only in the variable average Fx, both the 
Parkinsonian and control female scores were higher than male scores. Moreover, 
the scores of the two female Parkinsonian subjects (TZS2, GEI13) compared to 
their controls (BA3, THM5) showed in all variables opposite tendencies. This may 
be due either to age difference (20 years age difference between the two female 
Parkinsonian subjects) or idiosyncratic differences. Figure 26 shows the matched 
pair scores in the average Fx variable.
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Figure 26. Matched pair scores in the average Fx variable
The variable average Qx was the only one where the pattern of decreased 
individual scores of the Parkinsonian mildly dysarthric group compared to its control 
group is in accordance with the group means. Figure 27, shows the matched pair 
scores in average Qx variable.
□  Part<»nson
Control
(0 30
Bia AN2 KD4 BEI PM7KP9 SI10SB7
Subjects
T 2 S 2 B A 3  G EI13TH M 5
Figure 27. Matched pair scores in average Qx variable.
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4.3.2 Results of the main effect of Parkinson’s disease and speaking task
(reading and conversation) on voice
In review, the following variables were used in the current study in reading 
and conversation:
• Mean fundamental frequency, standard deviation and range (DFx1 and 
DFx2)
• Mean relative intensity, standard deviation and range (DAx1 and DAx2)
• Mean closed vocal fold contact, standard deviation and range (DQx1).
Table 11 presents a summary of the eiectroiaryngographic results in reading 
and conversation including variables, descriptive data, and analysis of variance 
(ANOVA). The data were analyzed using a two-way analysis of variance in which 
one variable of interest was Parkinson’s disease and the other was speaking task to 
observe their effects on aspects of voice. The results did not show any statistically 
significant differences between the Parkinsonian mildly dysarthric group and its 
matched control group in any logarithmically transformed variable.
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Table 11. Summary results including variables, descriptive data and anovas (N = 6)
VARIABLE -  SPEAKING TASK
DESCRIPTIVE DATA 
Comparison of scores between the two groups ANOVA
D Fxl Mean In Conv. (Hz)
- Increased scores in 5 of 6 PD subjects
- Increased scores in PD and controls females 
compared to males p > 0.05
DFxl Mean in Read. (Hz)
- No pattern
- Increased scores in PD and controls females 
compared to males p > 0.05
DFxl SD in Conv. (Hz) - No pattern p > 0.05
DFxl SD in Read. (Hz) - No pattern p > 0.05
DFxl 90% Range in Conv. (Octave)
- Equal distribution of increased and decreased 
scores p > 0.05
D Fxl 90% Range -  Read. (Octave) - Decreased scores in 4 of 6 PD subjects p > 0.05
DFx2 Mean -  Conv. (Hz)
- Increased scores in 5 of 6 PD subjects
- Increased scores in PD and controls females
compared to males
p > 0.05
DFx2 Mean -  Read. (Hz)
- No pattern
- Increased scores in PD and controls females 
compared to males
p > 0.05
DFx2 SD -  Conv. (Hz) - No pattern p > 0.05
DFx2 SD -  Read. (Hz) - No pattern p > 0.05
DFx2 90% Range -  Conv. (Octave)
- Equal distribution of increased and decreased 
scores p > 0.05
DFx2 90% Range -  Read. (Octave) - Decreased scores in 4 of 6 PD subjects p > 0.05
DAxI Mean -  Conv. (dB) - Decreased scores in 5 of 6 PD subjects p > 0.05
DAxI Mean -  Read. (dB) - No pattern p > 0.05
DAxI SD -  Conv. (dB) - No pattern p > 0.05
DAxI SD -  Read. (dB) - No pattern p > 0.05
DAxI 90% R an g e -C o n v . (dB) - Decreased scores in 4 of 6 PD subjects p > 0.05
DAxI 90% Range -  Read. (dB)
- Equal distribution of increased and decreased 
scores p > 0.05
DAx2 Mean -  Conv. (dB) - No pattern p > 0.05
DAx2 Mean -  Read. (dB) - No pattern p > 0.05
DAx2 SD -  Conv. (dB) - No pattern p > 0.05
DAx2 SD -  Read. (dB) - No pattern p > 0.05
DAx2 90% Range -  Conv. (dB) - Decreased scores in 4 of 6 PD subjects p > 0.05
DAx2 90% Range -  Read. (dB)
- Equal distribution of increased and decreased 
scores p > 0.05
D Q xl Mean -  Conv. (%) - Decreased scores in 4 of 6 PD subjects p > 0.05
D Q xl Mean -  Read. (%) - Decreased scores in 5 of 6 PD subjects p > 0.05
D Q xl SD -  Conv. (%) - No pattern p > 0.05
D Q xl SD -  Read. (%) - No pattern p > 0.05
D Q xl 90% Range -  Conv .(%)
- Decreased scores in 4 of 6 PD subjects
- Decreased scores of Parkinsonian females 
compared to their controls and to the males
p > 0.05
D Q xl 90% Range -  Read. '(%)
- Equal distribution of increased and decreased 
scores
- Decreased scores of Parkinsonian females 
compared to their controls and to the males
p > 0.05
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Table 12 below shows summary statistics of the variables measured during reading 
and conversation (means and standard deviations) in the two groups.
Table 12. Summary statistics of the variables measured during reading and conversation between 
Parkinsonian mildly dysarthric and the control groups (N = 6).
VARIABLE -  SPEAKING TASK
STUDY GROUP
Parkinson Control
Mean SD Mean SD
DFx1 Mean -  Conversation (Hz) 167.38 59.74 148.42 33.07
DFx1 Mean -  Reading (Hz) 159.05 67.06 147.79 33.55
DFx1 Standard Deviation -  Conversation (Hz) 0.12 0.03 0.12 0.02
DFx1 Standard Deviation -  Reading (Hz) 0.08 0.01 0.08 0.02
DFx1 90% Range -  Conversation (Octave) 1.15 0.39 1.21 0.33
DFx1 90% Range -  Reading (Octave) 0.62 0.14 0.77 0.25
DFx2 Mean -  Conversation (Hz) 174.46 56.95 154.59 36.40
DFx2 Mean -  Reading (Hz) 163.72 69.04 152.35 31.67
DFx2 Standard Deviation -  Conversation (Hz) 0.05 0.09 0.06 . 0.02
DFx2 Standard Deviation -  Reading (Hz) 0.03 0.006 0.04 0.009
DFx2 90% Range -  Conversation (Octave) 0.93 0.27 0.89 0.18
DFx2 90% Range -  Reading (Octave) 0.50 0.13 0.61 0.15
DAx1 Mean -  Conversation (dB) 56.11 6.11 54.81 7.40
DAx1 Mean -  Reading (dB) 58.05 6.17 57.04 6.88
DAx1 Standard Deviation -  Conversation (dB) 8.72 1.31 8.52 1.79
DAx1 Standard Deviation -  Reading (dB) 7.70 1.42 7.94 1.50
DAx1 90% Range -  Conversation (dB) 16.10 2.65 15.88 3.14
DAx1 90%  Range -  Reading (dB) 14.08 2.76 14.77 2.88
DAx2 Mean -  Conversation (dB) 57.22 6.25 56.02 7.69
DAx2 Mean -  Reading (dB) 59.07 6.26 58.42 6.42
DAx2 Standard Deviation -  Conversation (dB) 3.67 0.34 3.60 0.74
DAx2 Standard Deviation -  Reading (dB) 3.19 0.30 3.32 0.45
DAx2 90% Range -  Conversation (dB) 15.18 2.78 14.65 2.91
DAx2 90% Range -  Reading (dB) 12.12 2.29 13.02 3.10
DQ xl Mean -  Conversation (%) 38.50 5.80 42.33 4.96
DQx1 Mean -  Reading (%) 38.33 5.85 43.83 6.35
DQx1 Standard Deviation -  Conversation(%) 5.82 1.51 7.31 1.34
DQx1 Standard Deviation -  Reading (%) 4.80 0.91 5.76 1.40
DQx1 90% Range -  Conversation (%) 17.35 5.10 22.45 4.94
DQ xl 90% Range -  Reading (%) 13.80 3.11 17.55 4.54
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Careful observation of the individual scores in fundamental frequency (DFx1 
mean and DFx2 mean) in the conversation task showed a pattern of increased 
individual scores of the Parkinsonian mildly dysarthric subjects compared to their 
matched pairs. This pattern is in accordance with the group means of these 
variables. One subject (PM7) showed a lower score as compared to its matched 
pair control. However, this subject had been exposed to levodopa medication 6 
months before the neurological diagnosis and this may account for that finding. 
Higher fundamental frequency in Parkinson’s disease has been associated with the 
rigidity of the vocal folds (Hanson et al., 1983). However, this trend was not the 
same in reading where 2 Parkinsonian mildly dysarthric subjects showed higher 
scores, 2 showed lower scores and the last 2 subjects showed equal scores with 
their matched pair controls. Moreover, gender differences were observed in the 
DFxl and DFx2 mean variables in both reading and conversation tasks. Female 
scores (TZS2 and GEM 3) were increased compared to male scores (in both 
groups). Even though no normative data in fundamental frequency according to 
gender exist in the Greek language, this pattern of increased female scores is in 
accordance with English studies (Baken, 1997; Greene & Mathieson, 1997; Linville,
2000). Figures 28-31 show the matched pair scores in DFxl and DFx2 mean 
variables.
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Figure 28. Matched pair scores in DFx1 mean variable in conversation.
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Figure 29. Matched pair scores in DFx2 mean variable in conversation.
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Figure 30. Matched pair scores in DFx1 mean variable in reading.
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Figure 31. Matched pair scores in DFx2 mean variable in reading.
In relative intensity, a pattern of decreased scores in the Parkinsonian mildly 
dysarthric subjects was observed in DAx1 mean variable in conversation and not in 
reading. However, this pattern did not reappear in DAx2 mean in neither speaking 
tasks. Since, DAx2 mean is analogous to DFx2 mean which measures vocal fold 
vibrational regularity (Fourcin, 2000) the aforementioned pattern can be considered
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as accidental. In the range of relative intensity (DAx1 90% mean range and DAx2 
90% mean range) a tendency of decreased scores in Parkinsonian mildly dysarthric 
subjects in conversation was found. This tendency is not in accordance with the 
group means. No pattern was found in reading.
In voice quality quotients (DQx1 mean) a pattern of decreased scores in the 
Parkinsonian mildly dysarthric subjects was observed in both speaking tasks. This 
pattern is in accordance with the group means. As already has been said, the same 
pattern was observed in average Qx mean variable in sustained phonation. 
Appendix P shows the aforementioned tendencies of the individual scores in the 
variables mean DFx1 and mean DFx2 in conversation, mean DQx1 in reading and 
conversation, and average Qx in sustained phonation. Some authors state that Qx 
as a ratio of closed vocal fold contact duration to the total period is related to the 
quality of phonation (Abberton & Fourcin, 1984; Fourcin, 2000). The longer closed 
phase or a bigger Qx ratio might indicate a ‘better’ voice. Consequently, the 
tendencies in the mean Qx variables that were found lower in the Parkinsonian 
mildly dysarthric group might indicate a tendency for a breathier quality of phonation 
for that group as compared to the control group. Physiologically, this might indicate 
a proportionally increased open phase as compared to the closed phase of the 
vocal folds. Figure 32 and 33 show the matched pair scores in DQxl mean variable 
in conversation and reading.
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Figure 32. Matched pair scores in DQx1 mean variable in conversation.
□  Parkinson 
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Figure 33. Matched pair scores in DQxl mean variable in reading.
Finally, gender differences were observed in the DQx1 90% mean range 
variable in both reading and conversation tasks. Scores of the female Parkinsonian 
subjects were decreased compared to their matched pairs and the males.
In the lack of no statistically significant differences between the means of the 
group variables, the above observations could be explained only as tendencies that
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may become clearer as the disease progresses. Further research is needed to 
explore this assumption.
The observation of the individual scores in reading compared to conversation 
showed discrepancies between these tasks. Only, in DQx1 mean variable there was 
the same tendency of decreased scores in Parkinsonian mildly dysarthric subjects 
across speaking tasks. In all other variables, observation of raw data showed 
differences across speaking tasks. Even though, repeated measures analysis of 
variance (ANOVA) was applied to identify if there was a main effect of speaking 
task (reading as compared to conversation) on voice, its results should be taken 
with caution since the individual scores did not show the same tendencies with the 
means. In the Parkinsonian mildly dysarthric group and its matched control group 
(N = 6) statistically significant differences were found in the following variables: 
Standard deviation DFx1 (SDDFxl)
DFx1 90% range
Standard deviation DFx2 (SDDFx2)
DFx2 90% range 
DAx1 mean 
DAx1 90% range 
DAx2 mean
Standard deviation DAx2 (SDDAx2)
DAx2 90% range
Standard deviation DQx1 (SDDQxl)
DQx1 90% range.
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Table 13 below shows summary statistics of the Parkinsonian mildly 
dysarthric and the control groups in the variables that were found to be significant in 
the main effect of speaking task on voice. Appendix O shows the results in reading 
as compared to conversation in all variables between the groups.
Table 13. Summary statistics of the variables that were found to be significant 
in the main effect of speaking task on voice (N = 6).
Parkinson’s Group Control Group
Mean SD Median Range Mean SD Median Range
standard Deviation 
DFx1 (Hz)
Conversation 0.12 0.03 0.12 0.08 0.12 0.02 0.12 0.05
Reading 0.08 0.01 0.08 0.04 0.09 0.02 0.08 0.07
DFx1 90% Range 
(Hz)
Conversation 1.15 0.39 1.13 0.88 1.21 0.33 1.14 0.76
Reading 0.62 0.14 0.62 0.40 0.77 0.25 0.67 0.66
standard Deviation 
DFx2 (Hz)
Conversation 0.05 0.009 0.05 0.02 0.06 0.02 0.06 0.05
Reading 0.03 0.006 0.03 0.02 0.04 0.009 0.04 0.02
DFx2 90% Range 
(Hz)
Conversation 0.93 0.27 0.84 0.72 0.90 0.18 0.93 0.43
Reading 0.50 0.13 0.50 0.35 0.61 0.15 0.59 0.40
DAx1 Mean 
(dB)
Conversation 56.11 6.11 54.72 17.78 54.81 7.40 54.17 22.22
Reading 58.06 6.17 56.67 17.22 57.04 6.88 55.28 20.00
DAx1 90% Range 
(dB)
Conversation 16.10 2.65 16.70 6.10 15.88 3.14 16.00 9.20
Reading 14.08 2.76 13.85 7.40 14.77 2.88 14.05 7.50
DAx2 Mean 
(dB)
Conversation 57.22 6.25 56.11 18.33 56.02 7.69 55.83 23.34
Reading 59.07 6.26 58.06 17.78 58.43 6.42 56.95 18.89
Standard Deviation 
DAx2 (dB)
Conversation 3.67 0.34 3.76 0.97 3.60 0.74 3.56 2.20
Reading 3.19 0.30 3.20 0.79 3.32 0.45 3.32 1.34
DAx2 90% Range 
(dB)
Conversation 15.18 2.78 15.40 6.80 14.65 2.91 14.20 7.80
Reading 12.12 2.29 12.40 6.80 13.02 3.10 11.90 8.00
Standard Deviation 
DQx1 (%)
Conversation 5.82 1.51 6.14 3.41 7.32 1.34 7.15 3.61
Reading 4.80 0.91 4.81 2.75 5.77 1.40 5.33 3.64
DQx1 90% Range 
(%)
Conversation 17.35 5.10 17.40 11.10 22.45 4.94 20.80 11.40
Reading 13.80 3.11 13.85 8.40 17.55 4.54 16.35 11.70
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The lack of differences in mean fundamental frequency (DFx1 and DFx2) 
across speaking tasks (reading and conversation) in both groups support the 
observations by Brown and Docherty (1995) who found no changes in mean 
fundamental frequency across speaking tasks in a dysarthric and a control group.
In general, differentiation across speaking tasks is a characteristic shown 
most notably in normal rather than dysarthric speakers (Leuschel & Docherty, 1996,
2001). The results of the present study of the main effect of speaking task on voice 
do not support the findings by other researchers (Leuschel & Docherty, 1996, 2001) 
who showed no differentiation of speaking task in dysarthric speakers. No 
accordance of individual scores to the means (present study) is a prohibiting factor 
to the explanation of these results. Also, different instrumentation, differential 
selection of subjects and different severity level of dysarthria may be responsible for 
these discrepancies in the Leuschel and Docherty study. For example, only half of 
their subjects in both studies included Parkinsonian patients while the remaining 
included subjects with Multiple Sclerosis. The above observations support the 
notion that both tasks should be involved not only in speech (prosodic) assessment 
of dysarthria (Brown & Docherty, 1995; Leuschel & Docherty, 1996, 2001) but also 
in voice assessment (Fox & Ramig, 1997).
4.4 Summary of the between group results
In summary, 8 out of 12 subjects who were diagnosed with early Parkinson’s 
disease exhibited lower scoring in the Frenchay Dysarthria Assessment (FDA) as 
compared to a group of matched pair controls. This lower scoring involved primarily 
the tongue area (decreased in speed movement of the tongue) and followed by the
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laryngeal area (voicing time in extended sustained phonation, volume and pitch) 
and finally the lips area (decreased in speed movement of the lips).
No statistically significant intelligibility differences were found when either the 
entire Parkinsonian group or the Parkinsonian mildly dysarthric group who exhibited 
lower scoring in the FDA were compared to a matched pair control group. However, 
observation of the individual scores in the Parkinsonian mildly dysarthric group and 
its matched pair control group showed a tendency for slightly lower scores in 
intelligibility for the first group.
Eiectroiaryngographic measures were used to quantify aspects of voice in 
the two groups. The effect of Parkinson’s disease and the effect of speaking task on 
voice were measured. No statistically significant differences were found between 
the Parkinsonian mildly dysarthric subjects and their matched pair controls in the 
effect of Parkinson’s disease on voice in all speaking tasks. Observation of the 
individual scores showed a tendency of the Parkinsonian mildly dysarthric group for 
higher scores in fundamental frequency (DFx1 and DFx2) in conversation and for 
lower scores in voice quality (average Qx and DQx1) in all speaking tasks. The 
tendencies of DFx1 and DFx2 scores in conversation might be precursors of the 
stiffening of the vocal folds (rigidity) while the tendency in Qx scores in all speaking 
tasks might be a precursor of a breathier voice quality. Both, observation of 
individual scores and statistical analyses showed differentiation across speaking 
tasks (reading compared to conversation). The findings of the differentiation of 
reading as compared to conversation in the majority of voicing variables prove the 
overlapping of both groups and the normality in their scores. Dysarthria in the 
beginning of Parkinson’s disease appears to exhibit itself in isolated movements of
the articulators rather than in phonatory measures.
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CHAPTER 5. RESULTS WITHIN GROUP (MEDICATION)
This chapter describes the effects of medication on speech and voice. The 
structure of the results, as in chapter 4, follows the order of the speech assessment:
- The results of the Frenchay Dysarthria Assessment (FDA)
- The results of the intelligibility testing
- The eiectroiaryngographic (ELG) measurements.
In all of the above measurements, the Parkinsonian subjects who scored 
lower in the FDA (mildly dysarthric group), were used to observe the effect of 
medication (BI8, GEI13, KD4, PM7, SI10, TZS2). As mentioned in chapter 4, one 
subject (KA15), in whom it was not possible to establish ELG signal, left the study 
after beginning medication. Another subject (SB5) stopped taking medication two 
months after the initiation of therapy. Therefore, he was treated as a separate case 
and his results in aspects of voice are compared against the Parkinsonian mildly 
dysarthric group of males.
Subject PX9 was not included in the between group results because she 
reported laryngeal problems due to surgery of the parathyroid and one thyroid gland 
10 years before the diagnosis of Parkinson’s disease. This subject has never 
received voice therapy. PX9 was included in the within group results, to observe the 
effect of medication on the Frenchay Dysarthria Assessment (FDA), and especially 
on its maximum performance subtests (movement of tongue and lips). It was 
decided to include her also in the intelligibility and ELG analyses since she was
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diagnosed with Parkinson’s disease. However, the analyses took place both with 
and without her to avoid her laryngeal pathology confound the results.
5.1 Results of the Frenchay Dysarthria Assessment
The Frenchay Dysarthria Assessment (FDA) was re-administered to mildly 
dysarthric Parkinsonian subjects 3-3.5 months after starting medication. The results 
of the FDA are shown below in table 14. The positive sign (+) shows the areas in 
which the medication had a positive effect (i.e., b to a), the negative sign (-) shows 
the areas in which the medication had a negative effect (i.e., a to b) and the equal 
sign (=) shows the areas in which there was no effect. Table 14 also includes the 
remaining subjects of the experimental group (LI14, GN11, KP6), whose FDA 
results before medication showed no signs of dysarthria (“a” score), in order to 
examine if the medication had a negative effect on their speech. The findings 
showed no difference in the non dysarthric Parkinsonian subjects. In general, palate 
was an area of the FDA where no differences were found while reflex was an area 
in which two subjects gave different outcomes. PM7 had a positive outcome (+) 
while PX9 showed a negative outcome (-). Because reflex alone does not contribute 
much in dysarthria and because the majority of research in dysarthria (perceptual, 
acoustic and physiological) focus on the areas of lips, laryngeal and/or tongue, the 
reflex area was omitted from the table 14 (even though it was included in individual 
figures).
216
Table 14. Differences of the Parkinsonian group before and after medication 
in the Frenchay Dysarthria Assessment.
Subjects Lips Laryngeal Tongue
Males
KD4 before vs. KD4 after + +
KP6 before vs. KP6 after No difference
PM7 before vs. PM7 after - - -
BI8 before vs. 818 after + = +
3110 before vs. 8110 after No difference
G N 11 before vs. G N 11 after No difference
i l l 4 before vs. LI14 after No difference
Females
TZS2 before vs. TZS2 after + + +
G EM 3 before vs. GEMS after No difference
PX9 before vs. PX9 after + - +
Note: The three subjects presented in italics are the non dysarthric subjects.
Two mildly dysarthric subjects (GEI13, SI10) out of seven exhibited no 
differences in their FDA results before and after medication. Five subjects were 
found to exhibit differences in the Frenchay Dysarthria Assessment (FDA) before 
medication as compared to after medication condition (KD4, PM7, BI8, TZS2 and 
PX9). The outcome of medication in every subject was defined as the total number 
of his/her positive (+), negative (-) or equal signs (=). Four out of these five subjects 
(KD4, BI8, TZS2 and PX9) exhibited an overall individual positive outcome in the 
areas of lips, laryngeal and tongue (more positive signs than negative signs). One 
subject (PM7) exhibited an overall negative outcome (two negative signs).
In general, the tongue area of the FDA was the area where the medication 
had an overall positive impact across the mildly dysarthric group (4 positive signs 
and 1 negative sign), followed by the lips (3 positive signs) and the laryngeal area (2
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positive signs and 2 negative signs). The results of the five Parkinsonian mildly 
dysarthric subjects where differences were found are presented below in figures 34- 
38, in a descending order of the positive outcome of medication (subjects who 
exhibited more in number positive signs are presented first). The subsections of the 
Frenchay dysarthria assessment that are presented in figures 34-38 involve 
differences of a least a scale (i.e. a to b) in each subject before and after 
medication. All the other subsections did not present differences before and after 
medication.
TZS2 was the subject in whom the medication had the most impact in the 
area of lips and less impact'in the areas of laryngeal and tongue. Figure 34 below 
shows the areas of the FDA that TZS2 differed in before and after medication 
condition.
□  TZS2 before 
■  TZS2 after
Figure 34. Results of the Frenchay Dysarthria Assessment before and after medication
for subject TZS2.
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618 was the subject in whom the medication had the most impact in the area 
of tongue and less impact in the area of lips. Figure 35 below shows the areas of 
the FDA that BIB differed in before and after medication.
-• * ;
□  BI8 before 
■  BI8 after
Figure 35. Results of the Frenchay Dysarthria Assessment before and after medication
for subject BIS.
KD4 was the subject in whom the medication had the most impact in tongue 
and less impact in the laryngeal area (Figure 36).
□  KD4 before 
■  KD4 after
Figure 36. Results of the Frenchay Dysarthria Assessment before and after medication
for subject KD4.
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In subject PX9, medication had the most positive impact in the areas of tongue 
and lips and the most negative impact in the areas of laryngeal and reflex (Figure 
37). This subject reported laryngeal pathology due to surgery in 1990. In this study, 
her voice was perceived as harsh both before and after levodopa medication.
During the completion of the history form before medication, PX9 perceived her 
speech to be slower in the past 2 years. In the post medication session she 
reported better movement of her limbs and better speech and voice. Her scores in 
the laryngeal and reflex sections however, were lower after medication (more time 
to complete the task). The discrepancy of her scores in the FDA with her perception 
might be due to the fact that the laryngeal time and pitch tasks are tasks that aim to 
bring the larynx and tongue to their extremes (maximum performance tests) and 
they are not used in a natural conversation. Sustaining an [a ]  for as long as 
possible (laryngeal time) is not a task that people use in their voice every day. 
However, it seems interesting that the improvement of the performance of PX9 in 
the lips and tongue areas follows the trend of the majority of subjects.
□  PX9 before 
■  PX9 after
Figure 37. Results of the Frenchay Dysarthria Assessment before and after medication
for subject PX9.
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PM7 was the only subject in whom the medication had a negative impact in 
all areas of reflex, laryngeal and tongue (Figure 38). PM7 had received a number of 
medications that he reported to have stopped 6 months before the beginning of this 
study. This medication involved drugs such as Akineton (12/6/1998-17/12/1998), 
Sinemet (24/12/1998-6/1999) and Symmetrel (26/1/1999-6/1999). Even though he 
reported to have stopped medication 6 months before he was diagnosed with 
Parkinson’s disease from the consultant neurologist in the university clinic, the 
influence of different drugs and/or the progression of the disease itself, probably 
had a negative effect on his speech/voice.
PM7 before 
□  PM7 after
Figure 38. Results of the Frenchay Dysarthria Assessment before and after medication
for subject PM7.
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5.2 Intelligibility results
The intelligibility scores of the seven Parkinsonian mildly dysarthric subjects 
before and after medication are shown below in table 15. All intelligibility scores are 
in the form of a percentage and an average number of errors. Careful observation of 
the scores shows that all mildly dysarthric subjects exhibited an slight increase in 
intelligibility after medication. An exception to this finding was the subject PX9 (with 
the laryngeal pathology) in whom the intelligibility percentage lowered and the 
subject PM7 in whom the intelligibility percentage stayed the same.
Table 15. Intelligibility scores of the Parkinsonian group before and after medication.
Experimental Subjects 
Before Medication
Intelligibility
Scoring
Experimental Subjects 
After Medication
Intelligibility
Scoring
TZS2 96.42%
(67.5/70)
TZS2 97.85%
(68.5/70)
KD4 98.57%
(69/70)
KD4 99.28%
(69.5/70)
PM7 95.00%
(66.5/70)
PM7 95.00%
(66.5/70)
818 98.57%
(69/70)
818 99.28%
(69.5/70)
8110 96.42%
(67.5/70)
SI10 98.57%
(69/70)
GEI13 97.14%
(68/70)
GEI13 99.28%
(69.5/70)
PX9 98.57%
(69/70)
PX9 97.14%
(68/70)
Group Mean 97.24% Group Mean 98.06%
Standard Deviation 1.40 Standard Deviation 1.58
Group Mean Excluding 
Subject PX9
97.02% Group Mean Excluding 
Subject PX9
98.21%
Standard Deviation 1.39 Standard Deviation 1.67
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Statistical analyses to identify possible group differences took place. The 
Wilcoxon paired samples test was used to identify differences in the means of the 
Parkinsonian mildly dysarthric group before and after medication. The results 
showed that no statistically significant differences in intelligibility were found t (6) = 
-1.702, p > 0.05. Inspection of the means showed that the Parkinsonian mildly 
dysarthric group exhibited a higher intelligibility mean after medication.
The Wilcoxon paired samples test was used to identify differences between 
the Parkinsonian mildly dysarthric group before and after medication excluding the 
subject PX9, who except Parkinson’s disease, exhibited also laryngeal pathology 
from another cause. Statistically significant differences in intelligibility were found 
z = -2.032, p < 0.05.
5.3 Results in eiectroiaryngographic measures
The Parkinsonian mildly dysarthric group before and after medication was 
compared in three speaking tasks: sustained phonation, reading, and conversation. 
The results of eiectroiaryngographic measures in sustained phonation are presented 
first and are followed by the results of the main effect of medication and speaking task 
(reading and conversation) on voice.
Due to the small size of the sample, both descriptive analysis and statistical 
significance testing were employed. The descriptive analysis was used to show 
possible tendencies in the individual scores of the subjects, while the statistical 
analysis was used to examine if there are differences between the means of the 
groups. Logarithmically transformed data were used to ensure normality in the 
distributions of the group before and after medication. .
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5.3.1 Results in sustained phonation
In review, the following variables were used in sustained phonation to 
compare the mildly dysarthric group before and after medication:
• Average fundamental frequency and standard deviation
• Average closed vocal fold contact, standard deviation and range (Qx)
• Jitter and shimmer (‘short-term’ cycle to cycle variations in frequency and 
amplitude).
Table 16 presents a summary of the eiectroiaryngographic results in 
sustained phonation including variables, descriptive data, and t-tests. Paired 
samples T-tests were used to identify possible differences. They did not find any 
statistically significant differences in the Parkinsonian mildly dysarthric group (N = 7) 
before and after medication in any logarithmically transformed variable. Special 
attention will be given to the individual scores of subject PX9 with the laryngeal 
pathology which present differences from the rest of the group and particularly of 
the female group.
Table 16. Summary results including variables, descriptive data, and t-tests (N = 7).
VARIABLE
DESCRIPTIVE DATA 
Comparison of the scores in the Parkinsonian group 
before and after medication T  -  tests
Average Fx (Hz)
- No pattern
- Increased pre and post medication scores in PD 
females compared to males
- A large increase in PX9’s score after medication 
compared to all subjects approaching other 
females scores
p > 0.05
Standard deviation Fx (Hz) - No pattern p > 0.05
Average Qx (%)
- Small increases in scores in 5 of 7 PD subjects 
after medication p > 0.05
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Qx standard deviation (%) - No pattern p > 0.05
Qx Range (%) - No pattern p > 0.05
Jitter First (%) - No pattern p > 0.05
Shimmer First (%) - No pattern p > 0.05
Table 17 below, shows a summary of the statistics (means and standard deviations) 
in all variables measured during sustained phonation.
Table 17. Summary statistics of the variables measured during sustained phonation 
in the Parkinsonian group before and after medication (N = 7).
V A R IA B LE -C O N D IT IO N Mean SD
Average Fx Before Medication (Hz) 168.60 61.31
Average Fx After Medication (Hz) 171.76 66.28
Fx Standard Deviation Before Medication (Hz) 2.68 2.18
Fx Standard Deviation After Medication (Hz) 3.16 2.78
Average Qx Before Medication (%) 39.75 3.73
Average Qx After Medication (%) 39.77 3.38
Qx Standard Deviation Before Medication (%) 0.06 0.06
Qx Standard Deviation After Medication (%) 0.06 0.04
Qx Range Before Medication (%) 4.84 2.55
Qx Range After Medication (%)- 4.54 1.09
Jitter Before Medication (%) 1.29 1.39
Jitter After Medication (%) 1.34 1.27
Shimmer Before Medication (%) 4.39 1.93
Shimmer After Medication (%) 5.96 2.84
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An examination of the individual scores of the Parkinsonian mildly dysarthic 
group before and after medication showed no specific patterns. Gender differences 
exist before and after medication. The scores of the female subjects (TZS2, CE113, 
PX9) were higher than male scores. Figure 39 shows the individual scores before 
and after medication in average Fx variable.
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■Average Fx Post
Figure 39. Individual scores before and after medication in average Fx variable.
Only in variable average Qx a small increase in individual scores after 
medication was observed which is in accordance with a small increase (0.02%) in 
the mean of the group. Since these increases are very small, their interpretation 
must be made with caution. It is safer to assume that medication seems to stabilise 
voice quality (at least in this task) rather than improve it.
5.3.2 Results of the main effect of medication and speaking task (reading and 
conversation) on voice
In review, the following variables were used in the current study in reading 
and conversation:
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• Mean fundamental frequency,standard deviation and range (DFx1, DFx2)
• Mean relative intensity, standard deviation and range (DAx1, DAx2)
• Mean closed vocal fold contact, standard deviation and range (DQx1). 
Table 18 presents a summary of the electrolaryngographic results in reading and 
conversation including variables, descriptive data, and analysis of variance (ANOVA). 
The Parkinsonian mildly dysarthric group was compared to itself in the same number of 
voice variables as in the between group results. The resulting data were analysed using 
a two-way analysis of variance in which one variable of interest was medication and the 
other variable of interest was speaking task to observe their effects on aspects of voice. 
Repeated measures analysis of variance did not show any statistically significant 
differences in the Parkinsonian mildly dysarthric group before and after medication (N = 
7) in any logarithmically transformed variable.
Table 18. Summary results including variables, descriptive data and anovas in the Parkinsonian
group before and after medication (N = 7)
VARIABLE -  SPEAKING TASK
DESGRiPTiVE DATA 
Gomparison of the scores in the Parkinsonian 
group before and after medication ANOVA
DFx1 Mean in Gonv. (Hz)
- No pattern
- increased pre and post medication scores in
PD females compared to males
- A large decrease in the score of the older rriaie
subject BI8 (74.2) after medication compared 
to other males scores
p > 0.05
DFx1 Mean in Read. (Hz)
- No pattern
- increased pre and post medication scores in
PD femaies compared to males
- A large decrease in the score of the older male
subject BI8 (74.2) after medication compared 
to other males scores
p > 0.05
DFx1 SD in Gonv. (Hz)
- No pattern
- Decreased pre and post medication scores in
PD females compared to males
p > 0.05
DFx1 SD in Read. (Hz) - No pattern p > 0.05
DFx1 90% Range in Gonv. (Octave)
- Decreased scores in 5 of 7 PD subjects after
medication
- Increased pre and post medication scores in
p > 0.05
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PD males compared to females
DFx1 90% Range -  Read. (Octave)
- Increased scores in 5 of 7 PD subjects after
medication
- A large increase in ttie score of the older male
subject BI8 (74.2) after medication compared 
to other males scores
p > 0.05
DFx2 Mean -  Conv. (Hz)
- No pattern
- Increased pre and post medication scores in
PD females compared to males
- A large decrease in the score of the older male
subject 818 (74.2) after medication compared 
to other males scores
p > 0.05
DFx2 Mean -  Read. (Hz)
- No pattern
- Increased pre and post medication scores in
PD females compared to males
- A large decrease in the score of the older male
subject BI8 (74.2) after medication compared 
to other males scores
p > 0.05
DFx2.SD -  Conv. (Hz) - No pattern p > 0.05
DFx2 SD -  Read. (Hz) - No pattern p > 0.05
DFx2 90% Range -  Conv. (Octave)
- No pattern
- PX9 post medication score has a small
increase (0.03) p > 0.05
DFx2 90% Range -  Read. (Octave)
- Increased scores in 6 of 7 PD subjects after 
medication (PX9 post medication score was 
decreased)
p > 0.05
DAx1 Mean -  Conv. (dB) - No pattern p > 0.05
DAx1 Mean -  Read. (dB) - No pattern p > 0.05
DAx1 SD -  Conv. (dB) - No pattern p > 0.05
DAx1 SD -  Read. (dB) - No pattern p > 0.05
DAx1 90% Range -  Conv. (dB) - No pattern p > 0.05
DAxI 90% Range -  Read. (dB) - No pattern p > 0.05
DAx2 Mean -  Conv. (dB) - No pattern p > 0.05
DAx2 Mean -  Read. (dB) - No pattern p > 0.05
DAx2 SD -  Conv. (dB) - No pattern p > 0.05
DAx2 SD -  Read. (dB) - No pattern p > 0.05
DAx2 90% Range -  Conv. (dB) - No pattern p > 0.05
DAx2 90% Range -  Read. (dB) - No pattern p > 0.05
DQx1 Mean -  Conv. (%)
- Decreased scores in 5 of 7 PD subjects after
medication
- PX9 post medication score has a large
decrease (10%)
p > 0.05
DQx1 Mean -  Read. (%)
- Decreased scores in 5 of 7 PD subjects after 
medication
- PX9 post medication score has a large
decrease (11% )
p > 0.05
DQx1 SD -  Conv. (%) - No pattern p > 0.05
DQx1 SD -  Read. (%) - No pattern p > 0.05
DQx1 90% Range -  Conv .(%) - No pattern p > 0.05
DQx1 90% Range -  Read. (%) - No pattern p > 0.05
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Table 19 below shows summary statistics of the variables measured during 
reading and conversation (means and standard deviations) before and after 
medication.
Table 19. Summary statistics of the variables measured during reading and conversation 
in the Parkinsonian group before and after medication (N = 7).
V A R IA B LE -C O N D IT IO N
READING CONVERSATION
Mean SD Mean SD
DFx1 Mean Before Medication (Hz) 165.99 63.91 171.47 55.60
DFx1 Mean After Medication (Hz) 163.76 65.09 167.50 64.12
Standard Deviation DFx1 Before Medication (Hz) 0.08 0.01 0.11 0.03
Standard Deviation DFx1 After Medication (Hz) 0.08 0.02 0.11 0.03
DFx1 90% Range Before Medication (Octave) 0.62 0.13 1.09 0.39
DFx1 90% Range After Medication (Octave) 0.67 0.16 1.06 0.33
DFx2 Mean Before Medication (Hz) 170.87 65.80 179.21 53.48
DFx2 Mean After Medication (Hz) 165.57 63.29 172.77 65.34
Standard Deviation DFx2 Before Medication (Hz) 0.03 0.01 0.05 0.01
Standard Deviation DFx2 After Medication (Hz) 0.03 0.01 0.05 0.00
DFx2 90% Range Before Medication (Octave) 0.50 0.11 0.89 0.27
DFx2 90% Range After Medication (Octave) 0.58 0.12 0.89 0.22
DAx1 Mean Before Medication (dB) 59.64 7.02 57.66 6.92
DAx1 Mean After Medication (dB) 58.37 7.62 57.58 6.92
Standard Deviation DAx1 Before Medication (dB) 8.66 1.20 8.66 1.20
Standard Deviation DAx1 After Medication (dB) 8.57 0.97 8.57 0.97
DAx1 90% Range Before Medication (dB) 13.94 2.54 15.94 2.45
DAx1 90% Range After Medication (dB) 13.76 2.17 15.90 1.79
DAx2 Mean Before Medication (dB) 60.67 7.11 58.77 7.03
DAx2 Mean After Medication (dB) 59.40 7.74 58.69 6.95
Standard Deviation DAx2 Before Medication (dB) 3.70 0.31 3.70 0.31
Standard Deviation DAx2 After Medication (dB) 3.50 0.44 3.50 0.44
DAx2 90%  Range Before Medication (dB) 11.99 2.12 14.99 2.59
DAx2 90% Range After Medication (dB) 12.01 2.09 14.51 1.95
DQx1 Mean Before Medication (%) 38.93 5.56 38.79 5.35
DQx1 Mean After Medication (%) 36.07 4.04 36.79 5.50
Standard Deviation DQx1 Before Medication (%) 4.99 0.98 6.11 1.59
Standard Deviation DQxl After Medication (%) 4.95 1.33 6.37 1.87
DQx1 90% Range Before Medication (%) 14.49 3.37 18.31 5.31
DQx1 90% Range After Medication (%) 14.53 4.09 18.80 5.44
Careful observation of the individual scores revealed a pattern only in DQxl 
mean variables in both reading and conversation. This pattern is in accordance with
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the group means of these variables. The Parkinsonian mildly dysarthric group 
exhibited lower means after medication than before in reading and conversation 
(DQx1 mean). In sustained phonation this tendency was reversed but involved an 
increase of only 0.02% (Average Qx). The assumption that medication may affect 
negatively voice quality (lower DQx1 mean) as the individual scores seem to point 
out, needs further research. The sample size as well as the large decrease in PX9’s 
post medication score in DQx1 mean variable in conversation may account for the 
aforementioned pattern. Figures 40 and 41 show the individual scores before and 
after medication in DQxl mean variable in both conversation and reading.
□  DQx1 Mean Pre 
■  DQx1 Mean Post
818 KD4 PM7 TZS2 GE113 PX9
Figure 40. Individual scores before and after medication in DQxl mean variable in conversation.
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Figure 41. Individual scores before and after medication in DQx1 mean variable in reading.
As in chapter 4, gender differences were observed in the fundamental 
frequency variables in both conversation and reading (DFx1 and DFx2 mean 
variables). Female subjects’ (TZS2, GEM 3, PX9) scores were increased compared 
to male scores in both pre medication and post medication conditions. Figures 42 - 
45 show the aforementioned gender differences in these speaking tasks.
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Figure 42. Individual scores before and after medication in DFx1 mean variable in conversation.
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Figure 43. Individual scores before and after medication in DFxl mean variable in reading.
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Figure 44. Individual scores before and after medication in DFx2 mean variable in conversation.
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Figure 45. Individual scores before and after medication in DFx2 mean variable in reading.
Observation of the individual raw data shows that the after medication scores 
of the older male subject (BI8, 74.2 years old) had a large decrease in fundamental 
frequency in both reading and conversation (DFx1 and DFx2 mean variables) 
compared to other male scores (see the above figures). This decrease was 10 Hz in 
reading and 20 Hz in conversation. Further research is needed to clarify if 
medication affects fundamental frequency in older subjects.
Special attention must be given to subject PX9 who, apart from Parkinson’s 
disease, exhibited dysphonia due to another cause. This subject exhibited large 
decreases after medication in the DQxl scores (10%) in reading and conversation. 
Also, PX9 was the only subject whose after medication score was decreased in 
fundamental frequency range in reading (DFx2 90% range). The combination of her 
special pathology with the effect of medication may have caused these decreases.
In summary, from the observation of the individual scores it seems that 
medication has a differential effect in the Parkinsonian mildly dysarthric group. 
Factors such as age, gender, and dosage may interfere and cause these variations.
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More research is needed to explore this issue. The present study shows that 
Parkinsonian subjects who are at the beginning of Parkinson’s disease and who 
have received medication for the first time, are idiosyncratically affected by 
medication in the variables measured.
Along the same lines, the observation of the individual scores in reading 
compared to conversation before and after medication showed discrepancies 
between these tasks. Only, in DQx1 mean variable there was the same tendency of 
decreased scores with the group mean in Parkinsonian subjects after medication 
across speaking tasks. In all other variables, observation of raw data showed 
differences across speaking tasks. Repeated measures analysis of variance 
(ANOVA) was applied to identify if there was a main effect of speaking task (reading 
as compared to conversation) on voice®. In the Parkinsonian mildly dysarthric group 
(N = 7) before and after medication statistically significant differences were found. 
Table 20 below shows summary statistics of the Parkinsonian mildly dysarthric 
group before and after medication in the variables that were found to be significant 
in the main effect of speaking task on voice. Appendix R shows the results in 
reading as compared to conversation in all variables before and after medication.
® In two variables (DFx1 90% range and standard deviation DFx2) no normality of the distributions 
occurred. So, Wilcoxon paired sample tests were used.
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Table 20. Summary statistics of the variables that were found to be significant 
in the main effect of speaking task on voice before and after medication (N = 7).
Variable Task
Parkinson’s Group Before 
Medication
Parkinson’s Group After 
Medication
Mean SD Median Range Mean SD Median Range
Standard Deviation 
DFx1 
(Hz)
Conversation 0.11 0.03 0.10 0.08 0.11 0.03 0.11 0.06
Reading 0.08 0.01 0.07 0.04 0.08 0.02 0.07 0.06
DFx1 90% Range 
(Hz)
Conversation 1.09 0.39 0.90 0.88 1.06 0.33 1.10 0.86
Reading 0.62 0.13 0.59 0.40 0.67 0.16 0.72 0.45
Standard Deviation 
DFx2 
(Hz)
Conversation 0.05 0.01 0.05 0.02 0.05 0.00 0.05 0.01
Reading 0.03 0.01 0.03 0.02 0.03 0.01 0.03 0.02
DFx2 90% Range 
(Hz)
Conversation 0.89 0.27 0.79 0.72 0.89 0.22 0.89 0.53
Reading 0.50 0.11 0.51 0.35 0.58 0.12 0.65 0.27
DAx1 Mean 
(dB)
Conversation 57.66 6.92 55.83 18.33 57.58 6.92 57.50 18.34
Readina 59.64 7.02 58.61 17.78 58.37 7.62 58.06 21.67
DAx1 90% Range 
(dB)
Conversation 15.94 2.45 15.60 6.10 15.90 1.79 16.00 4.90
Reading 13.94 2.54 13.40 7.40 13.76 2.17 13.00 6.30
DAx2 Mean 
(dB)
Conversation 58.77 7.03 57.50 18.89 58.69 6.95 58.61 18.89
Reading 60.67 7.11 60.28 18.34 59.40 7.74 59.17 22.22
DAx2 90% Range 
(dB)
Conversation 14.99 2.59 15.30 6.80 14.51 1.95 14.70 5.90
Reading 11.99 2.12 12.10 6.80 12.01 2.09 12.10 6.30
Standard Deviation 
DQx1 (%)
Conversation 6.11 1.59 6.99 4.08 6.37 1.87 6.74 5.17
Reading 4.99 0.98 4.91 2.75 4.95 1.33 4.74 3.48
DQx1 90% range 
(%)
Conversation 18.31 5.31 21.00 12.10 18.80 5.44 19.30 14.40
Reading 14.49 3.37 14.60 8.40 14.53 4.09 13.80 11.70
Ten variables were found that exhibited an overall effect of speaking task on 
voice. In eight out of these variables (SDDFxl, DFx1 90% range, SDDFx2, DFx2 
90% range, DAx1 90% range, DAx2 90% range, SDDQxl and DQx1 90% range) 
differentiation between reading and conversation was in both before and after 
medication conditions. Medication did not seem to differentiate the results across 
speaking tasks in the above variables. Also, comparisons between the mean group 
variables that were found to have a main effect of speaking task on voice showed
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that DAx1 mean [ t(6) = -6.72; p < 0.01 ] and DAx2 mean [ t(6) = -5.97; p < 0.01 ] 
were significant only in the before medication condition. In general, since the 
individual scores do not show any pattern with the group means no conclusions can 
be derived from these findings and caution is needed in their interpretation.
In conclusion, the variables that were found to have an overall main effect of 
speaking task on voice were identical to both between group and within group 
analyses. The fact that there is a differentiation of speaking task on voice in both 
groups (Parkinsonian and control group) indicates that the voice of the Parkinsonian 
group is similar to that of people without the disease, as measured by the variables 
of the present study. In addition, this differentiation seems not to be affected by 
medication. However, this conclusion warrants further investigation due to the fact 
that no measurement of the speaking task on voice took place in the control group 
after 3-3.5 months, as it did in the Parkinsonian group due to variation of individual 
scores.
5.3.3 The main effect of medication on voice of the subject SB5 against the
group of male subjects who took the same type of medication
Further analysis of individual data in the reading and conversation tasks for
SB5 who stopped rriedication 1 month before the re-examination of his speech was
made. It was considered important to see if the scores of SB5 differed from the
scores of the group of the other 4 males who continued medication. For every
experimental subject in the male Parkinsonian group who took levodopa as
medication (S110, PM7, KD4, BI8 and SB5), a z score difference was computed to
determine the degree of the difference after medication as compared to the before
medication condition. A z score denotes the number of standard deviations by
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which a subject’s score differs from the mean of the group and it is defined by the 
formula;
z=  1^
In this study, the difference of performance in any variable after medication minus 
before medication in every subject, the mean of the differences of the group and the 
standard deviation of the differences of the group were employed. The z score 
difference was defined by the formula:
z difference^° = i after-before -  u differences 
cr differences
The relative intensity variables (DAx1 mean, DAx1 standard deviation, DAx1 
range and DAx2 mean) showed a decrease of performance of the subject SB5 as 
compared to the 4 other male subjects of the group (BI8, KD4, PM7, SI10). In other 
words, the relative mean intensity difference (intensity after medication -  intensity 
before medication) of the voice of subject SB5 is increased (large difference, the 
voice becomes quieter) and diverged as compared to the differences of the 
members of the group. This reduction ranged from 1.5 -1.80 standard deviations in 
both reading and conversation. These differences however, did not seem to be 
perceptually apparent. Table 21 below, shows the z difference scores of the subject 
SB5 and their corresponding probability. Appendix Q shows the raw scores of the 
male subgroup who received levodopa in reading and conversation.
 ^ i = individual score, \i = mean of the group, o = standard deviation of the group 
in performance after medication minus before medication
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Table 21. z differences in the logarithmically transformed scores of the subject SB5 
as compared to the male experimental group that took the same type of medication (levodopa).
VARIABLE
READING CONVERSATION
z Difference 
(sd)
P Value z Difference 
(sd)
P Value
DAx1 Mean -'M .57 0.06 -1.63 0.05
DAx1 Standard Deviation -1.74 0.04 -1.63 0.05
DAx1 Range -1.78 0.04 -1.62 0.05
DAx2 Mean -1.50 0.07 -1.67 0.05
“ The negative sign denotes a worsening of performance in each score after levodopa medication. 
All p values are rounded to 2 decimal places.
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Figures 46 and 47 below show the z difference in the scores of every subject of the
male Parkinsonian group against the subject SB5 in DAx1 mean in reading and
conversation, respectively.
SI 10
PM 7 0.57
■0.14 □  DAxImean (dB)
Bl 80
S8 5-1.57
-1.5 -0.5 0.5
Figure 46. z difference expressed in standard deviations of DAxI mean in reading.
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Figure 47. z difference expressed in standard deviations of DAxI mean in conversation.
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Figures 48 and 49 below show the z difference in the scores of every subject of the
male Parkinsonian group against the subject SB5 in DAx1 standard deviation in
reading and conversation, respectively.
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Figure 48. z difference expressed in standard deviations of standard deviation DAxI in reading.
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Figure 49. z difference expressed in standard deviations of standard deviation DAxI in conversation.
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Figures 50 and 51 below show the z difference in the scores of every subject of the
male Parkinsonian group against the subject SB5 in DAx1 range in reading and
conversation, respectively.
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Figure 50. z difference expressed in standard deviations of DAxI range in reading.
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Figure 51. z difference expressed in standard deviations of DAxI range in conversation.
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Figures 52 and 53 below show the z difference in the scores of every subject of the
male Parkinsonian group against the subject SB5 in DAx2 mean in reading and
conversation, respectively.
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Figure 52. z difference expressed in standard deviations of DAx2 mean in reading.
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Figure 53. z difference expressed in standard deviations of DAx2 mean in conversation.
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Examination of the individual data of subject SB5, who stopped medication 
one month before the re-examination of his voice against the group of male 
Parkinsonian subjects who continued levodopa medication, revealed decreases of 
performance (as expressed in z difference score) in relative intensity mean, 
standard deviation and range (p = 0.04-0.07). The other subjects of the group 
showed an increase of performance in the above variables but this was not 
statistically significant. This result points probably to a possible stabilisation effect of 
levodopa medication in relative intensity. Further research with more subjects is 
needed to prove this hypothesis.
5.4 Summary of the within group results
In summary, in the Frenchay Dysarthria Assessment (FDA) two mildly 
dysarthric Parkinsonian subjects showed no difference in their scores after 
medication (GE113, 8110), four subjects showed an improvement (B18, KD4, TZS2, 
PX9) and one subject showed a decline in performance (PM7). The improvement 
showed up primarily in the tongue area (increase in speed movement of the tongue) 
and the lips area (increased in speed movement of the lips). Medication seemed to 
have a variable effect in the laryngeal area during extended sustained phonation 
[(an improvement in two subjects in the laryngeal time and pitch subsections of the 
FDA (KD4, TZS2) and a decrease in two other subjects in the pitch, time and 
volume subsections of the FDA (PM7, PX9)]. The overall decline in one subject’s 
performance (PM7) in the laryngeal and tongue sections of the FDA as compared to 
the other subjects, was probably due to his previous exposure to different drugs 
including levodopa and/or the progression of the disease itself.
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No statistically significant differences in intelligibility were found when the 
group of the seven Parkinsonian mildly dysarthric subjects was compared to itself 
before and after medication. However, statistically significant intelligibility 
differences were found when the analyses were made without the subject PX9 who 
apart from Parkinson’s disease exhibited dysphonia due to another pathology.
Electrolaryngographic measures were used to quantify aspects of voice in 
this group of seven subjects. Both the effect of medication and the effect of 
speaking task on voice were measured before and after medication. Observation of 
the individual scores showed individual variations in all variables except DQx1 
mean variable. A decrease in the after medication scores in DQx1 mean variable 
was found in both reading and conversation even though this decrease did not 
reach statistical significance. However, this tendency warrants further investigation 
due to the small size of the sample. No statistically significant differences were 
found in the effect of medication on voice aspects. These variations may be due to 
different responses to medication that may have been caused by factors such as 
age, gender and dosage of medication. The present study shows that Parkinsonian 
mildly dysarthric subjects who are at the beginning of Parkinson’s disease and who 
have received medication for the first time, are idiosyncratically affected by 
medication in the variables measured.
In the effect of speaking task on voice, the same variables that were found to 
differentiate reading from conversation in the between groups results, were found 
also in the within group results. Only two variables (DAx1 mean and DAx2 mean) 
that differentiated reading from conversation in the before medication condition did 
not show the same pattern in the after medication condition. However, the individual
scores did not show any pattern and the validity of this finding is questionable.
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CHAPTER 6. DISCUSSION
6.1 Incidence of dysarthria in early Parkinson’s disease based on the
results of the Frenchay Dysarthria Assessment
Factors that may contribute to different results of the reported incidence of 
dysarthria are the severity of Parkinson’s disease at the time of assessment 
(neurological stage of the disease), the type of study (survey or clinical), the 
skills of the evaluator, possibly the medication at the time of assessment and the 
methods used for assessment. The majority of studies and reports have 
differences in one or all of the afore-mentioned factors. For example, two studies 
and one report included sûbjects with different neurological staging and 
medication during the dysarthria assessment (Hartelius & Svensson, 1994; 
Logemann et al., 1978; Scott et al., 1985). Also, the studies that employed a 
large number of subjects (more than 200 subjects) were either surveys (Hartelius 
& Svensson, 1994) or a combination of a survey and physical examination 
(Mutch et al., 1986) and their dysarthria assessment was based on either 
subjects’ reports or neurological scales. In addition, researchers in the medical 
field have selected speech as a symptom among many other symptoms to 
include in their studies (Hoehn & Yahr, 1967; Mutch et al., 1986). Consequently, 
their results may differ with the results of those examiners specialising in the field 
of speech pathology, who focus primarily on speech symptomatology and who 
use different methods to assess dysarthria.
The reported incidence may also involve differences in the definition of 
dysarthria. Some medical specialists seem to distinguish dysarthria from voicing 
problems or “hypophonia” in Parkinson’s disease (Hoehn & Yahr, 1967). In the 
current study, the definition of dysarthria follows the suggestions of other
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researchers in the field of speech pathology who see dysarthria as a term for a 
speech disorder which includes voicing problems (Darley et al., 1969a; Duffy, 
1995).
With the exception of one medical study (Hoehn & Yahr, 1967) which 
found that only 3% of the patients reported speech problems as initial symptoms 
of the disease, all other studies show high occurrence of dysarthria ranging from 
45%-90% (Coates & Bakheit, 1997; Hartelius & Svensson, 1994; Logemann et 
al., 1978; Mutch et al., 1986; Scott et al., 1985). The low incidence (3%) of 
speech symptomatology in the Hoehn and Yahr study may be due to factors 
such as the general speech assessment and the inclusion of all forms of 
Parkinsonism in their subjects. Even though no direct comparisons between the 
reported incidence of the majority of studies and the results of the present study 
can be made due to differences in the number of subjects, the results of the 
present study fall within the aforementioned range. Eight out of thirteen 
Parkinsonian subjects were found to score lower in the Frenchay Dysarthria 
Assessment (FDA) compared to a group of matched pair controls.
Special attention should be given to the results of one study (Coates & 
Bakheit, 1997) because it is one of the few studies that examines an incidence of 
dysarthria based on both clinical examination and patients' reports. Similar to the 
present study but using a different neurological scale and intelligibility 
assessment, Coates and Bakheit aimed to identify the incidence of verbal 
communication disability^^ in Parkinson’s disease. One third of patients were 
found unaware of their communication disability while half of patients (24/48 
patients) were mildly affected (mild speech disturbances) and had no significant 
verbal communication disability (reduced intelligibility).
Verbal communication disability was defined as the inability of the speech and language 
therapists to fully understand the speech of subjects (Coates & Bakheit, 1997).
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Three aspects of the study by Coates and Bakheit should be noted. First, 
the reported incidence does not involve testing of voicing aspects. The incidence 
of verbal communication disability probably would be different if voicing were 
measured. Second, the authors supported the notion that the subjective views of 
patients about their speech problems may be misleading because they tended to 
overestimate or underestimate their speech problems. This tendency of the 
patients may probably be caused by physiological decrements of function due to 
normal ageing and/or differences in personality. The normal ageing process may 
be a confounding factor and it may complicate and distort the results of the 
dysarthria assessment. Great variability between subjects in speech 
performance has been reported as a result of the ageing process (Liss et al., 
1990; Weismer, 1984a). Moreover, slowness of speech is considered an actual 
finding of the ageing process (Liss et al., 1990). Liss and her colleagues stated 
that ageing might involve speech processes very similar to those seen in a 
neurological disease. In fact, the sensory-motor performance of elderly people 
may be concomitant with neurochemical changes in the basal ganglia. The use 
of a control group matched in as many aspects as possible with the experimental 
group may be a solution to the potentially confounding effect of the normal 
ageing process on speech. Coates and Bakheit (1997) did not use a control 
group in their study. In the present study, a control group that was matched to 
the Parkinsonian group in age, gender and education was used to provide a 
clearer picture of the results regarding normal ageing.
Finally, all subjects (except two) in the study by Coates and Bakheit 
(1997) were on medication at the time they were examined. Some authors 
emphasise that the administration of dopamine therapy in Parkinsonian patients 
may have changed the character of dysarthria typically seen in such patients
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(Duffy, 1995; Ludlow & Bassich 1984). If medication act positively (the patients’ 
speech becomes better) then a lower incidence of dysarthria would be found. If it 
act negatively (the patients’ speech become worse) then a higher incidence of 
dysarthria would be found. The results of the current study suggest that in the 
Frenchay Dysarthria Assessment (FDA) the medication had a positive effect on 
the speech of the majority of subjects. If this is the case, then Coates and 
Bakheit possibly reported a lower incidence than the incidence without 
medication and so, the actual incidence of dysarthria in their subjects should be 
higher. The type/dosage of medication and the individual’s response to 
medication may play a crucial role in the incidence of speech symptomatology 
and these aspects need to be investigated in future studies.
Together, medication and neurological staging are factors that can 
undermine the results on incidence rates. If speech follows the other motor 
complications (dyskinesias) that take place some time after levodopa 
medication, then it is reasonable to hypothesise that speech will worsen. In fact, 
Marsden and Parkes (1976) reported peak-dose orofacial dyskinesias (1-2 hours 
after medication) that were accompanied by oromandibular dystonia and created 
difficulties in speech and swallowing. The authors emphasised that levodopa 
does not halt the progression of the underlying pathology in Parkinson’s disease 
(neurological stage) and that after 3-5 years of medication the major 
manifestations of the disease reappear in 60% of their patients. The evidence by 
Marsden and Parkes shows the direct or indirect relationship of levodopa and 
neurological staging with speech and as a consequence with the reported 
incidence.
In conclusion, the incidence of mild dysarthria in the present study is 
within the range of the majority of studies that focused on speech
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symptomatology. The role of medication on the incidence of dysarthria is not 
clear because all of the aforementioned studies reported incidence rates in 
medicated patients and/or different neurological status. Moreover, the incidence 
based on patients’ reports is subjective in nature especially in studies where no 
control group is investigated. The clinical nature of the present study, the 
homogeneity of the sample on neurological staging, the unmedicated status of 
the subjects and the use of a matched control group, avoids the effect of the 
confounding factors on incidence rate. The results of the present study are 
considered a modest contribution to the understanding of the incidence of 
dysarthria when all of the aforementioned factors are excluded.
6.2 Profile of the mildly dysarthric subjects based on the results of the
Frenchay Dysarthria Assessment
This section aims to discuss in depth those aspects of speech in which 
incidence of mild dysarthria was found. The Frenchay Dysarthria Assessment 
(FDA) was used to measure dysarthria in the present study (Enderby, 1983). 
The FDA measures dysarthria during maximum performance subtests of non 
speech activities (movement of lips and tongue without voicing), speech 
activities (repeated non sense /iu/ and CVCV /kala/), voicing (extended 
sustained phonation in the production of [ a ], intonation in singing a scale and 
loudness in counting numbers with increased loudness) (Leuschel & Docherty, 
2000), and conversation. This test is detailed and elaborate in measuring the 
timing of independent areas in speech production (lips, tongue, laryngeal, 
respiration and palate) during speech and non speech movement. Based on 
maximum performance subtests, the FDA alone does not describe the nature of
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speech errors in dysarthria but it could point to areas where the problem might 
appear.
In the present study, the general results of the FDA showed a longer 
timing of the articulators (lips and tongue) in most of the subjects and a shorter in 
duration sustained phonation in few subjects during individual tasks, but this did 
not occur during conversation tasks compared to their controls. The nature of the 
present study that included subjects in the beginning of Parkinson’s disease 
(immediately after the neurological diagnosis) is probably responsible for this 
finding. These findings come in accordance with other reports (Darley et al., 
1969b, 1975; Duffy, 1995; Parnell & Amerman, 1996), in which the individual 
movements of tongue ancf lips in hypokinetic dysarthria are accomplished slowly. 
One study (Chenery et al., 1988) reported mild disturbances in the movement of 
lips and jaw and moderate disturbances in the elevation of tongue together with 
the prominence of laryngeal problems. However, abnormalities in all areas of the 
FDA in conversation (lips, jaw, palate, laryngeal and tongue) have also been 
reported by Chenery et al. Because no report of disease duration and medication 
status has been given in this study, the inclusion of subjects with variable 
duration of disease might be responsible for these findings.
Only one study (Parnell & Amerman, 1996) examined Parkinson’s 
disease during the preclinical period (5 years before the official neurological 
diagnosis). This study found slowness of volitional non speech movements and a 
restricted range of tongue movement during elevation in one Parkinsonian 
subject. The results of the present study support its findings and emphasise that 
dysarthria in the beginning of the disease will be manifested as a longer timing of 
the articulators during non speech and speech movements (fast alternate 
movement of [ ui ]) but not during running speech. So, slowness of movement
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appears first as a distinguishing feature of hypokinetic dysarthria but it is not 
accompanied by a reduced range of movement in all subjects. Because other 
studies that reported subjects with a variable duration of disease and 
neurological status (Chenery et al., 1988; Darley et al., 1969a, 1969b) showed 
slow movements of lips, tongue and decreased extended sustained phonation 
(Canter, 1965a; Ludlow & Bassich, 1983), it seems that these are characteristics 
of dysarthria that appear in early disease state and continue to affect speech 
movement during the disease process. Later on, when the slowness of individual 
movements will be accompanied with a reduced range of movement in the 
articulators, the fast repetitive movements, a significant characteristic of 
hypokinetic dysarthria willappear (Duffy, 1995).
6.2.1 Between groups -  Frenchay Dysarthria Assessment
This subsection aims to discuss the findings of the Frenchay Dysarthria 
Assessment (FDA) and the intelligibility testing between the Parkinsonian and 
the control groups. Out of the 8 subjects who exhibited a lower scoring in the 
FDA compared to their matched pair controls, in 6 the tongue movement was 
decreased in speed, in 5 there was a disturbed phonation and in 4 the lip 
movement was slow. In 4 subjects, problems in separate independent areas 
existed (lips, tongue or laryngeal) while in the remaining 4 subjects, 2-3 areas 
(lips, tongue and laryngeal) were affected simultaneously. As stated above, the 
lower scoring involved maximum performance speech and non speech tasks 
rather than the conversation task of the FDA. The Parkinsonian subjects 
completed the tongue and lips tasks in a longer time compared to their matched 
controls. In contrast, the laryngeal tasks (extended phonation of [ a ] sound) 
were completed in less time by 3 Parkinsonian subjects. The latter finding
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supports the results of studies that have found a decrease in the duration of 
extended sustained phonation and so, less laryngeal stability (Canter, 1965a; 
Ludlow & Bassich, 1983).
Pathophysiologically, the slowness of movements of the articulators is 
probably related to the general neurological symptom of bradykinesia. Even 
though the terms akinesia, hypokinesia and bradykinesia have been used 
interchangeably to indicate loss of the ability to move (Marsden, 1989), 
bradykinesia and hypokinesia are employed in explaining the pathophysiological 
basis in the present study. The increased in time execution of tongue and lip 
movement of Parkinsonian subjects in the beginning of the disease may denote 
a slowness of movement (bradykinesia) while the decreased in time voicing 
during prolongation of the [ a ] sound may be explained by hypokinesia (reduced 
range of movement).
However, it is questionable whether this longer timing in all areas 
necessarily leads to articulatory problems at this stage of the disease. It might be 
more reasonable to say that slower movement as described by the Frenchay 
Dysarthria Assessment (FDA) could increase the possibility of speech errors 
when the rate of speech stays the same. Accordingly, Ackerman and Ziegler 
(1991) reported that the reduction of articulatory precision in consonant 
production in Parkinson's disease is accompanied by normal rate at the expense 
of movement excursion.
Disturbed tongue and lip movement increases the possibility of 
articulatory errors. Inadequate tongue elevation for complete closure in stop- 
plosives, fricatives and affricates was found in subjects with a variable course in 
Parkinson’s disease (Canter, 1965b; Logemann & Fisher, 1981; Parnell & 
Amerman, 1996). Canter (1965b) reported that the incidence of tongue
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involvement was higher than lip involvement in diadochokinetic rates. The 
prominence of slower tongue movement in the FDA of the present study does 
not support the findings by Logemann et al. (1978) or the report by Critchley 
(1981) that laryngeal and respiratory dysfunctions appear first in hypokinetic 
dysarthria. However, etiological, methodological differences and sample size 
variations might be responsible for these discrepancies.
Etiologically, these studies mentioned subjects with both idiopathic and 
postencephalitic Parkinsonism. Postencephalitic Parkinsonism was reported by 
Hoehn and Yahr (1967) to have a high occurrence of speech symptomatology 
(12/44 cases) as compared to idiopathic Parkinson’s disease (7/183 cases). 
Methodologically, the lack of a normal control group in the study by Logemann et 
al. (1978) might account for the reported prominence of laryngeal involvement. 
Weismer and Martin (1992) supported the notion that if the study by Logemann 
et al. had investigated the speech of normal geriatric control subjects which 
could have been matched with the experimental group, similar voicing problems 
with the Parkinsonian group would have been found. In acoustic studies, ageing 
seems to be associated with a loss of voicing control (Liss et al., 1990; Weismer, 
1984a) at least in the initial syllable position. Perceptually, normal ageing has 
been found to be associated with increased breathiness, vocal tremor, reduced 
loudness, slower speech rate and less precise articulation (Linville, 2000). These 
observations lead to the conclusion that the high incidence of laryngeal 
dysfunction that was found by Logemann et al. might indeed be lower at the 
beginning of the disease. Differences in the sample size between these studies 
and the present study may also be responsible for the reported discrepancies. 
The sample of the present study is too small (N = 13) to make generalisations 
about the prominence of tongue involvement in Parkinson’s disease. In addition.
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in the present study the Parkinsonian subjects were seen in the very beginning 
of the disease process compared to all the other studies that examined speech 
in Parkinson’s disease.
Finally, in the study by Logemann et al. (1978) there was no information 
about the duration of the disease, the duration of medication intake before the 
speech assessment or the neurological stage of the disease. As has already 
been mentioned, these factors may be important because they may be related 
directly or indirectly to speech and voice. Almost all of the studies that focused 
on hypokinetic dysarthria, either included subjects with different duration of the 
disease, neurological status, or involved subjects under medication at the time of 
assessment (Ackerman & Ziegler, 1991; Baker et al., 1998; Canter, 1965a; 
Chenery et al., 1988; Fox & Ramig, 1997; Gamboa et al., 1997; Hammen & 
Yorkston, 1996; Holmes et al., 2000; Kent et al., 1994; Kent & Rosenbek, 1982; 
LeDorze et al., 1998; Ludlow & Bassich, 1983, 1984; Ludlow et al., 1987; Penner 
et al., 2001; Weismer, 1984a; Zwirner & Barnes, 1992).
In conclusion, it is uncertain that the problems that were identified by the 
Frenchay Dysarthria Assessment in the present study could lead to speech 
errors. In other words, a longer time to produce a movement of the tongue might 
not be enough to create an error. If however, a slower movement of the tongue 
is accompanied by a regular rate of speech, then the possibility for errors is 
increased. In hypokinetic dysarthria, variability of rate as a main speech 
symptom is well established (Adams, 1997; Chenery et al., 1988; Hammen & 
Yorkston, 1996; Ludlow & Bassich, 1983, 1984; Netsell, 1986; Scott et al., 1985; 
Zwirner & Barnes, 1992) and thus no generalisations could" be made on the 
possibility of articulatory errors.
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6.2.1.1 Intelligibility between groups
It is well known that imprecise articulation is highly correlated to speech 
intelligibility (Chenery et al., 1988; Darley et al., 1969a). A lower intelligibility 
score may be reflected in an increased number of speech errors. The perceptual 
impression of the researcher during the completion of the history form was that 
no major problems in intelligibility existed in either group of subjects. The results 
of the intelligibility testing were similar to the researcher’s impressions. The 
Parkinsonian group and its matched pair control group had the same intelligibility 
mean (97.68% for the Parkinsonian group and 97.67% for the control group) and 
the individual scores were 90% and above.
The nature of errors in intelligibility assessment is susceptible to variability 
because of the lack of equivalence in each set of words given during testing. 
Every subject was exposed to the same number of words (70) but not to the 
same set of words. The finding that both groups had more or less the same 
number of intelligibility errors does not necessarily mean that the groups 
exhibited similar profiles. Even though the number of errors was similar, it is not 
clear if the nature of errors in both groups was the same. It is possible for a 
category of phonetic contrasts to be different between the two groups. 
Unfortunately, no such comparison can take place in the present Greek 
intelligibility list because of the heterogeneity of phonetic contrasts to which each 
subject was exposed (different sets of words).
In general, the findings of the present study for intelligibility focus on the 
number of errors and not the nature of errors. Another study that could use a list 
of intelligibility (preferably standardized) in which all subjects could be exposed 
to the same number of phonetic contrasts might reveal differences in the nature 
of errors between the two groups.
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Intelligibility has no straightforward relationship with duration of disease. 
The smaller duration of disease in the present study might not be responsible for 
the high intelligibility percentages of the Parkinsonian subjects. In the hypokinetic 
dysarthria of Parkinson’s disease, there are few studies that have measured 
intelligibility in Parkinson’s disease. Coates and Bakheit (1997) used the 
Assessment for Intelligibility in the Dysarthric Speech (AIDS) (1981a) as an 
assessment tool and found an intelligibility mean percentage of 84.2% in 48 
patients with Parkinson’s disease (mean duration of disease 6.7 years). Kent et 
al. (1994) reported intelligibility scores in 31 males and females having 
hypokinetic dysarthria with different duration of disease. Only, five subjects out of 
the overall sample had a lower duration of disease (1-4 years). Their intelligibility 
scores from Kent et al. are presented in table 22.
Table 22. Intelligibility scores of Parkinsonian subjects with duration of disease of up to 4 years.
Subjects Gender Duration of the Disease 
(years)
Intelligibility
BPM Male 1 96.7%
0P M Male 1 89.0%
APM Male 3 90.1%
PPM Male 4 91.8%
GPM Female 4 94.7%
A careful observation of the table shows that the short duration of disease 
does not necessarily lead to a higher intelligibility score. Persons with one year 
of duration of the disease exhibit almost 8% difference in their intelligibility 
scores. So, it is still not clear how duration of disease is related to intelligibility. 
Some studies have reported a negative correlation (Coates & Bakheit, 1997;
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Metter & Hanson, 1986; Netsell, 1986) while one study reported the opposite 
(Hartelius & Svenson, 1994). The results of the present study show that in the 
beginning of the disease, the Parkinsonian subjects obtained high intelligibility 
scores.
6.2.2 Within group (medication) -  Frenchay Dysarthria Assessment
The medication had an overall effect on the individual movements of the 
articulators as described by the Frenchay Dysarthria Assessment (FDA) in 5 out 
of the 7 Parkinsonian mildly dysarthric subjects. Four subjects exhibited a 
positive effect while one subject exhibited a negative effect. The same scoring 
was found in 2 subjects before and after medication, from which one subject 
(GEI13) used a different type of medication (dopamine agonist, “Mirapexin”). The 
Parkinsonian subjects who were affected by medication, exhibited the following 
differences in independent areas of the Frenchay Dysarthria Assessment:
• An improvement in the score of the tongue area in 4 out of 5 subjects. 
In the subject PM7, tongue movement before medication had been 
normal but worsened after medication.
• An improvement in the score of the lips area in 3 out of 5 subjects. The 
remaining two subjects scored equally after medication as compared 
to before medication.
• An improvement in the score of the laryngeal area in 2 out of 5 
subjects. Two other subjects scored lower after medication as 
compared to before. Finally, one subject scored the same before and 
after medication.
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Table 23 below shows the areas of the FDA that were improved after 
medication, the combination of medication and the age of the subjects.
Table 23. Age and combination of medication in the subjects who exhibited 
a positive effect of medication on the Frenchay Dysarthria Assessment.
Subiects Age Medication
Tongue Area
KD4 66.1
Madopar 1 x3 
Akineton % ^2 
Symmetrel 1 *2
BIS 74.2 Madopar % %3 Akineton 1x1
SB5 79.9 Madopar 1 x3
TZS2 64.8
M adopar1 x3 
Akineton 1 x3  
Symmetrel 1x3
PX9 63.8 M adopar1 x3 Akineton % x3
Lips Area
BI8 74.2 Madopar % x3 Akineton 1x1
TZS2 64.8
M adopar1 x3 
Akineton 1 x3 
Symmetrel 1 x3
PX9 63.8
M adopar1 x3  
Akineton % x3
Laryngeal Area
KD4 66.1
M adopar1 x3 
Akineton % x2 
Symmetrel 1x2
TZS2 64.8
M adopar1 x3  
Akineton 1 x3 
Symmetrel 1x3
In general, the combination of medication in the present study resulted in 
an improvement in the scores of the Frenchay Dysarthria Assessment (FDA) 
predominantly in the tongue area. Increases in the speed and rhythm were found 
in the lateral movement of tongue and the elevation of tongue. Also, the sealing 
of the lips and the appearance of the lips at rest were found to be positively 
affected by medication. In the laryngeal area however, the results were variable.
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This might be due not only to specific indiosyncracies of the subjects (for 
example, PX9 had undergone parathyroid surgery), but also to the nature of 
specific voicing tasks of the FDA (extended phonation, singing a scale and 
counting with an increasing volume). The lack of studies that measure speech 
and voice before and after medication using the FDA prohibits any further 
conclusions.
The combination of levodopa-benserazide (Madopar) and anticholinergics 
(Akineton, Symmetrel) seems to be the most effective agent to describe the 
positive effect on the scores of the FDA. Anticholinergic drugs alone (Artane, 
Cogentin, Akineton and Symmetrel) do not seem to improve speech (Critchley, 
1981). Their use is based on their ability to reduce tremor in the limbs, block the 
action of acetylcholine (Ach) and create a balance between dopamine and 
acetylcholine (Hermanowicz, 2001; Koller, 1992; Oertel & Quinn, 1997; Wills, 
1998). Levodopa-benserazide (Madopar) seems to be the agent responsible for 
the favourable effect on tongue and lip movements.
As has been stated before, pathophysiologically, the results of the 
Frenchay Dysarthria Assessment (FDA) in the present study are probably 
related to the neurological symptom of bradykinesia (slowness of movement) 
that appeared as an early symptom of the disease together with tremor in all 
subjects. Slowness of movement is considered as the most important symptom 
in the diagnosis of Parkinson’s disease (Hughes et al., 1992; Marsden, 1994; 
Tetrud, 1991). The general physical slowness of movement in the Parkinsonian 
subjects, might be responsible for the slowness in the individual movements of 
the articulators in the present findings of the FDA. This assumption confirms the 
clinical impression of the consultant neurologist that bradykinesia is responsible 
for dysarthria at this stage of Parkinson’s disease. Madopar alleviated this
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slowness of movement in both the limbs (as reported by the patients) and the 
isolated movements of the tongue and lips and less in the laryngeal area of the 
FDA. In the beginning of the disease, levodopa seems to have a beneficial effect 
on the individual movement of the articulators as measured in the FDA, but its 
role on the voicing tasks of the FDA is not so clear.
6.2.2.1 Intelligibility within group
As in between groups, medication showed a neutral effect on speech as 
measured by the “In Speech" subsections of the Frenchay Dysarthria 
Assessment (FDA) in the within group analysis. The scores of the FDA were 
normal before and after medication. Intelligibility as an index of communicative 
performance in the present study was improved. Only in one subject (PX9) with 
the laryngeal pathology, the intelligibility score after medication was lower than 
before medication. The mean intelligibility scores were statistically increased in 
the six remaining Parkinsonian mildly dysarthric subjects after medication. Even 
though no inferences about the nature of decreased intelligibility errors after 
medication can be made, some assumptions can be given about the number of 
intelligibility errors (after medication as compared to before medication 
condition). Before medication, the number of total errors that were found by both 
listeners was 21 compared to 12 (after medication).
These findings support the findings by Metter and Hanson (1986) that an 
improvement in intelligibility occurred when their patient was “on” levodopa 
medication. The current study supports the findings of studies that showed 
beneficial effects of levodopa on intelligibility as proven by an improvement in 
labial musculature (Leanderson et al., 1971; Nakano et al., 1973) and do not 
support the findings of other studies that did not show intelligibility improvement
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(Gentil et al., 1998; Gentil et al., 1999). The intelligibility scale in the latter studies 
was general (not detailed examination) as a part of a neurological scale (UPDRS 
with scale of severity from 1 to 4). Also, the Parkinsonian subjects in these 
studies exhibited a moderate disease involvement and it is possible that after 
some years the response to medication was not consistent.
There are a number of reports in the literature that relate intelligibility with 
articulation or imprecise consonants (Canter, 1965b; Chenery et al., 1988;
Darley et al., 1969a; Weismer & Martin, 1992). Canter (1965b) correlated the 
clarity of articulation with tongue movement (tip and back). If increased 
intelligibility after medication is due to more precise articulatory movements of 
the Parkinsonian dysarthric subjects, then it is possible that in the present study 
the higher scoring in the Frenchay Dysarthria Assessment subtests of the 
movements of the tongue followed by the lips and larynx, produced such 
increase. Further research is needed to correlate the isolated movements of the 
tongue area in the FDA with intelligibility scores in order to prove this hypothesis.
However, caution to the interpretation of the within group statistically 
significant results is needed due to a number of factors. First, all Parkinsonian 
subjects exhibited more than 90% intelligibility before medication. Second, the 
Greek word list (as all word identification tests) assesses intelligibility ignoring 
the context, and so it is not predictive of real-world communication situations 
(Hustad et al., 1998). Finally, no piloting of the Greek word list took place and 
weaknesses inherent to its development (differences in the frequency of 
contrasts between sets of words, differences in the overall number of each 
phonetic contrast category in each set) may limit the application of the 
statistically significant increase in intelligibility after medication.
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In addition to the relationship of articulation to intelligibility there is one 
study (Ramig, 1992) that examined the relationship between vocal function and 
perceptual measures of speech including intelligibility in Parkinsonian patients 
who had received intensive voice therapy. Even though high correlations of 
monotone and shaky voice (0.88 and 0.74 respectively) with speech intelligibility 
were found, differences in the neurological stage of Parkinson’s disease exist 
between the present study and Ramig’s study. Ramig’s study employed seven 
subjects with severe mobility problems implying an advanced neurological stage 
of Parkinson’s disease. In the present study, it is possible that phonation 
(laryngeal section of the FDA) is not the area that improved intelligibility as 
shown by the small number of subjects who improved after medication in the 
laryngeal section of the FDA (n = 2). The areas that showed the most 
improvement in the FDA after medication were the tongue and lips. 
Consequently, errors that involved tongue and lips might respond better to 
medication and so, an increased intelligibility scoring would result. Further 
research is needed to prove this assumption.
6.3 Electrolaryngographic results in sustained phonation, reading and
conversation between groups
6.3.1 Sustained phonation
Sustained phonation is a common task in the measurement of voice in 
neurological disorders. Kent et al. (1994) emphasised its frequent use in clinical 
voice evaluation. Despite its unnaturalness compared to conversation, simplicity 
and derivation of perceptual, acoustic or physiological measures make this task 
a preferential choice among researchers. Sustained phonation eliminates the 
effect of vocal tract configuration on the glottis and isolates the phonatory system
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(Zwirner et al., 1991). Also, basic aspects of laryngeal function such as 
periodicity and amplitude can be derived from sustained phonation. In acoustics 
and electrolaryngography, the most common measures in sustained phonation 
involve the average fundamental frequency, standard deviation of fundamental 
frequency, jitter and shimmer. In this section, the results of the present study will 
be compared with the findings of similar acoustic and electrolaryngographic 
studies.
The between group results of the present study showed no significant 
differences in the group means of all variables. The average fundamental 
frequency was invariably found to be higher (although not always statistically 
significant) in many studies in the Parkinsonian group (Gamboa et al., 1997; 
Gerratt et al., 1987; Hanson et al., 1983; Hertrich & Ackerman, 1995; Kent et al., 
1994; Ludlow & Bassich, 1983; Ludlow et al., 1983; Ramig et al., 1988). 
Statistical significance was reached in four studies (Gamboa et al., 1997; 
Hertrich & Ackerman, 1995; Ludlow & Bassich, 1983; Ludlow et al., 1983) while 
the non significant elevated fundamental frequency was found only in the male 
Parkinsonian group in another study (Kent et al., 1994). Two of the four studies 
reported that the statistically significant average fundamental frequency was 
found in their male subgroups (Gamboa et al., 1997; Hertrich & Ackerman,
1995). The other two studies (Ludlow & Bassich, 1983; Ludlow et al., 1983) 
despite their small number of Parkinsonian subjects (N = 7), they did not report 
any tendencies in the individual scores. In addition, bilaterality of symptoms and 
ambulatory problems indicate that the subjects in these studies were probably in 
an advanced stage of Parkinson’s disease (in contrast to the present study that 
employed subjects in the early beginning of the disease). In the present study, 
observation of the individual data showed a tendency of decreased scores of
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Parkinsonian subjects as compared to their controls in average Fx. The early 
stage of the disease may account for this discrepancy. Average Fx in sustained 
phonation may not be a sensitive measure in the beginning of Parkinson’s 
disease.
Standard deviation of fundamental frequency (SDFo), as a measure of a 
long term phonatory instability has been found to increase even though no 
statistical significance was found (Zwirner et al., 1991). In the present study, no 
statistically significant differences between the Parkinsonian and control groups 
were found in SDFo. Individual scores of Parkinsonian subjects were higher 
compared to their controls which support the findings by Zwirner et al. (1991).
Jitter (cycle-to-cyclé frequency perturbation) and shimmer (cycle-to-cycle 
amplitude perturbation) are also used very often to measure short-term variability 
in fundamental frequency and amplitude of the phonatory system (Baken, 1997). 
Many authors state that these measures are far from being standardised but 
because of their systematic examination in numerous studies they may be useful 
in clinical diagnosis (Heiberger & Horii, 1982; Horiguchi et al., 1987; Kent et al., 
1994).
Increased jitter (either statistically significant or non statistically significant 
but elevated) was found by many acoustic and electrolaryngographic studies 
when Parkinsonian and control groups were compared (Gamboa et al., 1997; 
Gerratt et al., 1987; Hertrich & Ackerman, 1995; Holmes et al., 2000; Kent et al., 
1994; Ramig et al., 1988; Zwirner et al., 1991). Statistically significant differences 
were found in three studies (Gamboa et al., 1997; Hertrich & Ackerman, 1995; 
Zwirner et al., 1991). In the Hertrich and Ackerman study, these differences were 
attributed only to the male subgroup while the remaining of the studies employed 
subjects with at least 6 years of disease duration who were at the stage II in
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Hoehn and Yahr scale and were receiving levodopa. Holmes et al. found that 
statistically increased jitter is attributed to late Parkinson’s disease rather than 
early Parkinson’s disease. The present study found neither statistical significant 
differences between the two groups nor any individual tendencies, supporting 
Holmes et al. (2000) finding regarding the disease stage.
In many studies, shimmer was found to increase in the Parkinsonian 
group but did not reach statistical significance (Gamboa et al., 1997; Gerratt et 
al., 1987; Holmes et al., 2000; Kent et al., 1994; Ramig et al., 1988). One study 
found a statistically increased shimmer in the female Parkinsonian group (Kent 
et al., 1994). The results of the present study support the results of the 
aforementioned studies that found no difference in mean shimmer value among 
Parkinsonian and control groups. Comparison of the Parkinsonian subjects’ 
scores with their matched pair controls revealed a tendency for decreased 
shimmer scores in 4 out of 6 Parkinsonian subjects. This tendency may reflect 
the different algorithm for the measurement of shimmer in the present study 
(Gold-Rabiner and cepstrum analysis from the corresponding to the Lx signal 
speech signal).
Qx was a variable used only in the present software for analysis (Speech 
Studio). Qx is described as a measure of voice quality (Abberton & Fourcin,
1997; Fourcin, 2000; Fourcin et al., 1995). Breathiness is reported to occur when 
the open phase of the vocal folds is extended in time as compared to the closed 
phase (Fourcin, 1981). In general, a lower Qx value reflects a voice with less 
stability in quality, as the mean percentage of time that the vocal folds are closed 
to the total period becomes smaller (a smaller time of closed vocal folds).
In the present study, the Qx mean variables that were found to be lower in 
the Parkinsonian group (although non statistically significant) compared to the
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control group included the average Qx, the standard deviation Qx and the Qx 
range. The average Qx mean variable was the only variable to be consistently 
lower in the Parkinsonian group in both group means and individual scores. 
Although non statistically significant, the lower Qx value is probably a precursor 
of breathiness in the Parkinsonian group. A decreased average Qx variable 
confirms one study that reported similar tendencies and using similar methods. 
Hanson et al. (1983) reported a lower time of the vocal folds in the most closed 
period (15% of the entire cycle) in one Parkinsonian subject. This subject was in 
an advanced neurological stage of the disease and his voice appeared to be 
weak and breathy. Average Qx range was also found to decrease in the 
Parkinsonian group as compared to the control group but this involved only the 
mean values and not the individual scores.
Even though no statistical significance was found, the results of the 
present study in sustained phonation show that tendencies in Parkinsonian 
individual scores and groups means for elevated standard deviation of 
fundamental frequency, and decreased Qx were found in the beginning of 
Parkinson’s disease. The results on the average Qx variable show that in the 
very beginning of the disease a lower closing time of the vocal folds during 
phonation may appear. More studies are needed especially on a longitudinal 
basis to observe if the average Qx variable is correlated to a perceived 
breathiness.
6.3.2 Reading and conversation
In the present study, fundamental frequency (DFxl and DFx2), intensity 
(DAxI and DAx2) and voice quality (DQxl) were measured during reading and 
conversation. The group results found non statistical significant differences in
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these variables between the mildly dysarthric Parkinsonian group compared to 
the control group in both reading and conversation. The individual scores of 5 
out of 6 Parkinsonian subjects in DFx1 and DFx2 in conversation were elevated 
compared to their controls, which is in accordance also with the group means of 
these variables. These tendencies did not appear in reading. In voice quality 
(DQx1), both in reading and conversation, comparison of individual scores and 
group means between Parkinsonian subjects and their matched pair controls, 
revealed lower scores and means for Parkinsonian subjects. These individual 
and group tendencies in the mean variables will be discussed against acoustic 
and electrolaryngographic studies that used similar measures.
Both DFx1 and DFx2 means (fundamental frequency of excitation) were 
found to be non statistically elevated in the Parkinsonian group compared to the 
control group in both speaking tasks. Statistically significant increased 
fundamental frequency during running speech was reported in three studies 
(Canter, 1963; Ludlow & Bassich, 1983, 1984). Although there was no 
information in these studies about the duration and neurological stage of the 
disease, inferences about bilateral symptoms probably imply that the 
Parkinsonian subjects were not at the beginning of the disease. Holmes et al. 
(2000) support the notion that statistically increased mean fundamental 
frequency is a characteristic of male subjects with late Parkinson’s disease (13 
years duration) rather than early Parkinson's disease. The findings in the present 
study of elevated fundamental frequency in conversation at the beginning of 
Parkinson’s disease may show that this variable may be a precursor of the 
rigidity of the vocal folds. The same tendency was not found in reading (the 
individual scores did not present the same tendency with the mean) probably 
because this speaking task is more structured than conversation and the small
267
differences between the groups in DFx1 and DFx2 means may not be apparent 
in reading.
The group means of the standard deviations of the fundamental frequency 
of excitation and the individual scores did not reveal any pattern. Standard 
deviation of fundamental frequency and intensity during reading, especially the 
first, might reflect the voice disturbance (monopitch and monoloudness) in the 
Parkinsonian population (Gamboa et al., 1997). This measure has been used to 
show variability in the frequency of glottal opening and closing during phonation 
(Ludlow & Bassich, 1983; Ramig et al., 1988; Zwirner & Barnes, 1992). It is used 
as an index of phonatory stability and voluntary laryngeal movements (Zwirner & 
Barnes, 1992). Recent studies (Gamboa et al., 1997; Holmes et al., 2000) use it 
not only in sustained phonation but also in reading and monologue. Gamboa et 
al. found significant differences between a Parkinsonian group and a control 
group in the means of the standard deviation of fundamental frequency during 
reading. The Parkinsonian group in the study by Gamboa et al. exhibited a lower 
mean standard deviation of fundamental frequency compared to the control 
group. The present study does not support the findings of the study by Gamboa 
et al. Differences in duration of disease, neurological status and medication are 
probably responsible for the discrepancies between the two studies. Holmes et 
al. consider that statistically significant standard deviation of fundamental 
frequency (SDFo) is attributed in the female subgroup of late disease compared 
to early Parkinson’s disease and controls.
Three studies (Canter, 1963; Gamboa et al., 1997; Ludlow & Bassich, 
1984) reported significant differences in fundamental frequency range between 
Parkinsonian and control groups during reading of a sentence. Smaller mean 
fundamental frequency ranges were reported for the Parkinsonian groups as
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compared to the control groups. The present study showed the same tendencies 
with the above studies, however, non statistically significant, in both the DFx1 
90% range and the DFx2 90% range in reading. This trend did not appear in 
conversation.
The present study found no statistically significant differences in the 
variables DAx1 and DAx2 (intensity of excitation) between the two groups. 
Observation of individual scores revealed no pattern as well. These findings 
support the findings by Canter (1963) who reported that his groups overlapped in 
intensity. Similar results were found when Parkinsonian patients with early 
disease were compared to Parkinsonian patients with late disease (Holmes et 
al., 2000). However, one study (Fox & Ramig, 1997) showed different results. 
The means of the sound pressure level in reading and monologue of the 
Parkinsonian subjects were decreased statistically up to 4 dB compared to 
healthy controls.
Standard deviation of intensity was found not to be significant when the 
Parkinsonian group with early disease was compared to the Parkinsonian group 
with late disease (Holmes et al., 2000). It seems that the standard deviation of 
intensity is not a sensitive measure for variation during the disease process. The 
findings of the present study agree with the above observations, intensity range 
in reading was found not to be statistically significant in the study by Canter 
(1963) which agrees with the present study. The present study however, showed 
a tendency for decreased scores of Parkinsonian subjects compared to their 
matched pair controls in DAxI 90% range and DAx2 90% range in conversation.
The means of the groups in DQxl in both speaking tasks were non- 
statistically lower in the Parkinsonian group. The tendency of a lower DQxl 
mean variable in all speaking tasks (sustained phonation, reading and
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conversation) is accompanied by lower individual scores. As in sustained 
phonation, this finding (even though it did not reach statistical significance) might 
be a precursor of breathiness in the Parkinsonian group. Future studies may 
show if the DQx1 mean variable will reach statistical significance as the disease 
progresses. DQx1 90% range in conversation also was found to be lower in the 
Parkinsonian group compared to the control group, as both group means and 
individual scores have showed.
In conclusion, the between group results showed tendencies in the means 
of a number of variables. The tendencies that were confirmed by the individual 
scores were considered more valid to discuss the phonatory mechanism in the 
very beginning of Parkinson’s disease. The mean Qx variable in all speaking 
tasks was found consistently lower in the majority of Parkinsonian subjects. 
Pathophysiologically, these tendencies might be precursors of breathiness in the 
Parkinsonian group. Similarly, the elevated mean fundamental frequency in 
conversation that was found in the majority of Parkinsonian subjects might be a 
precursor of rigidity of the vocal folds. Also, smaller ranges in both fundamental 
frequency and intensity (as agreement of the individual scores with the group 
means have shown) were found and may relate to monopitch and 
monoloudness. However, these tendencies in ranges were dependent on the 
speaking task. From the above findings which did not reach statistical 
significance, the voice disturbance in the mildly dysarthric Parkinsonian group of 
the present study is not apparent, yet, but as the disease progresses it may 
become more evident.
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6.4 Electrolaryngographic results in sustained phonation, reading and
conversation within group (medication)
In sustained phonation, the within group results (before and after 
medication) showed no statistically significant differences between the group 
means in all variables. Observation of individual data in average Fx and standard 
deviation Fx variables showed no specific patterns. The results of the present 
study confirm the findings of other studies that reported no significant differences 
in mean fundamental frequency and standard deviation of fundamental 
frequency in sustained phonation (Daniels et al., 1996; Jiang et al., 1999). An 
interesting finding is the large increase (32Hz) in subject’s PX9 score (subject 
with the laryngeal pathology) in average Fx variable after medication compared 
to all subjects and approaching other females’ scores. Her increase in average 
Fx may be considered as a positive sign of improvement and not as a negative 
sign, given her low pre-medication score.
Jitter and shimmer showed no statistical significant differences in group 
means before and after medication, which is in accordance with the lack of any 
pattern after observation of individual data. The results on jitter support the 
findings by Jiang et al. (1999) where no significant differences after medication 
were found. In contrast, the results on shimmer do not support the findings by 
Jiang et al. who found a significant decrease in shimmer values in 11 out of 15 
subjects in their study. Different algorithm of shimmer derivation might be 
possible reason for this discrepancy.
In variable average Qx a small increase in individual scores and group 
means after medication was observed. However, the increase is very small and 
probably indicates no alterations in the voice quality of the subjects after
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medication compared to before medication. It is safer to assume that medication 
either plays no role or has a stabilizing role on this measure of voice quality.
There is only one study that has used electrolaryngographic measures in 
reading and conversation before and after levodopa medication (Daniels et al.,
1996). The results of the present study support its findings that showed no 
statistically significant differences in all mean group variables before and after 
medication.
Observation of individual data showed some pattern in fundamental 
frequency ranges in both speaking tasks. These patterns were different across 
speaking tasks (in reading there was a tendency for increased scores after 
medication and in conversation the opposite), which may reflect the different 
demands of each speaking tasks on voice. Moreover, this differentiation across 
speaking tasks is a characteristic shown most notably in normal rather than 
dysarthric speakers (Leuschel & Docherty, 1996, 2001). Based on the above 
observation and the findings of the present study it is safer to say that in this 
early stage of the disease, voice is not yet affected.
A clear tendency of decreased individual scores in DQxl mean in both 
speaking tasks after medication, in accordance also with the non-significant 
lowering of the within group means, may reveal a possible interesting area of 
research. The effect of medication (indifferent, stabilizing, or worsening) on voice 
quality (DQxl) needs further research.
Statistically significant differences in relative intensity variables were 
found when z differences expressed in standard deviations were compared 
between the subject SB5 (stopped medication after 2 months) and the group of 
levodopa medicated male subjects who continued medication. These findings 
may indicate that the combination of levodopa and anticholinergics (especially
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levodopa) may act to stabilise the intensity of voice in the medicated male 
subgroup (all relative intensity variables were increased up to 1 standard 
deviation). These results support the findings by Metter and Hanson (1986) 
where the relative intensity was lower in one patient with Parkinson’s disease in 
the “off’ levodopa medication condition and was increased after levodopa 
administration. Further research is needed to examine the validity of this 
assumption and probably correlate the perceptual impressions of loudness 
decay in Parkinson’s disease (Darley et al., 1969b) with intensity in subjects 
before and after medication. However, the results of subject SB5 compared to 
the male medicated subgroup should be taken with caution for two reasons.
First, the small number of subjects does not allow for a generalisation of these 
findings. Second, the age of subject SB5 (the oldest experimental subject, 79.9 
years) might be responsible for the z differences in intensity and not the type of 
medication, per se. The ageing effect in healthy individuals involves a decrease 
of function in speech (Liss et al., 1990) and voice (Linville, 2000). Linville (2000) 
states that increases in mean fundamental frequency and intensity variability 
with age have been found in males. Along the same lines, the individual scores 
of one male subject who was 74,2 years old (BIB), second older after subject 
SB5, showed a large decrease (20 Hz) after medication compared to the other 
male scores in mean fundamental frequency in both speaking tasks.
6.5 Gender differences
In the present study, gender differences were found in fundamental 
frequency in all speaking tasks. Both, Parkinsonian and control female subjects, 
exhibited higher scores than males. These results are in accordance with studies
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reporting higher fundamental frequency in females compared to males in normal 
voice production (Baken, 1997; Greene & Mathieson, 1997).
In voice production in Parkinson’s disease, two studies (Hertrich & 
Ackermann, 1995; Gamboa et al., 1997) found increased mean fundamental 
frequency only in the male subgroup of their subjects compared to controls. In 
the present study, no such finding was observed. This may be due either to the 
early stage of the disease or to the small sample of the present study (4 male 
and 2 female Parkinsonian subjects completed the electrolaryngographic 
measures).
Observation of the individual data after medication did not reveal any 
gender specific patterns. Medication does not seem to differentiate between 
males and females regarding the variables examined in this study. Pre and post 
medication female scores in fundamental frequency remain increased compared 
to male scores.
6.6 Summary of the results and the discussion
According to the Frenchay Dysarthria Assessment (FDA), the 
Parkinsonian and the control group appeared to have differences in the 
individual movements of the articulators and not during the production of running 
speech. The number of errors in intelligibility testing was similar in both groups, 
with a slight increase of errors in the Parkinsonian group, while the nature of 
errors was not possible to be examined in the present study. 
Pathophysiologically, bradykinesia and tremor in the right limb were the 
predominant neurological symptoms for the group of Parkinsonian subjects.
Also, the perceptual impression of the consultant neurologist was that 
bradykinesia (slowness of movement) is associated to dysarthria at this stage of
274
the disease. In the first impression, this assumption comes in contrast to reports 
that hypokinetic dysarthria is caused by rigidity of the laryngeal (Jiang et al.,
1999; Kent, 1990), vocal tract (Kent, 1990) and respiratory musculature 
(Critchley, 1981). However, differences in neurological staging, duration of 
disease and medication status of the present study as compared to all other 
studies that investigated hypokinetic dysarthria could justify such an assumption. 
It would be reasonable to say that hypokinetic dysarthria in the very beginning of 
the disease appears as slowness of the articulators during volitional speech and 
non speech tasks (but not during running speech) and progresses to monopitch, 
monoloudness and reduced stress as the symptom of rigidity appears and 
affects the speech and voice musculature. Along the same lines, even though it 
was not statistically significant, an elevated fundamental frequency (in both 
group means and individual data) especially in the conversation task in the 
Parkinsonian group might be a precursor of rigidity in the laryngeal musculature. 
Similarly, a decreased Qx variable (in both group means and individual data) in 
all tasks in the Parkinsonian group might be a precursor of breathiness caused 
by rigidity.
In the after medication condition, important differences were found during 
the administration of the Frenchay Dysarthria Assessment (FDA), as compared 
to the before medication condition. These involved the individual movements of 
the tongue (lateral movement of tongue and the elevation of tongue) and lips 
(sealing of the lips and the appearance of the lips at rest) during non speech 
tasks that became more automatic and fast and less the individual movements of 
larynx. According to the FDA findings, levodopa seems to have a differential 
effect on the articulators rather than on voice.
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Regarding phonatory instrumental measures (electrolaryngography) the 
effect of medication based on the findings of the present study is not clear. 
Statistically significant differences in relative intensity variables were found when 
one male subject who stopped medication was compared to the group of male 
subjects who continued medication. Even though the number of subjects 
prohibits generalisations of this finding, the combination of carbidopa/levodopa 
and anticholinergics probably acts to stabilise intensity of voice. This finding 
supports recent findings that levodopa improves vocal efficiency by increasing 
respiratory volume or amplitude of vocal fold vibration, or both (Jiang et al.,
1999).
Observation of individual scores revealed tendencies in two mean 
variables in both speaking tasks: fundamental frequency ranges and DQxl. The 
way medication may affect these variables at this stage of Parkinson’s disease 
needs further research, due to the small sample of the present study and in view 
of the lack of other electrolaryngographic studies examining the aforementioned 
area. In summary, from the observation of the individual scores, it seems that the 
effect of medication on electrolaryngographic measures is not clear at this stage 
of the disease. The findings of the present study seem to point out that 
Parkinsonian subjects who are at the beginning of Parkinson’s disease and who 
have received medication for the first time, are idiosyncratically affected by 
medication.
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6.7 Hypokinetic dysarthria in the progression of Parkinson’s disease 
and explanation of the results in relation to medical, speech, and 
neuroscientific evidence
This section aims to discuss the findings of the current study in view of the 
progression of hypokinetic dysarthria in Parkinson’s disease. A major 
assumption of this study and of most of the studies on hypokinetic dysarthria is 
that speech symptomatology is the effect of neurological symptomatology in 
Parkinson’s disease (Darley et al., 1969a, 1969b; Duffy, 1995; Gentil & Poliak, 
1995; Jiang et al., 1999; Kent, 1990; Ludlow & Bassich, 1984). However, the 
timing of the emergence of hypokinetic dysarthria is not yet known.
As has been stated in the literature review, in the general framework of 
neural speech production (Kent & Tjaden, 1997), the normal inputs from motor 
cortex, supplementary motor area, premotor cortex, somatosensory cortex and 
superior parietal lobule to the basal ganglia are processed to the thalamus. The 
excessive output from the basal ganglia due to the lack of dopamine results in an 
increased tonic inhibition of thalamic and cortical neurons (supplementary motor 
area, premotor cortex, Broadman area 44, cingulate cortex and motor cortex). 
The function of motor cortex as a working funnel for movement information from 
cortical and subcortical areas is disrupted due to insufficient information from the 
basal ganglia and thalamus. The result is a consequent insufficient output from 
motor cortex to the spinal cord, brainstem, a-motoneurons (i.e., a decrease in 
the frequency of their firing), premotor cortex, thalamic nuclei, striatum and red 
nucleus. Even though this explanation is theoretical in nature and the existence 
of simultaneous activity of different loops in the basal ganglia complicates the 
picture, there is no doubt that the neurological symptomatology (bradykinesia, 
rigidity and tremor) and speech symptomatology (rigidity) are the results of the
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lack of dopamine. This fact is further enhanced by the existence of hypokinetic 
dysarthria and its differentiation when compared to the other types of dysarthria. 
The assignment of a sensory (impaired sensory trajectories) and motor role 
(Kent, 1990; Kent et al., 2000) or a sole motor role (Marsden, 1982, 1994) to the 
basal ganglia does not change this aforementioned fact. On a purely motor 
basis, for example, the muscle indices in the equations of constraint in the 
coordinative structures (action theory) may be set lower (without changing their 
fixed relationship) due to a reduced firing of a-motoneurons. Consequently, a 
reduced range of movement, as in hypokinetic dysarthria, can occur.
Bradykinesia and tremor were the predominant neurological symptoms in 
the sample of this study. In fact, bradykinesia (stow movement and difficulty 
initiating a movement) is reported to be the earliest symptom of Parkinson’s 
disease (Scharre & Mahler, 1994). Its importance is also manifested by the fact 
that it is considered the most basic symptom to diagnose idiopathic Parkinson’s 
disease (Hughes et al., 1992; Marsden, 1994; Tetrud, 1991). In addition, 
attempts of early diagnosis showed that the movement time for the upper limb 
(as a correlate of bradykinesia) was the most sensitive measure in detecting 
slight motor disturbances in early Parkinson’s disease (Watts et al., 1991). Even 
though it is clear from many studies that hypokinetic dysarthria is the result of 
rigidity of movement in the speech musculature (Darley et al., 1969a, 1969b; 
Duffy, 1995; Gentil & Poliak, 1995; Jiang et al., 1999; Kent, 1990; Ludlow & 
Bassich, 1984), the effect of bradykinesia on speech has been overlooked.
In speech, the results of the present study showed that in the very 
beginning of Parkinson’s disease bradykinesia may be the potential agent that 
affects the movement of the articulators. Slowness of limb movement as 
reported by the subjects of the present study was found to coincide with the
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clinical findings of slowness in lips and tongue during non speech and speech 
movement. On a neuroanatomical basis, the structural proximity of oroface to leg 
and arm in the somatotopic organisation of putamen has been hypothesised in 
experiments on monkeys (Alexander & Crutcher, 1990). Marsden (1994) 
hypothesised that brainstem centers that control posture, locomotion and speech 
may be involved in the problems of posture, gait, and speech. Along the same 
lines, Kent et al. (2001) emphasised that overlapping neural systems control 
speech and non speech motor behaviours (especially in the limbs). On a 
neuropathological basis, similarities between limb and speech movement have 
been suggested (Cammicioli et al., 1998; Ho et al., 1999; Tetrud, 1991). 
However, limb movement and speech movement was considered not to have a 
direct relationship at least in advanced Parkinson’s disease (Kent et al., 2001; 
Murdoch, 2001). Their functions were distinctive as proven by the fact that 
surgical and levodopa interventions have given a positive outcome on limb 
movement but not necessarily on speech (Kent et al., 2001). Moreover, some 
researchers suggest that there is a task dependency in speech movement of 
hypokinetic dysarthria (Connor & Abbs, 1991; Kent et al., 2000). They reported 
that in the proximity of ‘leg’, ‘arm’ and ‘face’ areas within the putamen and globus 
pallidus, there are cell groupings in each area that function in task-dependent 
movement effects. This was proven by the fact that differential effects were 
found in speech that were task dependent (visually guided jaw movements were 
found to increase in duration in jaw opening in non speech but not during a 
phrase production). These results were similar to visually guided arm 
movements.
In phonation, it has been stated in different studies that bradykinesia is 
responsible for the appearance of “hypophonie” speech (Baker et al., 1998;
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Quinn, 1997). Marsden (1989) states that the clinical differences of bradykinesia 
and hypokinesia are not clearly manifested. In the present study, a decrease in 
extended sustained phonation in the laryngeal section of the Frenchay . 
Dysarthria Assessment could be attributed either to bradykinesia or to 
hypokinesia. With the appearance of rigidity during the disease process, which 
may affect the laryngeal musculature, the phonatory impairment will become 
more evident. Along the same lines, the electrolaryngographic results of the 
present study (elevated fundamental frequency and a lower time for the closed 
period of the vocal folds) can be assumed to be precursors of rigidity.
Similarly to other studies that focused on finding sensitive measures of 
bradykinesia in early Parkinson’s disease (Watts et al., 1991), future studies can 
help in the early diagnosis of the disease by isolating correlates of speech with 
the neurological symptoms of the disease. Because instrumental studies 
(acoustic or physiological) can effectively isolate and quantitatively measure 
individual variables of speech and voice, they might be useful in finding 
correlates of bradykinesia in running speech. Other studies can investigate if 
volitional non speech or speech movements (excluding running speech) of the 
articulators can correlate with running speech. Along the same lines, Solomon et 
al. (1995) employed subjects with mild Parkinson’s disease (Hoehn and Yahr 
stages l-ll) and found that tongue weakness is associated with a greater number 
of articulatory errors. Gender differences may also show gender specific 
abnormalities in speech and voice as has been suggested by other researchers 
(Gamboa et al., 1997; Hertrich & Ackermann, 1995; Holmes et al., 2000; Kent et 
al., 1994).
In the progression of hypokinetic dysarthria, increased rigidity in the 
speech and voice musculature expressed perceptually as monopitch.
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monoloudness, reduced stress, short rushes of speech, variability in rate, and 
imprecise consonants will take place (Chenery et al., 1988; Darley et al., 1969a, 
1969b, 1975; Logemann et al., 1978; Ludlow & Bassich, 1984). Instrumentally, 
an increased fundamental frequency and standard deviation of fundamental 
frequency (measures of long-term phonatory instability), jitter and shimmer, and 
a reduced range of fundamental frequency are listed in the literature (Canter, 
1963; Gamboa et al., 1997; Hertrich & Ackermann, 1995; Kent et al., 1994; 
Ludlow & Bassich, 1983, 1984; Ludlow et al., 1983; Ramig et al., 1988; Zwirner 
& Barnes, 1992; Zwirner et al., 1991). Perceptually determined impairment in 
vocal loudness that accompanies the abnormalities in pitch (Duffy, 1995; Gentil 
& Poliak, 1995; Ludlow & Bassich, 1984; Schulz & Grant, 2000) has been 
expressed in intensity abnormalities in instrumental studies (Canter, 1965a; 
Ludlow & Bassich, 1983, 1984). Also, electromyographic evidence showed an 
increased activity of the thyroarytenoid muscle that was exhibited as reduced 
loudness (Baker et al., 1998) and breathiness (Gallena et al., 2001), high 
frequency discharges of the posterior cricoarytenoid and interarytenoid muscles 
(Guidi et al., 1981), and abnormalities in the function of the intrinsic laryngeal 
musculature (Hirose et al., 1988). This activity causes a slower opening of the 
vocal folds, a longer open phase, and stiffness of the vocal folds (Gerratt et al., 
1987; Hanson et al., 1983). During the disease process, perceptually determined 
articulatory imprecision described as incomplete closure for stops and 
insufficient constriction for fricatives (Canter, 1965b; Chenery et al., 1988; Darley 
et al., 1969a, 1969b, 1975; Logemann et al., 1978; Logemann & Fisher, 1981; 
Zwirner & Barnes, 1992) was proven by the acoustic analysis (Ackermann & 
Ziegler, 1991; Kent & Rosenbek, 1982; Weismer, 1984a). Again, rigidity of the 
articulators and a reduced range of movement (hypokinesia) are responsible for
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the production of imprecise consonants (Gentil & Poliak, 1995) and the 
perception of fast rate in Parkinson's disease (Kent & Rosenbek, 1982; Tjaden,
2000).
As the only study that measured voice in the progression of Parkinson’s 
disease. Holmes et al. (2000) supported the notion that progression in severity of 
phonatory features is accompanied by the progression of the disease. Increased 
clinical disability and severity of dysarthria has also been suggested to increase 
with the mean fundamental frequency (Metter & Hanson, 1986). The results of 
the current study support the above findings by showing that no differences exist 
between the Parkinsonian and control groups and that variables such as mean 
speaking fundamental fre<^ ;uency, standard deviation of fundamental frequency, 
jitter, and shimmer are not significant in patients with early Parkinson’s disease.
In theory, if the depletion of dopamine create slowness of movement in 
the articulators as signs of hypokinetic dysarthria, its replenishment with 
levodopa will ameliorate the speech symptomatology. One researcher has 
pointed out the importance of neurotransmitters to speech and voice production 
in neurological disorders (Critchley, 1981). In the beginning of Parkinson’s 
disease, the within group results of the present study showed an improvement in 
the subsections of tongue and lips of the Frenchay Dysarthria Assessment. In 
the voice subsections however, this improvement was not so evident.
In the literature, there is no general agreement about the favourable 
effects of medication on hypokinetic dysarthria. While most of the studies show a 
beneficial effect of levodopa on speech (Cahill et al., 1998; Gallena et al., 2001; 
Leanderson et al., 1971; Metter & Hanson, 1986; Nakano et al., 1973; Wolfe et 
al., 1975) this did not occur on voice parameters (Daniels et al., 1996; Jiang et 
al., 1999). Phonation seems to be resistant to the favourable effect of
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medication. The progression of Parkinson’s disease and the dosage of levodopa 
medication were both suggested to relate to speech and voice problems, through 
the motor fluctuations that occur after 3-5 years of medication (Critchley, 1976; 
Duffy, 1995; Marsden & Parkes, 1976). As has been stated throughout the 
present study the inclusion of Parkinsonian subjects in different neurological 
stages and disease duration may account for these inconsistencies. The present 
study showed that levodopa had a beneficial effect on the areas of tongue and 
lips but its effect on voice remains unclear. More research is needed to confirm 
this finding.
Generalisation of the findings of the present study should take place with 
caution due to limitations inherent to its development. A main limitation is that the 
present study was based on findings of studies that used English speaking 
samples. Hypokinetic dysarthria in Greek speaking populations may show 
different patterns due to linguistic differences. In addition, the lack of norms 
regarding fundamental frequency, fundamental frequency range and intensity in 
normal voice production in Greek may be a further complicating factor. The small 
sample of the present study is certainly a restricting factor regarding the 
generalisation of the findings.
Moreover, methodological issues such as the use of some tools that had 
to be either translated in another language or constructed may be also limiting 
factors to the application of the results. The lack of any dysarthria assessment 
tool in the Greek language was a complicating factor to be overcome. Even 
though, the use of the translated Frenchay dysarthria assessment (FDA) was 
justified compared to other dysarthria tests, stages such as translation and back 
translation were omitted. Furthermore, piloting of the tools used in this study was 
also omitted.
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In addition, some of the reported findings of the present study (slower 
movement of the articulators) are based on the maximum performance subtests 
of the FDA. Inherent weaknesses of such tasks exist and have been reported in 
the literature. Also, the use of a word list for intelligibility assessment (multiple 
choice testing) has its own limitations as well. It excludes factors such as 
situation and context and it is based on reading on the part of the subjects.
Finally, paralinguistic aspects such as mood (depression) were not 
assessed in the present study. Even though, there is a scarcity of studies that 
measure the effect of depression on voice in Parkinson’s disease, the different 
nature of the present study (the subjects have been just diagnosed with 
Parkinson’s disease) compared to the other studies, could justify its assessment.
The strength of the present study lies in the fact that it looks at speech- 
voice characteristics at the very beginning of Parkinson’s disease. Dysarthria 
assessment at this very early stage of the disease is important in order to clarify 
its characteristics, excluding confounding factors (disease duration, neurological 
stage, and medication). The sample of this study, although small, was 
homogeneous in the'sense that all subjects were just diagnosed with 
Parkinson’s disease and have not been medicated. In this stage of the disease, 
a thorough speech assessment may help in finding clinical markers of the 
disease and in facilitating neurological diagnosis, especially in Parkinson’s 
disease where the rate of error in the neurological diagnosis is high (20-25%). It 
was the intention of the present study to examine speech and voice variables 
that can mark the appearance of Parkinson’s disease. An important finding is 
that the identification of early indicators of the dysarthria in Parkinson’s disease 
needs to take into consideration not the phonatory characteristics of the disease
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but the non-speech characteristics such as the movements of the tongue and 
lips.
In addition, this study intended to examine the effect of medication on 
speech-voice characteristics at the beginning of Parkinson’s disease. Again, the 
sample of this study, although small, was homogeneous in the sense that all 
subjects had never been exposed to levodopa medication. The results showed 
that levodopa medication seems to affect the tongue and lips areas, while its 
effect on phonation needs further investigation. Even though the application of 
these findings on speech therapy is not direct, one can assume that since the 
slowness of movement of the articulators can be reversed with levodopa, the 
need for speech therapy at the beginning of the disease is not immediate.
Finally, even though there are inherent limitations in the use of a Greek 
sample (due to the lack of studies in the Greek language), the present study is 
the only one up to now that focused on the dysarthria of Parkinson’s disease on 
native speakers of Greek. It constitutes a basis, from which other studies can 
begin, can refine its tools (translation/back translation and piloting) and assess 
dysarthria in the Greek speaking population in Parkinson’s disease and other 
neurological disorders.
Future assessment with instrumental methods of non speech movements 
(see a review of such methods by Robin et al., 1997) and alternating motion 
rates (Parnell & Ammerman, 1996) may be able to add to the findings of the 
present study. An intelligibility assessment based on specific phonetic contrasts 
that require primarily tongue elevation may be tailored to relate the findings of 
the present study (slower movement of tongue and lips) to speech. For example, 
velar-null contrasts, stop-fricative contrasts, and voicing with velar involvement 
may show differences in patients being in the beginning of Parkinson’s disease.
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Logemann and Fisher (1981) report the high incidence of velars in phonetic 
errors in Parkinsonian subjects with variable disease duration.
In general, since there is a reported variability in Parkinsonian subjects in 
speech/voice (Duffy, 1995; Kent et al., 1994) and a difficulty inherent to the 
structure of the health system for large group studies, other research strategies 
may prove to be equally important. For example, research designs examining in 
depth the individual data of a small number of subjects may lay the groundwork 
for future research that will use larger groups of subjects by identifying variables 
that can be manipulated and by generating hypotheses that need to be tested 
(Schiavetti & Metz, 1997). Multiple measurements of speech/voice under 
different speaking tasks (time-series design) may show details that statistical 
comparisons of the averages may not be able to yield.
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APPENDICES
Appendix A 
Definitions of terms used in the study
Agnosia: It is the inability to recognise or attach meaning to sensory information, 
although the physiologic receptor mechanism is intact; usually associated 
with a central nervous system disorder.
Agonist: 1. The muscle directly engaged in contraction as distinguished from 
muscles that have to relax at the same time; thus, in bending the elbow, 
the biceps brachii is the agonist and the triceps the antagonist. 2. In 
pharmacology, a drug that binds to the receptor and stimulates the 
receptor’s function. Drugs that mimic the body’s own regulatory function 
are called agonists.
Alternating loudness: It is expressed as alternating changes in loudness.
Alternating motion rates: Alternate repetitive movements of tongue.
Amplitude fluctuation ratio: It is a measure of the mean phottoglottography 
amplitude fluctuation divided by the mean phottoglottography and 
multiplied by 1,000.'
Autosomal recessive forms of Parkinson’s disease: In general, individuals with 
autosomal recessive forms are genetically inherited to develop 
Parkinson’s disease.
Babinski sign: The existence of Babinski reflex in people more that 2 years old 
denotes some kind of incoordination, weakness and difficulty with muscle 
control. The Babinski reflex is the reflex of the great toe when it flexes to 
the top.
Basal ganglia: They involve masses of cells that are located deep in each
cerebral hemisphere. They involve the caudate nucleus, putamen and 
globus pallidus.
Bradykinesia: Slowness of movement.
Brain stem: Portion of the brain that connects the cerebral hemispheres with the 
spinal cord. Neuroanatomically, it is divided to midbrain, pons and 
medulla oblongata.
Breathy voice: The mode of vibration of the vocal folds is inefficient and it is 
accompanied by slight audible friction. The muscular effort in breathy 
voice is low, resulting in somewhat open glottis along most of its length, 
so the vocal folds never meet on the mid-line. Breathiness is 
characterised by minimal adductive tension and weak medial 
compression, just sufficient to allow aerodynamic forces in the 
comparatively large volume of transglottal airflow to superimpose on the 
outflowing air.
Contracture: It is an abnormal shortening of muscle tissue, rendering the muscle 
highly resistant to passive stretching.
Coronary heart disease: Disease that affects the heart muscle and the blood 
vessels and results in heart attack due to blockage of the coronary 
arteries that supply blood to the heart.
Encephalitis lethargica: It is an influenza epidemic that occurred between 1914- 
1930 and created symptoms like bradykinesia and chorea. The survivors 
of this epidemic produced a form of Parkinsonism a few months to 25 
years after the recovery of the disease.
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Eosinophillic cytoplasmic inclusions (Lewy bodies): There are coarse, round 
granules of uniform size that are found in the cytoplasm of the cell.
Executive function: It is defined as high-order cognitive tasks such as planning 
and goal directed behaviour. More specifically, it is the ability to maintain 
an appropriate problem-solving set for attainment of a future goal.
Festinating gait: It is an involuntary tendency to take short accelerating steps in 
walking.
Harsh voice: The predominant characteristic of harsh voice is the aperiodicity of 
the fundamental frequency (aperiodic mode of vibration of the vocal folds 
or irregularity of vocal fold vibration), which is heard as a component of 
auditory quality rather than of auditory pitch. The physiological correlate of 
harshness is laryngeal tension or excessive approximation of the vocal 
folds. The exaggerated laryngeal tension in harsh voice is a combination 
of extreme adductive tension and extreme medial compression, brought 
about by over-contraction of the muscles.
Heredodegenerative Parkinsonism: It is the Parkinsonism that it is under genetic 
influence.
Hoarse voice: Laver (1980) prefers the name harsh whispery voice. This type of 
voice is a compound phonation in which harshness boosts adductive 
tension and medial compression to an extreme degree, narrowing the 
glottal aperture and resulting in an audible whisper rising in amplitude until 
the gap is completely closed. Physiologically, the whisper component is 
maintained by a much greater effort on the part of the lateral 
cricoarytenoid muscles to keep the arytenoid triangle open against the 
vigorous attempt by the arytenoid muscles to close it. The interaction of 
harshness and whisper is primarily with the voice component rather than 
with each other in the particular respect of aperiodicity.
Hypernasality: Excessive nasal voice when the air is resonated by the nasal 
cavities.
Hyponasality: Denasal voice.
Imprecise consonants: Consonant sounds lack precision. They show slurring, 
inadequate sharpness, distortions, and lack of crispness. There is 
clumsiness in going from one consonant sound to another.
Incidence: It is the number of new cases of a disorder first developed or 
diagnosed during a specific time interval.
Irregular articulatory breakdown: Intermittent non systematic breakdown 
accuracy of articulation.
Jitter: Variations of fundamental frequency in successive glottal pulses
(Heiberger & Horii, 1982). Jitter measurements are concerned with how 
much a given period differs from the period that immediately follows it 
(short-term variation), and not how much it differs from a cycle at the other 
end of the utterance (Baken, 1997).
Levodopa: It is the direct metabolic precursor of dopamine, it acts as a
neurotransmitter in the brain and it restores the low cerebral dopamine 
levels in Parkinson's disease (Sinemet, Sinemet CR, Madopar).
Locus coeruleus: An area with neurons that is located in the lower brain in the 
pons.
Mesenchephalon: Midbrain, the upper part of the brain stem.
Monoloudness: Voice shows monotony of loudness. It lacks normal variations in 
loudness (Darley et al., 1969a).
Monopitch: Voice is characterised by a monotone. It lacks normal pitch and 
inflectional changes and it tends to stay at one pitch level.
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MPTP induced Parkinsonism: It is a form of Parkinsonism that was developed in 
young people when they were used a synthetic drug that was 
contaminated with the neurotoxin MPTP, MPTP-induced Parkinsonism 
mimics the symptoms of idiopathic Parkinson’s disease.
Non propositional speech: It indicates speech produced for other reasons than 
the transmission of ideas and involves the automatic speech.
Oculogyric crises: Refers to crises where the movement of the eye occurs in the 
anterioposterior axis.
Percent jitter: It is defined as the average jitter in milliseconds divided by the 
average period in milliseconds times 100 (% in milliseconds).
Percent shimmer: It is defined as the percentage of average differences of peak 
amplitudes among successive glottal pulses relative to the average peak 
amplitude of the phonation (Heiberger & Horii, 1982).
Phonotactic patterning: It is defined as the sequential arrangements of 
phonological units which occur in .a language (what counts as a 
phonologically well-formed word). For example, the consonant cluster /str/ 
is not used in the Greek language in the final position of a word.
Pigmented neurons: Coloured neurons.
Pitch breaks: Pitch of voice shows sudden and uncontrolled variation (falsetto 
breaks).
Pitch level: It refers to the voice that is judged to exceed the range of acceptable 
pitch for age and/or sex, being either too low or too high. Inappropriate 
pitch level is typically the hallmark of puberphonia, persistent glottal fry, 
and lack of pitch variability (high or low and a wide or narrow range). In 
neurological disorders the latter may affect the ability to control pitch and 
it may result in a monotone voice (Parkinson’s disease). Inappropriate 
pitch level is a deviation from the neutral setting in that moderate 
longitudinal tension, adductive tension, and medial compression 
(inadequate medial compression in case of Parkinson’s disease) result in 
a regular periodic vocal fold production.
Prevalence: It refers to the total number of persons with a disorder within a given 
population at a fixed point in time.
Progressive Supranuclear Palsy or Supranuclear Gaze Palsy: It is a neurological 
degenerative disease that destroys nerve cells of primarily the pons and 
the midbrain. Its symptoms include difficulty with voluntary eye movement, 
problems in walking, frequent falls or stiff slow movements of the arms 
and legs.
Propositional speech: Jonas (1981) describes it as the speech that is 
produced by a speaker who intends to transmit ideas.
Propulsion: It is a tendency to fall fon^/ard in walking.
Rate: Abnormally rapid or slow perceivable rate.
Reduced stress: Minimal amount of emphasis given a syllable in a word; such 
syllables are short, often low in pitch, and indefinite in quality.
Red nucleus, nucleus basalis and raphe nuclei: Cell bodies that are located in 
the midbrain.
Rétropulsion: It is defined as an abnormal gait in which the body is bent 
backward.
Shimmer: It is defined as variations of peak amplitude in successive glottal 
pulses (Heiberger & Horii, 1982).
Shy-Drager syndrome: Progressive neurological disorder that affects the motor 
components of the autonomic and somatic portions of the central nervous 
system.
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Short rushes of speech: They are defined as short rushes of speech that are 
separated by pauses.
Strained-strangied voice: It is expressed as an effort to squeeze the voice
through glottis. It is also called ventricular voice by Laver. It occurs when 
the ventricular folds become involved in the phonation of the true vocal 
folds, with the effect that the true and the ventricular folds combine to 
vibrate as more massive, composite elements. In order to bring the 
ventricular folds tot his position, a high degree of muscular tension is 
needed, and the effect is normally to make phonation auditorily very 
harsh.
Striatum: It is a part of the basal ganglia involving the structures, caudate 
nucleus and putamen.
Substantia nigra: It is a deeply pigmented area of the midbrain containing
dopamine-producing nerve cells. Neurophysiologically, the substantia 
nigra is considered as a part of the basal ganglia. Neuroanatomically, they 
are divided to substantia nigra pars compacta (cell region of large 
pigmented neurons) and substantia nigra pars reticulata.
Variable rate: Excessively fast or laboriously slow rates due to (among others)
neurological involvement. Persons who tend to talk very rapidly often tend 
to stretch vocalisation to the last bit of air they can squeeze out. The 
prosody of speech may be disturbed by vocal behaviour. In the vocal 
profile analysis protocol the inappropriate fast or slow rate of speech has 
been measured in severity in scalar degrees.
Ventral tegmental area: It is an area of the midbrain (upper part of brain stem) 
from which the axons that leaving the cells of the red nucleus decussate 
and course to the spinal cord.
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Appendix B 
Hoehn and Yahr Neurological Scale
Stage 0: No signs of disease.
Stage 1: Unilateral disease.
The disease in this stage is characterised by mild resting tremor,
rigidity, bradykinesia, dysarthria, trunk tilt, fine motor 
incoordination, and facial immobility. These symptoms are 
noticeable but not disabling. Symptoms often present in unilateral 
or hemiparetic fashion.
Stage 2: Bilateral disease, without impairment of balance.
The person is mildly disabled as symptoms appear bilaterally and 
standing posture becomes stooped. Gait is a shuffle. Fatigue, 
bradykinesia, and weakness impair home and work activities. The 
wrist assumes a slightly dorsiflexed position. The flexed 
metacarpophalangeal and distal and extended proximal 
interphalangeal joints characterise the hand deformity. A pattern of 
truncal and limb contracture is noted.
Stage 3: Mild to moderate bilateral disease.
Moderate disability involves a festinating gait. Rétropulsion initially 
and propulsion later interfere with stopping, starting, turning, and 
stepping backward. Self-care activities are tediously performed and 
often require attendant help. Falls become a real threat to the 
person's safety.
Stage 4: Severe disability.
Marked rigidity, akinesis, and poor standing balance are severely 
disabling, as is fine motor incoordination. Thus, safe independent
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ambulation is confined to the home at best and self-care skills 
require assistance. Contractures are increasingly more refractory 
to conventional stretching exercises. Tremor, interestingly, is less 
pronounced.
Stage 5: Wheelchair bound or bedridden.
This stage presents complete dependency and serious worsening 
of all preceding patterns of musculoskeletal disability. Aspiration, 
pneumonitis, weight loss, malnutrition, dehydration, and fecal 
impaction often necessitate a gastrostomy or nasogastric feeding 
tube. Many people do not reach this grave level of disability owing 
to fatal complications in earlier stages.
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Appendix C
Maximum 
Score Score
Patient
Examiner,
Date
“MINI-MENTAL STATE”
ORIENTATION
5 ( ) What is the (year) (season) (date) (day) (month)?
5 ( ) Where are we; (state) (county) (town) (hospital) (floor).
REGISTRATION
I ( ) Name'3 objects: 1 second to say each. Then ask the patient all
after you have said them. Then repeat them until he learns all 
Count trials and record.
T rials
ATTENTION AND CALCULATION
5 ( ) Serial 7’s. 1 point for each correct. Stop after 5 answers.
Alternatively spell “world” backwords.
RECALL
3 ( ) Ask for the 3 objects repeated above. Give 1 point for each
correct.
LANGUAGE
9 ( ) Name a pencil, and watch (2 points).
Repeat the following “No ifs, ands or buts.” (1 point)
Follow a 3-stage command:
“Take a paper in your right hand, fold it in half, 
and put it on the floor” (3 points)
Read and obey the following:
CLOSE YOUR EYES (1 point)
Write a sentence (1 point)
Copy design (1 point)
__________  Total score
ASSESS level of consciousness along a continuum
Alert Drowsy Stupor Coma
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Ovopa aa0£voùç
E^ETQOTnq_____
H|j£po|jnvia____
“MINI MENTAL STATE" 
Maximum 
Score Score.
nPOZANATOAIIMOI
5 ( ) rioia dvai (n xpoviâ) (q ettoxh ) (q qpEpopqvia) (q pépa) kqi (o  pqvaç);
5 ( ) rioLi PpioKopaaTE: (xwpa), (vopôç) (TTÔAq) (pépoç -o t t I t i ) ,  (ôpo<poç)
A N A r N Q P IZ H  -  M N H M H
3 ( ) OvopàoTE 3 TTpàYpaTa;1 5£UT£poÂ£TTTO yia TO KaSéva. M£Tâ pwTqoTE
TGV aa0£vq kqi yia TQ Tpîa a(poû tq éxete ovopâoEi ôAa. EiravaAâpETE 
pÉXpi va Ta pâ0£i Kai ta  ip ia. MEipqcnE irpocnTâ0EiEÇ xai ypaipiE riç
npocmrc[0£iEç :
h p o z o x H  -  Y n o A o n z M o i
5 ( ) METpàiE avâ 7. 'Eva pa0pô yia Kâ0£ acoaiq aTTdviqaq.
ZiapaTqaiE pEià aiTÔ 5 airavTqaEiç. EvaAÂaKTiKà 
va TTEi iqv AÉÇq -KÔapoç aiTÔ iqv avçiTTOÔq
M N H M H
3 ( ) P(jüTqai£ \\a  ra 3 TTpâypaTa a iqv  TrapaTrdvw daxqaq.
BdAiE Éva pa0pô yia Kd0£ acjjaiq aTrdviqaq.
T A O Z Z A
9 ( ) OvopdaiE Éva poAùpi, xai éva poAôi (2 |3a0poî)
ErravaAdpETE ro TTapaxdTW “IqpEpa éxei ttoA û Çéaiq é^w" (1 pa0p6ç) 
AKoAou0qai£ pîa evioAq 3 aiadlcav:
“ndpiE éva xapil a ie  ôeÇi aaç xépi, ôiirAcjaTE lo  a iq v  péaq xai 
pdAiE 10 QTO TTdTupa" (3 paépoî)
A iapàaiE xai aKoAou0qaT£ lo  TrapaxdTW:
K A E IIT E  TA MATIA l A I  (1 pa0pôç) 
rpdijJTE pia TTpôiaaq (1 pa0pôç)
AvTiypdijJTE TO axéôio (1 pa0pôç)
_____________  T eAiKÔ GKOp
Z Y N E IA H Z H
A^ioAbyqaiE lo ETTiTTEÔo auvEiôqaqç Tïâvoj oz pia auvExq ypappq  
I e  Eypqyopaq ZaAiapévoç/q Ze Aq0apyo Ze Kojpa
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Appendix D
E M n ilT E Y T IK O
Hpepo|jr|vi'a:______
ApiSpôç Aa0£voûç:. 
'Qpa 'EvapSnç____
IITOPIKO riA EKTIMHZH OMIAIAI
O vopa Aa0evoùç:________________________ Hpep/via révvnanç-HAiKia:
ETTÔYYEApa:_____________________ T ôttoc Tewriariç: ______
npoacüTTiKn K a îda iaa ri:________________ EKTraiôeuan:___________
OiKOYEveiQKn K a rd a ia a r):________________ OûAo:____________________
A i£û0uvar|:_________________________________________________________
Hp£p. AidYVwaqç:________ [______________ TrjAÉçwvo:______________
Nai Dxi
1. YTTàpx£i KâiToio laTopiKÔ TTpopAripâTwv Aôyou n opiAiaç
aipv TTQiôiKn aaç qAiKia; _______ ____
2 . A K oA ou0naaT£ Kdiroia 0£paTT£ia Yia auTÔ;________________ ________  _____
3. Ex£T£ KâTToia ôuoKoAia p£ Tqv axop aaç;______________ _______ ____
4. Av vai, TTÔT£ auTH £p(paviaTr)K£ kqi yiq irôao 5inpK£a£; ___________________
5. Exet£ KàTTOia irpopAnpoTa p£ Trjv ôpaan aaç;
6 . Av vai, Ti £i5ouç irpopA npoTa;_________________
7. M ttop£it£ kqi ôiapd(£T£ TrapôAa auTÔ tq irpopAnpoia;
8. Av 6x1, YiaTi a u p p a îv£ i auTÔ;____________________________
E|j(pàviari k q i  AidpKcia
9. 'Ex £T£ KàTTOia ôuoKoAia p£ Tr|v opiAia aaç;_______________
10. Av 6x1, £XEi KâTTOioç àAAoç avacp£p£i Yia Koppia aAAoYn
n TTp6pAr)pa a in v  opiAia aaç;___________________________
11. ri6T£ £pcpaviaTr|K£ to irpôpAnpa ainv opiAia aaç;.
12. EpcpaviaTnK£ a^cpvixa n aiaSiaKd;___________
13. rioi6ç TO avTiAn(p0riK£ TTpwToç, £a£iç n KÔTTOioç ôAAoç;.
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EMnilTEYTIKO
14. AvaTTTÛÇaTE KâTTOIEÇ âÂÂEÇ ÔUaKOÂÎEÇ ÔTQV TO TTpÔ(3Âr)|Ja 
a iriv  opiAia aaç epcpaviaTnKe;__________________________
15. Auréç E p c p a v ia T H K a v  T rp iv  n p E id  q t t ô  t o  wpôpAppa opiAîaç;______
1 6 .  'Exei aAAâ^ei t o  wpopAqpa opiAîaç;
KaAÛTEpQ _______ XEipÔTEpa
iTOSEpÔ _______
METapâAAETQI TTpOÇ (TTEplYpacpn)______ _
Nai D xi
1 7 . 'Exei ETTQVÉA0EI TTOTE n OpiAia QQÇ QTO KCVOVIKO;_______ _______  _____
18. Av v a i, TTÔTE Kai y ia  t t ô q o  ô id a T q p a ;________________________
19. 'Exete KÔTTOia ÔUGKoAia aTr)v p d a p a n ;
20. M httlüç EXETE TTapaTripnaEi va MHN uirâpxEi auppETpîa 
QTO TTpôawTTÔ aoç;
21. Ei'vai ôûaKoAo va pETaKivEiTE t o  cpaynTÔ yupoj pÉaa q t o  
QTÔpa aaç;
22. riaTi;_____________________________________
23. M httcüç TO (payrjTÔ koAAôei aTO pdyouAâ aaç q ctto Tidvw  
pÉpoç TOU aTÔpoTÔç aaç; _
24. Xpeid^ETai va t o  pyâ(ETE pE t o  ôdKTuAô aaç q Pe to  
TTqpoùvi; _
25. 'Exete ôuaKoAia va pETaKivEiTE to cpayqTÔ aTo TTiaw pÉpoç 
TOU aTÔpoTôç aaç, ÉTai waTE va apxîaETE va KaTaTTivETe;_
26. 'Exete ôuaKOAia aTqv KaTdTToaq;______________________ __
27. iT a  cpayqTÔ q aTa u yp â;________________________________
28. ‘E x e te  ôuaKoAîa ÔTav apx^ETETE v a  KaTaTTÎvETE;
29. l a ç  TTÉcpTEi eÇcjü aTTÔ TO a T o p a  aaç cpayqTÔ q u y p ô ;
30. K qtc i Tqv ôicâpKEia Tqç KaTcÎTToaqç exei tto te  EiaxcupqaEi 
q eÇéA6ei aTTÔ Tqv pÛTq aaç cpayqTÔ q uypô;
31. KaTEPaivEi tto te  cpayqTÔ q uypô TTpiv va KaTaTTiEÎTE,
ETOi waTE va aaç TTpoKaAÉaEi pqxa q Kai TTViÇipo;
32. MqTTCjüç aaç épXETai va PycîAETE to  cpayqTÔ
Ka0CÛÇ KaTaTTÎVETE;
33. MqTTCjüç PqxETE Aiyo pETÔ acpoû exete KaTairiE i;
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34. XpEiàQTnKE va cAAàÇETe Tr|v ôiaiid aaç Aôyw auTwv 
TCüv TTpopAriMâTOJv:
35. 'Exete x^aEi pôpoç;
Nai Dxi
36. 'E x e t e  TrapaTripnaEi Kappia aAAayri aTqv auvaiaGqpaTlKq
aaç KaTÔaTaan:_____________________________________ _______  _____
37. KAaÎTE n yEAÔTE t t io  e lik o A q  q t t io  ôûaKoAa
OTTÔ TO TTapEABÔV; ________  ______
38. riaipvETE KàTTOia cpâppaKc t to u  cpaîvETai ô t i  EirqpEâ(Ei
T q v  opiAia aaç; ' _______  _____
39. Av vai TTOia;_____________________
H avTi'Âriipn TOU octOe v o u ç  yia t o  i r p 6 p À r | | j a
40. riujç aKOuyôTav q opiAia/cpwvq aaç ÔTav tq  TrpôpAqpa dpxiaE;______
41. riEpiypâijJTE pou Tqv Twpivq ôuaKoAia arqv opiAia/(pU)vq aaç
TTIO ypqyopq _______ q _______  tt io  apyq
TTIO ô uvoT q  _______ q _______  tt io  aiyavq
TTIO QKpipqç _______ q _______  AiyÔTEpo OKpipqç
42. XpEid^ETOi cpuaiKq TrpoaTidGEia yia va piAqaETE;_______ _______  _______
43. 'E x e te  irapaTqpqaEi KÔTTOia aAAayq aTqv Epcpàviaq q
aTqv acpq to u  TTpoawTTou a a ç  Kai tou  aTÔpoTôç a aç ; ________  _____
44. Av vai, TÎ Eiôouç aAAayq;___________________________________________________
ZUVÉTTEIEÇ TOU T T p O p À q p a T O Ç
45. Oi dvGpwTTOi Êxouv irpôpAqpa va aaç KaTaAapaivouv; _____
46. Av vai, oz tto ieç  TTEpiTTTwaEiç;__________________________________
47. Ti KdvETE ÔTav auTÔ auppai'vEi;____________________________
48. XpEid^ETE TTOTE vo ypdijJETE yio va  aaç KaToAdpouv; _
49. Av vai, TO irpôpAqpa .aTqv opiAia aaç exei ETrqpsdaEi 
Tqv ôouAEid aaç; _
50. Av vai, aaç  éxei aTapaTqaEi aTTÔ to  va k ô v e te  OTiôqTTOTE;.
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AVTipETWTTiari
51. Ti £X£T£ Kàv£i y ia  va avT iO Ta8p io£T£ to  TTpôpÂ npa a in v  opiAia aaç;.
52. No}ji^£T£ ô t i xp£iûi^ecrT£ (3cn0£ia p£ iqv opiAîa aaç icüpa;.
E n iy v c ü c jr i T q ç  ô ia y v w o r r iç  k q i  T q ç  T T p o y v w a q g
53. Ti aaç éxouv TT£i yia Tqv aiTÎa auToû lou TTpo(3AnpaTOç;_______________
54. O aov acpopâ Tqv ôidyvwaq, yvwpi(£T£ n' 0a £TTaKoAou8qa£i;_
AAAeç TrapaïqpqcfEiç paaicrpévcç qto  laTOpiKÔ tou aaSevouç
KdTTViapa ______________________________________________________________
rioTÔ
AAAa
OappaK£UTiKn aywyq irpiv ir) ôidyvüuaq.
D p a  Traûanç:
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Date:
Subject Number: 
Tim e B eg u n :___
H IS T O R Y  F O R M  F O R  M O T O R  S P E E C H  E X A M IN A T IO N
Patient's  nam e:_____________________________ Date of B irth /A ge:___________
O c cu p a tio n :_______________;_________________ Place of Birth:  ______________
M arital Status: Education:
Fam ily S ta tu s :____________;__________________ Sex:
Address:
D ate  of Diagnosis____________________________Telephone:.
Y es No
1. W a s  there any history of childhood speech, and
language deficit?
2. H ave  you received any treatm ent for that?
3. Do you have any difficulty with your hearing?
4. If yes, when did that happen and for how long? _
5. Do you have any problems with your vision?
6 , If yes w hat is it? ____________________________
7. C an  you read despite these problems?
8 . If no, why is th a t? _____________________
Onset and Course
9. Do you have any difficulty with your speech?
10. If not, has anyone else com m ented on a change
or problem with your s p e e c h ? __________________
1 1 . W h en  did the speech problem begin?______________
12. Did it begin suddenly or g radu a lly?________________
13. W h o  noticed it first, you or som eone else?
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14. Did you develop any other difficulties when your speech?
problem b e g a n ? ______________________________________
15. W ere  there before or after the speech prob lem ?_________
16. Has the speech problem changed?
Better W orse
S ta b le  Fluctuating
B etter-then-Stable
17. Has your speech ever returned to normal?
18. If so, when and for how lo n g ? _____________
19. H ave you had any difficulty with chewing?
2 0 . Drooling?
21 . Is it difficult to m ove food around in your mouth?
22 . W hy? ___ _______________________________________
23. Does food get stuck in your cheeks or on the roof
of your mouth?
24 . Do you have to rem ove it with your finger or fork?
25. Do you have trouble moving food back in your
mouth to get a swallow started?
26 . Do you have trouble with swallowing?
27. Food or liq u id ? _______________ :___________________
Yes No
28. Do you have trouble getting a swallow started?
29. Do you loose food or liquid out of your mouth?
30. D oes food or liquid ever go into or out of your nose
w hen you swallow?
31. D oes food or liquid go down before you swallow
and cause coughing or choking?
32. Do you gag or choke when swallowing?
33. Do you choke or cough after completing a swallow?
34. H ave  you had to modify your diet because of
these problem s?
35. H ave  you lost weight?
36. H av e  you had any change in your emot. expression?
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37. Do you cry or laugh m ore easily or less easily than
in the past?
38. Are you taking any m edications that seem to affect
your speech?
39. S tate som e of them:
The patient's perception of deficit
40 . W h a t did your speech/voice sound like when the problem  
b e g a n ? __________________________________________
4 1 . Describe your current speech/voice difficulty: 
Faster vs Slow er
Louder vs ' Softer
Precise vs Less precise
Y es No
4 2. Is speaking effortful?
4 3 . H ave you noticed any change in the appearance
or feeling in your face or mouth?
4 4 . If yes, w h a t? ____________________________________
Consequences of the disorder
4 5 . Do people ever have trouble understanding you?
46. If yes, in which c a s e s ? __________
4 7 . W h a t do you do if that happens?________________________
4 8 . Do you ever have to write to m ake yourself understood?
49. If yes, has your speech problem affected your work?
50. If yes, does it prevent you from doing anything?
Management
51. W h a t have you done to com pensate for your speech  
difficu lty?_______________________________________________
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52. Do you think you need help with your speech now?_
Awareness of diagnosis and prognosis
53. W h at have you been told is the cause of this problem ?
54. In view  of this diagnosis, what is going to happen?
Other Remarks based on History
Sm oking_________________________________ ___________________
Drinking,
O ther
Medication before diagnosis.
T im e  Ended;
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I PA.
2.
I PA. 
3.
I PA.
I PA.
I PA.
6 .
I PA.
7.
I PA.
Appendix E
Phonetic  contrasts in the G reek  intelligibility list of w ords
Bad^ ^
□nÇu)
V 7ii(!^o
V7IiÇo-V7tE(!^ 0=
V7ïi(!^ o-V7tiao=
V7riÇo-VPi(I^ o=
Sip
Xwpa
V ^ o p ,6
V^O|a6-Vao|a6=
V^O)j.6-Vko|i6=
V ^ o |a 6 - V r o ) i 6 =
Spit
riAfjGoç
V T tA lT o C T
V i T oct
V7iX,iToa-V7riToc=
V7iA,iToa-VA,iToa=
V7ïA,iToa-ViToa=
Knot
Nora
Vvox6
V v 6 t6
V v o t 6 - V 4 o t 6 =
Vvox6-VvovS6=
Vvox6-Vv6x6 =
Sigh
rioao
TtoVCTO
TioVao-uoVTo -
7ïoV C TO -7toV xO =
7ioVao-7toVau=
Sheet
XfjTa
V^ix6
V^ix6-Vaix6=
V^ix6-VTix6=
V^ix6-Vix6=
Sticks
Kpi'pa
V k 4 i )i 6
V k 4 i ^ 6 - V k i |^6=
Bed Bat Pad
ria i^w  riia w  MtthÇo)
V7tE(!^ o VTtiGO VPi(!^ o
high-mid vowel contrast (vowel duration contrast in Kent’s 
list)
voicing contrast medial consonant (voicing contrast final
consonant in Kent's list)
voicing contrast initial consonant
Ship Tip Zip
Ewpa Kwpa fôpa
V a o p ô  V k o |o,6 V F o p ô
alveolar-velar place contrast (alveolar-palatal place contrast
in Kent's list)
stop-fricative contrast
voicing contrast initial consonant
Pit
nîGoç
Sit
AiGoç
It
'HGoç
V t iiT oct VAiToa
Dot
PÔTa
V 4 ox6
initial cluster-initial singleton contrast 
initial cluster-initial singleton contrast 
initial consonant-null contrast 
Nod 
Nwvtq 
Vvov06
Nut
Nara
nasal-glide contrast (stop-nasal contrast in Kent's list) 
voicing contrast medial consonants (voicing contrast final 
consonant in Kent's list)
mid-low vowel contrast (vowel duration contrast in Kent's list) 
Shy Tie Thigh
rioGw rioTO riocrou
ttoV T g TtoVxo TioVau
alveolar-dental place contrast (alveolar-palatal or 
postalveolar place contrast in Kent's list) 
stop-fricative contrast
high-mid vowel contrast (other fricative contrast in Kent's list) 
Seat Feet Eat
ZHTq G nia 'Htq
V ctix6 VTix6 V u6
alveolar-velar place contrast (alveolar-palatal or postalveolar 
place contrast in Kent's list)
Other fricative contrast 
initial consonant-null contrast 
Six Ticks Stick
Kupa Pnpa Kpfpaç
VKip6 V4i|i6 V k4 i |j,6ct
initial cluster-initial singleton contrast
The first row of each number (1, 2, etc.) represents Kent's et al. (1989) words and the 
second row the corresponding Greek words.
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V k 4 i |i 6 - V 4 i ^ 6 =  
V K 4 i | j .6 -V K 4 i |^ 6 a =
8 . Knew  
Tou 
I PA. XU
xu-xo=
TU-Xl=
xu-x6=
9. Leak 
A O aaa
I PA. \ /X ig 6
VA.ia6-VA,ua6=
VXia6-V?^ iÇ6=
VA,icr6-V4ia6=
10. Chair 
Tai'iJa
I PA. Vxai|i6
Vxai|j.6-Vai|i6=  
Vxai)i6-VTi|.i6=  
VxCTi|a6-Vi|i6 =
11. Nice 
M à a a
I PA. Vfi6a6
,  Vp.6a6-V|a6(i;6=
V|a6a6-V|i6x6=
V)^6a6-Vp6a6=
12. W rite  
Puar)
I PA. V4icri
V4iai-V4i(!^i=
V 4ia i-V A ,ia i=
V 4 ia i-V A ia i=
13. Side 
MayKa
I PA. V|a6y6
Vp6y6-V|j.6v6=
V|a6y6-V|j,6K6=
V|i6y6-|a6=
14. Pat
O a Z w a w
I PA. T6 Vaoao
T6 V aoao-T6 Vd^oao= 
T6 VCToao-T6 V a ia o =
T6 V aoao-T6 Vao(^o=
initial cluster-initial singleton contrast
final cluster-final singleton contrast 
Know Knee
To Ti
Gnaw
Ta
x6
Air
'Hpa
V i| i6
Dice
MTTâaa
V p 6 a 6
T O  X I
high-mid vowel contrast (high-low vowel contrast in Kent’s 
list)
front-back vowel contrast (front-back vowel contrast in Kent’s 
list)
high-low vowel contrast
Lick League Reek
Aoucra Ai'Ça Piora
VX,ua6 VA,i(^6 V 4 ia 6
front-back vowel contrast (vowel duration contrast in Kent’s 
list)
voicing contrast medial consonant (voicing contrast final 
consonant in Kent’s list)
/r/-/l/ glide-lateral approximant contrast (/r/-/l/ 
contrast in Kent’s list)
Share Tear
Zn |ja  T i'mg
V a i | i6  Vxi|j,6
fricative-affricate contrast 
stop-affricate contrast 
initial consonant-null contrast 
K nife N ight
MàÇa Mara
V|i6(^6 Vfj.6x6
voiced-voiceless fricative contrast (other fricative contrast in 
Kent's list)
stop-fricative contrast 
stop-nasal contrast
Ride Light White
PùÇi Aûan Auan
V4i<!^i VA.ICI VAiCTi
voicing contrast medial consonants (voicing contrast final 
consonants in Kent’s list)
/r/-/l/ glide-lateral approximant contrast (/r/-/l/ liquid) 
contrast in Kent’s list
glide-fricative contrast (/r/-/w / contrast in Kent’s list)
Sign Sight Sigh
Màvo Moikc Mg
V |i6 v 6  V[j.6k6 |i6
stop-nasal contrast
voicing contrast medial consonant (voicing contrast final 
consonant in Kent’s list)
disyllable-monosyllable contrast (final consonant-null 
contrast in Kent’s list)
Bat Pot Pad
O g Zw G W  O g Z n au ) O g  Z w ^ w
T 6 Vd^oao T6 V m a o  T 6  V aoÇ o
voicing contrast initial consonant 
front-back and high-low vowel contrast (front-back vowel 
contrast in Kent’s list)
voicing contrast medial consonant (voicing contrast final 
consonant in Kent’s list)
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15. Hand And Sand Fanned
XâAi AAAn ZdÀi ZdAq
IRA. V ^6A i V6X.I Va6Ai V (6Ai
V^6Ai-V6Ai= Initial velar-null contrast
V^6A.i“V cj6A,i— other fricative contrast
V^6Ai-VÇ6Ai= other fricative contrast
16. Ate Hate Aid Fate
H5n r î5 i 'H0n (Pi'5 i
IRA. V iA i VFiA i V iT i V(j)iAi
V iA i-V r iA i= initial velar-null contrast (initial glottal-null contrast
in Kent’s list)
V iA i-V iT i= voicing contrast medial consonant (voicing contrast final
consonant in Kent’s list)
ViAi-V(|)iAi= initial consonant-null contrast
17. Witch Wish Rich Wit
Aîiaa Auaaa Ni'iaa Aitq
IRA. VA,ita6 VA ict6 Vvixa6 VAix6
VA,iTa6-VX,ia6= fricative-affricate contrast
VA,ixcj6-Vvixa6= lateral-nasal contrast (/r/-/w/ contrast in Kent’s list)
VA,ixa6-VAix6= stop-affricate contrast
18. Much Mush Mut Muck
KdÇo KdvTO Kdvw Kdpo
IRA. V k6Ço V k60o V k6vo V k64o
V k 6(^o - V k 6S o = stop-fricative contrast (fricative-affricate contrast in Kent’s
list)
V k 6(!^ o - V k 6 v o = fricative-nasal contrast (stop-affricate contrast in Kent’s list)
V k 6Ç o - V k 6 4 o = fricative-glide contrast (stop-affricate contrast in Kent’s list)
19. Sew Shoe Toe Foe
' AÉV(JÜ ZÉVW NtEVCjJ Baivw
IRA. VAEvo V(^Evo VôEvo VraEvo
VAEvo-VÇEvo= alveolar-dental place contrast (alveolar-palatal place contrast
in Kent’s list)
VAEvo-V5Evo= stop-fricative contrast
V A E v o - V tdE v o = other fricative contrast
2 0 . Feed Food Feet Fee
Mnciç Mnaç MttiÇ Mtti
IRA. PlCT P 6a Pid^ pi
PLa-p6a= front-back and high-low vowel contrast (front-back vowel
contrast in Kent’s list)
Pia-Pi(^= voicing contrast final consonant
PlCT-Pl= final consonant-null contrast
2 1 . Hlm Hem Ham Hum
ndpa népa ndpa rioüpa
IRA. V tïi46 V tiE46 V tï646 V7tu46
V71i 4 6 - V tiE 4 6 = high-mid vowel contrast (high-low vowel contrast in
Kent’s list)
V7ii46-V7r646= high-low and front-back vowel contrast (high-low vowel
contrast in Kent’s list)
V7ii46-V7tü46= front-back vowel contrast
2 2 . At Hat Fat Add
Ei'5£ç Pîôeç Bi'ôeç E10EÇ
IRA. ViAEa VTiAEa VraiAEa
ViTEa
V iAEa-V7iAEa= initial velar-null contrast (initial glottal-null contrast in Kent’s
list)
V i AEa-V ra iAEa= initial consonant-null contrast
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V iA E a-V iT E a=
V 7 i AEct- V ra iAEa=
23. Air 
'Eva
IPA. VEv6
VEv6-V^Ev6=
V E v 6 - V tiE v 6 =
VEv6-V6v6=
24. Pit 
Bl'pa
IPA. Vrai46
Vrai46-VraE46=
Vrai46-Vra646=
Vrai46-V(|)i46=
25. Read 
Pl'lJQ
IPA. V4i|i6
V4i^6-VA,i^i6=
V4i|a6-V^i|.i6=
V4i)a6-V4En6=
26. Sell 
Zwvw
IPA. V(^ovo
V(!^ovo-Vrovo=
V^ovo-V5ovo=
V^ovo-Vaovo=
27. Blend 
OpEjjpa
IPA. VT4E|i6
VT4Ep6-VTE|i6=  
VT4E^i6-V4E^6=  
VT4Ep6-VE|j.6= initial
28. Shoot 
K o itq
IPA. Vicit6
V K ii6 - V 7 in : 6 =
V k u 6 - V k u t 6 =
V k i t 6 - V k o x 6 =
voicing contrast medial consonant (voicing contrast final 
consonant in Kent’s list)
other fricative contrast 
Hair Fair Are
XévG néva A v v q
V^Ev6 V tïE v 6 V 6 v 6
initial velar-null contrast (initial glottal-null contrast in Kent’s 
list)
initial consonant-null contrast
front-back and high-low vowel contrast (front-back vowel 
contrast in Kent’s list)
Pet Pat Bit
BÉpa Bapa (Pupa
VraE46 Vra646 V(j)i46
high-mid vowel contrast (high-low vowel contrast in Kent’s 
list)
high-low and front-back vowel contrast (high-low vowel 
contrast in Kent’s list) 
voicing contrast initial consonant 
Lead Weed Rrid
Ai'pa Xupa Pepa
VÀiji6 V^ip6 V4Ep6
/r/-/l/ glide-lateral approximant contrast (/r/-/l/ liquid contrast 
in Kent’s list)
glide-fricative contrast (/r/-/w/ in Kent’s list)
high-mid vowel contrast (vowel duration contrast in Kent’s
list)
Shell Tell Fell
r  ÔVO Niwvw Zwvw
VFovo V Ô O V O  Vaovo
alveolar-velar place contrast (alveolar-palatal place contrast 
in Kent’s list) 
stop-fricative contrast
voiced-voiceless fricative contrast (other fricative contrast in 
Kent’s list)
Bend Lend End
Oépa Pépa Ai'pa
VTEp6 V4Ep6 VEp6
initial cluster-initial singleton contrast 
initial cluster-initial singleton contrast 
cluster-null contrast 
Suit Sheet Shot
riiTa Kouia Kora
V tcit6 V k u t6 V k o t6
bilabial-velar place contrast (alveolar-palatal place contrast in 
Kent’s list)
front-back vowel contrast
high-mid and front-back vowel contrast (high-low vowel 
contrast)
29.
IPA.
See
Oupa
VTi46
VTi46-V(|)i46=
VTi46-V^ i46=
She He Tea
Oupa Xnpa Tqpa
V(j)i46 V^i46 V ti46
labiodental-dental place contrast (alveolar-palatal place 
contrast in Kent’s list) 
other fricative contrast
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V Ti46-Vxi46=
30. Slip 
npdaao
IPA. V 7x46 CTO
V7i4oao 
V7i46ao-V7t6ao= 
V7t46ao-V46ao=  
V7i46ao-V7t4oao=
31. Steak 
Tpi'ppa
IPA. V t4 i |o,6
Vx4i|a6-VT|ai|a6=
Vx4i)a6-Vxi|a6=
Vx4in6-V4i|a6=
32. Blow 
Zrpi'pEi
IPA. Vax4ixn i 
Vctx4ixijict 
Vax4iia I-Vx4ixiJi=
V ctx4 ix ü i- V axix !J i=
Vax4itiji-Vax4itiJia=
33. Beat 
KoiTri
IPA. V k ix i
V k i x i - V k E x i =
V k i x i - V k E xv=
V k i x i - V ^ i x i =
34. Sin 
ZoAa
IPA. VctoA6
VaoA.6-V(j)oA,6=
VaoA,6-VoA.6=
VaoA6-VxoA,6=
35. Rock 
PdpTTQ
IPA. V46p6
V46p6-VC6p6=
V46p6-VA6p6=
V46p6-V46p6a=
stop-fricative contrast
Sip
ndao
Vrcôao
Lip
Pdao
Sleep
npdaw
V46ao
initial cluster-initial singleton contrast 
initial cluster-initial singleton contrast 
mid-low vowel contrast (vowel duration contrast in Kent’s list) 
Snake Take Sake
Tpnpa Ti'pa Pqpa
Vx|o.i|j,6 Vxi|o,6 V4ip6
glide-nasal in a cluster contrast (stop-nasal contrast in Kent's 
list)
initial cluster-initial singleton contrast 
initial cluster-initial singleton contrast 
Low Bow Bloat
Ip i'pE i Zti'Pei Zrpi'pEiç
Vx4itni VcrxiTui
initial cluster (3 consonants)-initial cluster (2 consonants) 
contrast (initial cluster-initial singleton in Kent’s list) 
initial cluster (3 consonants)-initial cluster (2 consonants) 
contrast (initial cluster-initial singleton in Kent’s list) 
final consonant-null contrast 
Boot Bit Meat
Kaiiri Kdii Xuin
V k E x i V k 6x i V ^ ix i
high-mid vowel contrast (front-back vowel contrast in Kent’s 
list)
front-back and high-low vowel contrast (vowel duration 
contrast in Kent’s list)
stop-fricative contrast (stop-nasal contrast in Kent’s list)
Shin In Tin
OdAa OAa ToAa
V(|)oX,6 VoA6 VxoA6
alveolar-labiodental place contrast (alveolar-palatal place 
contrast in Kent’s list)
Initial consonant-null contrast 
stop-fricative contrast
W alk Lock Rocks
Zdpna AdpTTa PdpTraç
VÇ6p6 VA6P6 V46p6o
glide-fricative contrast (/r/-/w/ contrast in Kent’s list)
/r/-/l/ glide-lateral approximant contrast (/r/-/l/ liquid contrast 
in Kent’s list)
final consonant-null contrast (final cluster-final singleton 
contrast in Kent’s list)
36. Geese Goose Guess Gas
Kivw Kouvw K evo  Kavd
IPA. K iV v o  K u V vo  k E V v o  k 6 V v o
KiVvo-KuVvo= front-back vowel contrast
k iV vo-kEVvo= high-mid vowel contrast (high-low vowel contrast in Kent’s
list)
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k i V v o - k 6 V v o =
37. Chop 
Taipoç
IP A . V x a i4 o a
V T i4 o a
VTai4oa-VT:a64oa=
V xa i4o a-V ai4oa=
Vxai4oa-Vxi4oa=
38. Ship 
nÎTCTQ
IP A . Vkixœô  
V tiix6
V7rixa6-V7iExCT6=
V7iixa6-V7Tia6=
V7iixa6-V7iix6=
39. Feet 
XwGei
IP A . ^ o V T i
^oV T i-^ iV T i=
4o V T i-aoV T i=
^oVTi-^6VTi=
40. Coat 
TCTâp-rra
IP A . V xa 6p P 6  
’’ V x6pP 6  
Vxa6 |xP 6-VxÇ6|aP 6= 
Vxa6nP6-Vxa67t6=
Vxa6|ip6-Vx6|iP6=
41. Dug 
□nÇw
IP A . Vtck^o
V7Il(^0-VPl(^0=
V7ti(!^ o-V7:iao=
V7ii(^ o-VxiÇo=
42. Cash 
Miraaa
IP A . V p 6 a 6  
VP6C6
Vp6a6-Vn6a6=
Vp6a6-Vp6xa6=
Vp6o6-Vp6(^ 6=
43. Fill 
Oôpa
IP A . V(|)o46
V(j)o46-V^o46=
V(|)o46-Vxo46=
front-back and high-low vowel contrast (high-low vowel 
contrast in Kent’s list)
Chap Shop Top
Taâpoç Zùpoç Tûpoç
V x g 6 4 oct V ai4oa
front-back and high-low vowel contrast (front-back vowel 
contrast in Kent’s list)
fricative-affricate contrast 
stop-affricate contrast 
Sheep Chip Tip
riETaa ni'aaa ni'ra
VkExgô \fn ia6
high-mid vowel contrast (vowel duration contrast in Kent’s 
list)
fricative-affricate contrast 
stop-affricate contrast
Fit Heat Fat
XuOci ZcjOcf XaGci'
^iVTi aoVTi ^6VTi
front-back and high-mid vowel contrast (vowel duration 
contrast in Kent’s list) 
other fricative contrast
mid-low vowel contrast (high-low vowel contrast in Kent’s list) 
Goat Code Tote
TÇâpTra Taarra Tdpira
Vx(!^ 6|ip6 VxGÔTcô
voicing contrast initial consonant
voicing contrast medial consonant (voicing contrast final
consonant in Kent’s list)
stop-affricate contrast (consonant place contrast in Kent’s 
list)
Tug Duck Bug
MtthÇuj rii'au  TnÇu)
VPi(^o Vrtiao VxiÇo
voicing contrast initial consonant
voicing contrast medial consonant (voicing contrast final
consonant in Kent’s list)
consonant place contrast
Gash Catch Cat
ndcra MTTdiaa MrrdÇa
V7i6a6 Vp6xa6
voicing contrast initial consonant 
fricative-affricate contrast
voicing contrast medial consonant (stop-fricative contrast in 
Kent’s list)
Hill Pill
X w pa Tw pa
V^o46 Vxo46
other fricative contrast 
stop-fricative contrast
Full
cpdpa
V(|)646
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V(|)o46-V(t)646=
44. Hat 
Où|ja
IPA. VTi^6
VTi|a6-V^ijj.6=
VTi}o,6-VTiia6=
V Ti|^6-V ai|i6=
45. Hold 
rdpa
IRA. VF6^i6
Vr6p.6-V6p6=
Vr6n6-Vm6p6=
Vr6|i6-Vy6|a6=
46. Heat 
X à(j£
IRA. V^6(jE 
V^ ictE
V ^6aE -V 6aE =
V ^ 6oE-Vw 46aE=  
V^6gE-V^igE=
47. Bill 
Aipira
IRA. VXip6
/ VÀip6-VA,i|j.6= 
VXip6-VA,iô6= 
VXip6-VA.iy6=
48. Ache 
E6 w
IRA. EVAo
E VAo-EVAoa=
EVAo-EVro=
E VA o-E V vo=
49. Llp 
AÛTTn
IRA. VA.1711
VX,i7ii-VA.E7ti=
VX.l7tl-VA.lKl=
VX,l7ll-V4l7Il=
50. Reap  
PÉva
IRA. V4Ev6
V 4E v6-V 4iv6=
V4Ev6-VA,Ev6=
V 4E v6-V Ev6=
51. Rise
mid-low vowel contrast (front-back vowel contrast in Kent's 
list)
Fat Rat That
Xùpa Tipa Zqpa
V^i|i6 V t i|i 6 Vai|i6
Other fricative contrast 
stop-fricative contrast
other fricative contrast (alveolar-dental place contrast)
Old Fold Cold
Apa Bdppa TKdpa
V6p6 Vîü6p6 Vy6p6
initial velar-null contrast (initial glottal-null contrast
in Kent’s list)
other fricative contrast
stop-fricative contrast
Eat Feet Hate
A œe B pdae Xuae
V6ctE Vtu46CTE
initial velar-null contrast (initial glottal-null contrast in Kent’s 
list)
initial cluster-fricative contrast (other fricative contrast in 
Kent’s list)
high-low and front-back vowel contrast (high-low vowel 
contrast in Kent’s list)
Mill Dill Gill
Ai'pa A i'vtq  A i'yk q
VA,ip6 VA.IÔ6 VA,iy6
stop-nasal contrast 
consonant-place contrast 
consonant-place contrast
Aches Ape Ate
A iôljç  E yw  E vw
EVAoa EVEo EVvo
final consonant-null contrast (final cluster-final singleton in 
Kent’s list)
consonant place contrast
fricative-nasal contrast (consonant place contrast in Kent’s 
list)
Leap Lit Rip
A etti A ù k o i P i'ttoi
VXEtii VXiKi V4im
high-mid vowel contrast (vowel duration contrast in Kent’s 
list)
consonant place contrast
/r/-/l/ glide-lateral approximant contrast (/r/-/l/ liquid 
contrast in Kent’s list)
Rip Leap W eep
Pi'va AÉva 'E v a
V4iv6 V lE v 6  VEv6
high-mid vowel contrast (vowel duration contrast in Kent’s 
list)
/r/-/l/ glide-lateral approximant contrast (/r/-/l/ liquid contrast 
in Kent’s list)
initial consonant-null contrast (/r/-/w/ contrast in Kent’s list) 
Wise Lies Eyes
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Pdppa
IPA. V46^i6
V46u6-Vv6iJ,6=
V46a6-VA,6|o,6=
V46a6-V6n6=
52. Row 
Pùiroç
IPA. V 4 i !îo (t 
V lTtOCT
V4i7ioa-V4ETtoa=
V4l7IOO-VA,l7tOCT=
V4i7ioa-Vi7ioa=
53. W ax  
Aci'ijici
IPA.
VA,i7iai-VA,iai=
VA,i7iai-VA,i7ci=
VA,i7tai-V4i7rai=
54. Dock 
MtthÇei
IPA. VPlKGl 
VviKCTl
V P iKai-V p iK aia=
VPiKai-VniKai=
VPiKai-VviKGi=
55. Cheer 
nâGoç
IPA. V7c6Toa
V tiô^oct
V7i6Toa-V7riToa=
V7r6Toa-V7i6(j)oa=
V7i6To(j-V7t6^oa=
56. Hash 
Kdvw
IPA. V k6 vo
V k 6 v o - V k 6<î^ o =
V k 6 v o - V 6 v o =
V k 6 v o - V ^ 6 v o =
57. Tile 
©HKn
IPA. VTiKi
VTiKi-VAiKi=
VIlK l-V(j)lK l=
VIlK l-VviK l=
58. Bunch 
Adira
Ndpa Adpa Apa
Vv6p6 VA.6)i6 V6p6
glide-nasal contrast (/r/-/w/ contrast in Kent’s list)
/r/-/l/ glide-lateral approximant contrast (/r/-/l/ liquid contrast 
in Kent’s list)
initial consonant-null contrast
W oe Low Owe
PÉTTOÇ A iTTOÇ ITTTTOÇ
V4E7ro(7 VA.i7î0cr
high-mid vowel contrast (/r/-/w/ contrast in Kent’s list)
/r/-/l/ glide-lateral approximant contrast (/r/-/l/ liquid contrast 
in Kent’s list)
initial consonant-null contrast
W ack Lax Racks
Auaei A ei'ttei Piipr)
VA.ICJI VA,i7ri V4i7iai
medial double consonant-medial single consonant contrast 
(final cluster-final singleton contrast in Kent’s list) 
medial double consonant-medial single consonant contrast 
(/w/-/l/ contrast in Kent’s list)
/r/-/l/ glide-lateral approximant contrast (/r/-/w/ contrast in 
Kent’s list)
Docks Mock Knock
MirnÇEiç MùÇn NùÇn
VPlKCTlCT VpiKai
final consonant-null contrast (final cluster-final singleton 
contrast in Kent’s list) 
stop-nasal contrast 
stop-nasal contrast 
Sheer Sear
ni'Goç ndtpoç
V tïiT og
Tear
ndxoç
V7c6(j>oa
high-low and front-back vowel contrast (fricative-affricate 
contrast in Kent’s list)
other fricative contrast (fricative-affricate contrast in Kent’s 
list)
other fricative contrast (stop-affricate contrast in Kent’s list) 
Hatch Ash Dash
KdÇo Avw Xdvw
V k 6^ o V 6 vo  V ^ 6 vo
fricative-nasal contrast (fricative-affricate contrast in Kent’s 
list)
initial velar-null contrast (initial glottal-null contrast in Kent’s 
list)
stop-fricative contrast
Dial Pile Mile
A i' kh  OÙKI N i'kh
V A i KI V(|)lKl V v iK l
voicing contrast-initial consonant 
consonant place contrast
fricative-nasal contrast (stop-nasal contrast in Kent’s list) 
Much Punch Bun
Adpira Adpa Aa
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IP A . VA,6ti6
VA,67t6-VA.6p6=
VA,67i6-VA,6|a6=
VA,67i 6”A,6—
59 . E a s e  
'Octh
IP A . V oai
V o a i-V ia i=
V o a i-V xo a i=
Voai-V7ioai=
6 0 . S e e d  
AÉÇ
IP A . A E ct
AEa-AE=
AEa-TEa=
AEo-rEa=
61 . S ink
IP A . V4i7tCTi
V4i7iai-V4iai=
V4i7tai-VX,i7iCTi=
 ^ V4i7rai-Vi7iai=
62 . H arm  
X iip o ç
IP A . V^i4oa  
VCTi4oa 
V^i4oa-Vi4oa=
V^i4oa-Vr i4oa=
V^i4oa-Vai4oa=
6 3 . C a k e  
KÔTTia
IP A . Vkotï 6 
VoTt 6
V koti 6 -V ko7i  6a=
V k o u  6 -V xo7i  6=  
V koti 6 -V ot: 6=
6 4 . M e a t  
r io ivn
IP A . TciVvi
7 r i V v i - 7 r i =
7 i i V v i - 7 i i V v i a =
7riVvi-K iVvi=
6 5 . H ad  
réAa
V X 6P 6 V X 6 |i6  16
voicing contrast-medial consonant (stop-nasal contrast in 
Kent’s list)
stop-nasal contrast (voicing contrast initial consonant in 
Kent’s list)
Disyllable-monosyllable contrast (final consonant-null 
contrast in Kent’s list)
Is C h e e s e  P e a s
'Ian Toan rioan
ViCTi Vxoai VTtoai
front-back and high-mid vowel contrast (vowel duration
contrast in Kent’s list)
initial consonant-null contrast
initial consonant-null contrast
S e e  S ee d s  F e e d
Ae OÉÇ réç
AE TEo TEa
final consonant-null contrast
voicing contrast initial consonant (final cluster-final singleton 
contrast in Kent’s list) 
other fricative contrast
S ing Pink Ink
Pùari Anipn 'Yqjri
V 4 ia i V liT ta i V iT iai
medial double consonant-medial single consonant contrast 
(final cluster-final singleton contrast in Kent’s list)
/r/-/l/ glide-lateral approximant contrast (stop-fricative
contrast in Kent’s list)
initial consonant-null contrast
A rm  C harm  F arm
'Ipoç Fùpoç Zûpoç
V i4oa  V r i4 o a
Initial velar-null contrast (initial glottal-null contrast in Kent’s 
list)
voicing contrast initial consonants (fricative-affricate contrast 
in Kent’s list)
other fricative contrast (alveolar-velar place contrast)
C a k e s  T a k e  A c h e
KÔTTiaç lÔTTia 'Ottoiq
V k o ti 6 a  V xoti 6
final consonant-null contrast (final cluster-final singleton 
contrast in Kent’s list)
consonant place contrast 
initial consonant-null contrast 
M e  M e a ts  N e a t
□n noivnç Koivn
Til T llV v ia  K lV v i
final syllable-null contrast or disyllable-monosyllable contrast 
(final consonant-null contrast in Kent’s list) 
final consonant-null contrast (final cluster-final singleton in 
Kent’s list)
consonant place contrast
A dd P ad  Hid
'EAa r  keAq r  aAa
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IPA. VrEX6
VrE16-VEX6=
VEEX6-VyEX6=
VrEX6-VE6X6=
6 6 . Hail 
Xnpa
IPA. V^i46
V ^i46-V i46=
V^i46-VT i46=
V^i46-VEi46=
67. Hall 
Xwpoç
IPA. V^o4oct 
V 5 o 4 o g  
V^o4oa-Vo4oa=
V^o4oa-V7To4oa=
V^o4oa-V5o4oa=
6 8 . Fork
IT IÇ
IPA. a t ia
axia-GTi=
ax ia -V ax iaE =
ax ia -x ia=
69. Rake
PnÇn
IPA. V4iKCTi
V 4iK ai-4 i=
V 4 iK a i - V 4 iK i=
V 4 iK a i - V A , iK a i=
70. Leak 
Toao
IPA. Vxoao 
Vx6cto  
VxOCTO-XO=
V x o c T O -V x o a o a =
VxoCTo-Vx6ao=
VEÀ6 VyEA.6 Vr6%6
initial velar-null contrast (initial glottal-null contrast in Kent's 
list)
stop-fricative contrast
front-back vowel and mid-low vowel contrast (high-low vowel 
contrast in Kent’s list)
Ail Sail Tail
'Hpa ©npa rûpG
Vi46 VTi46 VEi46
initial velar-null contrast (initial glottal-null contrast in Kent's 
list)
other fricative contrast
voicing contrast initial consonant (stop-fricative contrast in 
Kent's list)
All Tall Ball
'Opoç nôpoç NTÔpOÇ
Vo4oa V;io4oa
initial velar-null contrast (initial glottal-null contrast in Kent's 
list)
stop-fricative contrast 
stop-fricative contrast 
Four Forks Cork
Z in  Zthcte T iç
CTXi VaxiaE x ic t
final consonant-null contrast (final cluster-final singleton 
contrast in Kent's list)
final vowel-null contrast (final cluster-final singleton contrast 
in Kent’s list)
initial cluster-initial singleton contrast (stop-fricative contrast 
in Kent's list)
Ray Rakes Lake
Pr| Re ik i AnÇn
4 l V 4 lK l V X lK G l
disyllable-monosyllable contrast (final consonant-null 
contrast in Kent's list)
medial double consonant-medial single consonant contrast 
(final cluster-final singleton contrast in Kent's list)
/r/-/l/ glide-lateral approximant contrast (/r/-/l/ liquid contrast 
in Kent's list)
Lee Leaks Luke
To Tôaoç Taao
xo VzoGoa
final syllable-null contrast or disyllable-monosyllable contrast 
(final consonant-null contrast in Kent's list) 
final consonant-null contrast (final cluster-final singleton 
contrast in Kent's list)
high-low vowel contrast (front-back vowel contrast in Kent's 
list)
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Appendix F 
Comparison between the Greek Intelligibility List and Kent’s List
SAME PARAMETERS
Greek List Number of Occur. Kent’s List Number of Occur
1. Consonant place contrast 8
2. Final consonant-null contrast 10
3. Final cluster-final singleton contrast 1
4. Fricative-affricate contrast 5
5. Front-back vowel contrast 5
6. High-low vowel contrast 2
7. Initial consonant-null contrast 14
8. Initial cluster-null contrast 1
9. Initial cluster-initial singleton contrast 11
10. Other fricative contrast 16
11. Stop-affricate contrast 4
12. Stop-fricative contrast 16
13. Stop-nasal contrast 6
14. Voicing contrast initial consonant 11
15. Voicing contrast final consonant 1
Consonant place contrast 9
Final consonant-null contrast 9
Final cluster-final singleton contrast 12
Fricative-affricate contrast 9
Front-back vowel contrast 11
High-low vowel contrast 12
Initial consonant-null contrast 14
Initial cluster-initial singleton contrast 12
Other fricative contrast 15
Stop-affricate contrast 6
Stop-fricative contrast 20
Stop-nasal contrast 10
Voicing contrast initial consonant 9
Voicing contrast final consonant 11
DIFFERENT PARAMETERS
16. Alveolar-dental place contrast 2
17. Alveolar-labiodental place contrast 1
18. Alveolar-velar place contrast 3
19. Bilabial-velar place contrast 1
20. Disylable-monosyllable contrast 5
21. Fricative-nasal contrast 4
22. Front-back and
high-low vowel contrast 10
23. Front-back and
mid-low vowel contrast 1
24. Glide-nasal in a cluster contrast 1
25. Glide-nasal contrast 2
26. Glide-fricative contrast 4
27. High-mid vowel contrast 12
28. Initial cluster-fricative contrast 1
29. Initial cluster (3)-
initial cluster (2) contr. 2
30. Initial velar-null contrast 11
31. Labiodental-dental place contrast 1
32. Medial double consonant-medial
single consonant contrast 4
33. Mid-low vowel contrast 4
34. /r/-/l/ (glide-lateral approximant 
contrast) 11
35. Voiced-voiceless fricative contrast 2
36. Voicing contrast medial consonant 12
37. Lateral-nasal contrast 1
38. Final vowel-null contrast 1
39. Front-back and high mid vowel
contrast 3
Alveolar-palatal place contrast
Vowel duration contrast
Initial glottal-null contrast
/r/-/l/ contrast
/r/-/w/ contrast
11
11
10
Total number of parameters: 39 Total number of parameters: 19
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Appendix G 
List of words for intelligibility estimation
1. 'pizo 'pszo 'piso 'bizo
2. 'xonne 'some 'kome 'yome
3. 'pliGos ‘piGos 'liGos 'iGos
4. 'note ‘rote 'nonde 'netB
5. po'so po'Go po'to po'su
6. 'xite 'site 'Bite 'itB
7. 'krime 'kime 'rime 'krimes
8. tu to ti tB
9. 'lise ‘lusB ■liZB 'rise
10. 'tsime 'sime 'time 'ime
11. 'mesB 'mezB 'mete 'besB
12. 'risi 'rizi ■lisi ■ôisi
13. 'mege 'mene 'meke me
14. Be 'soso 6 b  'z o s o Gb 'siso 6 b  ' s o z o
15. 'xeli 'eli 'SBli •zBli
16. ■iôi ■yiôi ■iGi ■fibi
17. 'litSB 'lise 'nitSB 'litB
18. 'kezo 'kedo 'keno 'kero
19. 'Ôeno ‘zeno 'deno 'veno
20. bis bes biz bi
21. 'pire 'pere 'pere 'pure
22. 'iôes 'Y iô e s 'viôss 'iBes
23. 'ene 'xene 'pene 'ene
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24. 'v ire 'verB 'VBfB 'firB
25. 'rime 'limB ‘xim B 'rerriB
26. 'zono 'yono 'dono 'sono
27. 'B rem e 'GenriB 'rem B 'erriB
28. 'kite 'pitB 'kutB 'kotB
29. 'Gire 'firB 'xirs 'tifB
30. 'p reso 'pBSO 'pBSO 'p ro so
31. 'tr im e 'tminriB 'tirriB 'rirriB
32. 's triv i 'triv i 'stivi 's triv is
33. 'kiti ' 'keti 'keti 'xiti
34. 'sole 'folB 'o Ib 'tolB
35. 're b e 'ZBbB 'iBbB 'fBbBS
36. ki'no ku'no ke'no kB'no
37. 'ts iros 'tsB ros 'siros 'tiros
38. 'pitSB 'petsB 'pisB 'pitB
39. xo'Gi xl'01 so'Gi xs'Gi
40. 'ts e m b e 'tzBm bB 'tSBpB 'tBm bB
41. 'p izo 'b izo 'p iso 'tizo
42. 'besB 'pBSB 'bBtSB 'bBZB
43. 'forB 'xorB 'to re 'fB re
44. 'GIit ib 'xirriB 'tirriB 'simB
45. 'y b it ib 'b it ib 'VBITIB 'gBITlB
46. 'XBSG 'b s £ 'vrBse 'xise
47. 'libB 'limB 'lidB 'lige
a46
48. e'ôo s'ôos e'yo e'no
49. ‘lipi ‘lepi 'liki 'ripi
50. 'rsne Vine ‘Isne 'ene
51. 'reme 'nBITlB 'leme 'eme
52. 'ripos 'rspos 'lipos 'ipos
53. 'lipsi 'lisi 'lipi 'ripsi
54. 'biksi 'biksis 'miksi 'niksi
55. 'peGos 'piGos 'pefos 'pexos
56. 'keno 'kezo 'eno 'xeno
57. 'Giki  ^ 'ôiki 'fiki 'niki
58. 'lepe 'lebe 'leme le
59. ‘osi 'isi ‘tosi 'posi
60. ôes ôe Ges yes
61. Vipsi 'risi 'lipsi 'ipsi
62. 'xiros 'iros 'yiros 'siros
63. 'kopiB 'kopjes 'topje 'opie
64. pi'ni pi pi'nis ki'ni
65. 'yele 'ele 'gele 'yele
6 6 . 'xire 'ire 'Gire 'yire
67. 'xoros 'oros 'poros 'doros
68. stis sti 'stise tis
69. 'riksi ri 'riki 'liksi
70. 'toso to 'tosos 'teso
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Appendix H
te elini'ke ni'sçe o'ktovrios xilje ejie'kosçg cnc'ninde s'nee
I e'Ibôb os 'xorB 'eyine yno'sti turisti'kB| prin B'po tri'BndB 'xronjiB| skse'tiBs ton 
ni'sçon tis|| B'ftB 'ins ps'npu 'xII]b| bh ke 'liyB kBti'kunde|| I zo'i e'ki pro'sferete ]b 'oIus| ke JB 
B'ftus pu '0elun ire'mlB B'kuyondBs 'mono tB dzi'dzikçB| b'Ib ke JB 'opjus '0elun nB 'viepun 
'kozmoll
tB ni'sçB tu e'yeu ‘ine kse'rB me liyo'stB 'ôendrBj e'no tB plBl'nB tu io'niu 'exun po'li 
xlo'riÔB|| 'oIb tB ni'sçB 'exun 'remBtB| 'omvrlB ne'rB ke vu'ns pu 'ftsnun se me'yslo 'ipsos|| se 
'o Ib 'ezisBn ke zun 'oxi 'mono 'spBnÎB pti'nB b'Ib ke ki'nB 'zoB| 'opos l'kotBj i 'yBtB ke I kB'tsikB|| 
se 'enB ni'si 'vrikBn 'enB 'iôos 'zou monBÔi'ko 'pBno sti yl| to kri‘kri||
tB me'yBlB ni'sçB 'ine 'mono 'pende ke 'exun 'Bf0ones B'ktesj pu 'kBnun ton 'kseno nB 
re'mvBzi SB'fto to '0BvmB tis 'fisis|| e'ôo| Sen 0b vris pu0e'nB 'ute tis s'prosites orosi'res 'ute tis 
'polis me tin 'molinsij tB 'geto ke tB 'BtsBie 'BxromB 'ktiri'B tus|| Bn '0elis 'veveej bo'ris nB vris 
sxe'ôon pe'ndu se 'o Ib tB ni'sçe 'kBti 'Bynostes ston po'li 'kozmo emu'ôçesj iôi'kB stis 'piso 
ple'vres tus|| 'tote 0b Bpo'iBfsis ti 'ôisi tu 'iAJu| e'ki pu 'zmiyi o ure'nos me ti '0bIbsb|| Bpo'pu 
'BfBye e'mbnefstike o so'fos 0e'os ] b nB 'piBsi B'fti tin pemptu'siB tis omo'rfçBs]]
se 'o Ib tB mi'kfB ni'sçB o 'kozmos 'ine si'ni0os ndrope'los b'Ib enôiB'ferete nB 
efxBri'stisi ton epi'skepti|| 'kBpji 'dinonde me tB ke'le tus 'ruxB 'oten 'erxonde 'ksenijj meri'ki 
fo'nBzunj kB'Ios ton 'kseno|| 'elB 'kBtse ne 'pçis ‘kBti|| ti ne se fi‘lepsume||
i 'kBtiki ton ni'sçon 'ine B'pli|| pi'stevun stin 'Bspili mo'rfi tis pBnB'yiBsjj B'komB ke 'tore 
B'kuyete 'oti sto 'tBÔe ni'si 'eyine '0BvmB|| pe'lçe 'itBn 'mono psB'rBÔes|| 'simerB me tin 'efksisi 
tu turi'smu o'0unde ke se 'eles Bsxo'lies|| si'xnB ‘yinonde ne'fti'ki ke ipire'tun se 'sinxronB 
ebori'kB 'plie| pu 'skizun tus okeB'nus|| 'telosj 'bü 'pçBnune sfu'gBrjBj ke 'bü e'ktrefun 'provete 
ke 'yiôjBlI
Pb'Içb | 'osb ni'sçB ôen kB'tixBn i 'frBgi ke i ene'tij 'isBn ormi'tiriB pire'ton i o'pii 'oryonen 
ti me'soyio '0bIbsb|| B'fti xrisimo'piusBn tB ni'sçe e'fte sen mo'xlus tis kirie'rxies tus|| ke'tepleen 
se e'prosites e'ktes] 'espernen simfo'res] 'evlepten tis Oe'lesies sigino'nies] 'vuljezen 'plie| 
sko'rpusen ton 'tromoj ki'nunden ipo'x0onie ke f0one'rB|| i 'dopji 'ixen 's0enos| b 'Ib i pire'tes 
'elenxen tin ke'testesi ke 'tsekizen 'ke0e B'distBsi|| e'ki 'opu kirie'rxusBn i 'fregi 'sozonde 
'simere te 'kestre me te e'mvlime'te tus ke 'ixni e'po te 'volje tus||
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Appendix I 
The Greek vowels
/ i /
/ 0 /
/ u /
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Appendix J
Combination of vowels in the reading passage
ni + Other Vowels 
[ii] -> Auaq, Oüariç 
[is] -> eivai 
[iu] Not found 
[io] -> eiôoç, ûijjoç 
[ia] -> qiav, Alya, piKpd
[u1 + Other Vowels 
[ui] Not found
[Ue] ->  OÙTE
[uu] Not found 
[uo] -4- Not found 
[ua] -> (3ouvd, pouxa
re1 + Other Vowels 
[el] - >  EKEI 
[EE] - >  TTEVTE 
[EU] ÉXOUV, 0 EÀOUV
[EO] YKETO 
[e o ] ->  TTÉpa
[o1 + Other Vowels 
[oi] ÔTI, 6x1, ttoAu , Çcjürî 
[ce ] ->  TOTE
[ou] -> ôAouq, Çdjou, auToùç
ÔTTOU 
[oo] ->  ÔTT(JÜÇ, Kôopo  
[oa] ->  Çclja, KOTO, x w p a
toi + Other Vowels 
[ai] ùkko\,  k 6 t i ,  irAdoEi 
[ q e ] - >  à k k z q ,  TQÔE
[au] -> auToûç, k ô v o u v ,  TravToû, cpTÔvouv
[ao] aTTÔ, auTÔ
[aa] -> auTÔ, ôAAa, Gaùpa
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Appendix K
Vowels and Consonants in the reading passage
Phonetic
Symbol
Initial
[L]
[E]
[a]
[o]
[a]
n (4 ), Ei'vai (2 ), YivovTOi, 
TTiao), 01 (3 ), HTOV (2 )
£va, evcjj, exouv (2), Eyive 
TTEVTE, pÉpaia, ekeI, eAq
TTOU0EVd, CUTE (2 )
Ô TI, ÔTTCuç, ( j j ç ,  ôÀouç, ôAa ( 3 ), 
O TTG IO I, Ô TO V , ocra, Ô TTO lO UÇ , 
OTTOU, 6 X 1, TTOAÜ, o ( 3 ) ,  K Ô TQ , 
aocpôç, Twpa
KÔTI, QTTÔ ( 3 ) ,  Y Ô T a , QV 
QKTÉÇ, aAAd, TOÔE 
ottAoI, ôAAeç
Medial
THÇ (3 ), THV, 
TTTnvd, TTEpiTTOU
p é p a io , TTou0Evâ
EXOUV,
TTEpiTTOUala
QKOÛYOVTaÇ
TOV, QTOV, 
GTTOAaLiaElÇ
pEyaAa, ôtqv, 
QTav
Final
Kpi, Jï], EKEI
k6 ti
KQI (2), dpQYE 
TÔÔE, TÔTE
TOU (2 ) , A iyo Io u , 
TTEpiTTOU,
GTTÔ TTOU 
GUTOÙÇ, TTOU 
TTGVTOÙ
Efôoç, GUTÔ 
QOrpÔÇ, TO 
GTO, GTTÔ
KOTG,
va, TQ (2 ) ,  
oAq ,Y dTQ,
KGTOiKO,
GUTG
[ai]
[Ol]
[II]
[lOU]
[lO]
[lO]
[p]
[b]
[t]
TTEpiTTOU, TTOAÛ, TTOU (2 ), 
TTGVÜJ
jJTTOpEiÇ
TOU, rn, THS, TG (3 )
TOUÇ, TWV
DIPTHONGS
TTAaiVG
OTHER DIPTHONGS
OTTOlOUÇ
vr)oiwv
CONSONANTS
Plosives
pAÉTTOUV
ÔTTCjJÇ
EpTTOplKG
TÔTE, ÔTGV 
KÔTG, YÜTG 
OÙTE
KQTTOIOI
riAiou
TTOAlâ, 
vgoiG (2)
TTEpiTTOU
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[d ] v T Ü v o v T a i
[k] KQI (4 ), KÔVOUV, KÔTa,
K O lvâ , KÔTi, K a i a k a
[g] YKÉTO
TTEVTE,
TTaVTOÛ
EKEI
auYKoivcüviEÇ
y i v o v i a i
K a T o iK o u v ia i
KQ TG IK a
[m ] \ i z  ( 2 ) .  m 6 v o .(2 )
[n ] v a ,  v n a iL ü v , v E p â
[r] p É p a T O , p o ù x a
Nasals 
' npepîa
EIVGI (2), EVCjü
Trill
VEpc, xwpa
av, EXOUV
QTOV,ÔEV 
TTpIV
aripepa
[ts]
[tz] T^IT^IKia
Affricates
àiaaAa, KaiaiKa 
KàiaE
T^ IT^ lKia
[f] cpüanç
[v] pouvâ
[0] GeAeiç, GÉAouv
Gg, Geôç
[1>] ÔÉVTpG, 6eV  (1) 
Sûari
[s] (TE (3), CGV, auxvà
[z ] ( w p ,  Çouv, SWG,
ÇcJOU
[X] X'Aia, xwpa
[y] yia (2), yiôiG, 
y â T G , y iv o v T G ! 
YH
Fricatives
. G0(p6g
TTpôpGTG
wGoÛVTGI,
ttouGevg
EiSoç, e5 cü
ElSlKG
vqaiwv, ôÛCTri 
vqcTid, vriCTl,
[I] Aiya
ÉCnoGV
EXOUV (1 ), 6X1 
eIxgv
Aiya, ÉyivE, 
GKOÛYOVTGÇ
Aiyaiou
Lateral Approximant
ôAg (2), xiAia
auvqGcjüç
EAAàôG
ttôAe iç , üjç , 
THS, TOUS, 
kg Acjüç,
GUTOÜS, ÔTTOüÇ, 
auvn0(jüç
G p a yE
pEydAG
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[x ] ^ é v o ,  Ç e p â , Ç évoi 
[p s ]  q ja p â ô e ç
[p t]  T T ir iv â
[b n ]
[ m p t ]
[k t]  K T ip ia
[k tr ]
[gt]
[ f0 ]
[fx ]
[fs ]
[ fs t]
[ft]
[fx]
[v m ]
[s0]
[s k ]
[sp]
[s t]
[sf]
[SX]
<p0ovEpà
(pTQVOUV
aQévoç
(7K l(0U V
OTTClVia
CTin, C7T0V 
aiiç
acpouYYÔpia
axEÔôv
[ z m ]  orpiYEi 
[X9]
Ixn]
aAAâ, ttoA û , 
ôAouç, âAAeç 
ttô A eiç  
Double Consonants
EÇaiTi'aç
ÜljJGÇ
(piÀÉ^ IOUpE
Consonant Blends 
Plosives
EpirVEUOTriKE 
TTEpTTTCUala 
QKTE^ (1) 
EKTpECpOUV
Fricatives
ETTiaKETTTr]
àcp0OVEÇ 
auSqon
EpirvEüaTriKE
auTof, auToûç 
VaUTIKOl, auTQ
EUXaplOTnOEl
B a u p a
ETTiaKETTTri 
dcjTTiAn, ÉaiTEpvav
8 a  q t t o A q ù c t e iç
AiYoaid
TTpOacpEpETQI
aaxoÂiEÇ
K ô a p o , K Ô ap o ç
uttoxQôviq
o u x v â , ix v p  
3 5 3
TOUpKJpOU
[xt]
[yn] yvcjüaTH ayvcuaTEç
[Im]
Lateral Approximant
ETTayyeApaia
[rp]
[ry]
[rn]
[rm] o p p n inp ia  
[rf]
[rx]
[mv]
[mvl]
[mvr]
[mf]
[ n i ]
[n ’^  r]
[ndr] VTpOTTaÂôç 
[ns]
Trill
aKopnoüaav
ôpyuüvav
Éorrepvav
pop<pr|
opoptpiâç
épxovTQi, Kupiapxîaç
Nasals
peppà^ Ei
EppAqpaTQ
ô p P p ia
auptpopEç
EvSiacpÉpETai
ÔEVTpa
pôAuvcq
[pl] TrAàQEi
[pr]
[v r ]
[tl]
(tr]
[ î l ]
[%r]
TrpOOCpEpETOI, TTpiV
Consonants with [1] and [r] 
KOTETTAEaV 
q t t A o »
□TTpÔaiTEÇ
T p ia V T O , Tpopo
354
[kl]
[kr] Kpi Kpi piKpâ
[Yl]
[yr]
[fi] - -
[fr] (PpàYYOi
[v l]  P A é t t o u v  é p A a -rr ia v
[v r ]  p p q K Q v , p p e iç  TTÀEupéç
[tl] -  -
[si]
[str] - ' KàcTpa
[zi]
[Xi] - poxAoûç
[Xr] xpôvia ôxpcopa
[yi]
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Appendix L
THE INTERNATIONAL PHONETIC ALPHABET (revised to 1993)
GREEK -  ENGLISH CONNECTIONS''*
Bilabial Labiodental Dental Alveolar Postalveolar Palatal Velar
Plosive P b 
P b
t d 
t d
k 9 
k g
Nasal m
m
n
n
Q
0
Tap or Flap
f
Affricates
ts dz
y dj
Fricative f  V 
f V
0 5
0 a
5 Z  
s z X Y
Approximant w j
Lateral
Approximant
1
1
14 With boldness stand the Greek consonant symbols and with plain stand the corresponding 
basic English symbols.
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Appendix M 
2nd MEETING
Recording Protocol 
Parkinson’s Project
Subject Number / Initials 
Date
A. Preparation: Take
1. Marrantz CP430 Tape recorder
2. Marrantz adaptor
One side in DC Input other side electricity
3. Headphones
Phones
4. Microphone 
Stereo/L
5. A blank tape TDK SA60
6. A battery for the microphone
7. Frenchay Dysarthria Assessment guidelines
8. Frenchay Dysarthria Scoring graph
9. Tongue depressor
10. Stopwatch
ADMINISTER THE FRENCHAY DYSARTHRIA ASSESSMENT
A D J U S T M E N T S
1. Tape recorder from the left to the right
Speaker -» On ___
Speaker —> L + R (ST) ___
- Monitor volume -> Middle position ___
- Mon/for-> Source position ___
Limiter Off ___
- Rec Volume -> adjusted according to the case_______________
(Left is the minimum)
Mic A T T 0 dB ___
- Microphone -> Stereo/L ___
Mic mode Stereo ___
- Pitch ^  0 position ;__
Bias Fine -> 0 position ___
- N.R. (noise reduction) -> Off____________________________
Tape —y Cr02___________________________________ ___
- MPX F i l t e r O f f _________________________________ ___
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- Memory REW Off
2. Cards
TAPE-RECORDING PROTOCOL
1. Insert a blank Cr02 tape
2. Push the Rec button and the Play button together. When needed 
The Pause button also.
3. Be careful not to have the Peak light -> On during recording.
4. The first thing I am going to ask you to do is to count to ten for me:
a. 1-10 do it again
b. 1-10 one more time
0. 1-10 CONTROL REC VOLUME NOT
RED
5. Read the cards with the words in a normal level (as you regularly
talk). Do not care if some of the words do not have a meaning.
Read whatever you see.
AFTER RECORDING
1. Mark cassette with Date
Subject initials (Surname first and then name)
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3rd MEETING
Recording Protocol 
Parkinson’s Project
Subject Number / Initials 
Date
A. Preparation: Take
1. Oscilloscope
2. Oscilloscope’s adaptor “Thandar”
3. Oscilloscope's cord connecting it with ELG
y Input Waveform
4. Laryngograph
5. Laryngograph’s processor battery charger
6^  A cord connecting battery charger with electricity
T  A cord from Laryngograph to DAT recorder
Tape In/Out Line In (3 black-3 red)
(4 yellow- 4 white)
Tape In/Out Line Out (1 red-1 black)
(2 white-2 red)
& A cord with 2 electrodes from the laryngograph
Lx
^  A microphone from the laryngograph
Speech
10. A DAT recorder
11. A Sony adaptor from the DAT recorder
DC In 6V to electricity
12. A set of headphones
Phones/Line Out
13. A blank tape for the DAT
ADJUSTMENTS
1. Oscilloscope from the Left to the Right
V/DIV-^ 5 (the amplitude level /high or low signal)
- Blue AC button pushed
- Blue DC button -> NOT pushed 
White AC button NOT pushed 
White DC button -> pushed
Trigger Level -> above the -  (controls the
stability of the signal/ to look like better) 
White BL button -> pushed 
White EGON button -> NOT pushed
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- Blue TRIG SWEEP button -> pushed
- Blue m sec button -> pushed
TIME/DIV button-^ 5 (controls how many hills
are per rectangle)
2. ELG from the Left to the Right
- INPUT Live
- OUTPUT
- Green a d ju s t e r Adjusted
- Blue adjuster ^  Adjusted
- Lx Left (same as Sp)
- Sp Left (same as Sp)
3. DAT Recorder from the Left to the Right
- AVLS-^ On
- REC MODE -> Manual
TAPE-RECORDING PROTOCOL
1. Turn on Oscilloscope, ELG, DAT recorder
2. The first thing I am going to ask you to do is to count to ten for me:
• §L 1-10 do it again
b. 1-10 one more time
c. 1-10 CONTROL REC LEVEL UNTIL 12
3. The next thing I’ll ask you to do is to repeat as fast as you can 
“papapa” until I’ll tell you to stop:
a. “papapa” do it again
b. “papapa” one more time
c. “papapa”
4. Say “tatata” as fast as you can
a. “tatata” do it again
b. “tatata” one more time
c. “tatata”
5. Say “kakaka” as fast as you can
a. “kakaka” do it again
b. “kakaka” one more time
d “kakaka”
6. Say “pataka” as fast as you can
a. “pataka” do it again
b. “pataka” one more time
c. “pataka”
7. Now I am going to ask you to do sustained phonation. It is to 
hold an “a" without a change of pitch:
a. “aaaaaa” do it again
b. “aaaaaa” one more time
c. “aaaaaa”
8. Now I am going to ask you to do sustained phonation. It is to 
hold an “u” without a change of pitch:
a. “uuuuuu” do it again
b. “uuuuuu” one more time
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c. uuuuuu
9. Now I am going to ask you to do sustained phonation. It is to 
hold an “i” without a change of pitch;
a.
b.
c.
” do it again 
" one more time
10. Now I am going to ask you to do sustained phonation. It is to 
hold an “s” without a change of pitch:
a. “eeeee” do it again
b. “eeees” one more time
c. “seeee" _
11. Now I am going to ask you to do sustained phonation. It is to 
hold an “o" without a change of pitch:
a. “oooooo” do it again
b. “oooooo” one more time
c. “oooooo”
12. Now we are going to read a passage. It is a story that has most of 
the sounds of the Greek language
13. Now we are going to talk a little bit about the earthquakes. What was 
your experience about an earthquake?
AFTER RECORDING
1. Mark cassette with Date
Subject initials/number
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Appendix N
Copies of the completed Frenchay Dysarthria Assessment forms
of all subjects
362
3)ÛJ
FAMILY NAME
I FR EN CH A Y D Y S A R TH R IA  A SSESSM kN  I
SC O R IN G  FO RM
F IR S T  N A M E /S
RE. V
D A T E  O F  A S S E S S M E N T  Q . 0 0  o
C L IE N T  N U M B E R
D A T E  O F  B IR T H
fjANTTTAL^^T^uJRYNGEALI REFLEX I RESP. | UPS TONGUE INTELL
SUMMARY
RECOM M ENDATIONS
INFLUENCING FACTORS
C ro s s  il co n trib u tin g  to s p e e c h  d is o rd e r X
HEARING
SIGHT
TEETH
LANGUAGE
MOOD
POSTURE
OTHER FACTORS
RATE (Wofds/Min)
SENSATION
UPPER LIP R
UPPER LIP
TO N G U E TIP
SUBJECTIVE REPORT ON SENSATION
SIGNED
rEt rT/^llo/~lO M ill P ro e o  1 Q p n  t \ l K q  rar.»r/^Hi locart D rifioK  I^nrrinir'oîrtr.»
MaoCddlVlKlN I
LO3)
FAMILY NAME
F IR S T  N A M E /S
A D D R E S S
S C O R IN G  FORM
SREECH THERAPY
N A M E  O F  T H E R A P IS T  \ <  \L
INFLUENCING FACTORS
Cross if contributing to speech disorder
HEARING
D A T E  O F  B IR T H
C L IE N T  N U M B E R  / \ U  ^  'pj^ G a u - W o \
D A T E  O F  A S S E S S M E N T  ( b  /  5 /  3 . 0 0 0
SUMMARY
RECOM M ENDATIONS
®  reproduced. British edition published bv permission
rT^W |PALAT^"lTR % TONGUE INTELL
%I
SIGHT
TEETH
LANGUAGE
MOOD
POSTURE
OTHER FACTORS
RATE (Words/Min)
SENSATION
UPPER LIP R
UPPER LIP
TO N G U E TIP
SUBJECTIVE REPORT ON SENSATION
SIGNED
FAMILY NAME
F IR S T  N A M E /S
A D D R E S S
I h K fc N U M A T  Ü Y S A H T M H IA  A tiü tS iS IV I 4T
S C O R IN G  FO RM
SPEECH THERAPY
N A M E  O F  T H E R A P IS T
C L IE N T  N U M B E R BA #  Cov\-Vtq\
D A T E  O F  B IR T H DATE OF ASSESSMENT Q.Q /-s/^ oo o
SUM M ARY
RECOM M ENDATIONS
TONGUERESP. UPS JAW PALATE LARYNGEAL INTELL
INFLUENCING FACTORS
Cross il contributing to speech disorder
HEARING
SIGHT
TEETH
LANGUAGE
MOOD
POSTURE
OTHER FACTORS
RATE (Words/Min)
SENSATION
UPPER LIP
UPPER LIP
TO N G U E  TIP
SUBJECTIVE REPORT ON SENSATION
SIGNED
©  College Hill Press 1983. Not to be reproduced. British edition published by permission.
FAMILY NAME
F IR S T  N A M E /S
A D D R E S S
I r  rkci>iv«i-ix ■ b» I  1 nrkiM. 1
S C O R IN G  FORM
S P E E C H  T H E R A P Y
N A M E  O F  T H E R A P IS T
C L IE N T  N U M B E R
D A T E  O F  B IR T H D A T E  O F  A S S E S S M E N T  (:Z , / b  / ^ o ü  Q
SUMMARY
RECOM M ENDATIONS
LIPS PALATE LARYNGEAL TONGUE INTELL.
/ / I
INFLUENCING FACTORS
Cross il contributing to speech disorder
HEARING
SIGHT
TEETH
LANGUAGE
MOOD
POSTURE
OTHER FACTORS
RATE (Words/Min)
SENSATION
UPPER LIP R
UPPER LIP
TO N G U E TIP
SUBJECTIVE REPORT ON SENSATION
SIGNED
©  College Hill Press 1983. Not to be reproduced. British edition published by permission.
FAMILY NAME
F IR S T  N A M E /S
A D D R E S S
D A T E  O F  B IR T H
REFLEX I RESP. AA I
SC O R IN G  F O R M
SPEECH THERAPY
N A M E  O F  T H E R A P IS T  L -  \C
C L IE N T  N U M B E R  ~ Y  H  N A  #  T S  G o v \ W o \
D A T E  O F  A S S E S S M E N T  / q  / s L Q Q
INTELL.
SUMMARY
RECOM M ENDATIONS
LIPS PALATE LARYNGEAL TONGUEJAW
IN F L .U £ N C IN G  FACTORS
Cross if contributing to speecti disorder
HEARING
SIGHT
TEETH
LANGUAGE
MOOD
POSTURE
OTHER FACTORS
RATE (Wofds/Min)
SENSATION
U P P E R  LIP
U P P E R  LIP
T O N G U E  TIP
SUBJECTIVE REPORT ON SENSATION
SIGNED
©  College Hill Press 1983. Not to be reproduced. British edition published by permission.
©  NFER-NELSON 1 QRR Tho m ccd mci r, -^-----—
LO3)
30
I
FAMILY NAME
F IR S T  N A M E /S
A D D R E S S
S C O R IN G  FORM
SPEECH THERAPY
N A M E  O F  T H E R A P IS T  | c \ C  .
D A T E  O F  B IR T H
C L IE N T  N U M B E R  T S T  ^  G  C o u V i O  \  
D A T E  O F  A S S E S S M E N T  a o O Q
SUM M ARY
RECOM M ENDATIONS
REFLEX RESP. JAW LARYNGEALLIPS TONGUE INTELL
INFLUENCING FACTORS
C ro s s  if co n trib u tin g  to  s p e e c h  d is o rd e r X
HEARING
SIGHT
TEETH
LANGUAGE
MOOD
POSTURE
OTHER FACTORS
RATE (Wofds/Min)
SENSATION
UPPER LIP R
UPPER LIP
TO NG UE TIP
SUBJECTIVE REPORT ON SENSATION
SIGNED
©  College Hill Press 1983. Not to be reproduced. British edition published bv oermissipn.
FAMILY NAME
F IR S T  N A M E /S
A D D R E S S
SC O R IN G  FORM
SPEECH THERAPY
N A M E  O F  T H E R A P IS T  V -
C L IE N T  N U M B E R  ^  4^  ~f C o v y - V ^ O  \
D A T E  O F  B IR T H D A T E  O F  A S S E S S M E N T  ( b  /  b  / 3 > O O Q
PALATE LARYNGEAL TONGUE INTELL.RESP. L PS JAW
SUMMARY
RECOM M ENDATIONS
IN F LU E N C IN G  F A C T O R S
Cross if contributing to speech disorder
HEARING
SIGHT
TEETH
LANGUAGE
MOOD
POSTURE
OTHER FACTORS
RATE (Wofds/Min)
SENSATION
UPPER LIP
UPPER LIP
TO NG UE TIP
SUBJECTIVE REPORT ON SENSATION
SIGNED
©  College Hill Press 1983. Not to be reproduced. British edition published hv riArrniR<inn
=)
FAMILY NAME
F IR S T  N A M E /S
A D D R E S S
D A T E  O F  B IR T H
SC O R IN G  FO RM
SPEECH THERAPY
N A M E  O F  T H E R A P IS T  K
C L IE N T  N U M B E R
D A T E  O F  A S S E S S M E N T
SUMMARY
RECOM M ENDATIONS
IN F LU E N C IN G  F A C T O R S
Cross ii conlribuling to speech disorder
HEARING
SIGHT
LARYNGEALL PS JAW PALATE TONGUE INTELL.
TEETH
LANGUAGE
MOOD
POSTURE
OTHER FACTORS
RATE (Woids/Min)
SENSATION
UPPER LIP R
UPPER LIP
TO NG UE TIP
SUBJECTIVE REPORT ON SENSATION
SIGNED
(£) C o l lp n p  H ill P rp c R  1 AA R N n l  In  h p  r p n r n d i i r .p H  R r ilis h  p r lit in n  n i ih lis h p r l h v  n p rm lR < in n
FAMILY NAME
F IR S T  N A M E /S
A D D R E S S
D A T E  O F  B IR T H
( FRENCHAY D Y S A R TH R IA  A SSESSM ENT
S C O R IN G  FO RM
SPEECH THERAPY
N A M E  O F  T H E R A P IS T  I C  \ C ___________________________
C L IE N T  N U M B E R
D A T E  O F  A S S E S S M E N T  I Q / 3 . / ; 2 q O |
SUMMARY
INFLUENCING FACTORS
Cross it contributing to speech disorder
HEARING
PALATE LARYNGEALRESP. TONGUE INTELL
SIGHT
TEETH
LANGUAGE
MOOD
POSTURE
OTHER FACTORS
RATE (Words/Min)
SENSATION
UPPER LIP R
UPPER LIP
TO NG UE TIP
RECOM M ENDATIONS SUBJECTIVE REPORT ON SENSATION
SIGNED
©  College Hill Press 1983. Not to be reproduced. British edition n iiN k h ^ d h v
Maocoom 1 1
LO
FAMILY NAME
F IR S T  N A M E /S
A D D R E S S
SC O R IN G  FORM
SPEECH THERAPY
N A M E  O F  T H E R A P IS T  \— \L^
C L IE N T  N U M B E R PE ^  \0
D A T E  O F  B IR T H D A T E  O F  A S S E S S M E N T  V\ / T  ~Lxx^q
GovvVvo I
SUMMARY
RECOM M ENDATIONS
INFLUENCING FACTORS
Cross if contributing to speech disorder
HEARING
RESP. LIPS JAW PALATE LARYNGEAL  
I
TONGUE INTELL
SIGHT
TEETH
LANGUAGE
MOOD
POSTURE
OTHER FACTORS
RATE (Words/Min)
SENSATION
UPPER LIP
UPPER LIP
TO NG UE TIP
SUBJECTIVE REPORT ON SENSATION
SIGNED
©  College Hill PresS 1983. Not to be reproduced. British edition published by permission.
rpi MCCD MCI W r\nr> -i-i . ------ -------
I FKtlNUI-tAY UY^MM I nrllM. AVOi>tlOOl¥lc.r* ■
SC O R IN G  FORM
SPEECH THERAPY
N A M E  O F  T H E R A P IS T  ___________________________________
INFLUENCING FACTORS
C ro s s  if co n trib u tin g  to s p e e c h  d is o rd e r
F A M IL Y  N A M E
F IR S T  N A M E /S
HEARINGA D D R E S S
___________________ P (0  II T"
DATE OF ASSESSMENT S  / l l  /  3 . 0  O n
CLIENT NUMBER
DATE OF BIRTH
S I G H T
JAW I PALATE I LARYNGEAL II REFLEX I RESP. TONGUELIPS INTELL.
TEETHP
LANGUAGE
MOOD
oz POSTURE
OTHER FACTORS
RATE (Words/Min)
SUM M ARY
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Appendix 0 
Statistical significance between the Parkinsonian and control groups 
in reading compared to conversation 
Within Subjects ANOVA^^
Variable
Parkinsonian Control
P
Overall effect 
P
DFx1 mean 
SD D Fxl
D F x1 .90% range 
DFx2 mean 
SDDFx2  
DFx2 90% range 
DAx1 mean 
SD D A xI
DAx1 90%  range
DAx2 mean
SDDAx2
DAx2 90%  range
DQx1 mean
S D D Q xl
DQx1 90% range
0.065  
0.002 
, 0.003  
0.116  
0.002 
0.001 
0.002 
0.028  
0.029  
0.004  
0.007 
0.007  
0.834  
0.055  
0.042
0.849
0.008
0.013
0.753
0.043
0.003
0.011
0.463
0.418
0.030
0.365
0.095
0.179
0.000
0.000
0.082
0.000
0.000
0.085
0.000
0.000
0.000
0.062
0.047
0.001
0,023
0.001
0.364
0.000
0.000
These results were confirmed with non parametrics (Wilcoxon) that showed the same 
statistical differences.
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Appendix P
Tendencies of the individual scores
Subjects DFx1 mean in 
conversation
DFx2 mean in 
conversation
DQxl mean in 
conversation
DQxl mean in 
reading
Average Qx in 
sustained 
phonation
B I8 155.56 169.64 . 44.50 44.50 45.41
AN 2 - 119.96 130.81 39.50 37.50 46.53
GEI13 201.74 207.65 35.50 37.50 35.49
T H M 6 190.42 201.74 44.50 46.50 43.12
K D 4 151.13 155.56 35.50 32.50 43.57
BE1 130.81 134.65 43.50 47.50 50.31
PM 7 110.00 110.00 45.50 45.50 38.04
KP,10 151.13 151.13 50.50 53.50 56.17
3110 116.54 ' 134.65 39.50 38.50 38.84
SB 8 113.22 113.22 39.50 39.50 42.04
TZS 2 269.29 269.29 .30.50, 31.50 40.89
BA 4 185.00 196.00 36.50 38.50 38.40
Bold = Parkinsonian subjects 
Plain = control subjects
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Appendix Q 
Raw scores of subject SB5 as compared to the male subgroup 
READING
Subjects DAxI
mean
8D DAxI DAxI
Range
DAx2
mean
SB5 before 52.50 7.61 14.20 53.61
SB5 after 44.72 4.76 9.00 44.72
B8 before 54.17 7.70 14.30 55.28
BI8 after 51.39 7.47 13.70 52.50
KD4 before 51.39 7.26 13.40 51.94
KD4 after 48.61 6.65 12.40 49.17
PM7 before 58.61 9.20 16.70 60.28
PM7 after 58.06 8.16 15.10 59.17
8110 before 54.72 9.49 17.60 55.83
8110 after 55.83 9.67 18.00 56.94
CONVERSATION
Subjects DAxI
mean
8D D A xI. DAxI
Range
DAx2
mean
8B5 before 53.06 7.98 14.90 54.17
8B5 after 45.28 5.48 10.80 45.28
BI8 before 53.06 10.08 18.90 54.17
BI8 after 51.39 8.66 16.30 52.50
KD4 before 48.61 8.37 15.60 49.17
KD4 after 50.83 7.80 14.40 51.39
PM7 before 55.83 9.87 18.30 57.50
PM7 after 57.50 10.10 18.30 58.61
8110 before 53.61 9.56 17.80 54.72
8110 after 52.50 9.45 17.90 54.17
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Appendix R 
Statistical significance between the Parkinsonian group before and after 
medication in reading compared to conversation
Within Subiects ANOVA^^ 
Parkinsonian 
(before medication)
Parkinsonian 
(after medication)
Overall effect
Variable
P P P
DFx1 mean 0.176 0.273
SDDFxl 0.001 0.001 0.000
DFx1 90% range ' 0.018 0.018 -
DFx2 mean 0.140 0.166 0.119
SDDFx2 0.017 0.020
DFx2 90% range 0.001 0.002 0.001
DAx1 mean 0.001 0.340 0.001
SDDAxI 1.00 1.00 • -
DAx1 90% range 0.012 0.004 0.005
DAx2 mean 0.001 0.364 0.002
SDDAx2 1.00 ' 1.00 -
DAx2 90% range 0.002 0.004 0.001
DQx1 mean 0.876 0.403 0.698
SDDQxl 0.022 0.012 0.003
DQx1 90% range 0.017 0.022 0.002
These results were confirmed with non parametrics (Wilcoxon) that showed the same 
statistical differences. There were 3 cases that no normality of distributions was found (DFx1 
mean, DFx1 90% range, SDDFx2). In these cases Wilcoxon paired samples test was used.
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